



(51) International Patent Classification:

C07D 405/14 (2006.01) C07D 487/08 (2006.01)
A61K 31/497 (2006.01) C07D 487/10 (2006.01)
C07D 403/14 (2006.01) C07D 491/107 (2006.01)
C07D 241/18 (2006.01) C07D 519/00 (2006.01)
C07D 241/20 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2019/017721

(22) International Filing Date:

12 February 2019 (12.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/630,187 13 February 2018 (13.02.2018) US
62/640,534 08 March 2018 (08.03.2018) US
62/763,116 19 April 2018 (19.04.2018) US
62/747,029 17 October 2018 (17.10.2018) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: AKTOUDIANAKIS, Evangelos; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). CHO, Aesop; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). DU, Zhimin; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). GRAUPE, Michael; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). LAD, Lateshkumar Thakorlal; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). MACHICAO TELLO, Paulo A.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). MEDLEY, Jonathan William; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). METOBO, Samuel E.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). MUKHERJEE, Prasenjit Kumar; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). NADUTHAMBI, Devan; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). PARKHILL, Eric Q.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). PHILLIPS, Barton W.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). SIMONOVICH, Scott Preston; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). SQUIRES, Neil H.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). WANG, Peiyuan; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). WATKINS, William J.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

ve, Foster City, California 94404 (US). XU, Jie; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). YANG, Kin Shing; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). ZIEBENHAUS, Christopher Allen; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: TANNER, Lorna L. et al.; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, California 94301-1479 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: PD-1/PD-L1 INHIBITORS

(57) Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.



PD-1/PD-L1 INHIBITORS**CROSS-REFERENCE TO RELATED APPLICATION**

This application claims the benefit under 35 U.S.C. § 119(e) of United States Provisional Application Nos. 62/630,187, filed February 13, 2018, 62/640,534, filed March 8, 2018, 62/763,116, filed April 19, 2018, and 62/747,029, filed October 17, 2018, each of which are hereby incorporated by reference in their entirety.

FIELD

The present disclosure generally relates to compounds useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Provided herein are compounds, compositions comprising such compounds, and methods for their use.

BACKGROUND

Programmed death-1 (CD279) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1, CD274, B7-H1) or PD-L2 (CD273, B7-DC). When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self-tolerance. Chronic antigen stimulation, such as that which occurs during tumor disease or chronic infections, results in T cells that express elevated levels of PD-1 and are dysfunctional with respect to activity towards the chronic antigen. This is termed "T cell exhaustion." B cells also display PD-1/PD-ligand suppression and "exhaustion."

Blockade of the PD-1/PD-L1 ligation using antibodies to PD-L1 has been shown to restore and augment T cell activation in many systems. Patients with advanced cancer benefit from therapy with a monoclonal antibody to PD-L1. Preclinical animal models of tumors and chronic infections have shown that blockade of the PD-1/PD-L1 pathway by monoclonal antibodies can enhance the immune response and result in tumor rejection or control of infection. Antitumor immunotherapy via PD-1/PD-L1 blockade may augment therapeutic immune response to a number of histologically distinct tumors.


Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1. Humanized mice infected with HIV-1 show enhanced protection against viremia and viral depletion of CD4+ T cells. Blockade of PD-1/PD-L1 through monoclonal antibodies to PD-L1 can restore in vitro antigen-specific functionality to T cells from HIV patients, HCV patients or HBV patients.

Accordingly, agents that block PD-1, PD-L1 and/or the PD-1/PD-L1 interaction are desired. Small molecule agents that block or inhibit PD-1, PD-L1 and/or the PD-1/PD-L1 interaction are

particularly desired. Applicants have discovered small molecule compounds that have activity as inhibitors of PD-1, PD-L1 or inhibitors of the interaction of PD-1 with PD-L1, and thus may be useful for treating patients having cancer, HIV, HCV and/or HBV.

SUMMARY

5 The present disclosure provides a compound of formula (I):



wherein:

each n is independently 0, 1, 2, 3 or 4;

each Z¹ is independently halo, -OR^a, -NO₂, -CN, -NR^aR^b, -N₃, -S(O)₂R^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl,
10 -C₂₋₆alkenyl, -C₂₋₆alkynyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl or -C₁₋₆ alkylC₃₋₈ cycloalkyl;

wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, -N₃, -OR^a, halo, and cyano;

Q is aryl, heteroaryl or heterocyclyl, wherein the aryl, heteroaryl and heterocyclyl group is optionally
15 substituted with 1 to 4 groups independently selected from the group consisting of halo, oxo, -OR^a, -SR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R², -O-C(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;

20 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl; and wherein the heteroaryl or heterocyclyl group
25 may be oxidized on a nitrogen atom to form an N-oxide or oxidized on a sulfur atom to form a sulfoxide or sulfone;


m is 0, 1 or 2;

each Z³ is independently halo, oxo, -OR^a, SR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R²,

-O-C(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl,
-O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is
optionally substituted with 1 to 4 groups independently selected from the group consisting of
5 oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b,
NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b,
-C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl;

each R^N is independently -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆ alkylNR¹R²,
-NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)OR¹,
10 -S-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOR^a, or



wherein

L¹ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

V is independently selected from the group consisting of a bond, C₁₋₆alkyl, C₂₋₆alkenyl,
15 and C₂₋₆alkynyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently
substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;

L² is independently a bond, O, NR^a, S, S(O), or S(O)₂;


ring A is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally
substituted with 1 to 4 groups independently selected from the group consisting
of oxo, -NO₂, N₃, -OR^a, halo, cyano, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl,
-C₂₋₆ alkynyl, -O-C₁₋₆ haloalkyl, NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN,
-C(O)NR^aR^b, -NR^aC(O)R^a, -NR^aC(O)OR^a, -NR^aC(O)OR^a, -C(O)N(R^a)OR^b,
25 -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b,
C₃₋₈cycloalkyl and C₁₋₆alkylC₃₋₈ cycloalkyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently
substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;

R^E and R^W are each independently -NR¹R², -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R²,
30 -C₁₋₆ alkylOC₁₋₆alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylN⁺R¹R²R³, -S-C₁₋₆ alkylNR¹R²,
-C(O)NR¹R², -S(O)₂R^a, -(CH₂)_uS(O)₂NR¹R², -(CH₂)_uNR^aS(O)₂NR^aR^b, -S(O)₂NR^aC₁₋₆ alkylNR¹R²,
-NR^aS(O)₂C₁₋₆ alkylNR¹R², -(CH₂)_uC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_uN⁺R¹R²O⁻, -(CH₂)_uP⁺R^bR^cR^d,

$-(\text{CH}_2)_u\text{P}^+\text{R}^c\text{R}^d\text{O}^-$, $-(\text{CH}_2)_u\text{P}^+\text{O}[\text{NR}^a\text{R}^b][\text{NR}^c\text{R}^d]$, $-(\text{CH}_2)_u\text{NR}^c\text{P}(\text{O})(\text{OR}^c)_2$, $-(\text{CH}_2)_u\text{CH}_2\text{OP}(\text{O})(\text{OR}^c)(\text{OR}^d)$,
 $-(\text{CH}_2)_u\text{OP}(\text{O})(\text{OR}^c)(\text{OR}^d)$, $-(\text{CH}_2)_u\text{OP}(\text{O})\text{NR}^a\text{R}^b(\text{OR}^a)$, or



wherein:

- 5 V^2 is independently a bond, O, NR^a , S, $\text{S}(\text{O})$, $\text{S}(\text{O})_2$, $\text{C}(\text{O})\text{NR}^a$, $\text{NR}^a\text{C}(\text{O})$, $\text{S}(\text{O})_2\text{NR}^1$, or $\text{NR}^a\text{S}(\text{O})_2$;
- L^3 is independently a bond, O, NR^a , S, $\text{S}(\text{O})$, $\text{S}(\text{O})_2$, $\text{C}(\text{O})\text{NR}^a$, $\text{NR}^a\text{C}(\text{O})$, $\text{S}(\text{O})_2\text{NR}^1$, or $\text{NR}^a\text{S}(\text{O})_2$;
- ring B is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;
- 10 T is independently H, $-\text{OR}^a$, $(\text{CH}_2)_q\text{NR}^1\text{R}^2$, $(\text{CH}_2)_q\text{NR}^a\text{C}(\text{O})\text{R}^e$ or $(\text{CH}_2)_q\text{C}(\text{O})\text{R}^e$;
- p is independently 0, 1, 2, 3, 4, or 5;
- q is independently 0, 1, 2, 3, 4, or 5;
- u is 0, 1, 2, 3 or 4;
- z is 0, 1, 2 or 3; and
- 15 wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group of R^E and R^W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b , halo, cyano, oxo, $-\text{OR}^a$, $-\text{C}_{1-6}$ alkyl, $-\text{C}_{1-6}$ haloalkyl, $-\text{C}_{1-6}$ cyanoalkyl, $-\text{C}_{1-6}$ alkyl NR^aR^b , $-\text{C}_{1-6}$ alkylOH, $-\text{C}_{3-8}$ cycloalkyl and $-\text{C}_{1-3}$ alkyl C_{3-8} cycloalkyl;
- provided that at least one of V^2 , L^3 , ring B and T contains a nitrogen atom;
- 20 each R^1 is independently selected from the group consisting of H, $-\text{C}_{1-8}$ alkyl, $-\text{C}_{2-6}$ alkenyl, $-\text{C}_{2-6}$ alkynyl, $-\text{C}_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-\text{C}_{1-6}$ alkylaryl, $-\text{C}_{1-6}$ alkylheteroaryl, $-\text{C}_{1-6}$ alkylheterocyclyl, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{OR}^a$, $-\text{C}_{2-6}$ alkenyl $\text{C}(\text{O})\text{OR}^a$, $-\text{S}(\text{O})_2\text{R}^a$, $-\text{S}(\text{O})_2\text{OR}^a$, $-\text{S}(\text{O})_2\text{NR}^a\text{R}^b$, $-\text{C}(\text{O})\text{NR}^a\text{S}(\text{O})_2\text{R}^a$, and C_{1-6} alkyl C_{3-8} cycloalkyl;
- wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally
- 25 substituted with 1 to 4 groups independently selected from the group consisting of $-\text{OR}^a$, $-\text{CN}$, $-\text{NO}_2$, halo, C_{1-6} alkyl, $-\text{C}_{1-6}$ alkyl OR^a , $-\text{C}_{1-6}$ cyanoalkyl, $-\text{C}_{1-6}$ haloalkyl, C_{3-8} cycloalkyl, heteroaryl, heterocyclyl, $-\text{C}_{1-3}$ alkyl C_{3-8} cycloalkyl, $-\text{C}(\text{O})\text{R}^a$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{R}^a$, $-\text{C}(\text{O})\text{OR}^a$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{OR}^a$, $-\text{NR}^a\text{R}^b$, $-\text{OC}(\text{O})\text{NR}^a\text{R}^b$, $-\text{NR}^a\text{C}(\text{O})\text{OR}^b$, $-\text{NR}^a\text{C}(\text{O})\text{R}^b$, $-\text{C}_{1-6}$ alkyl NR^aR^b , $-\text{C}(\text{O})\text{NR}^a\text{R}^b$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{NR}^a\text{R}^b$, $-\text{S}(\text{O})_2\text{R}^a$, $-\text{S}(\text{O})_2\text{OR}^a$, $-\text{C}_{1-6}$ alkyl $\text{S}(\text{O})_2\text{R}^a$, $-\text{S}(\text{O})_2\text{NR}^a\text{R}^b$,
- 30 $-\text{C}_{1-6}$ alkyl $\text{S}(\text{O})_2\text{NR}^a\text{R}^b$, $-\text{C}(\text{O})\text{NR}^a\text{S}(\text{O})_2\text{R}^b$, $-\text{NR}^a\text{C}(\text{O})\text{NR}^b$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{NR}^a\text{S}(\text{O})_2\text{R}^b$, $-\text{NR}^a\text{C}(\text{O})\text{R}^b$, and $-\text{C}_{1-6}$ alkyl $\text{NR}^a\text{C}(\text{O})\text{R}^b$;

each R² is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkyl-OR^a, -C₁₋₆ alkylC(O)OR^a, and -C₂₋₆ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b and -NR^aC(O)R^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, aryl, heteroaryl, heterocyclyl, -OR^a, -CN, halo, -C(O)OR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ haloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, C₁₋₆ alkylC(O)R^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -NR^aC(O)OR^b, -NR^aC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -NR^aS(O)₂R^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, and C₁₋₆ alkylS(O)₂NR^aR^b;

each R³ is independently H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkyl-OR^a, -C₁₋₆ alkylC(O)OR^a, or -C₂₋₆ alkenylC(O)OR^a;

each R^a is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S; wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆ alkylOR^f, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆ alkylC(O)R^f, -C(O)OR^f, -C₁₋₆ alkylC(O)OR^f, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆ alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, -S(O)₂NR^fR^g, -C₁₋₆ alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

each R^c is independently selected from the group consisting of H, OH, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl; and

each R^d is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;


5 each R^e is independently selected from the group consisting of H, -C₁₋₆ alkyl, -O-C₁₋₆alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C₃₋₈ cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆alkylheteroaryl, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆ alkylC(O)NR^fR^g, -NHS(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, and -C₁₋₆ alkylS(O)₂NR^fR^g;

10 each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

15 The present disclosure further provides a compound of formula (I):



wherein:

each n is independently 0, 1, 2, 3 or 4;

20 each Z¹ is independently halo, -OR^a, -NO₂, -CN, -NR^aR^b, -N₃, -S(O)₂R^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl or -C₁₋₆ alkylC₃₋₈ cycloalkyl;

wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, -N₃, -OR^a, halo, and cyano;

25 Q is aryl, heteroaryl or heterocyclyl, wherein the aryl, heteroaryl and heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of halo, oxo, -OR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R², -OC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;


wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b,
 5 -C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl; and wherein the heteroaryl or heterocyclyl group may be oxidized on a nitrogen atom to form an N-oxide or oxidized on a sulfur atom to form a sulfoxide or sulfone;

m is 0, 1 or 2;

each Z³ is independently halo, oxo, -OR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a,
 10 -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R², -OC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of
 15 oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl;

each R^N is independently -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆ alkylNR¹R²,
 20 -N-R^aC₁₋₆ alkylNR¹R², -C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)OR¹, -S-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOR^a, or



wherein

L¹ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

V is independently selected from the group consisting of a bond, C₁₋₆alkyl, C₂₋₆alkenyl,
 25 and C₂₋₆alkynyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;

L² is independently a bond, O, NR^a, S, S(O), or S(O)₂;


ring A is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting
 30 of oxo, -NO₂, N₃, -OR^a, halo, cyano, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -O-C₁₋₆ haloalkyl, NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN,

-C(O)NR^aR^b, -NR^aC(O)R^a, -NR^aC(O)OR^a, -NR^aC(O)OR^a, -C(O)N(R^a)OR^b,
 -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b,
 C₃₋₈cycloalkyl and C₁₋₆alkylC₃₋₈cycloalkyl;

5 wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈cycloalkyl;

R^E and R^W are each independently -NR¹R², -C₁₋₆alkylNR¹R², -O-C₁₋₆alkylNR¹R²,
 -C₁₋₆alkylOC₁₋₆alkylNR¹R², -NR^a-C₁₋₆alkylNR¹R², -C₁₋₆alkylN⁺R¹R²R³, -SC₁₋₆alkylNR¹R²,
 -C(O)NR¹R², -S(O)₂R^a, -(CH₂)_uS(O)₂NR¹R², -(CH₂)_uNR^aS(O)₂NR^aR^b, -S(O)₂NR^aC₁₋₆alkylNR¹R²,
 -NR^aS(O)₂C₁₋₆alkylNR¹R², -(CH₂)_uC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_uN⁺R¹R²O⁻, -(CH₂)_uP⁺R^bR^cR^d,
 10 -(CH₂)_uP⁺R^cR^dO⁻, -(CH₂)_uP⁺O[NR^aR^b][NR^cR^d], -(CH₂)_uNR^cP(O)(OR^c)₂,
 -(CH₂)_uCH₂OP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)NR^aR^b(OR^a), or



wherein:

V² is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or
 15 NR^aS(O)₂;

L³ is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or
 NR^aS(O)₂;

ring B is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^e or (CH₂)_qC(O)R^e;

20 p is independently 0, 1, 2, 3, 4, or 5;

q is independently 0, 1, 2, 3, 4, or 5;

u is 0, 1, 2, 3 or 4;

z is 0, 1, 2 or 3; and

25 wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl of R^E or R^W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b, halo, cyano, oxo,

-OR^a, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -C₁₋₆cyanoalkyl, -C₁₋₆alkylNR^aR^b, -C₁₋₆alkylOH,
 -C₃₋₈cycloalkyl and -C₁₋₃alkylC₃₋₈cycloalkyl;

provided that at least one of V², L³, ring B and T contains a nitrogen atom;

30 each R¹ is independently selected from the group consisting of H, -C₁₋₈alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₆cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl,

$-C_{1-6}$ alkylheterocyclyl, $-C_{1-6}$ alkylC(O)OR^a, $-C_{2-6}$ alkenylC(O)OR^a, $-S(O)_2R^a$, $-S(O)_2NR^aR^b$,
 $-C(O)NR^aS(O)_2R^a$, and C_{1-6} alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN,
 5 halo, C_{1-6} alkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, C_{3-8} cycloalkyl,
 $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, $-C_{1-6}$ alkylC(O)R^a, $-C(O)OR^a$, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$,
 $-OC(O)NR^aR^b$, $NR^aC(O)OR^b$, $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, $-C_{1-6}$ alkylC(O)NR^aR^b, $-S(O)_2R^a$,
 $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, $-C_{1-6}$ alkylS(O)₂NR^aR^b, $-C(O)NR^aS(O)_2R^b$,
 $-C_{1-6}$ alkylC(O)NR^aS(O)₂R^b, $-NR^aC(O)R^b$, and $-C_{1-6}$ alkylNR^aC(O)R^b;

10 each R² is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl,
 $-C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl,
 $-C_{1-6}$ alkylheterocyclyl, $-C_{2-6}$ alkyl-OR^a, $-C_{1-6}$ alkylC(O)OR^a, and $-C_{2-6}$ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN,
 15 halo, C_{1-6} alkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, $-C_{3-8}$ cycloalkyl,
 $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, $-C_{1-6}$ alkylC(O)R^a, $-C(O)OR^a$, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$,
 $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, C_{1-6} alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a,
 $-S(O)_2NR^aR^b$, $-C_{1-6}$ alkylS(O)₂NR^aR^b, $-C(O)NR^aS(O)_2R^b$ and $-NR^aC(O)R^b$;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional

20 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1
 to 3 groups independently selected from the group consisting of oxo, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl,
 $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, -OR^a, $-C(O)OR^a$, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ haloalkyl,
 $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, C_{1-6} alkylC(O)R^a, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$, $-C_{1-6}$ alkylNR^aR^b,
 $-C(O)NR^aR^b$, $-C_{1-6}$ alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, and
 25 C_{1-6} alkylS(O)₂NR^aR^b;

each R³ is independently H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl,
 $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, $-C_{1-6}$ alkylheterocyclyl, $-C_{2-6}$ alkyl-OR^a, $-C_{1-6}$ alkylC(O)OR^a, or
 $-C_{2-6}$ alkenylC(O)OR^a;

each R^a is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, aryl,
 30 heteroaryl, heterocyclyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, and
 $-C_{1-6}$ alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, aryl,
 heteroaryl, heterocyclyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, and
 $-C_{1-6}$ alkylheterocyclyl;

or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S; wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆ alkylOR^f, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆ alkylC(O)R^f, -C(O)OR^f, -C₁₋₆ alkylC(O)OR^f, -NR^fR^g,
 5 -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆ alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, -S(O)₂NR^fR^g, -C₁₋₆ alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

each R^c is independently selected from the group consisting of H, OH, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

10 each R^d is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

each R^e is independently selected from the group consisting of H, -C₁₋₆ alkyl, -O-C₁₋₆alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C₃₋₈ cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl,
 15 -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆alkylheteroaryl, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆ alkylC(O)NR^fR^g, -NHS(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, and -C₁₋₆ alkylS(O)₂NR^fR^g;

each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

20 each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

Also provided herein are compounds of Table 1, or a pharmaceutically acceptable salt,
 25 stereoisomer, mixture of stereoisomers, or tautomer thereof.

The present disclosure provides a method of inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction comprising administering a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, to a patient in need thereof.

The present disclosure provides a method of treating cancer comprising administering a
 30 therapeutically effective amount of a compound formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, to a patient in need thereof.

One embodiment provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, for the treatment of cancer or a condition in a patient that is amenable to treatment by inhibiting PD-1, PD-L1 or the PD-1/PD-L1 interaction
 35 comprising administering said compound of formula (I) to said patient in need thereof.

In one embodiment, provided is a method for treating a cancer wherein the cancer is pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer or colon cancer, comprising administering a therapeutically effective amount of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof to a patient in need thereof.

In one embodiment, provided is a method for treating a cancer or a condition in a patient that is amenable to treatment by inhibiting PD-1, PD-L1 or the PD-1/PD-L1 interaction selected from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer and colon cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof to a patient in need thereof, further comprising administering at least one additional anticancer agent or therapy to a patient in need thereof. In certain embodiments, the additional anticancer agent or therapy is selected from nivolumab, pembrolizumab, atezolizumab, ipilimumab, chemotherapy, radiation therapy, and resection therapy, to a patient in need thereof.

In one embodiment, provided is a method for treating hepatitis B virus (HBV), comprising administering a therapeutically effective amount of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof to a patient in need thereof.

In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, for the treatment of cancer or a condition in a patient selected from lymphoma, multiple myeloma, and leukemia. Additional diseases or conditions that may be treated include, but are not limited to acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldstrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL).

In one embodiment, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, in combination with at least one additional anti-cancer agent selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, and ipilimumab.

In one embodiment, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, in combination with at least one additional check-point inhibitor selected from nivolumab, pembrolizumab, atezolizumab, and ipilimumab.

5 In one embodiment, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

10 In one embodiment, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one additional anticancer agent and at least one pharmaceutically acceptable carrier or excipient.

15 In one embodiment, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, at least one additional therapeutic agent suitable for treating an HBV infection, and at least one pharmaceutically acceptable carrier or excipient.

In one embodiment, the present disclosure provides a kit that includes a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, a label and/or instructions for use of the compound in the treatment of cancer or a disease or condition mediated by PD-1, PD-L1 activity or the PD-1/PD-L1 interaction.

20 In one embodiment, the present disclosure provides a kit that includes a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, at least one additional anticancer agent, a label(s) and/or instructions for use of the compound(s) in the treatment of a disease or condition mediated by PD-1, PD-L1 activity or PD-1/PD-L1 interaction.

25 In one embodiment, the present disclosure provides articles of manufacture that include a compound of formula (I) or a pharmaceutically acceptable salt, or solvate thereof; and a container. In one embodiment, the container may be a vial, jar, ampoule, preloaded syringe, or an intravenous bag.

In one embodiment, the present disclosure provides a compound of formula (I) for use in therapy.

30 In another embodiment, the present disclosure provides a compound of formula (I) for use in the manufacture of a medicament for treating cancer.

DESCRIPTION OF THE FIGURES

Figure 1, panels A (Figure 1A) and B (Figure 1B), show that compound 139 enhances IFN- γ and Granzyme B Production in chronic hepatitis B (CHB) CD8⁺ T Cells.

Figure 2, panels A (Figure 2A) and B (Figure 2B), show that compound 139 enhances IFN- γ and Granzyme B Production in chronic hepatitis B (CHB) CD4⁺ T Cells.

Figure 3 shows the experimental design for mouse PD-L1 knockout and replacement with human PD-L1 in MC38 mouse colorectal tumor cell line.

5 Figure 4 shows the relationship between PK (Figure 4A) and TO (Figure 4B) for compound 139 on Day 6 in a human PD-L1 MC38 C57BL/6 mouse tumor model.

Figure 5 shows the anti-tumor activity of compound 139 in a human PD-L1 MC38 mouse model.

DETAILED DESCRIPTION

Definitions

10 As used in the present disclosure, the following words and phrases are generally intended to have the meanings as set forth below unless expressly indicated otherwise or the context in which they are used indicates otherwise.

The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.

15

As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(O)NH₂ is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.

20

A squiggly line on a chemical group as shown below, for example,  indicates a point of attachment, i.e., it shows the broken bond by which the group is connected to another described group.

25

The prefix “C_{u-v}” indicates that the following group has from u to v carbon atoms. For example, “C₁₋₆ alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms.

Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter *per se*. In certain embodiments, the term “about” includes the indicated amount $\pm 10\%$. In other embodiments, the term “about” includes the indicated amount $\pm 5\%$. In certain other embodiments, the term “about” includes the indicated amount $\pm 1\%$. Also, to the term “about X” includes description of “X”. Also, the singular forms “a” and “the” include plural references unless the context clearly dictates otherwise. Thus, e.g., reference to “the compound” includes a plurality

30

of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art.

The term “substituted” means that any one or more (e.g., one to three, or one to five) hydrogen atoms on the designated atom or group is replaced with one or more (e.g., one to three, or one to five) substituents other than hydrogen, provided that the designated atom’s normal valence is not exceeded. The one or more (e.g., one to three, or one to five) substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocycloalkyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof. Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein, whether the substituents are the same or different. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term “substituted” may describe other chemical groups defined herein. For example, the term “substituted aryl” includes, but is not limited to, “alkylaryl.” Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.

A “substituted” group also includes embodiments in which a monoradical substituent is bound to a single atom of the substituted group (e.g., forming a branch), and also includes embodiments in which the substituent may be a diradical bridging group bound to two adjacent atoms of the substituted group, thereby forming a fused ring on the substituted group.

“Alkyl” refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C₁₋₂₀ alkyl), 1 to 8 carbon atoms (i.e., C₁₋₈ alkyl), 1 to 6 carbon atoms (i.e., C₁₋₆ alkyl), or 1 to 4 carbon atoms (i.e., C₁₋₄ alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e., -(CH₂)₃CH₃), sec-butyl (i.e., -CH(CH₃)CH₂CH₃), isobutyl (i.e., -CH₂CH(CH₃)₂) and tert-butyl (i.e., -C(CH₃)₃); and “propyl” includes n-propyl (i.e., -(CH₂)₂CH₃) and isopropyl (i.e., -CH(CH₃)₂).

“Alkenyl” refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C₂₋₂₀ alkenyl), 2 to 8 carbon atoms (i.e., C₂₋₈ alkenyl), 2 to 6

carbon atoms (i.e., C₂₋₆ alkenyl), or 2 to 4 carbon atoms (i.e., C₂₋₄ alkenyl). Examples of alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl, and 1,3-butadienyl).

“Alkynyl” refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C₂₋₂₀ alkynyl), 2 to 8 carbon atoms (i.e., C₂₋₈ alkynyl), 2 to 6 carbon atoms (i.e., C₂₋₆ alkynyl), or 2 to 4 carbon atoms (i.e., C₂₋₄ alkynyl). The term “alkynyl” also includes those groups having one triple bond and one double bond.

“Alkoxy” refers to the group “alkyl-O-” or “-O-alkyl”. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

“Haloalkoxy” refers to an alkoxy group as defined above, wherein one or more (e.g., one to three, or one to five) hydrogen atoms are replaced by a halogen.

“Amino” refers to the group -NR^yR^z wherein R^y and R^z are independently selected from hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl; each of which may be optionally substituted.

“Aryl” refers to a monoradical or diradical aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused ring systems wherein one or more (e.g., one, two, or three) fused rings is/are fully or partially unsaturated. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., C₆₋₂₀ aryl), 6 to 12 carbon ring atoms (i.e., C₆₋₁₂ aryl), or 6 to 10 carbon ring atoms (i.e., C₆₋₁₀ aryl). Non-limiting examples of aryl groups as used herein include phenyl, naphthyl, fluorenyl, indanyl, tetrahydroindanyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl. The classification of mono or diradical indicates whether the aryl group terminates the chain (monoradical) or is within a chain (diradical). The above definition does not preclude additional substituents on the aryl group. For example, as used herein, the aryl group in “A-aryl-B” is a diradical whereas the aryl group in “A-B-aryl” is monoradical, though additional substituents may be present on each aryl group.

The term “alkylsulfinyl” refers to the group -S(O)-alkyl, where alkyl is as defined above, and includes optionally substituted alkyl groups as also defined above.

The term “alkylsulfonyl” refers to the group -S(O)₂-alkyl, where alkyl is as defined above, and includes optionally substituted alkyl groups as also defined above.

“Cycloalkyl” refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C₃₋₂₀ cycloalkyl), 3 to 12 ring carbon atoms (i.e., C₃₋₁₂ cycloalkyl), 3 to 10 ring carbon atoms (i.e., C₃₋₁₀ cycloalkyl), 3 to 8 ring carbon atoms (i.e., C₃₋₈ cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C₃₋₆ cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl,

cyclopentyl, and cyclohexyl. As used herein the term “cycloalkenyl” refers to the non-aromatic carbocyclic (partially saturated cyclic alkyl) group having at least one double bond.

“Cyanoalkyl” refers to an alkyl group substituted with cyano (CN).

“Halogen” or “halo” includes fluoro, chloro, bromo, and iodo.

5 The term “haloalkyl” refers to a monoradical or diradical having the indicated carbon atoms of the alkyl group wherein one or more (e.g., one to three, or one to five) hydrogen atoms have been substituted by a halogen. Examples of haloalkyl groups include -CH₂F, -CHF₂, -CF₃, -CH₂CF₃, -CHFCH₂F, -CF₂-, -CHF-, and the like. Similarly, the term “haloalkoxy”, e.g., -O-C₁₋₃haloalkyl, refers to an alkoxy group wherein one or more (e.g., one to three, or one to five) hydrogen atoms of the alkyl
10 group have been substituted by a halogen. Examples of haloalkoxy groups include -OCH₂F, -OCHF₂, -OCF₃, -OCH₂CF₃, -OCHFCH₂F, and the like. One of skill in the art is aware that similar definitions apply for the alkenyl and alkynyl analogs (e.g., C₂₋₄haloalkenyl, -O-C₂₋₄haloalkynyl).

 “Heteroalkyl” refers to an alkyl group in which one or more (e.g., one to three, or one to five) of
15 the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic groups. The term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NR-, -O-, -S-, -S(O)-, -S(O)₂-, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl,
20 heteroaryl, or heterocycloalkyl, each of which may be optionally substituted. Examples of heteroalkyl groups include -OCH₃, -CH₂OCH₃, -SCH₃, -CH₂SCH₃, -NRCH₃, and -CH₂NRCH₃, where R is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. As used herein, heteroalkyl includes 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.

 “Heteroaryl” refers to a monoradical or diradical aromatic group having a single ring, multiple
25 rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. The term includes fused ring systems wherein one or more (e.g., one, two, or three) fused rings is/are fully or partially unsaturated. As used herein, heteroaryl include 1 to 20 ring carbon atoms (i.e., C₁₋₂₀ heteroaryl), 3 to 12 ring carbon atoms (i.e., C₃₋₁₂ heteroaryl), or 3 to 8 carbon ring atoms
30 (i.e., C₃₋₈ heteroaryl); and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Non-limiting examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, benzodioxanyl, indolinyl, and pyrazolyl. The classification of mono or diradical indicates whether the heteroaryl group terminates the chain (monoradical) or is within a chain (diradical). The above definition
35 does not preclude additional substituents on the heteroaryl group. For example, the heteroaryl group in “A-heteroaryl-B” is a diradical whereas the heteroaryl group in “A-B-heteroaryl” is monoradical, though

additional substituents may be present on each heteroaryl group. Heteroaryl does not encompass or overlap with aryl as defined above.

“Heterocycloalkyl” refers to a saturated or unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. A heterocycloalkyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro. As used herein, heterocycloalkyl has 2 to 20 ring carbon atoms (i.e., C₂₋₂₀ heterocycloalkyl), 2 to 12 ring carbon atoms (i.e., C₂₋₁₂ heterocycloalkyl), 2 to 10 ring carbon atoms (i.e., C₂₋₁₀ heterocycloalkyl), 2 to 8 ring carbon atoms (i.e., C₂₋₈ heterocycloalkyl), 3 to 12 ring carbon atoms (i.e., C₃₋₁₂ heterocycloalkyl), 3 to 8 ring carbon atoms (i.e., C₃₋₈ heterocycloalkyl), or 3 to 6 ring carbon atoms (i.e., C₃₋₆ heterocycloalkyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen. Examples of heterocycloalkyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidyl, and morpholinyl. As used herein, the term “bridged-heterocycloalkyl” refers to a four- to ten-membered cyclic moiety connected at two non-adjacent atoms of the heterocycloalkyl with one or more (e.g., 1 or 2) four- to ten-membered cyclic moiety having at least one heteroatom where each heteroatom is independently selected from nitrogen, oxygen, and sulfur. As used herein, bridged-heterocycloalkyl includes bicyclic and tricyclic ring systems. Also used herein, the term “spiro-heterocycloalkyl” refers to a ring system in which a three- to ten-membered heterocycloalkyl has one or more additional ring, wherein the one or more additional ring is three- to ten-membered cycloalkyl or three- to ten-membered heterocycloalkyl, where a single atom of the one or more additional ring is also an atom of the three- to ten-membered heterocycloalkyl. Examples of spiro-heterocycloalkyl include bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl.

The term “heterocyclyl,” “heterocycle,” or “heterocyclic” refers to a monoradical or diradical saturated or unsaturated group having a single ring or multiple condensed rings, having from 3 to 12 carbon atoms, from 1 to 6 hetero atoms, or from 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring. Where the group does not terminate the molecule, it is a diradical and is construed as such i.e., also referred to as heterocyclylene or heterocyclene.

The term “heterocyclyl” includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond), bridged-heterocyclyl groups, fused-heterocyclyl groups, and spiro-heterocyclyl groups. A heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro. Any non-aromatic ring containing at least one heteroatom is considered a heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom). Further, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to an aryl or heteroaryl ring, regardless of the attachment to the remainder of the molecule. A heterocyclyl may contain one or more (e.g., one or two) oxo and/or thioxo groups.

Exemplary heterocyclic groups include, but are not limited to, 2,5-diazaspiro[3.4]octan-6-one (e.g., compound 1), azetidine (e.g., compound 2), 2,6-diazaspiro[3.3]heptane (e.g., compound 4),

pyrrolidin-2-one (e.g., compound 6), tetrahydrofuran (e.g., compound 11), pyrrolidine (e.g., compound 17), piperidin-2-one (e.g., compound 36), piperazin-2-one (e.g., compound 41), 5-oxa-2,7-diazaspiro[3.4]octan-6-one (e.g., compound 50), 3-azabicyclo[3.1.0]hexane (e.g., compound 52), 2-azabicyclo[2.1.1]hexane (e.g., compound 53), tetrahydro-2H-pyran (e.g., compound 55), 2,6-diazaspiro[3.4]octan-7-one (e.g., compound 61), 4,5-dihydro-1H-imidazole (e.g., compound 114), 1,4,5,6-tetrahydropyrimidine (e.g., compound 119), piperidine (e.g., compound 158), 1,2,4-oxadiazol-5(2H)-one (e.g., compound 161), 2,5,7-triazaspiro[3.4]octan-6-one (e.g., compound 168), 2,7-diazaspiro[4.4]nonan-3-one (e.g., compound 193), 1,7-diazaspiro[4.4]nonan-2-one (e.g., compound 197), 2-azaspiro[4.4]nonan-3-one (e.g., compound 202), 1,8-diazaspiro[4.5]decan-2-one (e.g., compound 203), 2-azaspiro[3.3]heptane (e.g., compound 208), oxazolidin-2-one (e.g., compound 210), octahydrocyclopenta[b]pyrrole (e.g., compound 216), octahydrocyclopenta[c]pyrrole (e.g., compound 230), 2-oxa-7-azaspiro[4.4]nonan-1-one (e.g., compound 232), 6-oxa-2-azaspiro[3.4]octane (e.g., compound 234), piperazine (e.g., compound 250), 1,1-dioxotetrahydrothiophene (e.g., compound 286), hexahydropyrrolo[3,4-b]pyrrol-6(1H)-one (e.g., compound 287), 1,3,8-triazaspiro[4.5]decane-2,4-dione (e.g., compound 290), 2-methyl-1,3,7-triazaspiro[4.5]dec-2-en-4-one (e.g., compound 291), 1,3,7-triazaspiro[4.4]nonane-2,4-dione (e.g., compound 292), 1,3,7-triazaspiro[4.5]decane-2,4-dione (e.g., compound 293), 6-azaspiro[3.4]octane (e.g., compound 298), 1-thia-6-azaspiro[3.3]heptane 1,1-dioxide (e.g., compound 301), pyridin-2(1H)-one (e.g., compound 305), isothiazolidine 1,1-dioxide (e.g., compound 306), thietane 1,1-dioxide (e.g., compound 311), hexahydropyrrolo[3,4-b]pyrrol-2(1H)-one (e.g., compound 312), 2,5,7-triazaspiro[3.4]octane-6,8-dione (e.g., compound 313), 3-azabicyclo[3.1.0]hexan-2-one (e.g., compound 324), 5-azaspiro[2.4]heptan-4-one (e.g., compound 331), oxetane (e.g., compound 333), morpholine (e.g., compound 351), 2-thiaspiro[3.3]heptane 2,2-dioxide (e.g., compound 363), hexahydrocyclopenta[b]pyrrol-2(1H)-one (e.g., compound 388), pyrrolidine-2,5-dione (e.g., compound 403), 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine (e.g., compound 414), and 1,3-dioxolane (e.g., compound 433).

“Acyl” refers to a group -C(=O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

The term “N-alkylated” means an alkyl group is substituted for one of the hydrogen atoms of a mono substituted amine, or a di-substituted amine group or a tri substituted amine group. When the alkylation is on a tri-substituted amine group an alkonium salt is generated i.e., a positive charge is generated on the nitrogen atom. N-alkylation is commonly associated with alkyl substitution on a ring nitrogen atom.

The term “cyano” refers to the group -CN.

The term “oxo” refers to a group =O.

The term “carboxy” refers to a group -C(O)OH.

The term “ester” or “carboxyl ester” refers to the group $-C(O)OR$, where R is alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, which may be optionally further substituted, for example, by alkyl, alkoxy, halogen, CF_3 , amino, substituted amino, cyano or $-S(O)_yR^z$, in which R^z is alkyl, aryl, or heteroaryl, and y is 0, 1 or 2.

5 The term “substituted amino” refers to the group $-NRR$, where each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which may be optionally substituted, or a group as described or exemplified herein, or where both R groups are joined to form a heterocyclic group (e.g., morpholino) as described or exemplified herein, which also may be optionally substituted.

10 The term “amido” refers to the group $-C(O)NRR$ where each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which may be optionally substituted, or a group as described or exemplified herein, or where both R groups are joined to form a heterocyclic group (e.g., morpholino) as described or exemplified herein, which also may be optionally substituted.

15 The term “sulfoxide” refers to a group $-S(O)R$, in which R is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which may be optionally substituted.

 The term “sulfone” refers to a group $-S(O)_2R$, in which R is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which may be optionally substituted.

 As used herein, the terms “alkylcycloalkyl,” “alkylaryl,” “alkylheteroaryl” and “alkylheterocyclyl” are intended to refer to a cycloalkyl, aryl, heteroaryl or heterocyclyl group which is
20 bound to the remainder of the molecule via an alkyl moiety, where the terms “alkyl,” “cycloalkyl,” “aryl,” “heteroaryl” and “heterocyclyl” are as defined herein. Exemplary alkylaryl groups include benzyl, phenethyl, and the like.

 “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and
25 instances in which it does not.

 Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group, an “arylene” group or an “arylenyl” group, respectively. Also, unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, e.g.,
30 arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.

 Where a group is represented by a bond, multiple adjacent groups whether the same or different, when represented by bonds, constitute a single bond. For example the group “ $-L^1-V^1-L^2-$ ” constitutes a single bond if each of L^1 , V^1 and L^2 is a bond.

Where a given group (moiety) is described herein as being attached to a second group and the site of attachment is not explicit, the given group may be attached at any available site of the given group or to any available site of the second group. For example, an “alkyl-substituted phenyl”, where the attachment sites are not explicit, may have any available site of the alkyl group attached to any available site of the phenyl group. In this regard, an “available site” is a site of the group at which hydrogen of the group may be replaced with a substituent.

“Isomers” are different compounds that have the same molecular formula. Isomers include stereoisomers, enantiomers and diastereomers.

“Stereoisomers” are isomers that differ only in the way the atoms are arranged in space.

“Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term “(±)” is used to designate a racemic mixture where appropriate.

“Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.

The compounds of the disclosure may possess one or more asymmetric centers and may be produced as a racemic mixture or as individual enantiomers or diastereoisomers. The number of stereoisomers present in any given compound of a given formula depends upon the number of asymmetric centers present (there are 2^n stereoisomers possible where n is the number of asymmetric centers). The individual stereoisomers may be obtained by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis or by resolution of the compound by conventional means. The individual stereoisomers (including individual enantiomers and diastereoisomers) as well as racemic and non-racemic mixture of stereoisomers are encompassed within the scope of the present disclosure, all of which are intended to be depicted by the structures of this specification unless otherwise specifically indicated.

The absolute stereochemistry is specified according to the Cahn Ingold Prelog R S system. When the compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. A resolved compound whose absolute configuration is unknown may be designated (+) or (-) depending on the direction (dextro- or laevorotary) that it rotates the plane of polarized light at the wavelength of the sodium D line.

Some of the compounds exist as tautomeric isomers. Tautomeric isomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.

The term “solvate” refers to a complex formed by combining a compound of formula (I), or any other formula as disclosed herein and a solvent.

The term “hydrate” refers to the complex formed by the combining of a compound of formula (I), or any formula disclosed herein, and water.

5 The term “prodrug” refers to compounds of formula (I), or derivatives of formula (I) disclosed herein, that include chemical groups which, *in vivo*, can be converted and/or can be split off from the remainder of the molecule to provide for the active drug. Pharmaceutically acceptable salts or biologically active metabolites thereof of the prodrug of a compound of formula (I) are also within the ambit of the present disclosure.

10 Any formula or structure given herein, including formula (I), or any formula disclosed herein, is intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more (e.g., one to three, or one to five) atoms are replaced by an isotope having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of
15 the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to ^2H (deuterium, D), ^3H (tritium), ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}F , ^{31}P , ^{32}P , ^{35}S , ^{36}Cl , and ^{125}I . Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as ^3H , ^{13}C and ^{14}C are incorporated, are within the ambit of the present disclosure. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic
20 studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in treatment of patients. Such isotopically labeled analogs of compounds of the present disclosure may also be useful for treatment of diseases disclosed herein because they may provide improved pharmacokinetic and/or pharmacodynamic properties over the unlabeled forms of the same compounds. Such isotopically
25 leveled forms of or analogs of compounds herein are within the ambit of the present disclosure. One of skill in the art is able to prepare and use such isotopically labeled forms following procedures for isotopically labeling compounds or aspects of compounds to arrive at isotopic or radiolabeled analogs of compounds disclosed herein.

The term “pharmaceutically acceptable salt” of a given compound refers to salts that retain the
30 biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl
35 amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl)

amines, substituted cycloalkyl amines, di-substituted cycloalkyl amine, tri-substituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, di-substituted cycloalkenyl amine, tri-substituted cycloalkenyl amines, aryl amines, diaryl amines, triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroaryl amines, heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amines where at least two of the substituents on the amine are different and are selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group. Amines are of general structure $N(R^{30})(R^{31})(R^{32})$, wherein mono-substituted amines have two of the three substituents on nitrogen (R^{30} , R^{31} , and R^{32}) as hydrogen, di-substituted amines have one of the three substituents on nitrogen (R^{30} , R^{31} , and R^{32}) as hydrogen, whereas tri-substituted amines have none of the three substituents on nitrogen (R^{30} , R^{31} , and R^{32}) as hydrogen. R^{30} , R^{31} , and R^{32} are selected from a variety of substituents such as hydrogen, optionally substituted alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, and the like.

Specific examples of suitable amines include, by way of example only, isopropyl amine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, diethanolamine, 2-dimethylamino ethanol, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.

As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial, and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, or unless otherwise indicated herein, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

The term “anticancer agent” is any drug that is effective in the treatment of a malignant, or cancerous disease. Effectiveness may mean inhibition, partial, or full remission, prolongation of life, improvement in quality of life, or cure. There are several major classes of anticancer drugs including chemical compositions as disclosed herein or known to one of skill in the art e.g., PD-1, PD-L1, PD-1/PD-L1 interaction inhibitors, alkylating agents, antimetabolites, natural products, and hormones.

The term “additional anticancer agent” as used herein means the use or combination of a second, third, fourth, fifth, etc., anticancer agent(s) in addition to a compound according to formula (I) disclosed herein.

5 The term “anticancer therapy” means any currently known therapeutic methods for the treatment of cancer.

The term “blockade agent” or “check point inhibitors” are classes of immune oncology agents that inhibit PD-1, PD-L1, or the PD-1/PD-L1 interaction.

10 The term “treatment” or “treating” means any administration of a compound or compounds according to the present disclosure to a subject (e.g., a human) having or susceptible to a condition or disease disclosed herein for the purpose of: 1) preventing or protecting against the disease or condition, that is, causing the clinical symptoms not to develop; 2) inhibiting the disease or condition, that is, arresting or suppressing the development of clinical symptoms; or 3) relieving the disease or condition that is causing the regression of clinical symptoms. In some embodiments, the term “treatment” or “treating” refers to relieving the disease or condition or causing the regression of clinical symptoms.

15 As used herein, the term “preventing” refers to the prophylactic treatment of a patient in need thereof. The prophylactic treatment can be accomplished by providing an appropriate dose of a therapeutic agent to a subject at risk of suffering from an ailment, thereby substantially averting onset of the ailment. The presence of a genetic mutation or the predisposition to having a mutation may not be alterable. However, prophylactic treatment (prevention) as used herein has the potential to
20 avoid/ameliorate the symptoms or clinical consequences of having the disease engendered by such genetic mutation or predisposition.

It will be understood by those of ordinary skill in the art that in human medicine, it is not always possible to distinguish between “preventing” and “suppressing” since the ultimate inductive event or events may be unknown, latent, or the patient is not ascertained until well after the occurrence of the
25 event or events. Therefore, as used herein, the term “prophylaxis” is intended as an element of “treatment” to encompass both “preventing” and “suppressing” as defined herein. The term “protection,” as used herein, is meant to include “prophylaxis.”


30 The term “patient” typically refers to a “mammal” which includes, without limitation, human, monkeys, rabbits, mice, domestic animals, such as dogs and cats, farm animals, such as cows, horses, or pigs, and laboratory animals. In some embodiments, the term patient refers to a human in need of treatment as defined herein.

Compounds

35 Provided herein are compounds that function as PD-1 inhibitors, PD-L1 inhibitors, and/or PD-1/PD-L1 interaction inhibitors, methods of using such compounds and compositions comprising such compounds optionally in combination with one or more additional anticancer agents or therapies. In all

embodiments discussed herein where there is more than one occurrence of a group or variable, it is intended that the group or variable is independently selected the list that follows. It is further contemplated that all embodiments directed to compounds include any pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, solvate, prodrug or tautomer thereof.

5 In one embodiment, provided is a compound of formula (I):



wherein:

each n is independently 0, 1, 2, 3 or 4;

each Z¹ is independently halo, -OR^a, -NO₂, -CN, -NR^aR^b, -N₃, -S(O)₂R^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl,
10 -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl or -C₁₋₆ alkylC₃₋₈ cycloalkyl;

wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, -N₃, -OR^a, halo, and cyano;

Q is aryl, heteroaryl or heterocyclyl, wherein the aryl, heteroaryl and heterocyclyl group is optionally
15 substituted with 1 to 4 groups independently selected from the group consisting of halo, oxo, -OR^a, -SR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R², -O-C(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;


20 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl; and wherein the heteroaryl or heterocyclyl group
25 may be oxidized on a nitrogen atom to form an N-oxide or oxidized on a sulfur atom to form a sulfoxide or sulfone;

m is 0, 1 or 2;

each Z³ is independently halo, oxo, -OR^a, SR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R²,
30 -O-C(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b,
 5 -C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl;

each R^N is independently -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆ alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)OR¹, -S-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOR^a, or



10 wherein

L¹ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

V is independently selected from the group consisting of a bond, C₁₋₆alkyl, C₂₋₆alkenyl, and C₂₋₆alkynyl;

15 wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;


L² is independently a bond, O, NR^a, S, S(O), or S(O)₂;

ring A is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

20 wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ haloalkyl, NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, -NR^aC(O)R^a, -NR^aC(O)OR^a, -NR^aC(O)OR^a, -C(O)N(R^a)OR^b, -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, C₃₋₈cycloalkyl and C₁₋₆alkylC₃₋₈ cycloalkyl;

25 wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;

30 R^E and R^W are each independently -NR¹R², -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylN⁺R¹R²R³, -S-C₁₋₆ alkylNR¹R², -C(O)NR¹R², -S(O)₂R^a, -(CH₂)_uS(O)₂NR¹R², -(CH₂)_uNR^aS(O)₂NR^aR^b, -S(O)₂NR^aC₁₋₆ alkylNR¹R², -NR^aS(O)₂C₁₋₆ alkylNR¹R², -(CH₂)_uC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_uN⁺R¹R²O⁻, -(CH₂)_uP⁺R^bR^cR^d, -(CH₂)_uP⁺R^cR^dO⁻, -(CH₂)_uP⁺O[NR^aR^b][NR^cR^d], -(CH₂)_uNR^cP(O)(OR^c)₂, -(CH₂)_uCH₂OP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)NR^aR^b(OR^a), or



wherein:

V^2 is independently a bond, O, NR^a , S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

5 L^3 is independently a bond, O, NR^a , S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

ring B is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^c or (CH₂)_qC(O)R^c;

p is independently 0, 1, 2, 3, 4, or 5;

10 q is independently 0, 1, 2, 3, 4, or 5;

u is 0, 1, 2, 3 or 4;

z is 0, 1, 2 or 3; and

wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group of R^E and R^W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b,

15 halo, cyano, oxo, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, -C₃₋₈ cycloalkyl and -C₁₋₃ alkylC₃₋₈cycloalkyl;

provided that at least one of V^2 , L^3 , ring B and T contains a nitrogen atom;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl,

-C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl,

20 -C₁₋₆ alkylheterocyclyl, -C₁₋₆ alkylC(O)OR^a, -C₂₋₆ alkenylC(O)OR^a, -S(O)₂R^a, -S(O)₂OR^a,

-S(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^a, and C₁₋₆ alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN,

-NO₂, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl,

25 heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a,

-C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -OC(O)NR^aR^b, -NR^aC(O)OR^b, -NR^aC(O)R^b, -C₁₋₆ alkylNR^aR^b,

-C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -S(O)₂OR^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b,

-C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b, -NR^aC(O)NR^b, -C₁₋₆ alkylC(O)NR^aS(O)₂R^b,

-NR^aC(O)R^b, and -C₁₋₆alkylNR^aC(O)R^b;

30 each R² is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl,

-C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl,

-C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkyl-OR^a, -C₁₋₆ alkylC(O)OR^a, and -C₂₋₆ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b,
 5 -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆alkylS(O)₂R^a,
 -S(O)₂NR^aR^b, -C₁₋₆alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b and -NR^aC(O)R^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1

10 to 3 groups independently selected from the group consisting of oxo, -C₁₋₆alkyl, -C₃₋₈cycloalkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, aryl, heteroaryl, heterocyclyl, -OR^a, -CN, halo, -C(O)OR^a, -C₁₋₆cyanoalkyl, -C₁₋₆alkylOR^a, -C₁₋₆haloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -NR^aC(O)OR^b, -NR^aC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -NR^aS(O)₂R^b, -C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆alkylS(O)₂R^a, -S(O)₂NR^aR^b, and C₁₋₆alkylS(O)₂NR^aR^b;

15 each R³ is independently H, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₃₋₆cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, -C₁₋₆alkylheterocyclyl, -C₂₋₆alkyl-OR^a, -C₁₋₆alkylC(O)OR^a, or -C₂₋₆alkenylC(O)OR^a;

each R^a is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl,
 20 and -C₁₋₆alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, and -C₁₋₆alkylheterocyclyl;

or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S;

25 wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆alkylOR^f, -C₁₋₆cyanoalkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆alkylC(O)R^f, -C(O)OR^f, -C₁₋₆alkylC(O)OR^f, -NR^fR^g, -C₁₋₆alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆alkylS(O)₂R^f, -S(O)₂NR^fR^g, -C₁₋₆alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

30 each R^c is independently selected from the group consisting of H, OH, -C₁₋₆alkyl, -C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, and -C₁₋₆alkylheterocyclyl; and

each R^d is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, and
 35 -C₁₋₆alkylheterocyclyl;

each R^e is independently selected from the group consisting of H, -C₁₋₆ alkyl, -O-C₁₋₆alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C₃₋₈ cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆alkylheteroaryl, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆ alkylC(O)NR^fR^g, -NHS(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, and -C₁₋₆ alkylS(O)₂NR^fR^g;


- 5 each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆

- 10 alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

The present disclosure provides further a compound of formula (I):



wherein:

- 15 each n is independently 0, 1, 2, 3 or 4;

each Z¹ is independently halo, -OR^a, -NO₂, -CN, -NR^aR^b, -N₃, -S(O)₂R^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl or -C₁₋₆ alkylC₃₋₈ cycloalkyl;

wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, -N₃, -OR^a, halo, and cyano;

- 20 Q is aryl, heteroaryl or heterocyclyl, wherein the aryl, heteroaryl and heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of halo, oxo, -OR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R², -OC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b,
 25 -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b,

- 30


-C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl; and wherein the heteroaryl or heterocyclyl group may be oxidized on a nitrogen atom to form an N-oxide or oxidized on a sulfur atom to form a sulfoxide or sulfone;

m is 0, 1 or 2;

- 5 each Z³ is independently halo, oxo, -OR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R², -OC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;

- 10 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl;

- 15 each R^N is independently -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆ alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)OR¹, -S-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOR^a, or



wherein

L¹ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

- 20 V is independently selected from the group consisting of a bond, C₁₋₆alkyl, C₂₋₆alkenyl, and C₂₋₆alkynyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;


L² is independently a bond, O, NR^a, S, S(O), or S(O)₂;

- 25 ring A is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

- 30 wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -O-C₁₋₆ haloalkyl, NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, -NR^aC(O)R^a, -NR^aC(O)OR^a, -NR^aC(O)OR^a, -C(O)N(R^a)OR^b, -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, C₃₋₈cycloalkyl and C₁₋₆alkylC₃₋₈ cycloalkyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;

R^E and R^W are each independently -NR¹R², -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylN⁺R¹R²R³, -S-C₁₋₆ alkylNR¹R², -C(O)NR¹R², -S(O)₂R^a, -(CH₂)_uS(O)₂NR¹R², -(CH₂)_uNR^aS(O)₂NR^aR^b, -S(O)₂NR^aC₁₋₆ alkylNR¹R², -NR^aS(O)₂C₁₋₆ alkylNR¹R², -(CH₂)_uC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_uN⁺R¹R²O⁻, -(CH₂)_uP⁺R^bR^cR^d, -(CH₂)_uP⁺R^cR^dO⁻, -(CH₂)_uP⁺O[NR^aR^b][NR^cR^d], -(CH₂)_uNR^cP(O)(OR^c)₂, -(CH₂)_uCH₂OP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)NR^aR^b(OR^a), or



10 wherein:

V² is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

L³ is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

15 ring B is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^e or (CH₂)_qC(O)R^e;

p is independently 0, 1, 2, 3, 4, or 5;

q is independently 0, 1, 2, 3, 4, or 5;

u is 0, 1, 2, 3 or 4;

20 z is 0, 1, 2 or 3; and

wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl of R^E or R^W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b, halo, cyano, oxo, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, -C₃₋₈ cycloalkyl and -C₁₋₃ alkylC₃₋₈cycloalkyl;

25 provided that at least one of V², L³, ring B and T contains a nitrogen atom;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₁₋₆ alkylC(O)OR^a, -C₂₋₆ alkenylC(O)OR^a, -S(O)₂R^a, -S(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^a, and C₁₋₆ alkylC₃₋₈cycloalkyl;

30 wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl,

-C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b,
 -OC(O)NR^aR^b, NR^aC(O)OR^b, -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a,
 -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b,
 -C₁₋₆ alkylC(O)NR^aS(O)₂R^b, -NR^aC(O)R^b, and -C₁₋₆alkylNR^aC(O)R^b;

- 5 each R² is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkyl-OR^a, -C₁₋₆ alkylC(O)OR^a, and -C₂₋₆ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN,
 10 halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b and -NR^aC(O)R^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional
 15 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -OR^a, -C(O)OR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ haloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, C₁₋₆ alkylC(O)R^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, and
 20 C₁₋₆ alkylS(O)₂NR^aR^b;

each R³ is independently H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkyl-OR^a, -C₁₋₆ alkylC(O)OR^a, or -C₂₋₆ alkenylC(O)OR^a;

each R^a is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl,
 25 heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S;
 wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆ alkylOR^f, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆ alkylC(O)R^f, -C(O)OR^f, -C₁₋₆ alkylC(O)OR^f, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆ alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, -S(O)₂NR^fR^g,
 35 -C₁₋₆ alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

each R^e is independently selected from the group consisting of H, OH, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

5 each R^d is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;


10 each R^e is independently selected from the group consisting of H, -C₁₋₆ alkyl, -O-C₁₋₆alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C₃₋₈ cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆alkylheteroaryl, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆ alkylC(O)NR^fR^g, -NHS(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, and -C₁₋₆ alkylS(O)₂NR^fR^g;

each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

15 each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

In certain embodiments, provided is a compound of Formula (I):



20 wherein:

each n is independently 0, 1, 2, 3 or 4;

each Z¹ is independently halo, -OR^a, -NO₂, -CN, -NR^aR^b, -N₃, -S(O)₂R^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, monocyclic -C₃₋₈ cycloalkyl or monocyclic -C₁₋₆ alkylC₃₋₈ cycloalkyl;

25 wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, -N₃, -OR^a, halo, and cyano;

Q is monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl, wherein each

30 Q is monocyclic group is optionally substituted with 1 to 4 groups independently selected from the group consisting of halo, oxo, -OR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a,

-NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R², -OC(O)NR^aR^b,
 -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl,
 monocyclic -C₃₋₈ cycloalkyl, monocyclic -C₁₋₆ alkylC₃₋₈ cycloalkyl, monocyclic aryl, and R^N;

5 wherein the alkyl, alkenyl, alkynyl, monocyclic C₃₋₈ cycloalkyl, or monocyclic aryl group is
 optionally substituted with 1 to 4 groups independently selected from the group consisting of
 oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b,
 NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b,
 -C(O)NR^aS(O)₂NR^aR^b and monocyclic -C₃₋₈ cycloalkyl; and wherein the monocyclic heteroaryl
 or monocyclic heterocyclyl group may be oxidized on a nitrogen atom to form an N-oxide or
 10 oxidized on a sulfur atom to form a sulfoxide or sulfone;

m is 0, 1 or 2;

each Z³ is independently halo, oxo, -OR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b,
 -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R²,
 -OC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl,
 15 -O-C₁₋₆ alkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic -C₁₋₆ alkylC₃₋₈ cycloalkyl, monocyclic aryl,
 and R^N;

wherein the alkyl, alkenyl, alkynyl, monocyclic C₃₋₈ cycloalkyl, or monocyclic aryl group is
 optionally substituted with 1 to 4 groups independently selected from the group consisting of
 oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b,
 20 NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b,
 -C(O)NR^aS(O)₂NR^aR^b and monocyclic -C₃₋₈ cycloalkyl;

each R^N is independently -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆ alkylNR¹R²,
 -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)OR¹,
 -S-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOR^a, or

25
$$L^1 - V - L^2 - \textcircled{A};$$

wherein

L¹ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

V is independently selected from the group consisting of a bond, C₁₋₆alkyl, C₂₋₆alkenyl,
 and C₂₋₆alkynyl;

30 wherein the alkyl, alkenyl or alkynyl group is optionally independently
 substituted with -OR^a, halo, cyano, NR^aR^b and monocyclic -C₃₋₈ cycloalkyl;

L² is independently a bond, O, NR^a, S, S(O), or S(O)₂;

ring A is independently monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl;

5 wherein the monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl, or monocyclic heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ haloalkyl, NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, -NR^aC(O)R^a, -NR^aC(O)OR^a, -NR^aC(O)OR^a, -C(O)N(R^a)OR^b, -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, monocyclic C₃₋ 10 s-cycloalkyl and monocyclic C₁₋₆alkylC₃₋₈ cycloalkyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and monocyclic -C₃₋₈ cycloalkyl;

R^E and R^W are each independently -NR¹R², -C₁₋₆ alkylINR¹R², -O-C₁₋₆ alkylINR¹R², 15 -C₁₋₆ alkylOC₁₋₆alkylINR¹R², -NR^a-C₁₋₆ alkylINR¹R², -C₁₋₆ alkylIN⁺R¹R²R³, -S-C₁₋₆ alkylINR¹R², -C(O)NR¹R², -S(O)₂R^a, -(CH₂)_uS(O)₂NR¹R², -(CH₂)_uNR^aS(O)₂NR^aR^b, -S(O)₂NR^aC₁₋₆ alkylINR¹R², -NR^aS(O)₂C₁₋₆ alkylINR¹R², -(CH₂)_uC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_uN⁺R¹R²O⁻, -(CH₂)_uP⁺R^bR^cR^d, -(CH₂)_uP⁺R^cR^dO⁻, -(CH₂)_uP⁺O[NR^aR^b][NR^cR^d], -(CH₂)_uNR^cP(O)(OR^c)₂, -(CH₂)_uCH₂OP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)NR^aR^b(OR^a), or

20
$$-V^2-(CR^cR^d)_p-L^3-\textcircled{B}-\text{---}(T)_z$$
 ;

wherein:

V² is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

25 L³ is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

ring B is independently monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl or spirocyclic heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^e or (CH₂)_qC(O)R^e;

p is independently 0, 1, 2, 3, 4, or 5;

30 q is independently 0, 1, 2, 3, 4, or 5;

u is 0, 1, 2, 3 or 4;

z is 0, 1, 2 or 3; and

wherein the alkyl, monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl or spirocyclic heterocyclyl of R^E or R^W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b, halo, cyano, oxo, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, monocyclic

5

-C₃₋₈ cycloalkyl and monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl;

provided that at least one of V², L³, ring B and T contains a nitrogen atom;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, monocyclic -C₃₋₆ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆ alkylheteroaryl, monocyclic -C₁₋₆ alkylheterocyclyl,

10

-C₁₋₆ alkylC(O)OR^a, -C₂₋₆ alkenylC(O)OR^a, -S(O)₂R^a, -S(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^a, and monocyclic C₁₋₆ alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆

15

cyanoalkyl, -C₁₋₆ haloalkyl, monocyclic C₃₋₈ cycloalkyl, monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -OC(O)NR^aR^b, NR^aC(O)OR^b, -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b, -C₁₋₆ alkylC(O)NR^aS(O)₂R^b, -NR^aC(O)R^b, and -C₁₋₆alkylNR^aC(O)R^b;

20

each R² is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, monocyclic -C₃₋₆ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆ alkylheteroaryl, monocyclic -C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkyl-OR^a, -C₁₋₆ alkylC(O)OR^a, and -C₂₋₆ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆

25

cyanoalkyl, -C₁₋₆ haloalkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b and -NR^aC(O)R^b;

30

or R¹ and R², when bound to the same atom, may combine with the atom to which they are attached to form a monocyclic heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, -C₁₋₆ alkyl, monocyclic -C₃₋₈ cycloalkyl,

35

-C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -OR^a, -C(O)OR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ haloalkyl, monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, C₁₋₆ alkylC(O)R^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b,

$-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, $-C_{1-6}$ alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, and C_{1-6} alkylS(O)₂NR^aR^b;

each R³ is independently H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, monocyclic $-C_{3-6}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, monocyclic $-C_{1-6}$ alkylheterocyclyl, $-C_{2-6}$ alkyl-OR^a, $-C_{1-6}$ alkylC(O)OR^a, or $-C_{2-6}$ alkenylC(O)OR^a;

each R^a is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, and monocyclic $-C_{1-6}$ alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, and monocyclic $-C_{1-6}$ alkylheterocyclyl;

or R^a and R^b, when bound to the same atom, may combine together to form a monocyclic ring consisting of 3-8 ring atoms that are C, N, O, or S; wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of $-OR^f$, $-CN$, halo, $-C_{1-6}$ alkylOR^f, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^f$, $-C_{1-6}$ alkylC(O)R^f, $-C(O)OR^f$, $-C_{1-6}$ alkylC(O)OR^f, $-NR^fR^g$, $-C_{1-6}$ alkylNR^fR^g, $-C(O)NR^fR^g$, C_{1-6} alkylC(O)NR^fR^g, $-S(O)_2R^f$, $-C_{1-6}$ alkylS(O)₂R^f, $-S(O)_2NR^fR^g$, $-C_{1-6}$ alkylS(O)₂NR^fR^g, $-C(O)NR^fS(O)_2R^g$ and $-NR^fC(O)R^g$;

each R^c is independently selected from the group consisting of H, OH, $-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, and monocyclic $-C_{1-6}$ alkylheterocyclyl;

each R^d is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, and monocyclic $-C_{1-6}$ alkylheterocyclyl;


each R^e is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-O-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-O-C_{3-8}$ cycloalkyl, monocyclic $-O$ -aryl, monocyclic $-O$ -heteroaryl, monocyclic $-O$ -heterocyclyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, $-NR^fR^g$, $-C_{1-6}$ alkylNR^fR^g, $-C(O)NR^fR^g$, $-C_{1-6}$ alkylC(O)NR^fR^g, $-NHS(O)_2R^f$, $-C_{1-6}$ alkylS(O)₂R^f, and $-C_{1-6}$ alkylS(O)₂NR^fR^g;

each R^f is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-C_{1-3}$ alkyl C_{3-8} cycloalkyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, and monocyclic $-C_{1-6}$ alkylheterocyclyl;

- 5 each R^g is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-C_{1-3}$ alkyl C_{3-8} cycloalkyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, and monocyclic $-C_{1-6}$ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

- 10 Also provided are compounds of Formula (Ia):




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

each X is independently CH, CZ^3 or N;

- 15 each m is independently 0, 1 or 2; and

Z^1 , Z^3 , R^E , R^W and n are as defined herein.

Also provided are compounds of Formula (Ib):




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

- 20

each m is independently 0, 1 or 2; and

Z^1 , Z^3 , R^E , R^W and n are as defined herein.


Also provided are compounds of Formula (Ic):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

- 5 each m is independently 0, 1 or 2; and
 Z^1 , Z^3 , R^E , R^W and n are as defined herein.


Also provided are compounds of Formula (Id):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

- 10 each m is independently 0, 1 or 2; and
 Z^1 , Z^3 , R^E , R^W and n are as defined herein.


Also provided are compounds of Formula (II):



- 15 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

Z^1 , Z^3 , R^E and R^W are as defined herein.

Also provided are compounds of formula (III):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

each X is independently CH, CZ³ or N;


5 each n is independently 0, 1, 2, 3 or 4;

each m is independently 0, 1 or 2;

each R⁵ is independently selected from the group consisting of NR^aR^b, halo, cyano, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, -C₃₋₈ cycloalkyl and -C₁₋₃ alkylC₃₋₈cycloalkyl; and

10 R¹, R², Z¹, Z³, R^E and R^W are as defined herein.

The present disclosure provides a compound of formula (III):



wherein:

each X is independently CH, CZ³ or N;

15 each n is independently 0, 1, 2, 3 or 4;

each Z¹ is independently halo, -OR^a, -NO₂, -CN, -NR^aR^b, -N₃, -S(O)₂R^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl or -C₁₋₆ alkylC₃₋₈ cycloalkyl;

wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, -N₃, -OR^a, halo, and cyano;

20


each m is independently 0, 1 or 2;

each Z³ is independently halo, oxo, -OR^a, SR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R²,

-O-C(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl,
-O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkylC₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is
optionally substituted with 1 to 4 groups independently selected from the group consisting of
5 oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b,
NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b,
-C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl;

each R^N is independently -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆ alkylNR¹R²,
-NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)OR¹,
10 -S-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOR^a, or



wherein

L¹ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

V is independently selected from the group consisting of a bond, C₁₋₆alkyl, C₂₋₆alkenyl,
15 and C₂₋₆alkynyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently
substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;

L² is independently a bond, O, NR^a, S, S(O), or S(O)₂;

ring A is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally
substituted with 1 to 4 groups independently selected from the group consisting
of oxo, -NO₂, N₃, -OR^a, halo, cyano, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl,
-C₂₋₆ alkynyl, -O-C₁₋₆ haloalkyl, NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN,
-C(O)NR^aR^b, -NR^aC(O)R^a, -NR^aC(O)OR^a, -NR^aC(O)OR^a, -C(O)N(R^a)OR^b,
25 -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b,
C₃₋₈cycloalkyl and C₁₋₆alkylC₃₋₈ cycloalkyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently
substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl,
30 -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl,
-C₁₋₆ alkylheterocyclyl, -C₁₋₆ alkylC(O)OR^a, -C₂₋₆ alkenylC(O)OR^a, -S(O)₂R^a, -S(O)₂OR^a,
-S(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^a, and C₁₋₆ alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, -NO₂, halo, C₁₋₆alkyl, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₆haloalkyl, C₃₋₈cycloalkyl, heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -OC(O)NR^aR^b, -NR^aC(O)OR^b, -NR^aC(O)R^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -S(O)₂OR^a, -C₁₋₆alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b, -NR^aC(O)NR^b, -C₁₋₆alkylC(O)NR^aS(O)₂R^b, -NR^aC(O)R^b, and -C₁₋₆alkylNR^aC(O)R^b;

each R² is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₆cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, -C₁₋₆alkylheterocyclyl, -C₂₋₆alkyl-OR^a, -C₁₋₆alkylC(O)OR^a, and -C₂₋₆alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b and -NR^aC(O)R^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, -C₁₋₆alkyl, -C₃₋₈cycloalkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, aryl, heteroaryl, heterocyclyl, -OR^a, -CN, halo, -C(O)OR^a, -C₁₋₆cyanoalkyl, -C₁₋₆alkylOR^a, -C₁₋₆haloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -NR^aC(O)OR^b, -NR^aC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -NR^aS(O)₂R^b, -C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆alkylS(O)₂R^a, -S(O)₂NR^aR^b, and C₁₋₆alkylS(O)₂NR^aR^b;

each R³ is independently H, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₃₋₆cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, -C₁₋₆alkylheterocyclyl, -C₂₋₆alkyl-OR^a, -C₁₋₆alkylC(O)OR^a, or -C₂₋₆alkenylC(O)OR^a;

each R⁵ is independently selected from the group consisting of NR^aR^b, halo, cyano, -OR^a, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -C₁₋₆cyanoalkyl, -C₁₋₆alkylNR^aR^b, -C₁₋₆alkylOH, -C₃₋₈cycloalkyl and -C₁₋₃alkylC₃₋₈cycloalkyl;

each R^a is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, and -C₁₋₆alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S;

- 5 wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆ alkylOR^f, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆ alkylC(O)R^f, -C(O)OR^f, -C₁₋₆ alkylC(O)OR^f, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆ alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, -S(O)₂NR^fR^g, -C₁₋₆ alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

- 10 each R^c is independently selected from the group consisting of H, OH, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;


each R^d is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and

- 15 -C₁₋₆ alkylheterocyclyl;

each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

- 20 each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.



- 25 wherein:

each X is independently CH, CZ³ or N;

each Z¹ is independently halo or -C₁₋₆ alkyl;

each n is independently 0, 1, 2, 3 or 4;

each Z³ is independently halo or -O-C₁₋₆ alkyl;

each m is independently 0, 1 or 2;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₁₋₆ alkylC(O)OR^a, -C₂₋₆ alkenylC(O)OR^a, -S(O)₂R^a, -S(O)₂NR^aR^b,
5 -C(O)NR^aS(O)₂R^a, and C₁₋₆ alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b,
10 -OC(O)NR^aR^b, NR^aC(O)OR^b, -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b, -C₁₋₆ alkylC(O)NR^aS(O)₂R^b, -NR^aC(O)R^b, and -C₁₋₆alkylNR^aC(O)R^b;

each R² is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl,
15 -C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkylOR^a, -C₁₋₆ alkylC(O)OR^a, and -C₂₋₆ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b,
20 -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b and -NR^aC(O)R^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl,
25 -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -OR^a, -C(O)OR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ haloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, C₁₋₆ alkylC(O)R^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, and C₁₋₆ alkylS(O)₂NR^aR^b;

each R⁵ is independently selected from the group consisting of NR^aR^b, halo, cyano, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, -C₃₋₈ cycloalkyl and
30 -C₁₋₃ alkylC₃₋₈cycloalkyl;

each R^a is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S;

- 5 wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆ alkylOR^f, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆ alkylC(O)R^f, -C(O)OR^f, -C₁₋₆ alkylC(O)OR^f, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆ alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, -S(O)₂NR^fR^g, -C₁₋₆ alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;


- 10 each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and

- 15 -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

The present disclosure provides a compound of formula (IIIa):



wherein:

- 20 each X is independently CH, CZ³ or N;

each Z¹ is independently halo or -C₁₋₆ alkyl;

each Z³ is independently halo or -O-C₁₋₆ alkyl;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl,

- 25 -C₁₋₆ alkylheterocyclyl, -C₁₋₆ alkylC(O)OR^a, -C₂₋₆ alkenylC(O)OR^a, -S(O)₂R^a, -S(O)₂OR^a, -S(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^a, and C₁₋₆ alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN,

- 30 -NO₂, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -OC(O)NR^aR^b, -NR^aC(O)OR^b, -NR^aC(O)R^b, -C₁₋₆ alkylNR^aR^b,

-C(O)NR^aR^b, -C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -S(O)₂OR^a, -C₁₋₆alkylS(O)₂R^a, -S(O)₂NR^aR^b,
 -C₁₋₆alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b, -NR^aC(O)NR^b, -C₁₋₆alkylC(O)NR^aS(O)₂R^b,
 -NR^aC(O)R^b, and -C₁₋₆alkylNR^aC(O)R^b;

each R² is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl,
 5 -C₃₋₆cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl,
 -C₁₋₆alkylheterocyclyl, -C₂₋₆alkylOR^a, -C₁₋₆alkylC(O)OR^a, and -C₂₋₆alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally
 substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN,
 halo, C₁₋₆alkyl, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl,
 10 -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b,
 -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆alkylS(O)₂R^a,
 -S(O)₂NR^aR^b, -C₁₋₆alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b and -NR^aC(O)R^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional
 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1
 15 to 3 groups independently selected from the group consisting of oxo, -C₁₋₆alkyl, -C₃₋₈cycloalkyl,
 -C₂₋₆alkenyl, -C₂₋₆alkynyl, aryl, heteroaryl, heterocyclyl, -OR^a, -CN, halo, -C(O)OR^a, -C₁₋₆cyanoalkyl,
 -C₁₋₆alkylOR^a, -C₁₋₆haloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a,
 -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -NR^aC(O)OR^b, -NR^aC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b,
 -NR^aS(O)₂R^b, -C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆alkylS(O)₂R^a, -S(O)₂NR^aR^b, and
 20 C₁₋₆alkylS(O)₂NR^aR^b;

each R^a is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -C₃₋₈
 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl,
 and -C₁₋₆alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₁₋₆haloalkyl, -C₃₋₈
 25 cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl,
 and -C₁₋₆alkylheterocyclyl;


or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S;
 wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group
 consisting of -OR^f, -CN, halo, -C₁₋₆alkylOR^f, -C₁₋₆cyanoalkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl,
 30 -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆alkylC(O)R^f, -C(O)OR^f, -C₁₋₆alkylC(O)OR^f, -NR^fR^g,
 -C₁₋₆alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆alkylS(O)₂R^f, -S(O)₂NR^fR^g,
 -C₁₋₆alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

each R^f is independently selected from the group consisting of H, -C₁₋₆alkyl, -C₃₋₈cycloalkyl, aryl,
 heteroaryl, heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, and -C₁₋₆
 35 alkylheterocyclyl;

each R² is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.


5 The present disclosure provides a compound of formula (IIIb):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

Z¹, Z³, R¹ and R² are as defined herein.


10 The present disclosure provides a compound of formula (IIIc):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

Z¹, Z³, R¹ and R² are as defined herein.

15 The present disclosure provides a compound of formula (III d):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

Z¹, Z³, R¹ and R² are as defined herein.



20 In one embodiment, Q is selected from the group consisting of phenyl, pyridinyl, indazolyl, and thienyl each optionally substituted with 1 to 2 groups independently selected from the group consisting of halo, -OR^a, N₃, NO₂, -CN, -NR^aR^b, -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)NR^aR^b, -C₁₋₆ alkyl, -O-C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -C₁₋₆alkylC₃₋₈ cycloalkyl.

25 In another embodiment, Q is selected from the group consisting of phenyl, pyridinyl and indanyl each optionally substituted with 1 to 3 groups independently selected from the group consisting of halo,


-OR^a, N₃, NO₂, -CN, -NR^aR^b, -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)NR^aR^b, -C₁₋₆ alkyl, -O-C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -C₁₋₆alkylC₃₋₈ cycloalkyl.

In one embodiment, Q is optionally substituted aryl. In one embodiment, Q is optionally substituted phenyl.

5 In one embodiment, Q is optionally substituted heteroaryl. In one embodiment, Q is optionally substituted monocyclic heteroaryl. In one embodiment, Q is an optionally substituted 5- or 6-membered heteroaryl. In one embodiment, Q is an optionally substituted 5-membered heteroaryl. In one embodiment, Q is an optionally substituted 6-membered heteroaryl. In one embodiment, Q is optionally substituted pyridyl. In one embodiment, Q is optionally substituted pyrazinyl.




15 In one embodiment, substituents on Q are independently selected from the group consisting of OH, halo, CN, -C₁₋₆ alkyl, -C₁₋₆haloalkyl -O-C₁₋₆ alkyl, -O-C₁₋₆haloalkyl, -S(O)₂C₁₋₆alkyl,



In one embodiment, Q is optionally substituted with 1 to 3 groups independently selected from the group consisting of OH, halo, CN, S(O)₂R^a, -C₁₋₆alkyl, and -O-C₁₋₆alkyl.

5 In one embodiment, Q is optionally substituted with 1 to 3 groups independently selected from the group consisting of OH, halo, CN, S(O)₂R^a, -C₁₋₆alkyl, and -O-C₁₋₆alkyl.

In one embodiment, R^E and R^W are each independently -NR¹R², -C₁₋₆alkylNR¹R², -O-C₁₋₆alkylNR¹R², -C₁₋₆alkylOC₁₋₆alkylNR¹R², -NR^a-C₁₋₆alkylNR¹R², -C₁₋₆alkylN⁺R¹R²R³, -S-C₁₋₆alkylNR¹R², -S(O)₂R^a, -(CH₂)_uS(O)₂NR¹R², -(CH₂)_uNR^aS(O)₂NR^aR^b, -S(O)₂NR^aC₁₋₆alkylNR¹R²,
 10 -NR^aS(O)₂C₁₋₆alkylNR¹R², -(CH₂)_uC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_uN⁺R¹R²O⁻, -(CH₂)_uP⁺R^bR^cR^d, -(CH₂)_uP⁺R^cR^dO⁻, -(CH₂)_uP⁺O[NR^aR^b][NR^cR^d], -(CH₂)_uNR^cP(O)(OR^c)₂, -(CH₂)_uCH₂OP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)NR^aR^b(OR^a), or



wherein:

15 V² is independently a bond, O, NR^a, S, S(O), S(O)₂, S(O)₂NR¹, or NR^aS(O)₂;

L³ is independently a bond, O, NR^a, S, S(O), S(O)₂, S(O)₂NR¹, or NR^aS(O)₂;

ring B is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^c or (CH₂)_qC(O)R^c;

p is independently 0, 1, 2, 3, 4, or 5;

20 q is independently 0, 1, 2, 3, 4, or 5;

u is 0, 1, 2, 3 or 4;

z is 0, 1, 2 or 3; and

wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl of R^E or R^W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b,

halo, cyano, oxo, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b,
-C₁₋₆ alkylOH, -C₃₋₈ cycloalkyl and -C₁₋₃ alkylC₃₋₈cycloalkyl;

provided that at least one of V², L³, ring B and T contains a nitrogen atom.

In one embodiment, R^E and R^W are independently selected from -NR¹R², -C₁₋₆ alkylNR¹R²,
5 -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylN⁺R¹R²R³,
-S-C₁₋₆ alkylNR¹R², -C(O)NR¹R², -S(O)₂R^a, -(CH₂)_nS(O)₂NR¹R², -(CH₂)_nNR^aS(O)₂NR^aR^b,
-S(O)₂NR^aC₁₋₆ alkylNR¹R², -NR^aS(O)₂C₁₋₆ alkylNR¹R², -(CH₂)_nC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_nN⁺R¹R²O⁻,
-(CH₂)_nP⁺R^bR^cR^d, -(CH₂)_nP⁺R^cR^dO⁻, -(CH₂)_nP⁺O[NR^aR^b][NR^cR^d], -(CH₂)_nNR^cP(O)(OR^c)₂,
-(CH₂)_nCH₂OP(O)(OR^c)(OR^d), -(CH₂)_nOP(O)(OR^c)(OR^d), and -(CH₂)_nOP(O)NR^aR^b(OR^a); wherein

10 each R¹ is independently selected from H, -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-
OR^a, or -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2
groups independently selected from -OR^a, -CN, halo, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl,
-C₁₋₃haloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b,
15 and -C₁₋₆alkylC(O)NR^aR^b;

each R² is independently selected from -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, heterocyclyl, -C₂₋₆ alkyl-OR^a,
and -C₁₋₆ alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2
groups independently selected from -OR^a, -CN, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl,
20 -C₁₋₃haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a,
-C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and C₁₋₆alkylC(O)NR^aR^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing an additional
heteroatom selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3
groups independently selected from oxo, -C₁₋₆alkyl, -OR^a, -C(O)OR^a, -C(O)R^a, C₁₋₆alkylC(O)R^a,
25 -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, and -C(O)NR^aR^b;

each R³ is independently H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl,
heterocyclyl,
-C₁₋₆ alkylaryl;

each R^a is independently H or -C₁₋₆ alkyl;

30 each R^b is independently H or -C₁₋₆ alkyl;

each R^c is independently selected from H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, and
-C₁₋₃ alkylC₃₋₈ cycloalkyl;

each R^d is independently selected from H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, and
-C₁₋₃ alkylC₃₋₈ cycloalkyl; and

each u is independently 0, 1, 2, or 3.

In one embodiment, R^E and R^W are independently selected from $-C(O)NR^1R^2$, $-S(O)_2R^a$, $-(CH_2)_uS(O)_2NR^1R^2$, $-(CH_2)_uNR^aS(O)_2NR^aR^b$, $-S(O)_2NR^aC_{1-6}alkylNR^1R^2$, $-NR^aS(O)_2C_{1-6}alkylNR^1R^2$, and $-(CH_2)_uC(O)NR^aS(O)_2NR^aR^b$; wherein

5 each R^1 is independently selected from H, $-C_{1-6}alkyl$, $-C_{3-6}cycloalkyl$, heterocyclyl, $-C_{2-6}alkyl-OR^a$, or $-C_{1-6}alkylC(O)OR^a$;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from $-OR^a$, $-CN$, halo, $-C_{1-6}alkylOR^a$, $-C_{1-6}cyanoalkyl$, $-C_{1-3}haloalkyl$, $-C(O)R^a$, $-C_{1-6}alkylC(O)R^a$, $-C(O)OR^a$, $-C_{1-6}alkylC(O)OR^a$, $-C(O)NR^aR^b$, and $-C_{1-6}alkylC(O)NR^aR^b$;

10

each R^2 is independently selected from $-C_{1-6}alkyl$, $-C_{3-6}cycloalkyl$, heterocyclyl, $-C_{2-6}alkyl-OR^a$, and $-C_{1-6}alkylC(O)OR^a$;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from $-OR^a$, $-CN$, $-C_{1-6}alkylOR^a$, $-C_{1-6}cyanoalkyl$, $-C_{1-3}haloalkyl$, $-C_{3-8}cycloalkyl$, $-C_{1-3}alkylC_{3-8}cycloalkyl$, $-C(O)R^a$, $-C_{1-6}alkylC(O)R^a$, $-C(O)OR^a$, $-C_{1-6}alkylC(O)OR^a$, $-C(O)NR^aR^b$, and $-C_{1-6}alkylC(O)NR^aR^b$;

15

or R^1 and R^2 combine to form a heterocyclyl optionally containing an additional heteroatom selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3 groups independently selected from oxo, $-C_{1-6}alkyl$, $-OR^a$, $-C(O)OR^a$, $-C(O)R^a$, $C_{1-6}alkylC(O)R^a$, $-C_{1-6}alkylC(O)OR^a$, $-NR^aR^b$, $-C_{1-6}alkylNR^aR^b$, and $-C(O)NR^aR^b$;

20

each R^a is independently H or $-C_{1-6}alkyl$;

each R^b is independently H or $-C_{1-6}alkyl$; and

each u is independently 0, 1, 2, or 3.

In one embodiment, R^E and R^W are independently selected from $-(CH_2)_uN^+R^1R^2O^-$, $-(CH_2)_uP^+R^bR^cR^d$, $-(CH_2)_uP^+R^cR^dO^-$, $-(CH_2)_uP^+O[NR^aR^b][NR^cR^d]$, $-(CH_2)_uNR^cP(O)(OR^c)_2$, $-(CH_2)_uCH_2OP(O)(OR^c)(OR^d)$, $-(CH_2)_uOP(O)(OR^c)(OR^d)$, and $-(CH_2)_uOP(O)NR^aR^b(OR^a)$; wherein

25

each R^1 is independently selected from H, $-C_{1-6}alkyl$, $-C_{3-6}cycloalkyl$, heterocyclyl, $-C_{2-6}alkyl-OR^a$, and $-C_{1-6}alkylC(O)OR^a$;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from $-OR^a$, $-CN$, halo, $-C_{1-6}alkylOR^a$, $-C_{1-6}cyanoalkyl$, $-C_{1-3}haloalkyl$, $-C(O)R^a$, $-C_{1-6}alkylC(O)R^a$, $-C(O)OR^a$, $-C_{1-6}alkylC(O)OR^a$, $-C(O)NR^aR^b$, and $-C_{1-6}alkylC(O)NR^aR^b$;

30

each R^2 is independently selected from $-C_{1-6}alkyl$, $-C_{3-6}cycloalkyl$, heterocyclyl, $-C_{2-6}alkyl-OR^a$, and $-C_{1-6}alkylC(O)OR^a$;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, -C₁₋₆alkylOR^a, -C₁₋₆cycloalkyl, -C₁₋₃haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and C₁₋₆alkylC(O)NR^aR^b;

5 or R¹ and R² combine to form a heterocyclyl optionally containing an additional heteroatom selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3 groups independently selected from oxo, -C₁₋₆alkyl, -OR^a, -C(O)OR^a, -C(O)R^a, C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, and -C(O)NR^aR^b;

each R^a is independently H or -C₁₋₆alkyl;

10 each R^b is independently H or -C₁₋₆alkyl;

each R^c is independently selected from H, -C₁₋₆alkyl, -C₃₋₈cycloalkyl, and -C₁₋₃alkylC₃₋₈cycloalkyl;

each R^d is independently selected from H, -C₁₋₆alkyl, -C₃₋₈cycloalkyl, and -C₁₋₃alkylC₃₋₈cycloalkyl; and

15 each u is independently 0, 1, 2 or 3.

In one embodiment, R^E and R^W are each independently -NR¹R², -C₁₋₆alkylNR¹R², -O-C₁₋₆alkylNR¹R², -C₁₋₆alkylOC₁₋₆alkylNR¹R², -NR^aC₁₋₆alkylNR¹R², or

$$-V^2-(CR^cR^d)_p-L^3-\textcircled{B}-(T)_z;$$

wherein

V² is independently a bond, O, NR^a, S, S(O) or S(O)₂;

20 R^c is independently selected from H, OH, -C₁₋₆alkyl, and -C₃₋₈cycloalkyl;

R^d is independently selected from H, -C₁₋₆alkyl, and -C₃₋₈cycloalkyl;

L³ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

ring B is independently cycloalkyl, aryl, heteroaryl, or heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^e or (CH₂)_qC(O)R^e;

25 R^e is independently selected from H, -C₁₋₆alkyl, -O-C₁₋₆alkyl, -C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C₃₋₈cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, -NR^fR^g, -C₁₋₆alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆alkylC(O)NR^fR^g, -NHS(O)₂R^f, -C₁₋₆alkylS(O)₂R^f, and -C₁₋₆alkylS(O)₂NR^fR^g;

p is independently 0, 1, 2, 3, 4, or 5;

30 q is independently 0, 1, 2, 3, 4, or 5; and

z is 0, 1, or 2;

and wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b , halo, cyano, $-\text{OR}^a$, $-\text{C}_{1-6}$ alkyl, $-\text{C}_{1-6}$ haloalkyl, $-\text{C}_{1-6}$ cyanoalkyl, $-\text{C}_{1-6}$ alkyl NR^aR^b , $-\text{C}_{1-6}$ alkylOH, $-\text{C}_{3-8}$ cycloalkyl, and $-\text{C}_{1-3}$ alkyl C_{3-8} cycloalkyl;

5 provided that at least one of V^2 , L^3 , ring B and T contains a nitrogen atom;

each R^1 is independently selected from H, $-\text{C}_{1-6}$ alkyl, $-\text{C}_{3-6}$ cycloalkyl, heterocyclyl, $-\text{C}_{2-6}$ alkyl- OR^a , or $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{OR}^a$;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from $-\text{OR}^a$, $-\text{CN}$, halo, $-\text{C}_{1-6}$ alkyl OR^a , $-\text{C}_{1-6}$ cyanoalkyl, $-\text{C}_{1-3}$ haloalkyl, $-\text{C}(\text{O})\text{R}^a$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{R}^a$, $-\text{C}(\text{O})\text{OR}^a$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{OR}^a$, $-\text{C}(\text{O})\text{NR}^a\text{R}^b$, and $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{NR}^a\text{R}^b$;

10

each R^2 is independently selected from $-\text{C}_{1-6}$ alkyl, $-\text{C}_{3-6}$ cycloalkyl, heterocyclyl, $-\text{C}_{2-6}$ alkyl- OR^a , and $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{OR}^a$;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from $-\text{OR}^a$, $-\text{CN}$, $-\text{C}_{1-6}$ alkyl OR^a , $-\text{C}_{1-6}$ cyanoalkyl, $-\text{C}_{1-3}$ haloalkyl, $-\text{C}_{3-8}$ cycloalkyl, $-\text{C}_{1-3}$ alkyl C_{3-8} cycloalkyl, $-\text{C}(\text{O})\text{R}^a$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{R}^a$, $-\text{C}(\text{O})\text{OR}^a$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{OR}^a$, $-\text{C}(\text{O})\text{NR}^a\text{R}^b$, and $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{NR}^a\text{R}^b$;

15

or R^1 and R^2 combine to form a heterocyclyl group optionally containing an additional heteroatom selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3 groups independently selected from oxo, $-\text{C}_{1-6}$ alkyl, $-\text{OR}^a$, $-\text{C}(\text{O})\text{OR}^a$, $-\text{C}(\text{O})\text{R}^a$, C_{1-6} alkyl $\text{C}(\text{O})\text{R}^a$, $-\text{C}_{1-6}$ alkyl $\text{C}(\text{O})\text{OR}^a$, $-\text{NR}^a\text{R}^b$, $-\text{C}_{1-6}$ alkyl NR^aR^b , and $-\text{C}(\text{O})\text{NR}^a\text{R}^b$;


20

each R^a is independently H or $-\text{C}_{1-6}$ alkyl; and

each R^b is independently H or $-\text{C}_{1-6}$ alkyl.

In one embodiment, R^E and R^W are each independently $-\text{NR}^1\text{R}^2$, $-\text{C}_{1-6}$ alkyl NR^1R^2 , $-\text{O}-\text{C}_{1-6}$ alkyl NR^1R^2 , $-\text{C}_{1-6}$ alkyl OC_{1-6} alkyl NR^1R^2 , $-\text{NR}^a-\text{C}_{1-6}$ alkyl NR^1R^2 , or

25



wherein

V^2 is independently a bond, O, NR^a , S, $\text{S}(\text{O})$ or $\text{S}(\text{O})_2$;

L^3 is independently a bond, O, NR^a , S, $\text{S}(\text{O})$, or $\text{S}(\text{O})_2$;

30 ring B is independently cycloalkyl, aryl, heteroaryl, or heterocyclyl;

T is independently H, $-\text{OR}^a$, $(\text{CH}_2)_q\text{NR}^1\text{R}^2$, $(\text{CH}_2)_q\text{NR}^a\text{C}(\text{O})\text{R}^c$ or $(\text{CH}_2)_q\text{C}(\text{O})\text{R}^c$;

p is independently 0, 1, 2, or 3;

q is independently 0, 1, 2, or 3;

z is 0, 1, 2, or 3;

and wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b, halo, cyano, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, -C₃₋₈ cycloalkyl, and -C₁₋₃ alkylC₃₋₈cycloalkyl;

provided that at least one of V², L³, ring B and T contains a nitrogen atom;

each R¹ is independently selected from H, -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, or -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl group is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, halo, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and -C₁₋₆alkylC(O)NR^aR^b;

each R² is independently selected from -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, and -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and -C₁₋₆alkylC(O)NR^aR^b;

or R¹ and R² combine to form a heterocyclyl optionally containing an additional heteroatom selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3 groups independently selected from oxo, -C₁₋₆alkyl, -OR^a, -C(O)OR^a, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, and -C(O)NR^aR^b;

each R^a is independently H or -C₁₋₆alkyl;

each R^b is independently H or -C₁₋₆alkyl;


each R^c is independently selected from H, OH, -C₁₋₆alkyl, and -C₃₋₈cycloalkyl;

each R^d is independently selected from H, -C₁₋₆alkyl, and -C₃₋₈cycloalkyl;

R^e is selected from H, -C₁₋₆alkyl, -O-C₁₋₆alkyl, -C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C₃₋₈cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C₁₋₆alkylaryl, -C₁₋₆alkylheteroaryl, -NR^fR^g, -C₁₋₆alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆alkylC(O)NR^fR^g, -NHS(O)₂R^f, -C₁₋₆alkylS(O)₂R^f, and -C₁₋₆alkylS(O)₂NR^fR^g;

each R^f is independently selected from H, -C₁₋₆alkyl, and -C₃₋₈cycloalkyl;

each R^g is independently selected from H, -C₁₋₆alkyl, and -C₃₋₈cycloalkyl.



In one embodiment, R^E and R^W are each

wherein

V² is independently a bond, O, NR^a, S, S(O) or S(O)₂;

R^c is independently selected from H, OH, -C₁₋₆ alkyl, and -C₃₋₈ cycloalkyl;

5 R^d is independently selected from H, -C₁₋₆ alkyl, and -C₃₋₈ cycloalkyl;

L³ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

ring B is independently cycloalkyl, aryl, heteroaryl, or heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^e or (CH₂)_qC(O)R^e;

10 R^e is selected from H, -C₁₋₆ alkyl, -O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -O-C₃₋₈ cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆alkylheteroaryl, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆ alkylC(O)NR^fR^g, -NHS(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, and -C₁₋₆ alkylS(O)₂NR^fR^g;

R^f is independently selected from H, -C₁₋₆ alkyl, and -C₃₋₈ cycloalkyl;

R^g is independently selected from H, -C₁₋₆ alkyl, and -C₃₋₈ cycloalkyl;

15 p is independently 0, 1, 2, or 3;

q is independently 0, 1, 2, or 3;

z is 0, 1, 2, or 3;

and wherein the alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b, halo, cyano, 20 -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, -C₃₋₈ cycloalkyl, and -C₁₋₃ alkylC₃₋₈cycloalkyl;

provided that at least one of V², L³, ring B and T contains a nitrogen atom.

In one embodiment, R^E and R^W are each independently -NR¹R², -C₁₋₆ alkylNR¹R², or -O-C₁₋₆ alkylNR¹R²;

25 each R¹ is independently selected from H, -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, or -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, halo, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -C(O)NR^aR^b, and 30 -C₁₋₆ alkylC(O)NR^aR^b;

each R² is independently selected from -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, heterocyclyl, -C₂₋₆ alkyl-OR^a, and -C₁₋₆ alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and C₁₋₆alkylC(O)NR^aR^b;

or R¹ and R² combine to form a heterocyclyl optionally containing 1 or 2 additional heteroatoms independently selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3 groups independently selected from oxo, -C₁₋₆alkyl, -OR^a, -C(O)OR^a, -C(O)R^a, C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, and -C(O)NR^aR^b;

each R^a is independently H or -C₁₋₆ alkyl;

each R^b is independently H or -C₁₋₆ alkyl.

In one embodiment, R^E and R^W are each -C₁₋₆alkylOC₁₋₆alkylNR¹R²;

each R¹ is selected from H, -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, and -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, halo, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and -C₁₋₆alkylC(O)NR^aR^b;

each R² is selected from -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, and -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and C₁₋₆alkylC(O)NR^aR^b; or

R¹ and R² combine to form a heterocyclyl optionally containing 1 or 2 additional heteroatoms independently selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3 groups independently selected from oxo, -C₁₋₆alkyl, -OR^a, -C(O)OR^a, -C(O)R^a, C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, and -C(O)NR^aR^b;

each R^a is independently H or -C₁₋₆alkyl; and

each R^b is independently H or -C₁₋₆alkyl.

In one embodiment, provided is a compound of formula (I), wherein R^E and R^W are each -O-C₁₋₆alkylNR¹R²;

R¹ is selected from H, -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, and -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, halo, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and
5 -C₁₋₆alkylC(O)NR^aR^b;

R² is selected from -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, and -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a,
10 -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and C₁₋₆alkylC(O)NR^aR^b; or

R¹ and R² combine to form a heterocyclyl group optionally containing 1 or 2 additional heteroatoms independently selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3 groups independently selected from oxo, -C₁₋₆alkyl, -OR^a, -C(O)OR^a, -C(O)R^a, C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, and -C(O)NR^aR^b;

15 R^a is independently H or -C₁₋₆alkyl; and

R^b is independently H or -C₁₋₆alkyl.

In one embodiment, R^E and R^W are each -NR¹R²;

R¹ is selected from H, -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, and -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, halo, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and
20 -C₁₋₆alkylC(O)NR^aR^b;

R² is selected from -C₁₋₆alkyl, -C₃₋₆cycloalkyl, heterocyclyl, -C₂₋₆alkyl-OR^a, and -C₁₋₆alkylC(O)OR^a;

wherein each alkyl, cycloalkyl, or heterocyclyl group is optionally substituted with 1 to 2 groups independently selected from -OR^a, -CN, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₃haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a,
25 -C₁₋₆alkylC(O)OR^a, -C(O)NR^aR^b, and C₁₋₆alkylC(O)NR^aR^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing an additional heteroatom selected from oxygen, sulfur or nitrogen, and optionally substituted with 1 to 3 groups independently
30 selected from oxo, -C₁₋₆alkyl, -OR^a, -C(O)OR^a, -C(O)R^a, C₁₋₆alkylC(O)R^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, and -C(O)NR^aR^b;

R^a is independently H or -C₁₋₆alkyl; and

R^b is independently H or -C₁₋₆alkyl.

In one embodiment, R^E and R^W do not contain an amide group (i.e., $-NC(O)-$ or $-C(O)N-$). In one embodiment, at least one on R^E and R^W contains a heterocyclyl moiety which optionally comprises an oxo.


In one embodiment, R^E and R^W are each independently $-NR^1R^2$, $-C_{1-6}$ alkyl NR^1R^2 ,
 5 $-O-C_{1-6}$ alkyl NR^1R^2 , $-C_{1-6}$ alkyl OC_{1-6} alkyl NR^1R^2 , $-NR^a-C_{1-6}$ alkyl NR^1R^2 , $-C_{1-6}$ alkyl $IN^+R^1R^2R^3$,
 $-S-C_{1-6}$ alkyl NR^1R^2 , $-C(O)NR^1R^2$, $-S(O)_2R^a$, $-(CH_2)_uS(O)_2NR^1R^2$, $-(CH_2)_uNR^aS(O)_2NR^aR^b$,
 $-S(O)_2NR^aC_{1-6}$ alkyl NR^1R^2 , $-NR^aS(O)_2C_{1-6}$ alkyl NR^1R^2 ;

each R^1 is independently $-C_{1-6}$ alkylheterocyclyl;


wherein each heterocyclyl is independently 2,5-diazaspiro[3.4]octan-6-one, azetidine, 2,6-
 10 diazaspiro[3.3]heptane, pyrrolidin-2-one, tetrahydrofuran, pyrrolidine, piperidin-2-one (36),
 piperazin-2-one, 5-oxa-2,7-diazaspiro[3.4]octan-6-one, 3-azabicyclo[3.1.0]hexane, 2-
 azabicyclo[2.1.1]hexane, tetrahydro-2H-pyran, 2,6-diazaspiro[3.4]octan-7-one, 4,5-dihydro-1H-
 imidazole, 1,4,5,6-tetrahydropyrimidine, piperidine, 1,2,4-oxadiazol-5(2H)-one, 2,5,7-
 triazaspiro[3.4]octan-6-one, 2,7-diazaspiro[4.4]nonan-3-one, 1,7-diazaspiro[4.4]nonan-2-one, 2-
 15 azaspiro[4.4]nonan-3-one, 1,8-diazaspiro[4.5]decan-2-one, 2-azaspiro[3.3]heptane, oxazolidin-2-
 one, octahydrocyclopenta[b]pyrrole, octahydrocyclopenta[c]pyrrole, 2-oxa-7-
 azaspiro[4.4]nonan-1-one, 6-oxa-2-azaspiro[3.4]octane, piperazine, 1,1-
 dioxotetrahydrothiophene, hexahydropyrrolo[3,4-b]pyrrol-6(1H)-one, 1,3,8-
 triazaspiro[4.5]decane-2,4-dione, 2-methyl-1,3,7-triazaspiro[4.5]dec-2-en-4-one, 1,3,7-
 20 triazaspiro[4.4]nonane-2,4-dione, 1,3,7-triazaspiro[4.5]decane-2,4-dione, 6-azaspiro[3.4]octane,
 1-thia-6-azaspiro[3.3]heptane 1,1-dioxide, pyridin-2(1H)-one, isothiazolidine 1,1-dioxide,
 thietane 1,1-dioxide, hexahydropyrrolo[3,4-b]pyrrol-2(1H)-one, 2,5,7-triazaspiro[3.4]octane-6,8-
 dione, 3-azabicyclo[3.1.0]hexan-2-one, 5-azaspiro[2.4]heptan-4-one, oxetane, morpholine, 2-
 thiaspiro[3.3]heptane 2,2-dioxide, hexahydrocyclopenta[b]pyrrol-2(1H)-one, pyrrolidine-2,5-
 25 dione, 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine, or 1,3-dioxolane, and each is optionally
 substituted with 1 to 4 groups independently selected from the group consisting of $-OR^a$, $-CN$,
 halo, C_{1-6} alkyl, $-C_{1-6}$ alkyl OR^a , $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, C_{3-8} cycloalkyl,
 $-C_{1-3}$ alkyl C_{3-8} cycloalkyl, $-C(O)R^a$, $-C_{1-6}$ alkyl $C(O)R^a$, $-C(O)OR^a$, $-C_{1-6}$ alkyl $C(O)OR^a$, $-NR^aR^b$,
 $-OC(O)NR^aR^b$, $NR^aC(O)OR^b$, $-C_{1-6}$ alkyl INR^aR^b , $-C(O)NR^aR^b$, $-C_{1-6}$ alkyl $C(O)NR^aR^b$, $-S(O)_2R^a$,
 30 $-C_{1-6}$ alkyl $S(O)_2R^a$, $-S(O)_2NR^aR^b$, $-C_{1-6}$ alkyl $S(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2R^b$,
 $-C_{1-6}$ alkyl $C(O)NR^aS(O)_2R^b$, $-NR^aC(O)R^b$, and $-C_{1-6}$ alkyl $INR^aC(O)R^b$; and

each R^2 is H.


In one embodiment, R^W and R^E are each independently selected from:




In one embodiment, each R^W and R^E is independently selected from:





In one embodiment, each R^W and R^E is independently selected from:







5 In one embodiment, each R^W and R^E is independently selected from:










In one embodiment, each R^W and R^E is independently selected from:



In certain embodiments, each Z^1 is independently halo or $-C_{1-6}$ alkyl. In certain embodiments, each Z^1 is fluoro, chloro, or methyl.

In certain embodiments, each Z^1 is independently halo. In certain embodiments, each Z^1 is chloro.

In certain embodiments, each Z^3 is independently $-C_{1-6}$ alkyl, $-O-C_{1-6}$ alkyl, or $-O-C_{3-8}$ cycloalkyl. In certain embodiments, each Z^3 is methyl, methoxy, or cyclopropoxy.

In certain embodiments, each Z^3 is independently C_{1-6} alkoxy. In certain embodiments, each Z^3 is methoxy.

In certain embodiments, neither of R^E or R^W is an optionally substituted fused 5,6-aromatic or 5,6-heteromatic ring. In certain embodiments, none of Z^1 , Z^3 , R^N , R^E or R^W is an optionally substituted fused 5,6-aromatic or 5,6-heteromatic ring.

In certain embodiments, provided is a compound as shown in Table 1, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

In certain embodiments, the compound as provided herein has a molecular weight of less than about 850 g/mol, or less than about 800 g/mol, or less than about 750 g/mol, or less than about 700 g/mol, or between about 500 to about 850 g/mol, or between about 500 to about 600 g/mol, or between about 550 to about 650 g/mol, or between about 600 to about 700 g/mol, or between about 650 to about 750 g/mol, or between about 700 to about 800 g/mol, or between about 750 to about 850 g/mol.

One of skill in the art is aware that each and every embodiment of a group (e.g., R^E) disclosed herein may be combined with any other embodiment of each of the remaining groups (e.g., R^W, Z¹, Z³, etc.) to generate a complete compound of formula (I) as disclosed herein; each of which is deemed within the ambit of the present disclosure.

5 *Formulations and Methods*

PD-1 and its ligand, PD-L1, are monomeric type I transmembrane proteins that play critical roles in T cell inhibition and exhaustion. PD-L1 is composed of two extracellular immunoglobulin (Ig)-like domains whereas PD-1 is composed of a single extracellular Ig like domain and an intracellular tail. The crystal structure of the PD-1/PD-L1 complex reveals that PD-1 binds to PD-L1 with a 1:1 stoichiometry to form a monomeric complex (see, e.g., Cheng et al. *J Biol Chem*, 2013; 288(17); 11771-85, Lin et al. *Proc Natl Acad Sci USA*, 2008; 105(8); 3011-6, Zak et al. *Structure*, 2015; 23(12); 2341-8). This arrangement represents a distinct ligand-binding mode and signaling mechanism that differs from other co-inhibitory receptor/ligand interactions such as CTLA-4/B7, where oligomerization plays an important role in signaling (see, e.g., Schwartz et al. *Nature*, 2001; 410(6828); 604-8). Engagement of PD-1 to PD-L1, along with TCR signaling, leads to phosphorylation of the cytoplasmic domain tyrosines on PD-1 and recruitment of Src-homology 2-containing tyrosine phosphatases (SHP-1 and SHP-2). These phosphatases dephosphorylate TCR-associated proteins, resulting in alteration of downstream signaling including blocking phosphoinositide 3 kinase (PI3K) and Akt kinase activation, disrupting glucose metabolism, and inhibiting IL-2 and IFN- γ secretion (see, e.g., Hofmeyer et al. *J Biomed Biotechnol*, 2011; 2011; 451694, Latchman et al. *Nature immunology*, 2001; 2(3); 261-8).

Monoclonal antibodies developed for cancer immunotherapy binding to either PD-1 or PD-L1 have demonstrated significant response rates in patients, particularly for melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and bladder cancer. Many of these studies have shown that blockade of the PD-1/PD-L1 axis leads to an enhancement in T cell cytotoxic activity at the tumor site (see, e.g., Wherry EJ. *Nat Immunol*, 2011; 12(6); 492-9). In addition to cancer, inhibition of this pathway has also shown promise for the control or elimination of chronic viral infections, such as HBV (see, e.g., Bengsch et al. *J Hepatol*, 2014; 61(6);1212-9, Fisicaro et al. *Gastroenterology*, 2010; 138(2), 682-93, 93 e1-4, Fisicaro et al. *Gastroenterology*, 2012; 143(6), 1576-85 e4).

Methods

30 In one embodiment, the present disclosure provides a compound of formula (I) useful as an inhibitor of PD-1, PD-L1 and/or the PD-1/PD-L1 interaction. In some embodiments, compounds disclosed herein inhibit the PD-1/PD-L1 interaction by dimerizing PD-L1, or by inducing or stabilizing PD-L1 dimer formation.

In one embodiment, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.

The present disclosure provides a compound of formula (I) for use in therapy.

In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, useful for treating an HBV infection or a condition in a patient that is amenable to treatment by inhibiting PD-1, PD-L1 or the PD-1/PD-L1 interaction.

In one embodiment, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, at least one additional therapeutic agent suitable for treating an HBV infection, and at least one pharmaceutically acceptable carrier or excipient.

In another embodiment, the present disclosure provides a compound of formula (I) for use in the manufacture of a medicament for treating or eliminating HBV. Elimination of HBV during acute infection is associated with the emergence of functional HBV-specific CD8⁺ T cells. In contrast, chronic infection is marked by the presence of dysfunctional HBV-specific CD8⁺ T cells that are unable to control viral infection (see, e.g., Boni et al. *J Virol*, 2007; 81(8); 4215-4225, Ferrari, *Liver Int*, 2015; 35; Suppl 1:121-8, Fisicaro et al., *Gastroenterology*, 2010; 138(2); 682-693, 93 e1-4, Guidotti et al. *Cell*, 2015; 161(3); 486-500). Mechanisms that may contribute to the dysfunction of HBV-specific T cells in CHB include upregulation of inhibitory T cell receptors (e.g. PD-1, CTLA-4 and TIM-3), due to persistent high viral load and antigen levels (see, e.g., Boni et al. *J Virol*, 2007; 81(8); 4215-4225, Franzese et al. *J Virol*, 2005; 79(6); 3322-3328, Peppas et al. *J Exp Med*, 2013; 210(1); 99-114, Wherry EJ. *Nature immunology* 2011; 12(6); 492-499). Among all inhibitory immune receptors, PD-1 is most frequently upregulated on HBV-specific T cells. Furthermore, multiple studies have confirmed that the majority of circulating and intrahepatic HBV-specific CD8⁺ T cells in CHB patients are exhausted and express high levels of PD-1 (see, e.g., Bengsch et al. *J Hepatol*, 2014; 61(6); 1212-1219, Fisicaro et al., *Gastroenterology*, 2010; 138(2); 682-693, 93 e1-4). Notably, the defects in effector cytokine production by HBV-specific CD4⁺ and CD8⁺ T cells were partially reversed by blocking the PD-1/PD-L1 interaction with an anti-PD-L1 antibody in PBMCs isolated from CHB patients (see, e.g., Bengsch et al. *J Hepatol*, 2014; 61(6); 1212-1219, Fisicaro et al., *Gastroenterology*, 2010; 138(2); 682-693, 93 e1-4, Fisicaro et al. *Gastroenterology*, 2012; 143(6); 1576-1585 e4). Consistent with these pre-clinical data, a clinical study evaluating α -PD-1 therapy in CHB subjects showed significant reductions in HBsAg levels in the majority of subjects which includes three out of twenty patients with reduction in HBsAg levels of over 0.5 log₁₀ and one subject that experienced a functional cure (sustained HBsAg loss and appearance of anti-HBsAb) (see, e.g., Gane et al. "A phase I study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients", Abstract PS-044, European Association for the Study of the Liver (EASL); 2017; April 19-23; Amsterdam, The Netherlands). Taken together, these findings demonstrate that inhibiting the PD-1/PD-L1 axis may improve T cell function in CHB patients and increase the rates of functional cure. Disclosed herein are selective and potent PD-L1 small molecule

inhibitors that bind specifically to PD-L1 and inhibit the PD-1/PD-L1 interaction by inducing PD-L1 dimerization (see, e.g., Biological Example 2).

In one embodiment, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one additional anticancer agent and at least one pharmaceutically acceptable excipient.

In one embodiment, the present disclosure provides a method of treating cancer in a patient in need thereof, comprising administering a compound of formula (I) in combination with one or more check-point inhibitors selected from nivolumab, pembrolizumab, and artezolizumab.

In another embodiment, the present disclosure provides a compound of formula (I) for use in the manufacture of a medicament for treating cancer.

In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, useful for the treatment of cancer or a condition in a patient that is amenable to treatment by inhibiting PD-1, PD-L1 or the PD-1/PD-L1 interaction. Cancers that may be treated with the compounds of formula (I) disclosed herein include pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer and colon cancer.

In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, useful for the treatment of cancer or a condition in a patient that is amenable to treatment by inhibiting PD-1, PD-L1 or the PD-1/PD-L1 interaction including, but not limited to, lymphoma, multiple myeloma, and leukemia. Additional diseases or conditions that may be treated include, but are not limited to acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldstrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL).

"Administering" or "administration" refers to the delivery of one or more therapeutic agents to a patient. In one embodiment, the administration is a monotherapy wherein a compound of formula (I) is the only active ingredient administered to the patient in need of therapy. In another embodiment, the administration is co-administration such that two or more therapeutic agents are delivered together during the course of the treatment. In one embodiment, two or more therapeutic agents may be co-formulated into a single dosage form or "combined dosage unit", or formulated separately and subsequently

combined into a combined dosage unit, as is typically for intravenous administration or oral administration as a mono or bilayer tablet or capsule.

In one embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered to a human patient in need thereof in an effective amount, such as, from about 0.1 mg to about 1000 mg per day of said compound. In one embodiment, the effective amount is from about 0.1 mg to about 200 mg per day. In one embodiment, the effective amount is from about 1 mg to about 100 mg per day. In other embodiments, the effective amount is about 1 mg, about 3 mg, about 5 mg, about 10 mg, about 15 mg, about 18 mg, about 20 mg, about 30 mg, about 40 mg, about 60 mg, about 80 mg, or about 100 mg per day.

In one embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one additional anticancer agent is administered to a human patient in need thereof in an effective amount of each agent, independently from about 0.1 mg to about 1000 mg per compound or formulation per day per compounds. In one embodiment, the effective amount of the combination treatment of a compound of formula (I) and an additional compound is independently from about 0.1 mg to about 200 mg per compound per day. In one embodiment, the effective amount of the combination treatment of a compound of formula (I) and an additional compound is independently from about 1 mg to about 100 mg per compound per day. In other embodiments, the effective amount of the combination treatment of a compound of formula (I) and an additional compound is for each component, about 1 mg, about 3 mg, about 5 mg, about 10 mg, about 15 mg, about 18 mg, about 20 mg, about 30 mg, about 40 mg, about 60 mg, about 80 mg, about 100 mg, about 200 mg, or about 500 mg each per day.

In one embodiment, the compound of formula (I) and/or a combination of the compound of formula (I) and an additional anticancer agent or a pharmaceutically acceptable salt thereof is administered once a day. In yet another embodiment, the compound of formula (I) and/or an additional anticancer agent or a pharmaceutically acceptable salt thereof is administered as a loading dose of from about 10 mg to about 500 mg per compound on the first day and each day or on alternate days or weekly for up to a month followed by a regular regimen of a compound of formula (I) and/or one or more additional anticancer agents or therapies. The maintenance dose may be 1-500 mg daily or weekly for each component of a multi component drug regimen. A qualified care giver or treating physician is aware of what dose regimen is best for a particular patient or particular presenting conditions and will make appropriate treating regimen decisions for that patient. Thus, in another embodiment, the qualified caregiver is able to tailor a dose regimen of the compound of formula (I) and/or an additional agent(s) as disclosed herein to fit with the particular needs of the patient. Thus, it will be understood that the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof and the amount of an additional agent actually administered will usually be determined by a physician, in light of the relevant circumstances, including the condition(s) to be treated, the chosen route of administration, the actual compound (e.g., salt or free base) administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

Co-administration may also include administering component drugs e.g., one or more compounds of formula (I) and one or more additional (e.g., a second, third, fourth or fifth) anticancer or other therapeutic agent(s). Such combination of one or more compounds of formula (I) and one or more additional anticancer or other therapeutic agent(s) may be administered simultaneously or in sequence (one after the other) within a reasonable period of time of each administration (e.g., about 1 minute to 24 hours) depending on the pharmacokinetic and/or pharmacodynamics properties of each agent or the combination. Co-administration may also involve treatment with a fixed combination wherein agents of the treatment regimen are combinable in a fixed dosage or combined dosage medium e.g., solid, liquid or aerosol. In one embodiment, a kit may be used to administer the drug or drug components.

Thus, one embodiment of the present disclosure is a method of treating a disease amenable to treatment with a PD-1, PD-L1 inhibitor or a PD-1/PD-L1 interaction inhibitor e.g., cancer, comprising administering therapeutically effective amounts of formulations of one or more compounds of formula (I) and one or more additional anticancer agents, including for example, via a kit to a patient in need thereof. It will be understood that a qualified care giver will administer or direct the administration of a therapeutically effective amount of any of the compound(s) or combinations of compounds of the present disclosure.

“Intravenous administration” is the administration of substances directly into a vein, or “intravenously.” Compared with other routes of administration, the intravenous (IV) route is a faster way to deliver fluids and medications throughout the body. An infusion pump can allow precise control over the flow rate and total amount of medication delivered. However, in cases where a change in the flow rate would not have serious consequences, or if pumps are not available, the drip is often left to flow simply by placing the bag above the level of the patient and using the clamp to regulate the rate. Alternatively, a rapid infuser can be used if the patient requires a high flow rate and the IV access device is of a large enough diameter to accommodate it. This is either an inflatable cuff placed around the fluid bag to force the fluid into the patient or a similar electrical device that may also heat the fluid being infused. When a patient requires medications only at certain times, intermittent infusion is used which does not require additional fluid. It can use the same techniques as an intravenous drip (pump or gravity drip), but after the complete dose of medication has been given, the tubing is disconnected from the IV access device. Some medications are also given by IV push or bolus, meaning that a syringe is connected to the IV access device and the medication is injected directly (slowly, if it might irritate the vein or cause a too-rapid effect). Once a medicine has been injected into the fluid stream of the IV tubing there must be some means of ensuring that it gets from the tubing to the patient. Usually this is accomplished by allowing the fluid stream to flow normally and thereby carry the medicine into the bloodstream; however, a second fluid injection is sometimes used, as a “flush”, following the injection to push the medicine into the bloodstream more quickly. Thus in one embodiment, compound(s) or combination of compounds described herein may be administered by IV administration alone or in combination with administration of certain components of the treatment regimen by oral or parenteral routes.

“Oral administration” is a route of administration where a substance is taken through the mouth, and includes buccal, sub labial, and sublingual administration, as well as enteral administration and that through the respiratory tract, unless made through e.g., tubing so the medication is not in direct contact with any of the oral mucosa. Typical form for the oral administration of therapeutic agents includes the use of tablets or capsules. Thus in one embodiment, compound(s) or combination of compounds described herein may be administered by oral route alone or in combination with administration of certain components of the treatment regimen by IV or parenteral routes.

Pharmaceutical Formulations

The compound(s) of formula (I) or a pharmaceutically acceptable salt thereof may be administered in a pharmaceutical formulation. Pharmaceutical formulations/compositions contemplated by the present disclosure comprise, in addition to a carrier, the compound of formula (I), or a pharmaceutically acceptable salt thereof, or a combination of compound of formula (I), or a pharmaceutically acceptable salt thereof, optionally in combination with an additional agent such as for example, ipilimumab, or a pharmaceutically acceptable salt thereof.

Pharmaceutical formulations/compositions contemplated by the present disclosure may also be intended for administration by injection and include aqueous solutions, oil suspensions, emulsions (with sesame oil, corn oil, cottonseed oil, or peanut oil) as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

Sterile injectable solutions are prepared by incorporating the component compound(s) in the required amount in the appropriate solvent with various other ingredients as enumerated above or as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient(s) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

In making pharmaceutical compositions that comprise compound of formula (I), or a pharmaceutically acceptable salt thereof, optionally in combination with an additional agent/therapy useful for the purpose or pharmaceutically acceptable salt thereof, the active ingredient is usually diluted by an excipient or carrier and/or enclosed or mixed with such a carrier that may be in the form of a

capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments
5 containing, for example, up to 20% by weight of the active compounds, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations
10 can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents.

The compositions of the disclosure may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures
15 known in the art. In one embodiment, sustained release formulations are used. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations.

Certain compositions are preferably formulated in a unit dosage form. The term “unit dosage forms” or “combined dosage unit” refers to physically discrete units suitable as unitary dosages for
20 human subjects and other mammals, each unit containing a predetermined quantity of one or more of the active materials (e.g., compound (I), optionally in combination with an additional agent calculated to produce the desired effect, in association with a suitable pharmaceutical excipient in for example, a tablet, capsule, ampoule or vial for injection. It will be understood, however, that the amount of each active agent actually administered will be determined by a physician, in the light of the relevant
25 circumstances, including the condition to be treated, the chosen route of administration, the actual compounds administered and their relative activity, the age, weight, and response of the individual patient, the severity of the patient’s symptoms, and the like.

For preparing solid compositions such as tablets, the principal active ingredient(s) is /are mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous
30 mixture of a compound of the present disclosure. When referring to these pre-formulation compositions as homogeneous, it is meant that the active ingredient(s) are dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.

The tablets or pills comprising compound of formula (I) or a pharmaceutically acceptable salt
35 thereof of the present disclosure optionally in combination with the second agent may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to

protect from the acidic conditions of the stomach. For example, the tablet or pill can comprise an inner dosage and an outer dosage element, the latter being in the form of an envelope over the former. In one embodiment, the inner dosage element may comprise the compound (I) and the outer dosage element may comprise the second or additional agent or *vice versa*. Alternatively, the combined dosage unit may be side by side configuration as in a capsule or tablet where one portion or half of the tablet or capsule is filled with a formulation of the compound of formula (I) while the other portion or half of the table or capsule comprises the additional agent

A variety of materials may be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate. One of ordinary skill in the art is aware of techniques and materials used in the manufacture of dosages of formulations disclosed herein.

A “sustained release formulation” or “extended release formulation” is a formulation which is designed to slowly release a therapeutic agent into the body over an extended period of time, whereas an “immediate release formulation” is a formulation which is designed to quickly release a therapeutic agent into the body over a shortened period of time. In some cases the immediate release formulation may be coated such that the therapeutic agent is only released once it reaches the desired target in the body (e.g., the stomach). One of ordinary skill in the art is able to develop sustained release formulations of the presently disclosed compounds without undue experimentation. Thus in one embodiment, compound(s) or combination of compounds described herein may be delivered via sustained released formulations alone or in combination with administration of certain components of the treatment regimen by oral, IV or parenteral routes.

A lyophilized formulation may also be used to administer a compound of formula (I) singly or in combination with an additional anticancer agent. One of skill in the art is aware of how to make and use lyophilized formulations of drug substances amenable to lyophilization.

Spray-dried formulation may also be used to administer a compound of formula (I) singly or in combination with an additional anti-cancer agent. One of skill in the art is aware of how to make and use spray-dried formulations of drug substances amenable to spray-drying. Other known formulation techniques may also be employed to formulate a compound or combination of compounds disclosed herein.

Articles of Manufacture

Articles of manufacture comprising a container in which a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier are contained are provided. The article of manufacture may be a bottle, vial, ampoule, single-use disposable applicator, or the like, containing the pharmaceutical composition provided in the present disclosure. The container may be formed from a variety of materials, such as glass or plastic and in one aspect also

contains a label on, or associated with, the container which indicates directions for use in the treatment of cancer or inflammatory conditions.

It should be understood that the active ingredient may be packaged in any material capable of providing reasonable chemical and physical stability, such as an aluminum foil bag.

5 Unit dosage forms of the pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier are also provided.

Any pharmaceutical composition provided in the present disclosure may be used in the articles of manufacture, the same as if each and every composition were specifically and individually listed for use
10 an article of manufacture.

Also provided is a kit that includes a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof; a label, and/or instructions for use of the compound in the treatment of a disease or condition mediated by PD-1, PD-L1 activity or PD-1/PD-L1 interaction.

15 In one embodiment, the instructions are directed to use of the pharmaceutical composition for the treatment of cancer, including for example, leukemia or lymphoma. In specific embodiments, the cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), indolent non-Hodgkin's
20 lymphoma (iNHL), refractory iNHL, non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldstrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, and diffuse large B-cell lymphoma (DLBCL). In one embodiment, the cancer is T-cell acute lymphoblastic leukemia (T-ALL), or B-cell acute lymphoblastic leukemia (B-ALL). The non-Hodgkin lymphoma encompasses the indolent B-cell diseases that include, for example, follicular lymphoma,
25 lymphoplasmacytic lymphoma, Waldenstrom macroglobulinemia, and marginal zone lymphoma, as well as the aggressive lymphomas that include, for example, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). In one embodiment, the cancer is indolent non-Hodgkin's lymphoma (iNHL)

In a particular variation, the instructions are directed to use of the pharmaceutical composition
30 for the treatment of an autoimmune disease. Specific embodiments of an autoimmune disease include asthma, rheumatoid arthritis, multiple sclerosis, and lupus.

Also provided is an article of manufacture which includes a compound of formula (I) or a pharmaceutically acceptable salt, prodrug, or solvate thereof; and a container. In one embodiment, the container may be a vial, jar, ampoule, preloaded syringe, or an intravenous bag.

Formulations of compound(s) of the present disclosure i.e., a compound of formula (I) or the combination of a compound of formula (I) and an additional agent may be accomplished by admixing said compounds or salt thereof with one or more non-toxic, pharmaceutically acceptable vehicles, carriers and/or diluents and/or adjuvants collectively referred to herein as excipients or carrier materials.

5 The compounds of the disclosure may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such route, and in a therapeutically effective dose. The compounds or the combination of compounds for the disclosure may be delivered orally, mucosally, parenterally, including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intranasally in dosage formulations containing conventional pharmaceutical excipients.

10 In one embodiment, the combination of a compound formula (I), or a pharmaceutically acceptable salt thereof, and an additional agent useful for the treatment of cancer may be formulated in a fixed dose or combined dose formulation in a tablet, capsule or premixed IV solution. In another embodiment, the fixed dose combination preferably comprises of compound formula (I), and an additional anticancer agent. Other fixed dose formulations may include premixed liquids, suspensions, 15 elixirs, aerosolized sprays or patch presentations. As used herein fixed dose or combined dose formulations are synonymous with simultaneous co-administration of the active ingredients of the compound (I) and at least one additional agent.

Combination Therapy

Also provided are methods of treatment in which a compound of formula (I) or a 20 pharmaceutically acceptable salt thereof, is given to a patient in combination with one or more additional active agents or therapy. The compound described herein may be used or combined with one or more of the additional therapeutic agents. The one or more therapeutic agents include, but are not limited to, an inhibitor, agonist, antagonist, ligand, modulator, stimulator, blocker, activator or suppressor of a gene, ligand, receptor, protein, factor such as Abelson murine leukemia viral oncogene homolog 1 gene (ABL, 25 such as ABL1), Acetyl-CoA carboxylase (such as ACC1/2), activated CDC kinase (ACK, such as ACK1), Adenosine deaminase, adenosine receptor (such as A2B, A2a, A3), Adenylate cyclase, ADP ribosyl cyclase-1, adrenocorticotrophic hormone receptor (ACTH), Aerolysin, AKT1 gene, Alk-5 protein kinase, Alkaline phosphatase, Alpha 1 adrenoceptor, Alpha 2 adrenoceptor, Alpha-ketoglutarate dehydrogenase (KGDH), Aminopeptidase N, AMP activated protein kinase, anaplastic lymphoma kinase 30 (ALK, such as ALK1), Androgen receptor, Angiopoietin (such as ligand-1, ligand-2), Angiotensinogen (AGT) gene, murine thymoma viral oncogene homolog 1 (AKT) protein kinase (such as AKT1, AKT2, AKT3), apolipoprotein A-I (APOA1) gene, Apoptosis inducing factor, apoptosis protein (such as 1, 2), apoptosis signal-regulating kinase (ASK, such as ASK1), Arginase (I), Arginine deiminase, Aromatase, Asteroid homolog 1 (ASTE1) gene, ataxia telangiectasia and Rad 3 related (ATR) serine/threonine 35 protein kinase, Aurora protein kinase (such as 1, 2), Axl tyrosine kinase receptor, Baculoviral IAP repeat containing 5 (BIRC5) gene, Basigin, B-cell lymphoma 2 (BCL2) gene, Bcl2 binding component 3, Bcl2 protein, BCL2L11 gene, BCR (breakpoint cluster region) protein and gene, Beta adrenoceptor, Beta-

catenin, B-lymphocyte antigen CD19, B-lymphocyte antigen CD20, B-lymphocyte cell adhesion molecule, B-lymphocyte stimulator ligand, Bone morphogenetic protein-10 ligand, Bone morphogenetic protein-9 ligand modulator, Brachyury protein, Bradykinin receptor, B-Raf proto-oncogene (BRAF), Bcr-Abl tyrosine kinase, Bromodomain and external domain (BET) bromodomain containing protein (such as BRD2, BRD3, BRD4), Bruton's tyrosine kinase (BTK), Calmodulin, calmodulin-dependent protein kinase (CaMK, such as CAMKII), Cancer testis antigen 2, Cancer testis antigen NY-ESO-1, cancer/testis antigen 1B (CTAG1) gene, Cannabinoid receptor (such as CB1, CB2), Carbonic anhydrase, casein kinase (CK, such as CKI, CKII), Caspase (such as caspase-3, caspase-7, Caspase-9), caspase 8 apoptosis-related cysteine peptidase CASP8-FADD-like regulator, Caspase recruitment domain protein-15, Cathepsin G, CCR5 gene, CDK-activating kinase (CAK), Checkpoint kinase (such as CHK1,CHK2), chemokine (C-C motif) receptor (such as CCR2, CCR4, CCR5, CCR8), chemokine (C-X-C motif) receptor (such as CXCR4, CXCR1 and CXCR2), Chemokine CC21 ligand, Cholecystokinin CCK2 receptor, Chorionic gonadotropin, c-Kit (tyrosine-protein kinase Kit or CD117), Claudin (such as 6, 18), cluster of differentiation (CD) such as CD4, CD27, CD29, CD30, CD33, CD37, CD40, CD40 ligand receptor, CD40 ligand, CD40LG gene, CD44, CD45, CD47, CD49b, CD51, CD52, CD55, CD58, CD66e, CD70 gene, CD74, CD79, CD79b, CD79B gene, CD80, CD95, CD99, CD117, CD122, CDw123, CD134, CDw137, CD158a, CD158b1, CD158b2, CD223, CD276 antigen; clusterin (CLU) gene, Clusterin, c-Met (hepatocyte growth factor receptor (HGFR)), Complement C3, Connective tissue growth factor, COP9 signalosome subunit 5, CSF-1 (colony-stimulating factor 1 receptor), CSF2 gene, CTLA-4 (cytotoxic T-lymphocyte protein 4) receptor, Cyclin D1, Cyclin G1, cyclin-dependent kinases (CDK, such as CDK1, CDK1B, CDK2-9), cyclooxygenase (such as 1, 2), CYP2B1 gene, Cysteine palmitoyltransferase porcupine, Cytochrome P450 11B2, Cytochrome P450 17, cytochrome P450 17A1, Cytochrome P450 2D6, cytochrome P450 3A4, Cytochrome P450 reductase, cytokine signalling-1, cytokine signalling-3, Cytoplasmic isocitrate dehydrogenase, Cytosine deaminase, cytosine DNA methyltransferase, cytotoxic T-lymphocyte protein-4, DDR2 gene, Delta-like protein ligand (such as 3, 4), Deoxyribonuclease, Dickkopf-1 ligand, dihydrofolate reductase (DHFR), Dihydropyrimidine dehydrogenase, Dipeptidyl peptidase IV, discoidin domain receptor (DDR, such as DDR1), DNA binding protein (such as HU-beta), DNA dependent protein kinase, DNA gyrase, DNA methyltransferase, DNA polymerase (such as alpha), DNA primase, dUTP pyrophosphatase, L-dopachrome tautomerase, echinoderm microtubule like protein 4, EGFR tyrosine kinase receptor, Elastase, Elongation factor 1 alpha 2, Elongation factor 2, Endoglin, Endonuclease, Endoplasmin, Endosialin, Endostatin, endothelin (such as ET-A, ET-B), Enhancer of zeste homolog 2 (EZH2), Ephrin (EPH) tyrosine kinase (such as EphA3, EphB4), Ephrin B2 ligand, epidermal growth factor, epidermal growth factor receptors (EGFR), epidermal growth factor receptor (EGFR) gene, Epigen, Epithelial cell adhesion molecule (EpCAM), Erb-b2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2) tyrosine kinase receptor, Erb-b3 tyrosine kinase receptor, Erb-b4 tyrosine kinase receptor, E-selectin, Estradiol 17 beta dehydrogenase, Estrogen receptor (such as alpha, beta), Estrogen related receptor, Eukaryotic translation initiation factor 5A (EIF5A) gene, Exportin 1, Extracellular signal related kinase (such as 1, 2), Extracellular signal-

regulated kinases (ERK), Factor (such as Xa, VIIa), farnesoid x receptor (FXR), Fas ligand, Fatty acid synthase (FASN), Ferritin, FGF-2 ligand, FGF-5 ligand, fibroblast growth factor (FGF, such as FGF1, FGF2, FGF4), Fibronectin, Fms-related tyrosine kinase 3 (Flt3), FMS-like tyrosine kinase-3 ligand (FLT3L), focal adhesion kinase (FAK, such as FAK2), folate hydrolase prostate-specific membrane antigen 1 (FOLH1), Folate receptor (such as alpha), Folate, Folate transporter 1, FYN tyrosine kinase, paired basic amino acid cleaving enzyme (FURIN), Beta-glucuronidase, Galactosyltransferase, Galectin-3, Ganglioside GD2, Glucocorticoid, glucocorticoid-induced TNFR-related protein GTR receptor, Glutamate carboxypeptidase II, glutaminase, Glutathione S-transferase P, glycogen synthase kinase (GSK, such as 3-beta), Glypican 3 (GPC3), gonadotropin-releasing hormone (GNRH), Granulocyte macrophage colony stimulating factor (GM-CSF) receptor, Granulocyte-colony stimulating factor (GCSF) ligand, growth factor receptor-bound protein 2 (GRB2), Grp78 (78 kDa glucose-regulated protein) calcium binding protein, molecular chaperone groEL2 gene, Heme oxygenase 1 (HO1), Heat shock protein (such as 27, 70, 90 alpha, beta), Heat shock protein gene, Heat stable enterotoxin receptor, Hedgehog protein, Heparanase, Hepatocyte growth factor, HERV-H LTR associating protein 2, Hexose kinase, Histamine H2 receptor, Histone methyltransferase (DOT1L), histone deacetylase (HDAC, such as 1, 2, 3, 6, 10, 11), Histone H1, Histone H3, HLA class I antigen (A-2 alpha), HLA class II antigen, Homeobox protein NANOG, HSPB1 gene, Human leukocyte antigen (HLA), Human papillomavirus (such as E6, E7) protein, Hyaluronic acid, Hyaluronidase, Hypoxia inducible factor-1 alpha (HIF1 α), Imprinted Maternally Expressed Transcript (H19) gene, mitogen-activated protein kinase kinase kinase 1 (MAP4K1), tyrosine-protein kinase HCK, I-Kappa-B kinase (IKK, such as IKKbe), IL-1 alpha, IL-1 beta, IL-12, IL-12 gene, IL-15, IL-17, IL-2 gene, IL-2 receptor alpha subunit, IL-2, IL-3 receptor, IL-4, IL-6, IL-7, IL-8, immunoglobulin (such as G, G1, G2, K, M), Immunoglobulin Fc receptor, Immunoglobulin gamma Fc receptor (such as I, III, IIIA), indoleamine 2,3-dioxygenase (IDO, such as IDO1), indoleamine pyrrole 2,3-dioxygenase 1 inhibitor, insulin receptor, Insulin-like growth factor (such as 1, 2), Integrin alpha-4/beta-1, integrin alpha-4/beta-7, Integrin alpha-5/beta-1, Integrin alpha-V/beta-3, Integrin alpha-V/beta-5, Integrin alpha-V/beta-6, Intercellular adhesion molecule 1 (ICAM-1), interferon (such as alpha, alpha 2, beta, gamma), Interferon inducible protein absent in melanoma 2 (AIM2), interferon type I receptor, Interleukin 1 ligand, Interleukin 13 receptor alpha 2, interleukin 2 ligand, interleukin-1 receptor-associated kinase 4 (IRAK4), Interleukin-2, Interleukin-29 ligand, isocitrate dehydrogenase (such as IDH1, IDH2), Janus kinase (JAK, such as JAK1, JAK2), Jun N terminal kinase, kallikrein-related peptidase 3 (KLK3) gene, Killer cell Ig like receptor, Kinase insert domain receptor (KDR), Kinesin-like protein KIF11, Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, Kisspeptin (KiSS-1) receptor, KIT gene, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) tyrosine kinase, lactoferrin, Lanosterol-14 demethylase, LDL receptor related protein-1, Leukotriene A4 hydrolase, Listeriolysin, L-Selectin, Luteinizing hormone receptor, Lyase, lymphocyte activation gene 3 protein (LAG-3), Lymphocyte antigen 75, Lymphocyte function antigen-3 receptor, lymphocyte-specific protein tyrosine kinase (LCK), Lymphotoxin, Lyn (Lck/Yes novel) tyrosine kinase, lysine demethylases (such as KDM1, KDM2, KDM4, KDM5, KDM6, A/B/C/D),

Lysophosphatidate-1 receptor, lysosomal-associated membrane protein family (LAMP) gene, Lysyl oxidase homolog 2, lysyl oxidase protein (LOX), lysyl oxidase-like protein (LOXL, such as LOXL2), Hematopoietic Progenitor Kinase 1 (HPK1), Hepatocyte growth factor receptor (MET) gene, macrophage colony-stimulating factor (MCSF) ligand, Macrophage migration inhibitory fact, MAGEC1 gene, MAGEC2 gene, Major vault protein, MAPK-activated protein kinase (such as MK2), Mas-related G-protein coupled receptor, matrix metalloprotease (MMP, such as MMP2, MMP9), Mcl-1 differentiation protein, Mdm2 p53-binding protein, Mdm4 protein, Melan-A (MART-1) melanoma antigen, Melanocyte protein Pmel 17, melanocyte stimulating hormone ligand, melanoma antigen family A3 (MAGEA3) gene, Melanoma associated antigen (such as 1, 2,3,6), Membrane copper amine oxidase, Mesothelin, MET tyrosine kinase, Metabotropic glutamate receptor 1, Metalloreductase STEAP1 (six transmembrane epithelial antigen of the prostate 1), Metastin, methionine aminopeptidase-2, Methyltransferase, Mitochondrial 3 ketoacyl CoA thiolase, mitogen-activate protein kinase (MAPK), mitogen-activated protein kinase (MEK, such as MEK1, MEK2), mTOR (mechanistic target of rapamycin (serine/threonine kinase), mTOR complex (such as 1,2), mucin (such as 1, 5A, 16), mut T homolog (MTH, such as MTH1), Myc proto-oncogene protein, myeloid cell leukemia 1 (MCL1) gene, myristoylated alanine-rich protein kinase C substrate (MARCKS) protein, NAD ADP ribosyltransferase, natriuretic peptide receptor C, Neural cell adhesion molecule 1, Neurokinin 1 (NK1) receptor, Neurokinin receptor, Neuropilin 2, NF kappa B activating protein, NIMA-related kinase 9 (NEK9), Nitric oxide synthase, NK cell receptor, NK3 receptor, NKG2 A B activating NK receptor, Noradrenaline transporter, Notch (such as Notch-2 receptor, Notch-3 receptor, Notch-4 receptor), Nuclear erythroid 2-related factor 2, Nuclear Factor (NF) kappa B, Nucleolin, Nucleophosmin, nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), 2 oxoglutarate dehydrogenase, 2,5-oligoadenylate synthetase, O-methylguanine DNA methyltransferase, Opioid receptor (such as delta), Ornithine decarboxylase, Orotate phosphoribosyltransferase, orphan nuclear hormone receptor NR4A1, Osteocalcin, Osteoclast differentiation factor, Osteopontin, OX-40 (tumor necrosis factor receptor superfamily member 4 TNFRSF4, or CD134) receptor, P3 protein, p38 kinase, p38 MAP kinase, p53 tumor suppressor protein, Parathyroid hormone ligand, peroxisome proliferator-activated receptors (PPAR, such as alpha, delta, gamma), P-Glycoprotein (such as 1), phosphatase and tensin homolog (PTEN), phosphatidylinositol 3-kinase (PI3K), phosphoinositide-3 kinase (PI3K such as alpha, delta, gamma), phosphorylase kinase (PK), PKN3 gene, placenta growth factor, platelet-derived growth factor (PDGF, such as alpha, beta), Platelet-derived growth factor (PDGF, such as alpha, beta), Pleiotropic drug resistance transporter, Plexin B1, PLK1 gene, polo-like kinase (PLK), Polo-like kinase 1, Poly ADP ribose polymerase (PARP, such as PARP1, 2 and 3), Preferentially expressed antigen in melanoma (PRAME) gene, Prenyl-binding protein (PrPB), Probable transcription factor PML, Progesterone receptor, Programmed cell death 1 (PD-1), Programmed cell death ligand 1 inhibitor (PD-L1), Prosaposin (PSAP) gene, Prostanoid receptor (EP4), prostate specific antigen, Prostatic acid phosphatase, proteasome, Protein E7, Protein farnesyltransferase, protein kinase (PK, such as A, B, C), protein tyrosine kinase, Protein tyrosine phosphatase beta, Proto-oncogene serine/threonine-protein kinase (PIM, such as PIM-1, PIM-2, PIM-3), P-Selectin, Purine

nucleoside phosphorylase, purinergic receptor P2X ligand gated ion channel 7 (P2X7), Pyruvate dehydrogenase (PDH), Pyruvate dehydrogenase kinase, Pyruvate kinase (PYK), 5-Alpha-reductase, Raf protein kinase (such as 1, B), RAF1 gene, Ras gene, Ras GTPase, RET gene, Ret tyrosine kinase receptor, retinoblastoma associated protein, retinoic acid receptor (such as gamma), Retinoid X receptor, 5 Rheb (Ras homolog enriched in brain) GTPase, Rho (Ras homolog) associated protein kinase 2, ribonuclease, Ribonucleotide reductase (such as M2 subunit), Ribosomal protein S6 kinase, RNA polymerase (such as I, II), Ron (Recepteur d'Origine Nantais) tyrosine kinase, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) gene, Ros1 tyrosine kinase, Runt-related transcription factor 3, Gamma-secretase, S100 calcium binding protein A9, Sarco endoplasmic calcium ATPase, Second 10 mitochondria-derived activator of caspases (SMAC) protein, Secreted frizzled related protein-2, Semaphorin-4D, Serine protease, serine/threonine kinase (STK), serine/threonine-protein kinase (TBK, such as TBK1), signal transduction and transcription (STAT, such as STAT-1, STAT-3, STAT-5), Signaling lymphocytic activation molecule (SLAM) family member 7, six-transmembrane epithelial antigen of the prostate (STEAP) gene, SL cytokine ligand, smoothened (SMO) receptor, Sodium iodide 15 cotransporter, Sodium phosphate cotransporter 2B, Somatostatin receptor (such as 1, 2, 3, 4, 5), Sonic hedgehog protein, Son of sevenless (SOS), Specific protein 1 (Sp1) transcription factor, Sphingomyelin synthase, Sphingosine kinase (such as 1, 2), Sphingosine-1-phosphate receptor-1, spleen tyrosine kinase (SYK), SRC gene, Src tyrosine kinase, STAT3 gene, Steroid sulfatase, Stimulator of interferon genes (STING) receptor, stimulator of interferon genes protein, Stromal cell-derived factor 1 ligand, SUMO 20 (small ubiquitin-like modifier), Superoxide dismutase, Survivin protein, Synapsin 3, Syndecan-1, Synuclein alpha, T cell surface glycoprotein CD28, tank-binding kinase (TBK), TATA box-binding protein-associated factor RNA polymerase I subunit B (TAF1B) gene, T-cell CD3 glycoprotein zeta chain, T-cell differentiation antigen CD6, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), T-cell surface glycoprotein CD8, Tec protein tyrosine kinase, Tek tyrosine kinase receptor, 25 telomerase, Telomerase reverse transcriptase (TERT) gene, Tenascin, TGF beta 2 ligand, Thrombopoietin receptor, Thymidine kinase, Thymidine phosphorylase, Thymidylate synthase, Thymosin (such as alpha 1), Thyroid hormone receptor, Thyroid stimulating hormone receptor, Tissue factor, TNF related apoptosis inducing ligand, TNFR1 associated death domain protein, TNF-related apoptosis-inducing ligand (TRAIL) receptor, TNFSF11 gene, TNFSF9 gene, Toll-like receptor (TLR 30 such as 1-13), topoisomerase (such as I, II, III), Transcription factor, Transferase, Transferrin, Transforming growth factor (TGF, such as beta) kinase, Transforming growth factor TGF- β receptor kinase, Transglutaminase, Translocation associated protein, Transmembrane glycoprotein NMB, Trop-2 calcium signal transducer, trophoblast glycoprotein (TPBG) gene, Trophoblast glycoprotein, Tropomyosin receptor kinase (Trk) receptor (such as TrkA, TrkB, TrkC), Tryptophan 5-hydroxylase, 35 Tubulin, Tumor necrosis factor (TNF, such as alpha, beta), Tumor necrosis factor 13C receptor, tumor progression locus 2 (TPL2), Tumor protein 53 (TP53) gene, Tumor suppressor candidate 2 (TUSC2) gene, Tyrosinase, Tyrosine hydroxylase, tyrosine kinase (TK), Tyrosine kinase receptor, Tyrosine kinase with immunoglobulin-like and EGF-like domains (TIE) receptor, Tyrosine protein kinase ABL1

inhibitor, Ubiquitin, Ubiquitin carboxyl hydrolase isozyme L5, Ubiquitin thioesterase-14, Ubiquitin-conjugating enzyme E21 (UBE2I, UBC9), Urease, Urokinase plasminogen activator, Uteroglobin, Vanilloid VR1, Vascular cell adhesion protein 1, vascular endothelial growth factor receptor (VEGFR), V-domain Ig suppressor of T-cell activation (VISTA), VEGF-1 receptor, VEGF-2 receptor, VEGF-3
5 receptor, VEGF-A, VEGF-B, Vimentin, Vitamin D3 receptor, Proto-oncogene tyrosine-protein kinase Yes, Wee-1 protein kinase, Wilms' tumor antigen 1, Wilms' tumor protein, X-linked inhibitor of apoptosis protein, Zinc finger protein transcription factor or any combination thereof.

Thus, in one embodiment, a method of treating cancer and/or diseases or symptoms that co-present or are exacerbated or triggered by the cancer e.g., an allergic disorder and/or an autoimmune
10 and/or inflammatory disease, and/or an acute inflammatory reaction, comprises administering to a patient in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with an additional agent (e.g., a second, third, fourth or fifth active agent) which can be useful for treating a cancer, an allergic disorder and/or an autoimmune and/or inflammatory disease, and/or an acute inflammatory reaction incident to or co-presenting with a cancer.
15 Treatment with the second, third, fourth or fifth active agent may be prior to, concomitant with, or following treatment with a compound of formula (I) or a pharmaceutically acceptable salt thereof. In one embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is combined with another active agent in a single dosage form. Suitable antitumor or anticancer therapeutics that may be used in combination with a compound of formula (I) or a pharmaceutically acceptable salt thereof
20 include, but are not limited to, chemotherapeutic agents, for example mitomycin C, carboplatin, taxol, cisplatin, paclitaxel, etoposide, doxorubicin, or a combination comprising at least one of the foregoing chemotherapeutic agents. Radiotherapeutic antitumor agents may also be used, alone or in combination with chemotherapeutic agents.

A compound of formula (I) or a pharmaceutically acceptable salt thereof can be useful as chemo-
25 sensitizing agents, and thus, can be useful in combination with other chemotherapeutic drugs, in particular, drugs that induce apoptosis. Thus, in one embodiment, the present disclosure provides a method for increasing sensitivity of cancer cells to chemotherapy, comprising administering to a patient in need of or undergoing chemotherapy, a chemotherapeutic agent together with a compound of formula (I), or a pharmaceutically acceptable salt thereof in an amount sufficient to increase the sensitivity of
30 cancer cells to the chemotherapeutic agent.

Anti-Cancer Combination Therapy

The compounds described herein may be used or combined with one or more of a chemotherapeutic agent, an anti-cancer agent, an anti-angiogenic agent, an anti-fibrotic agent, an immunotherapeutic agent, a therapeutic antibody, a bispecific antibody and "antibody-like" therapeutic
35 protein (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs®, Fab derivatives), an antibody-drug conjugate (ADC), a radiotherapeutic agent, an anti-neoplastic agent, an anti-proliferation agent, an

oncolytic virus, a gene modifier or editor (such as CRISPR/ Cas9, zinc finger nucleases or synthetic nucleases, TALENs), a CAR (chimeric antigen receptor) T-cell immunotherapeutic agent, an engineered T cell receptor (TCR-T), or any combination thereof. These therapeutic agents may be in the forms of compounds, antibodies, polypeptides, or polynucleotides. In one embodiment, the application provides a product comprising a compound described herein and an additional therapeutic agent as a combined preparation for simultaneous, separate, or sequential use in therapy.

As used herein, the term “chemotherapeutic agent” or “chemotherapeutic” (or “chemotherapy” in the case of treatment with a chemotherapeutic agent) is meant to encompass any non-proteinaceous (*i.e.*, non-peptidic) chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include but not limited to: alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodepa, carboquone, meturedepa, and uredepa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate, and trimethylolmelamine; acetogenins, especially bullatacin and bullatacinone; a camptothecin, including synthetic analog topotecan; bryostatin, callystatin; CC-1065, including its adozelesin, carzelesin, and bizelesin synthetic analogs; cryptophycins, particularly cryptophycin 1 and cryptophycin 8; dolastatin; duocarmycin, including the synthetic analogs KW-2189 and CBI-TMI; eleutherobin; 5-azacytidine; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cyclophosphamide, glufosfamide, evofosfamide, bendamustine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard; nitrosoureas such as carmustine, chlorozotocin, foremustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (*e.g.*, calicheamicin, especially calicheamicin gammaII and calicheamicin phiII), dynemicin including dynemicin A, bisphosphonates such as clodronate, an esperamicin, neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores, aclacinomycins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, carabycin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as demopterin, methotrexate, pteropterin, and trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone; anti-adrenals such as aminoglutethimide, mitotane, and trilostane; folic acid replenishers such as froinic acid; radiotherapeutic

agents such as Radium-223; trichothecenes, especially T-2 toxin, verracurin A, roridin A, and anguidine; taxoids such as paclitaxel (TAXOL[®]), abraxane, docetaxel (TAXOTERE[®]), cabazitaxel, BIND-014, tesetaxel; platinum analogs such as cisplatin and carboplatin, NC-6004 nanoplatin; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil; bisantrene; 5 edatraxate; defofamine; demecolcine; diaziquone; elformthine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; leucovorin; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; losoxantrone; fluoropyrimidine; folinic acid; podophyllinic acid; 2-ethylhydrazide; procarbazine; polysaccharide-K (PSK); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; 10 trabectedin, triaziquone; 2,2',2''-tricyclohexylmethylamine; urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiopeta; chlorambucil; gemcitabine (GEMZAR[®]); 6-thioguanine; mercaptopurine; methotrexate; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vancristine; vinorelbine (NAVELBINE[®]); novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeoloda; ibandronate; CPT-11; 15 topoisomerase inhibitor RFS 2000; difluoromethylornithine (DFMO); retinoids such as retinoic acid; capecitabine; NUC-1031; FOLFIRI (fluorouracil, leucovorin, and irinotecan); and pharmaceutically acceptable salts, acids, or derivatives of any of the above.

The compound described herein may be used or combined with one or more of the additional therapeutic agents. Therapeutic agents may be categorized by their mechanism of action into, for 20 example, the following groups:

anti-metabolites/anti-cancer agents, such as pyrimidine analogs floxuridine, capecitabine, cytarabine, CPX-351 (liposomal cytarabine, daunorubicin), and TAS-118;

purine analogs, folate antagonists (such as pralatrexate), and related inhibitors;

antiproliferative/antimitotic agents including natural products, such as vinca alkaloids 25 (vinblastine, vincristine) and microtubule disruptors such as taxane (paclitaxel, docetaxel), vinblastin, nocodazole, epothilones, vinorelbine (NAVELBINE[®]), and epipodophyllotoxins (etoposide, teniposide);

DNA damaging agents, such as actinomycin, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide (CYTOXAN[®]), dactinomycin, daunorubicin, doxorubicin, epirubicin, iphosphamide, melphalan, merchloroethamine, mitomycin C, mitoxantrone, nitrosourea, procarbazine, 30 taxol, Taxotere, teniposide, etoposide, and triethylenethiophosphoramide;

DNA-hypomethylating agents, such as guadecitabine (SGI-110), ASTX727;

antibiotics such as dactinomycin, daunorubicin, doxorubicin, idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin);

enzymes such as L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine;

antiplatelet agents;

DNAi oligonucleotides targeting Bcl-2, such as PNT2258;

5 agents that activate or reactivate latent human immunodeficiency virus (HIV), such as panobinostat and romidepsin;

asparaginase stimulators, such as crisantaspase (Erwinase®) and GRASPA (ERY-001, ERY-ASP), calaspargase pegol;

pan-Trk, ROS1 and ALK inhibitors, such as entrectinib, TPX-0005;

10 anaplastic lymphoma kinase (ALK) inhibitors, such as alectinib, ceritinib;

antiproliferative/antimitotic alkylating agents, such as nitrogen mustard cyclophosphamide and analogs (melphalan, chlorambucil, hexamethylmelamine, thiotepa), alkyl nitrosoureas (carmustine) and analogs, streptozocin, and triazenes (dacarbazine);

antiproliferative/antimitotic antimetabolites, such as folic acid analogs (methotrexate);

15 platinum coordination complexes (cisplatin, oxiloplatinim, and carboplatin), procarbazine, hydroxyurea, mitotane, and aminoglutethimide;

hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, and nilutamide), and aromatase inhibitors (letrozole and anastrozole);

anticoagulants such as heparin, synthetic heparin salts, and other inhibitors of thrombin;

20 fibrinolytic agents such as tissue plasminogen activator, streptokinase, urokinase, aspirin, dipyridamole, ticlopidine, and clopidogrel;

antimigratory agents;

antisecretory agents (breveldin);

immunosuppressives, such as tacrolimus, sirolimus, azathioprine, and mycophenolate;

25 growth factor inhibitors, and vascular endothelial growth factor inhibitors;

fibroblast growth factor inhibitors, such as FPA14;

- anti-VEGFR antibodies, such as IMC-3C5, GNR-011, tanibirumab;
- anti-VEGF/DDL4 antibodies, such as ABT-165;
- anti-cadherins antibodies, such as HKT-288;
- anti-CD70 antibodies, such as AMG-172;
- 5 anti-leucine-rich repeat containing 15 (LRRC15) antibodies, such as ABBV-085, and ARGX-110;
- angiotensin receptor blockers, nitric oxide donors;
- antisense oligonucleotides, such as AEG35156, IONIS-KRAS-2.5Rx, EZN-3042, RX-0201, IONIS-AR-2.5Rx, BP-100 (prexigebersen), IONIS-STAT3-2.5Rx;
- 10 DNA interference oligonucleotides, such as PNT2258, AZD-9150;
- anti-ANG-2 antibodies, such as MEDI3617, and LY3127804;
- anti-ANG-1/ANG-2 antibodies, such as AMG-780;
- anti-MET/EGFR antibodies, such as LY3164530;
- anti-EGFR antibodies, such as ABT-414, AMG-595, necitumumab, ABBV-221, depatuxizumab
- 15 mafodotin (ABT-414), tomuzotuximab, ABT-806, vectibix, modotuximab, RM-1929;
- anti-CSF1R antibodies, such as emactuzumab, LY3022855, AMG-820, FPA-008 (cabiralizumab);
- anti-CD40 antibodies, such as RG7876, SEA-CD40, APX-005M, ABBV-428;
- anti-endoglin antibodies, such as TRC105 (carotuximab);
- 20 anti-CD45 antibodies, such as 131I-BC8 (lomab-B);
- anti-HER3 antibodies, such as LJM716, GSK2849330;
- anti-HER2 antibodies, such as margetuximab, MEDI4276, BAT-8001;
- anti-HLA-DR antibodies, such as IMMU-114;
- anti-IL-3 antibodies, such as JNJ-56022473;

anti-OX40 antibodies, such as MEDI6469, MEDI6383, MEDI0562 (tavolixizumab), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368;

anti-EphA3 antibodies, such as KB-004;

5 anti-CD20 antibodies, such as obinutuzumab, IGN-002;

anti-CD20/CD3 antibodies, such as RG7828;

anti-CD37 antibodies, such as AGS67E, otlertuzumab (TRU-016);

anti-ENPP3 antibodies, such as AGS-16C3F;

anti-FGFR-3 antibodies, such as LY3076226, B-701;

10 anti-FGFR-2 antibodies, such as GAL-F2;

anti-C5 antibodies, such as ALXN-1210;

anti-CD27 antibodies, such as varlilumab (CDX-1127);

anti-TROP-2 antibodies, such as IMMU-132

anti-NKG2a antibodies, such as monalizumab;

15 anti-VISTA antibodies, such as HMBD-002;

anti-PVRIG antibodies, such as COM-701;

anti-EpCAM antibodies, such as VB4-845;

anti-BCMA antibodies, such as GSK-2857916

anti-CEA antibodies, such as RG-7813;

20 anti- cluster of differentiation 3 (CD3) antibodies, such as MGD015;

anti-folate receptor alpha antibodies, such as IMGN853;

MCL-1 inhibitors, such as AMG-176, AMG-397, S-64315, and AZD-5991, 483-LM, A-1210477, UMI-77, JKY-5-037;

epha2 inhibitors, such as MM-310;

25 anti LAG-3 antibodies, such as relatlimab (ONO-4482), LAG-525, MK-4280, REGN-3767;

- raf kinase/VEGFR inhibitors, such as RAF-265;
- polycomb protein (EED) inhibitors, such as MAK683;
- anti-fibroblast activation protein (FAP)/IL-2R antibodies, such as RG7461;
- anti-fibroblast activation protein (FAP)/TRAIL-R2 antibodies, such as RG7386;
- 5 anti-fucosyl-GM1 antibodies, such as BMS-986012;
- p38 MAP kinase inhibitors, such as ralimetinib;
- PRMT1 inhibitors, such as MS203;
- Sphingosine kinase 2 (SK2) inhibitors, such as opaganib;
- FLT3-ITD inhibitors, such as BCI-332;
- 10 Nuclear erythroid 2-related factor 2 stimulators, such as omaveloxolone (RTA-408);
- Tropomyosin receptor kinase (TRK) inhibitors, such as LOXO-195, ONO-7579;
- anti-ICOS antibodies, such as JTX-2011, GSK3359609;
- anti-DR5 (TRAIL2) antibodies, such as DS-8273;
- anti-GD2 antibodies, such as APN-301;
- 15 anti-interleukin-17 (IL-17) antibodies, such as CJM-112;
- anti- carbonic anhydrase IX antibodies, such as TX-250;
- anti-CD38-attenukine, such as TAK573;
- anti-Mucin 1 antibodies, such as gatipotuzumab;
- Mucin 1 inhibitors, such as GO-203-2C;
- 20 MARCKS protein inhibitors, such as BIO-11006;
- Folate antagonists, such as arfolitixorin;
- Galectin-3 inhibitors, such as GR-MD-02;
- Phosphorylated P68 inhibitors, such as RX-5902;

- CD95/TNF modulators, such as ofranergene obadenovec;
- PI3K/Akt/mTOR inhibitors, such as ABTL-0812;
- pan-PIM kinase inhibitors, such as INCB-053914;
- IL-12 gene stimulators, such as EGEN-001, tavokinogene telseplasmid;
- 5 Heat shock protein HSP90 inhibitors, such as TAS-116, PEN-866;
- VEGF/HGF antagonists, such as MP-0250;
- SYK tyrosine kinase/FLT3 tyrosine kinase inhibitors, such as TAK-659;
- SYK tyrosine kinase/ JAK tyrosine kinase inhibitors, such as ASN-002;
- FLT3 tyrosine kinase, such as FF-10101;
- 10 FMS-like tyrosine kinase-3 ligand (FLT3L), such as CDX-301;
- FLT3/MEK1 inhibitors, such as E-6201;
- IL-24 antagonist, such as AD-IL24;
- RIG-I agonists, such as RGT-100;
- Aerolysin stimulators, such as topsalysin;
- 15 P-Glycoprotein 1 inhibitors, such as HM-30181A;
- CSF-1 antagonists, such as ARRY-382, BLZ-945;
- CCR8 inhibitors, such as I-309, SB-649701, HG-1013, RAP-310;
- anti-Mesothelin antibodies, such as SEL-403;
- Thymidine kinase stimulators, such as aglatimagene besadenovec;
- 20 Polo-like kinase 1 inhibitors, such as PCM-075;
- TLR-7 agonists, such as TMX-101 (imiquimod);
- NEDD8 inhibitors, such as pevonedistat (MLN-4924), TAS-4464;
- Pleiotropic pathway modulators, such as avadomide (CC-122);

- FoxM1 inhibitors, such as thiostrepton;
- Anti-MUC1 antibodies, such as Mab-AR-20.5;
- anti-CD38 antibodies, such as isatuximab, MOR-202;
- UBA1 inhibitors, such as TAK-243;
- 5 Src tyrosine kinase inhibitors, such as VAL-201;
- VDAC/HK inhibitors, such as VDA-1102;
- BRAF/PI3K inhibitors, such as ASN-003;
- Elf4a inhibitors, such as rohinitib, eFT226;
- TP53 gene stimulators, such as ad-p53;
- 10 PD-L1/EGFR inhibitors, such as GNS-1480;
- Retinoic acid receptor alpha (RAR α) inhibitors, such as SY-1425;
- SIRT3 inhibitors, such as YC8-02;
- Stromal cell-derived factor 1 ligand inhibitors, such as olaptosed pegol (NOX-A12);
- IL-4 receptor modulators, such as MDNA-55;
- 15 Arginase-I stimulators, such as pegzilarginase;
- Topoisomerase I inhibitor/ hypoxia inducible factor-1 alpha inhibitors, such as PEG-SN38 (firtecan pegol);
- Hypoxia inducible factor-1 alpha inhibitors, such as PT-2977, PT-2385;
- CD122 agonists such as NKTR-214;
- 20 p53 tumor suppressor protein stimulators such as kevetrin;
- Mdm4/Mdm2 p53-binding protein inhibitors, such as ALRN-6924;
- kinesin spindle protein (KSP) inhibitors, such as filanesib (ARRY-520);
- CD80-fc fusion protein inhibitors, such as FPT-155;
- Menin and mixed lineage leukemia (MLL) inhibitors such as KO-539;

- Liver x receptor agonists, such as RGX-104;
- IL-10 agonists, such as AM-0010;
- EGFR/ErbB-2 inhibitors, such as varlitinib;
- VEGFR/PDGFR inhibitors, such as vorolanib;
- 5 IRAK4 inhibitors, such as CA-4948;
- anti-TLR-2 antibodies, such as OPN-305;
- Calmodulin modulators, such as CBP-501;
- Glucocorticoid receptor antagonists, such as relacorilant (CORT-125134);
- Second mitochondria-derived activator of caspases (SMAC) protein inhibitors, such as BI-
10 891065;
- Lactoferrin modulators, such as LTX-315;
- Kit tyrosine kinase/PDGF receptor alpha antagonists such as DCC-2618;
- KIT inhibitors, such as PLX-9486;
- Exportin 1 inhibitors, such as eltanexor;
- 15 EGFR/ErbB2/Ephb4 inhibitors, such as tesevatinib;
- anti-CD33 antibodies, such as IMGN-779;
- anti-KMA antibodies, such as MDX-1097;
- anti-TIM-3 antibodies, such as TSR-022, LY-3321367, MBG-453;
- anti-CD55 antibodies, such as PAT-SC1;
- 20 anti-PSMA antibodies, such as ATL-101;
- anti-CD100 antibodies, such as VX-15;
- anti-EPHA3 antibodies, such as fibatuzumab;
- anti-ErbB antibodies, such as CDX-3379, HLX-02, seribantumab ;
- anti-APRIL antibodies, such as BION-1301;

Anti-Tigit antibodies, such as BMS-986207, RG-6058;

CHST15 gene inhibitors, such as STNM-01;

RAS inhibitors, such as NEO-100;

Somatostatin receptor antagonist, such as OPS-201;

5 CEBPA gene stimulators, such as MTL-501;

DKK3 gene modulators, such as MTG-201;

p70s6k inhibitors, such as MSC2363318A;

methionine aminopeptidase 2 (MetAP2) inhibitors, such as M8891, APL-1202;

arginine N-methyltransferase 5 inhibitors, such as GSK-3326595;

10 anti-programmed cell death protein 1 (anti-PD-1) antibodies, such as nivolumab (OPDIVO®, BMS-936558, MDX-1106), pembrolizumab (KEYTRUDA®, MK-3477, SCH-900475, lambrolizumab, CAS Reg. No. 1374853-91-4), pidilizumab, PF-06801591, BGB-A317, GLS-010 (WBP-3055), AK-103 (HX-008), MGA-012, BI-754091, REGN-2810 (cemiplimab), AGEN-2034, JS-001, JNJ-63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, BAT-1306, and anti-

15 programmed death-ligand 1 (anti-PD-L1) antibodies such as BMS-936559, atezolizumab (MPDL3280A), durvalumab (MEDI4736), avelumab, CK-301, (MSB0010718C), MEDI0680, CX-072, CBT-502, PDR-001 (spartalizumab), TSR-042 (dostarlimab), JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308, FAZ-053, and MDX1105-01;

PD-L1/VISTA antagonists such as CA-170;

20 anti-PD-L1/TGFβ antibodies, such as M7824;

anti-transferrin antibodies, such as CX-2029;

anti-IL-8 (Interleukin-8) antibodies, such as HuMax-Inflam;

ATM (ataxia telangiectasia) inhibitors, such as AZD0156;

CHK1 inhibitors, such as GDC-0575, LY2606368 (prexasertib), SRA737, RG7741 (CHK1/2);

25 CXCR4 antagonists, such as BL-8040, LY2510924, burixafor (TG-0054), X4P-002, X4P-001-IO;

EXH2 inhibitors, such as GSK2816126;

HER2 inhibitors, such as neratinib, tucatinib (ONT-380);

KDM1 inhibitors, such as ORY-1001, IMG-7289, INCB-59872, GSK-2879552;

CXCR2 antagonists, such as AZD-5069;

GM-CSF antibodies, such as lenzilumab;

5 DNA dependent protein kinase inhibitors, such as MSC2490484A (nedisertib), VX-984, AsiDNA (DT-01);

protein kinase C (PKC) inhibitors, such as LXS-196, and sotrastaurin;

Selective estrogen receptor downregulators (SERD), such as fulvestrant (Faslodex®), RG6046, RG6047, elacestrant (RAD-1901) and AZD9496;

10 Selective estrogen receptor covalent antagonists (SERCAs), such as H3B-6545;

selective androgen receptor modulator (SARM), such as GTX-024, and darolutamide;

transforming growth factor-beta (TGF-beta) kinase antagonists, such as galunisertib;

anti-transforming growth factor-beta (TGF-beta) antibodies, such as LY3022859, NIS793, and XOMA 089;

15 bispecific antibodies, such as MM-141 (IGF-1/ErbB3), MM-111 (Erb2/Erb3), JNJ-64052781 (CD19/CD3), PRS-343 (CD-137/HER2), AFM26 (BCMA/CD16A), JNJ-61186372 (EGFR/cMET), AMG-211 (CEA/CD3), RG7802 (CEA/CD3), ERY-974 (CD3/GPC3) vancizumab (angiopoietins/VEGF), PF-06671008 (Cadherins/CD3), AFM-13 (CD16/CD30), APVO436 (CD123/CD3), flotetuzumab (CD123/CD3), REGN-1979 (CD20/CD3), MCLA-117 (CD3/CLEC12A),
20 MCLA-128 (HER2/HER3), JNJ-0819, JNJ-7564 (CD3/heme), AMG-757 (DLL3-CD3), MGD-013 (PD-1/LAG-3), AK-104 (CTLA-4/PD-1), AMG-330 (CD33/CD3), AMG-420 (BCMA/CD3), BI-836880 (VEFG/ANG2), JNJ-63709178 (CD123/CD3), MGD-007 (CD3/gpA33), and MGD-009 (CD3/B7H3);

mutant selective EGFR inhibitors, such as PF-06747775, EGF816 (nazartinib), ASP8273, ACEA-0010, and BI-1482694;

25 anti-GITR (glucocorticoid-induced tumor necrosis factor receptor-related protein) antibodies, such as MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, and GWN-323;

anti-delta-like protein ligand 3 (DDL3) antibodies, such as rovalpituzumab tesirine;

anti-clusterin antibodies, such as AB-16B5;

- anti-Ephrin-A4 (EFNA4) antibodies, such as PF-06647263;
- anti-RANKL antibodies, such as denosumab;
- anti- mesothelin antibodies, such as BMS-986148, and anti-MSLN-MMAE;
- anti- sodium phosphate cotransporter 2B (NaP2B) antibodies, such as lifastuzumab
- 5 anti-c-Met antibodies, such as ABBV-399;
- adenosine A2A receptor antagonists, such as CPI-444, AZD-4635, preladenant, and PBF-509;
- alpha-ketoglutarate dehydrogenase (KGDH) inhibitors, such as CPI-613;
- XPO1 inhibitors, such as selinexor (KPT-330);
- isocitrate dehydrogenase 2 (IDH2) inhibitors, such as enasidenib (AG-221);
- 10 IDH1 inhibitors such as AG-120, and AG-881 (IDH1 and IDH2), IDH-305, and BAY-1436032;
- interleukin-3 receptor (IL-3R) modulators, such as SL-401;
- Arginine deiminase stimulators, such as pegarginase (ADI-PEG-20);
- antibody-drug conjugates, such as MLN0264 (anti-GCC, guanylyl cyclase C), T-DM1 (trastuzumab emtansine, Kadcycla), milatuzumab-doxorubicin (hCD74-DOX), brentuximab vedotin, DCDT2980S, polatuzumab vedotin, SGN-CD70A, SGN-CD19A, inotuzumab ozogamicin, lorvotuzumab mertansine, SAR3419, isactuzumab govitecan, enfortumab vedotin (ASG-22ME), ASG-15ME, DS-8201 ((trastuzumab deruxtecan), 225Ac-lintuzumab, U3-1402, 177Lu-tetraxetan-tetuloa, tisotumab vedotin, anetumab ravtansine, CX-2009, SAR-566658, W-0101, polatuzumab vedotin, and ABBV-085;
- 15 claudin-18 inhibitors, such as claudiximab;
- 20 β -catenin inhibitors, such as CWP-291;
- anti-CD73 antibodies, such as MEDI-9447 (oleclumab), CPX-006, IPH-53, BMS-986179, and NZV-930;
- CD73 antagonists, such as AB-680, PSB-12379, PSB-12441, PSB-12425, and CB-708;
- CD39/CD73 antagonists, such as PBF-1662;
- 25 chemokine receptor 2 (CCR) inhibitors, such as PF-04136309, CCX-872, and BMS-813160 (CCR2/CCR5)

thymidylate synthase inhibitors, such as ONX-0801;

ALK/ROS1 inhibitors, such as lorlatinib;

tankyrase inhibitors, such as G007-LK;

Mdm2 p53-binding protein inhibitors, such as CMG-097, and HDM-201;

5 c-PIM inhibitors, such as PIM447;

BRAF inhibitors, such as dabrafenib, vemurafenib, encorafenib (LGX818), and PLX8394;

sphingosine kinase-2 (SK2) inhibitors, such as Yeliva® (ABC294640);

cell cycle inhibitors, such as selumetinib (MEK1/2), and sapacitabine;

10 AKT inhibitors such as MK-2206, ipatasertib, afuresertib, AZD5363, and ARQ-092, capivasertib,
and triciribine;

anti-CTLA-4 (cytotoxic T-lymphocyte protein-4) inhibitors, such as tremelimumab, AGEN-
1884, and BMS-986218;

c-MET inhibitors, such as AMG-337, savolitinib, tivantinib (ARQ-197), capmatinib, and
tepotinib, ABT-700, AG213, AMG-208, JNJ-38877618 (OMO-1), merestinib, and HQP-8361;

15 c-Met/VEGFR inhibitors, such as BMS-817378, and TAS-115;

c-Met/RON inhibitors, such as BMS-777607;

BRAF/EGFR inhibitors, such as BGB-283;

bcr/abl inhibitors, such as rebastinib, asciminib;

MNK1/MNK2 inhibitors, such as eFT-508;

20 mTOR inhibitor/cytochrome P450 3A4 stimulators, such as TYME-88

lysine-specific demethylase-1 (LSD1) inhibitors, such as CC-90011;

Pan-RAF inhibitors, such as LY3009120, LXH254, and TAK-580;

Raf/MEK inhibitors, such as RG7304;

CSF1R/KIT and FLT3 inhibitors, such as pexidartinib (PLX3397);

25 kinase inhibitors, such as vandetanib;

E selectin antagonists, such as GMI-1271;

differentiation inducers, such as tretinoin;

epidermal growth factor receptor (EGFR) inhibitors, such as osimertinib (AZD-9291);

5 topoisomerase inhibitors, such as doxorubicin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan, mitoxantrone, pixantrone, sobuzoxane, topotecan, irinotecan, MM-398 (liposomal irinotecan), vosaroxin and GPX-150, aldoxorubicin, AR-67, mavelertinib, AST-2818, avitinib (ACEA-0010), and irofulven (MGI-114);

corticosteroids, such as cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prednisolone;

10 growth factor signal transduction kinase inhibitors;

nucleoside analogs, such as DFP-10917;

Axl inhibitors, such as BGB-324 (bemcentinib), and SLC-0211;

BET inhibitors, such as INCB-054329, INCB057643, TEN-010, AZD-5153, ABT-767, BMS-986158, CC-90010, GSK525762 (molibresib), NHWD-870, ODM-207, GSK-2820151, GSK-1210151A, 15 ZBC246, ZBC260, ZEN3694, FT-1101, RG-6146, CC-90010, mivebresib, BI-894999, PLX-2853, PLX-51107, CPI-0610, and GS-5829;

PARP inhibitors, such as olaparib, rucaparib, veliparib, talazoparib, ABT-767, and BGB-290;

proteasome inhibitors, such as ixazomib, carfilzomib (Kyprolis®), marizomib;

glutaminase inhibitors, such as CB-839;

20 vaccines, such as peptide vaccine TG-01 (RAS), GALE-301, GALE-302, nelipepimut-s, SurVaxM, DSP-7888, TPIV-200, PVX-410, VXL-100, DPX-E7, ISA-101, 6MHP, OSE-2101, galinpepimut-S, SVN53-67/M57-KLH, IMU-131; bacterial vector vaccines such as CRS-207/GVAX, axalimogene filolisbac (ADXS11-001); adenovirus vector vaccines such as nadofarogene firadenovec; autologous Gp96 vaccine; dendritic cells vaccines, such as CVactm, stapuldencel-T, eltrapuldencel-T, 25 SL-701, BSK01TM, rocapuldencel-T (AGS-003), DCVAC, CVactm, stapuldencel-T, eltrapuldencel-T, SL-701, BSK01TM, ADXS31-142; oncolytic vaccines such as, talimogene laherparepvec, pexastimogene devacirepvec, GL-ONC1, MG1-MA3, parvovirus H-1, ProstAtak, enadenotucirev, MG1MA3, ASN-002 (TG-1042); therapeutic vaccines, such as CVAC-301, CMP-001, PF-06753512, VBI-1901, TG-4010, ProscavaxTM; tumor cell vaccines, such as Vigil® (IND-14205), Oncoquest-L vaccine; live attenuated, 30 recombinant, serotype 1 poliovirus vaccine, such as PVS-RIPO; Adagloxad simolenin; MEDI-0457;

DPV-001 a tumor-derived, autophagosome enriched cancer vaccine; RNA vaccines such as , CV-9209, LV-305; DNA vaccines, such as MEDI-0457, MVI-816, INO-5401; modified vaccinia virus Ankara vaccine expressing p53, such as MVA-p53; DPX-Survivac; BriaVax™; GI-6301; GI-6207; and GI-4000;

anti-DLL4 (delta like ligand 4) antibodies, such as demcizumab;

5 STAT-3 inhibitors, such as napabucasin (BBI-608);

ATPase p97 inhibitors, such as CB-5083;

smoothened (SMO) receptor inhibitors, such as Odomzo® (sonidegib, formerly LDE-225), LEQ506, vismodegib (GDC-0449), BMS-833923, glasdegib (PF-04449913), LY2940680, and itraconazole;

10 interferon alpha ligand modulators, such as interferon alpha-2b, interferon alpha-2a biosimilar (Biogenomics), ropeginterferon alfa-2b (AOP-2014, P-1101, PEG IFN alpha-2b), Multiferon (Alfanative, Viragen), interferon alpha 1b, Roferon-A (Canferon, Ro-25-3036), interferon alfa-2a follow-on biologic (Biosidus)(Inmutag, Inter 2A), interferon alfa-2b follow-on biologic (Biosidus - Bioferon, Citopheron, Ganapar, Beijing Kawin Technology – Kaferon), Alfaferone, pegylated interferon alpha-1b,
15 peginterferon alfa-2b follow-on biologic (Aomega), recombinant human interferon alpha-1b, recombinant human interferon alpha-2a, recombinant human interferon alpha-2b, veltuzumab-IFN alpha 2b conjugate, Dynavax (SD-101), and interferon alfa-n1 (Humoferon, SM-10500, Sumiferon);

interferon gamma ligand modulators, such as interferon gamma (OH-6000, Ogamma 100);

IL-6 receptor modulators, such as tocilizumab, siltuximab, and AS-101 (CB-06-02, IVX-Q-101);

20 Telomerase modulators, such as, tertomotide (GV-1001, HR-2802, Riavax) and imetelstat (GRN-163, JNJ-63935937);

DNA methyltransferases inhibitors, such as temozolomide (CCRG-81045), decitabine, guadecitabine (S-110, SGI-110), KRX-0402, RX-3117, RRx-001, and azacitidine;

DNA gyrase inhibitors, such as pixantrone and sobuzoxane;

25 Bcl-2 family protein inhibitors, such as ABT-263, venetoclax (ABT-199), ABT-737, and AT-101;

Notch inhibitors, such as LY3039478 (crenigacestat), tarextumab (anti-Notch2/3), and BMS-906024;

anti-myostatin inhibitors, such as landogrozumab;

- hyaluronidase stimulators, such as PEGPH-20;
- Wnt pathway inhibitors, such as SM-04755, PRI-724, and WNT-974;
- gamma-secretase inhibitors, such as PF-03084014, MK-0752, and RO-4929097;
- Grb-2 (growth factor receptor bound protein-2) inhibitors, such as BP1001;
- 5 TRAIL pathway-inducing compounds, such as ONC201, and ABBV-621;
- Focal adhesion kinase inhibitors, such as VS-4718, defactinib, and GSK2256098;
- hedgehog inhibitors, such as saridegib, sonidegib (LDE225), glasdegib and vismodegib;
- Aurora kinase inhibitors, such as alisertib (MLN-8237), and AZD-2811, AMG-900, barasertib, and ENMD-2076;
- 10 HSPB1 modulators (heat shock protein 27, HSP27), such as brivudine, and apatorsen;
- ATR inhibitors, such as BAY-937, AZD6738, AZD6783, VX-803, VX-970 (berzosertib) and VX-970;
- mTOR inhibitors, such as sapanisertib and vistusertib (AZD2014), and ME-344;
- mTOR/PI3K inhibitors, such as gedatolisib, GSK2141795, omipalisib, and RG6114;
- 15 Hsp90 inhibitors, such as AUY922, onalespib (AT13387), SNX-2112, SNX5422;
- murine double minute (mdm2) oncogene inhibitors, such as DS-3032b, RG7775, AMG-232, HDM201, and idasanutlin (RG7388);
- CD137 agonists, such as urelumab, utomilumab (PF-05082566);
- STING agonists, such as ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, AdvCA0848, GSK-532, SYN-STING, MSA-1, SR-8291;
- 20 FGFR inhibitors, such as FGF-401, INCB-054828, BAY-1163877, AZD4547, JNJ-42756493, LY2874455, and Debio-1347;
- fatty acid synthase (FASN) inhibitors, such as TVB-2640;
- anti-KIR monoclonal antibodies, such as lirilumab (IPH-2102), and IPH-4102;
- 25 antigen CD19 inhibitors, such as MOR208, MEDI-551, AFM-11, and inebilizumab;

- CD44 binders, such as A6;
- protein phosphatase 2A (PP2A) inhibitors, such as LB-100;
- CYP17 inhibitors, such as seviteronel (VT-464), ASN-001, ODM-204, CFG920, and abiraterone acetate;
- 5 RXR agonists, such as IRX4204;
- hedgehog/smoothened (hh/Smo) antagonists, such as taladegib, and patidegib;
- complement C3 modulators, such as Imprime PGG;
- IL-15 agonists, such as ALT-803, NKTR-255, and hetIL-15;
- EZH2 (enhancer of zeste homolog 2) inhibitors, such as tazemetostat, CPI-1205, GSK-2816126;
- 10 oncolytic viruses, such as pelareorep, CG-0070, MV-NIS therapy, HSV-1716, DS-1647, VCN-01, ONCOS-102, TBI-1401, tasadenoturev (DNX-2401), vocimagene amiretrorepvec, RP-1, CVA21, Celyvir, LOAd-703, and OBP-301;
- DOTIL (histone methyltransferase) inhibitors, such as pinometostat (EPZ-5676);
- toxins such as Cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, diphtheria toxin, and caspase activators;
- 15 DNA plasmids, such as BC-819;
- PLK inhibitors of PLK 1, 2, and 3, such as volasertib (PLK1);
- WEE1 inhibitors, such as AZD1775 (adavosertib);
- Rho kinase (ROCK) inhibitors, such as AT13148, and KD025;
- 20 ERK inhibitors, such as GDC-0994, LY3214996, and MK-8353;
- IAP inhibitors, such as ASTX660, debio-1143, birinapant, APG-1387, and LCL-161;
- RNA polymerase inhibitors, such as lurbinectedin (PM-1183), and CX-5461;
- tubulin inhibitors, such as PM-184, BAL-101553 (lisavanbulin), OXI-4503, fluorapacin (AC-0001), and plinabulin;
- 25 Toll-like receptor 4 (TL4) agonists, such as G100, GSK1795091, and PEPA-10;

elongation factor 1 alpha 2 inhibitors, such as plitidepsin;

CD95 inhibitors, such as APG-101, APO-010, and asunerecept;

WT1 inhibitors, such as DSP-7888;

splicing factor 3B subunit1 (SF3B1) inhibitors, such as H3B-8800

5 PDGFR alpha/KIT mutant-specific inhibitors such as BLU-285;

SHP-2 inhibitors, such as TNO155 (SHP-099), RMC-4550, JAB-3068, and RMC-4630; or

retinoid Z receptor gamma (ROR γ) agonists, such as LYC-55716.

Examples of other chemotherapeutic drugs that can be used in combination with compounds of formula (I), or a pharmaceutically acceptable salt thereof include topoisomerase I inhibitors
10 (camptothecin or topotecan), topoisomerase II inhibitors (e.g., daunomycin and etoposide), alkylating agents (e.g., cyclophosphamide, melphalan and BCNU), tubulin directed agents (e.g., taxol and vinblastine), and biological agents (e.g., antibodies such as anti CD20 antibody, IDEC 8, immunotoxins, and cytokines).

In some embodiments, the compound(s) of formula (I), or a pharmaceutically acceptable salt
15 thereof is used in combination with Rituxan® (Rituximab) and/or other agents that work by selectively depleting CD20+ B-cells.

Included herein are methods of treatment in which a compound of formula (I), or a pharmaceutically acceptable salt thereof is administered in combination with an anti-inflammatory agent. Anti-inflammatory agents include but are not limited to NSAIDs, non-specific and COX-2 specific
20 cyclooxygenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptors antagonists, immunosuppressants and methotrexate.

Examples of NSAIDs include, but are not limited to ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone,
25 sulfasalazine, tolmetin sodium, and hydroxychloroquine. Examples of NSAIDs also include COX-2 specific inhibitors (i.e., a compound that inhibits COX-2 with an IC₅₀ that is at least 50-fold lower than the IC₅₀ for COX-1) such as celecoxib, valdecoxib, lumiracoxib, etoricoxib and/or rofecoxib.

In a further embodiment, the anti-inflammatory agent is a salicylate. Salicylates include but are not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.

30 The anti-inflammatory agent may also be a corticosteroid. For example, the corticosteroid may be chosen from cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, and prednisone.

In some embodiments, the anti-inflammatory therapeutic agent is a gold compound such as gold sodium thiomalate or auranofin.


In some embodiments, the anti-inflammatory agent is a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.

In one embodiment, the compound(s) of formula (I), or a pharmaceutically acceptable salt thereof is used in combination with at least one anti-inflammatory compound that is an anti-C5 monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist, such as entanercept, or infliximab, which is an anti-TNF alpha monoclonal antibody.


In one embodiment, the compound(s) of formula (I), or a pharmaceutically acceptable salt thereof is used in combination with at least one active agent that is an immunosuppressant compound such as methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, or mycophenolate mofetil.

In other embodiments, the compound(s) of formula (I), or a pharmaceutically acceptable salt thereof is used in combination with one or more phosphatidylinositol 3-kinase (PI3K) inhibitors, including for example, Compounds A, B and C (whose structures are provided below), or a pharmaceutically acceptable salt thereof.


Compound A



Compound B



Compound C



Compounds A, B and C are disclosed in WO2015/017460 and WO2015/100217. PI3K inhibitors include inhibitors of PI3K γ , PI3K δ , PI3K β , PI3K α , and/or pan-PI3K. Additional examples of PI3K inhibitors include, but are not limited to, ACP-319, AEZA-129, AMG-319, AS252424, AZD8186, BAY 10824391, BEZ235, buparlisib (BKM120), BYL719 (alpelisib), CH5132799, copanlisib (BAY 80-6946), duvelisib, GDC-0941, GDC-0980, GSK2636771, GSK2269557, idelalisib (Zydelig®), IPI-145, IPI-443, IPI-549, KAR4141, LY294002, LY3023414, MLN1117, OXY111A, PA799, PX-866, RG7604, rigosertib, RP5090, tasislisib, TG100115, TGR-1202 (umbralisib), TGX221, WX-037, X-339, X-414, XL147 (SAR245408), XL499, XL756, wortmannin, ZSTK474, and the compounds described in WO 2005/113556 (ICOS), WO 2013/052699 (Gilead Calistoga), WO 2013/116562 (Gilead Calistoga), WO 2014/100765 (Gilead Calistoga), WO 2014/100767 (Gilead Calistoga), and WO 2014/201409 (Gilead Sciences). Further examples of PI3K inhibitors include, but are not limited to, GDC-0032, GDC-0077, INCB50465, RP6530, and SRX3177.

In yet another embodiment, the compound(s) of formula (I) may be used in combination with Spleen Tyrosine Kinase (SYK) Inhibitors. Examples of SYK inhibitors include, but are not limited to, 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, BAY-61-3606, cerdulatinib (PRT-062607), entospletinib, fostamatinib (R788), HMPL-523, NVP-QAB 205 AA, R112, R343, 5 tamatinib (R406), and those described in U.S. 8450321 (Gilead Connecticut) and those described in U.S. 2015/0175616.

In yet another embodiment, the compounds of formula (I) may be used in combination with Tyrosine-kinase Inhibitors (TKIs). TKIs may target epidermal growth factor receptors (EGFRs) and receptors for fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular 10 endothelial growth factor (VEGF). Examples of TKIs include, but are not limited to, afatinib, ARQ-087, asp5878, AZD3759, AZD4547, bosutinib, brigatinib, cabozantinib, cediranib, crenolanib, dacomitinib, dasatinib, dovitinib, E-6201, erdafitinib, erlotinib, gefitinib, gilteritinib (ASP-2215), FP-1039, HM61713, icotinib, imatinib, KX2-391 (Src), lapatinib, lestaurtinib, midostaurin, nintedanib, ODM-203, osimertinib (AZD-9291), ponatinib, poziotinib, quizartinib, radotinib, rociletinib, sulfatinib (HMPL-012), sunitinib, 15 and TH-4000. In certain embodiments, TKIs include, but are not limited to, afatinib, ARQ-087 (derazantinib), asp5878, AZD3759, AZD4547, bosutinib, brigatinib, cabozantinib, cediranib, crenolanib, dacomitinib, dasatinib, dovitinib, E-6201, erdafitinib, erlotinib, gefitinib, gilteritinib (ASP-2215), FP-1039, HM61713, icotinib, imatinib, KX2-391 (Src), lapatinib, lestaurtinib, lenvatinib, midostaurin, nintedanib, ODM-203, osimertinib (AZD-9291), ponatinib, poziotinib, quizartinib, radotinib, rociletinib, 20 sulfatinib (HMPL-012), sunitinib, tivoanib, TH-4000, and MEDI-575 (anti-PDGFR antibody).

In yet other embodiments, the compound(s) of formula (I), or a pharmaceutically acceptable salt thereof is used in combination with one or more inhibitors of lysyl oxidase-like 2 (LOXL) or a substance that binds to LOXL, including for example, a humanized monoclonal antibody (mAb) with an immunoglobulin IgG4 isotype directed against human LOXL2. LOXL inhibitors include inhibitors of 25 LOXL1, LOXL2, LOXL3, LOXL4, and/or LOXL5. Examples of LOXL inhibitors include, but are not limited to, the antibodies described in WO 2009/017833 (Arresto Biosciences). Examples of LOXL2 inhibitors include, but are not limited to, the antibodies described in WO 2009/017833 (Arresto Biosciences), WO 2009/035791 (Arresto Biosciences), and WO 2011/097513 (Gilead Biologics).

In yet another embodiment, the compounds of formula (I) may be used in combination with Toll- 30 like receptor 8 (TLR8) inhibitors. Examples of TLR8 inhibitors include, but are not limited to, E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, VTX-1463, and VTX-763.

In yet another embodiment, the compounds of formula (I) may be used in combination with Toll- like receptor (TLR9) inhibitors. Examples of TLR9 inhibitors include, but are not limited to, AST-008, 35 IMO-2055, IMO-2125, lefitolimod, litemimod, MGN-1601, and PUL-042.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with a BTK (Bruting's Tyrosine kinase) inhibitor. An example of such BTK inhibitor is a compound disclosed in U.S. patent 7,405,295. Additional examples of BTK inhibitors include, but are not limited to, (S)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one, acalabrutinib (ACP-196), BGB-3111, HM71224, ibrutinib, M-2951 (evobrutinib), tirabrutinib (ONO-4059), PRN-1008, spebrutinib (CC-292), and TAK-020. Further examples of BTK inhibitors include, but are not limited to, CB988, M7583, vecabrutinib, ARQ-531, SHR-1459, DTRMWXHS-12, and TAS-5315.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with a BET inhibitor. An example of such BET inhibitor is a compound disclosed in WO2014/182929, the entire contents of which are incorporated herein by reference.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with a TBK (Tank Binding kinase) inhibitor. An example of such TBK inhibitor is a compound disclosed in WO2016/049211.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with a MMP inhibitor. Exemplary MMP inhibitors include inhibitors of MMP1 through 10. Additional examples of MMP9 inhibitors include, but are not limited to, marimastat (BB-2516), cipemastat (Ro 32-3555), GS-5745 (andecaliximab) and those described in WO 2012/027721 (Gilead Biologics).

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with a OX40 inhibitor. An example of such OX40 inhibitor is a compound disclosed in U.S. 8,450,460, the entire contents of which are incorporated herein by reference.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with a JAK-1 inhibitor. An example of such JAK-1 inhibitor is a compound disclosed in WO2008/109943. Examples of other JAK inhibitors include, but are not limited to, AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110 (itacitinib), lestaurtinib, momelotinib (CYT0387), NS-018, pacritinib (SB1518), peficitinib (ASP015K), ruxolitinib, tofacitinib (formerly tasocitinib), INCB052793, and XL019.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with an Indoleamine-pyrrole-2,3-dioxygenase (IDO) inhibitors. An example of such IDO inhibitor is a compound disclosed in WO2016/186967. In one embodiment, the compounds of formula (I) are useful for the treatment of cancer in combination with IDO1 inhibitors including but not limited to BLV-0801, epacadostat, F-001287, GBV-1012, GBV-1028, GDC-0919, indoximod, NKTR-218, NLG-919-based vaccine, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK-200802, and shIDO-ST. Other examples of IDO1 inhibitors include, but are not limited to, BMS-986205, EOS-200271, KHK-2455, LY-3381916.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with a Mitogen-activated Protein Kinase (MEK) Inhibitors. MEK inhibitors useful for combination treatment with a compound(s) of formula (I) includes antroquinonol, binimetinib, cobimetinib (GDC-0973, XL-518), MT-144, selumetinib (AZD6244), sorafenib, trametinib (GSK1120212), uprosertib and trametinib. Other exemplary MEK inhibitors include PD-0325901, 5 pimasertib, LTT462, AS703988, CC-90003, and refametinib.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with an Apoptosis Signal-Regulating Kinase (ASK) Inhibitors: ASK inhibitors include but are not limited to those described in WO 2011/008709 (Gilead Sciences) and WO 2013/112741 (Gilead 10 Sciences) including, for example, selonsertib.

In one embodiment, the compounds of formula (I) may be combined with Cluster of Differentiation 47 (CD47) inhibitors.

Examples of CD47 inhibitors include, but are not limited to anti-CD47 mAbs (Vx-1004), anti-human CD47 mAbs (CNTO-7108), CC-90002, CC-90002-ST-001, humanized anti-CD47 antibody 15 (Hu5F9-G4), NI-1701, NI-1801, RCT-1938, and TTI-621.

In one embodiment, the compounds of formula (I) may be combined with Cyclin-dependent Kinase (CDK) Inhibitors. CDK inhibitors include inhibitors of CDK 1, 2, 3, 4, 6 and 9, such as abemaciclib, alvocidib (HMR-1275, flavopiridol), AT-7519, FLX-925, LEE001, palbociclib, ribociclib, rigosertib, selinexor, UCN-01, and TG-02. Other exemplary CDK inhibitors include dinaciclib, ibrance, 20 SY1365, CT-7001, SY-1365, G1T38, milciclib, and trilaciclib.

In one embodiment, the compounds of formula (I) may be combined with Discoidin Domain Receptor (DDR) Inhibitors for the treatment of cancer. DDR inhibitors include inhibitors of DDR1 and/or DDR2. Examples of DDR inhibitors include, but are not limited to, those disclosed in WO 2014/047624 (Gilead Sciences), US 2009-0142345 (Takeda Pharmaceutical), US 2011-0287011 25 (Oncomed Pharmaceuticals), WO 2013/027802 (Chugai Pharmaceutical), and WO 2013/034933 (Imperial Innovations).

In one embodiment, the compounds of formula (I) may be combined with Histone Deacetylase (HDAC) Inhibitors such as those disclosed in U.S. Patent 8,575,353 and equivalents thereof. Additional examples of HDAC inhibitors include, but are not limited to, abexinostat, ACY-241, AR-42, BEBT-908, 30 belinostat, CKD-581, CS-055 (HBI-8000), CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ-26481585), resminostat, ricolinostat, SHP-141, valproic acid (VAL-001), vorinostat. Further examples of HDAC inhibitors include, but are not limited to, tinozamustine, remetinostat, entinostat.

In one embodiment, the compounds of formula (I) may be combined with a Hematopoietic 35 Progenitor Kinase 1 (HPK1) inhibitor. Examples of Hematopoietic Progenitor Kinase 1 (HPK1)

inhibitors include, but are not limited to, those described in WO18183956, WO18183964, WO18167147, and WO16090300.

Anti-hormonal Agents: Also included in the definition of “chemotherapeutic agent” are anti-hormonal agents such as anti-estrogens and selective estrogen receptor modulators (SERMs), inhibitors of the enzyme aromatase, anti-androgens, and pharmaceutically acceptable salts, acids or derivatives of any of the above that act to regulate or inhibit hormone action on tumors.

Examples of anti-estrogens and SERMs include, for example, tamoxifen (including NOLVADEXTM), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (FARESTON[®]).

10 Inhibitors of the enzyme aromatase regulate estrogen production in the adrenal glands. Examples include 4(5)-imidazoles, aminoglutethimide, megestrol acetate (MEGACE[®]), exemestane, formestane, fadrozole, vorozole (RIVISOR[®]), letrozole (FEMARA[®]), and anastrozole (ARIMIDEX[®]).

Examples of anti-androgens include apalutamide, abiraterone, enzalutamide, flutamide, galeterone, nilutamide, bicalutamide, leuprolide, goserelin, ODM-201, APC-100, ODM-204.

15 Examples of progesterone receptor antagonist include onapristone.

Anti-angiogenic Agents: Anti-angiogenic agents include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN[®], ENDOSTATIN[®], regorafenib, necuparanib, suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulphated chitin derivatives (prepared from queen crab shells), sulphated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism including proline analogs such as l-azetidine-2-carboxylic acid (LACA), cishydroxyproline, d,I-3,4-dehydroproline, thiaproline, α,α' -dipyridyl, beta-aminopropionitrile fumarate, 4-propyl-5-(4-pyridinyl)-2(3h)-oxazolone, methotrexate, mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chicken inhibitor of metalloproteinase-3 (ChIMP-3), chymostatin, beta-cyclodextrin tetradecasulfate, eponemycin, fumagillin, gold sodium thiomalate, d-penicillamine, beta-1-anticollagenase-serum, alpha-2-antiplasmin, bisantrene, lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid disodium or “CCA”, thalidomide, angiostatic steroid, carboxy aminoimidazole, metalloproteinase inhibitors such as BB-94, inhibitors of S100A9 such as tasquinimod .

20
25
30 Other anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF, and Ang-1/Ang-2.

Anti-fibrotic Agents: Anti-fibrotic agents include, but are not limited to, the compounds such as beta-aminopropionitrile (BAPN), as well as the compounds disclosed in US 4965288 relating to

inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen and US 4997854 relating to compounds which inhibit LOX for the treatment of various pathological fibrotic states, which are herein incorporated by reference. Further exemplary inhibitors are described in US 4943593 relating to compounds such as 2-isobutyl-3-fluoro-, chloro-, or bromo-allylamine, US 5021456, US 5059714, US 5120764, US 5182297, US 5252608 relating to 2-(1-naphthylloxymethyl)-3-fluoroallylamine, and US 2004-0248871, which are herein incorporated by reference.

Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product stabilized by resonance, such as the following primary amines: ethylenediamine, hydrazine, phenylhydrazine, and their derivatives; semicarbazide and urea derivatives; aminonitriles such as BAPN or 2-nitroethylamine; unsaturated or saturated haloamines such as 2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine, 3-bromopropylamine, and p-halobenzylamines; and selenohomocysteine lactone.

Other anti-fibrotic agents are copper chelating agents penetrating or not penetrating the cells. Exemplary compounds include indirect inhibitors which block the aldehyde derivatives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases. Examples include the thiolamines, particularly D-penicillamine, and its analogs such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetamidoethyl)dithio)butanoic acid, p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid, sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sulphinate, and sodium-4-mercaptobutanesulphinate trihydrate.

Immunotherapeutic Agents: The immunotherapeutic agents include and are not limited to therapeutic antibodies suitable for treating patients. Some examples of therapeutic antibodies include abagovomab, ABP-980, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatumumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, CC49, cetuximab, citatumumab, cixutumumab, clivatuzumab, conatumumab, dacetuzumab, dalotuzumab, daratumumab, detumomab, dinutuximab, drozitumab, duligotumab, dusigitumab, ecomeximab, elotuzumab, emibetuzumab, ensituximab, ertumaxomab, etaracizumab, farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab (YERVOY®, MDX-010, BMS-734016, and MDX-101), iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatumumab, minretumomab, mitumomab, mogamulizumab, moxetumomab, naptumomab, narnatumab, necitumumab, nimotuzumab, nofetumomab, OBI-833, obinutuzumab, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatumumab,

pasudotox, patritumab, pentumomab, pertuzumab, pintumomab, primumab, racotumomab, radretumab, ramucirumab (Cyramza®), rilotumumab, rituximab, robatumumab, samalizumab, satumomab, sibrotuzumab, siltuximab, solitomab, simtuzumab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucozumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, and 3F8. Rituximab can be used for treating indolent B-cell cancers, including marginal-zone lymphoma, WM, CLL and small lymphocytic lymphoma. A combination of Rituximab and chemotherapy agents is especially effective.

The exemplified therapeutic antibodies may be further labeled or combined with a radioisotope particle such as indium-111, yttrium-90 (90Y-clivatuzumab), or iodine-131.

10 *Cancer Gene Therapy and Cell Therapy:* Cancer Gene Therapy and Cell Therapy including the insertion of a normal gene into cancer cells to replace a mutated or altered gene; genetic modification to silence a mutated gene; genetic approaches to directly kill the cancer cells; including the infusion of immune cells designed to replace most of the patient's own immune system to enhance the immune response to cancer cells, or activate the patient's own immune system (T cells or Natural Killer cells) to
15 kill cancer cells, or find and kill the cancer cells; genetic approaches to modify cellular activity to further alter endogenous immune responsiveness against cancer.

Gene Editors: The genome editing system is selected from the group consisting of: a CRISPR/Cas9 system, a zinc finger nuclease system, a TALEN system, a homing endonucleases system, and a meganuclease system.

20 *CAR-T cell therapy and TCR-T cell therapy:* A population of immune effector cells engineered to express a chimeric antigen receptor (CAR), wherein the CAR comprises a tumor antigen-binding domain. The immune effector cell is a T cell or an NK cell. TCR-T cells are engineered to target tumor derived peptides present on the surface of tumor cells. Cells can be autologous or allogeneic.

In some embodiments, the CAR comprises an antigen binding domain, a transmembrane domain, and an intracellular signaling domain. In some embodiments, the intracellular domain comprises a primary signaling domain, a costimulatory domain, or both of a primary signaling domain and a costimulatory domain. In some embodiments, the primary signaling domain comprises a functional signaling domain of one or more proteins selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCERIG), FcR beta (Fc Epsilon RIb), CD79a, CD79b, Fc gamma RIIa, DAP10, and DAP12.

In some embodiments, the costimulatory domain comprises a functional domain of one or more proteins selected from the group consisting of CD27, CD28, 4-1BB(CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-I), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80

(KLRFI), CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD 1 ld, ITGAE, CD103, ITGAL, CD 1 la, LFA-1, ITGAM, CD1 lb, ITGAX, CD1 lc, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96
 5 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, NKp44, NKp30, NKp46, and NKG2D.

In some embodiments, the transmembrane domain comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28,
 10 CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD1 la, CD18), ICOS (CD278), 4-1BB(CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R u, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1 ld, ITGAE, CD103, ITGAL, CD1 la, LFA-1, ITGAM, CD1 lb, ITGAX, CD1 lc, ITGB1, CD29, ITGB2,
 15 CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKp44, NKp30, NKp46, NKG2D, and NKG2C.

In some embodiments, the antigen binding domain binds a tumor antigen. In some
 20 embodiments, the tumor antigen is selected from the group consisting of: CD19; CD123; CD22; CD30; CD171; CS-1 (also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECLI); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3 (aNeuSAc(2-8)aNeuSAc(2-3)bDGaIp(1-4)bDGlcp(1-1)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GaINAcu-Ser/Thr));
 25 prostate-specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (RORI); Fms-Like, Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); Mesothelin; Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 21(Testisin or PRSS21);
 30 vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y)antigen; CD24; Platelet-derived growth factor receptor beta (PDGFR-beta); Stage-specific embryonic antigen-4 (SSEA-4); CD20; delta like 3 (DLL3); Folate receptor alpha; Receptor tyrosine-protein kinase, ERBB2 (Her2/neu); Mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); Prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); Ephrin B2;
 35 fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100 (gp100); oncogene fusion protein consisting of breakpoint cluster region (BCR) and Abelson

murine leukemia viral oncogene homolog 1 (Abl) (bcr-abl); tyrosinase; ephrin type-A receptor 2 (EphA2);
 Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeuSAc(2-3)bDGalp(1-
 4)bDGlc(1-1)Cer); transglutaminase 5 (TGS5); high molecular weight-melanoma-associated antigen
 (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor beta; tumor endothelial marker 1
 5 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); six transmembrane epithelial antigen of
 the prostate I (STEAP1); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-
 coupled receptor class C group 5, member D (GPRCSD); chromosome X open reading frame 61
 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Polysialic acid; placenta-specific 1
 (PLAC1); hexasaccharide portion of globoH glycosphingolipid (GloboH); mammary gland differentiation
 10 antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor
 beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6
 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (ORS IE2); TCR Gamma Alternate Reading Frame
 Protein (TARP); Wilms tumor protein (WT1); Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen
 2 (LAGE-1a); Melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6, located on
 15 chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1);
 angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MADCT-1);
 melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53, (p53); p53
 mutant; prostein; survivin; telomerase; prostate carcinoma tumor antigen-1 (PCTA-1 or Galectin 8),
 melanoma antigen recognized by T cells 1 (MelanA or MART1); Rat sarcoma (Ras) mutant; human
 20 Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of
 apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl
 glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; v-
 myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog
 Family Member C (RhoC); Tyrosinase-related protein 2 (TRP-2); Cytochrome P450 1B1 (CYP 1B1);
 25 CCCTC-Binding Factor (Zinc Finger Protein)-Like (BORIS or Brother of the Regulator of Imprinted
 Sites), Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3); Paired box protein Pax-5
 (PAX5); proacrosin binding protein sp32 (OY-TES I); lymphocyte-specific protein tyrosine kinase
 (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Receptor for
 Advanced Glycation Endproducts (RAGE-I); renal ubiquitous 1 (RUI); renal ubiquitous 2 (RU2);
 30 legumain; human papilloma virus E6 (HPV E6); human papilloma virus E7 (HPV E7); intestinal
 carboxyl esterase; heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72; Leukocyte-
 associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89);
 Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like
 family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow
 35 stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2);
 lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin
 lambda-like polypeptide 1 (IGLL1).

In some embodiments, the tumor antigen is selected from CD150, 5T4, ActRIIA, B7, BMCA, CA-125, CCNA1, CD123, CD126, CD138, CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25, CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40, CD40L, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, CD74, CD8, CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII, EGP-2, EGP-4, EPHA2, ErbB2, ErbB3, ErbB4, FBP, GD2, GD3, HER1-HER2 in combination, HER2-HER3 in combination, HERV-K, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, HLA-DR, HM1.24, HMW-MAA, Her2, Her2/neu, IGF-1R, IL-11Ralpha, IL-13R-alpha2, IL-2, IL-22R-alpha, IL-6, IL-6R, Ia, Ii, L1-CAM, L1-cell adhesion molecule, Lewis Y, LI-CAM, MAGE A3, MAGE-A1, MART-1, MUC1, NKG2C ligands, NKG2D Ligands, NYESO-1, OEPHa2, PIGF, PSCA, PSMA, ROR1, T101, TAC, TAG72, TIM-3, TRAIL-R1, TRAIL-R1 (DR4), TRAIL-R2 (DR5), VEGF, VEGFR2, WT-I, a G-protein coupled receptor, alphafetoprotein (AFP), an angiogenesis factor, an exogenous cognate binding molecule (ExoCBM), oncogene product, anti-folate receptor, c-Met, carcinoembryonic antigen (CEA), cyclin (D 1), ephrinB2, epithelial tumor antigen, estrogen receptor, fetal acetylcholine e receptor, folate binding protein, gp100, hepatitis B surface antigen, kappa chain, kappa light chain, kdr, lambda chain, livin, melanoma-associated antigen, mesothelin, mouse double minute 2 homolog (MDM2), mucin 16 (MUC16), mutated p53, mutated ras, necrosis antigens, oncofetal antigen, ROR2, progesterone receptor, prostate specific antigen, tEGFR, tenascin, P2-Microglobulin, and Fc Receptor-like 5 (FcRL5).

Non limiting examples of cell therapies include Algenpantucel-L, Sipuleucel-T, (BPX-501) rivogenlecleucel US9089520, WO2016100236, AU-105, ACTR-087, activated allogeneic natural killer cells CNDO-109-AANK, MG-4101, AU-101, BPX-601, FATE-NK100, LFU-835 hematopoietic stem cells, Imilecleucel-T, baltaleucel-T, PNK-007, UCARTCS1, ET-1504, ET-1501, ET-1502, ET-190, CD19-ARTEMIS, ProHema, FT-1050-treated bone marrow stem cell therapy, CD4CARNK-92 cells, CryoStim, AlloStim, lentiviral transduced huCART-meso cells, CART-22 cells, EGFRt/19-28z/4-1BBL CAR T cells, autologous 4H11-28z/fIL-12/EGFRt T cell, CCR5-SBC-728-HSPC, CAR4-1BBZ, CH-296, dnTGFbRII-NY-ESOc259T, Ad-RTS-IL-12, IMA-101, IMA-201, CARMA-0508, TT-18, CMD-501, CMD-503, CMD-504, CMD-502, CMD-601, CMD-602, and CSG-005.

Additional agents include those where the tumor targeting antigen is:

Alpha-fetoprotein, such as ET-1402, and AFP-TCR;

30 Anthrax toxin receptor 1, such as anti-TEM8 CAR T-cell therapy;

B cell maturation antigens (BCMA), such as bb-2121, UCART-BCMA, ET-140, KITE-585, MCM-998, LCAR-B38M, CART-BCMA, SEA-BCMA, BB212, UCART-BCMA, ET-140, P-BCMA-101, and AUTO-2 (APRIL-CAR);

Anti-CLL-1 antibodies, such as KITE-796;

B7 homolog 6, such as CAR-NKp30 and CAR-B7H6;

B-lymphocyte antigen CD19, such as TBI-1501, CTL-119 huCART-19 T cells, JCAR-015 US7446190, JCAR-014, JCAR-017, (WO2016196388, WO2016033570, WO2015157386), axicabtagene ciloleucel (KTE-C19), US7741465, US6319494, UCART-19, EBV-CTL, T tisagenlecleucel-T
 5 (CTL019), WO2012079000, WO2017049166, CD19CAR-CD28-CD3zeta-EGFRt-expressing T cells, CD19/4-1BBL armored CAR T cell therapy, C-CAR-011, CIK-CAR.CD19, CD19CAR-28-zeta T cells, PCAR-019, MatchCART, DSCAR-01, and IM19 CAR-T ;

B-lymphocyte antigen CD20, such as ATTCK-20;

B-lymphocyte cell adhesion, such as UCART-22, and JCAR-018 (WO2016090190);

10 NY-ESO-1, such as GSK-3377794, and TBI-1301;

Carbonic anhydrase, such as DC-Ad-GMCAIX;

Caspase 9 suicide gene, such as CaspaCIDE DLI, and BPX-501;

CCR5, such as SB-728;

CDw123, such as MB-102, and UCART-123;

15 CD20m such as CBM-C20.1;

CD4, such as ICG-122;

CD30, such as CART30 (CBM-C30.1);

CD33, such as CIK-CAR.CD33;

CD38, such as T-007, UCART-38;

20 CD40 ligand, such as BPX-201;

CEACAM protein 4 modulators, such as MG7-CART;

Claudin 6, such as CSG-002;

EBV targeted , such as CMD-003;

EGFR, such as autologous 4H11-28z/fIL-12/EGFRt T cell;

25 Endonuclease, such as PGN-514, PGN-201;

- Epstein-Barr virus specific T-lymphocytes , such as TT-10;
- ErbB2 , such as CST-102, CIDE CAR;
- Ganglioside (GD2), such as 4SCAR-GD2;
- Glutamate carboxypeptidase II, such as CIK-CAR.PSMA, CART-PSMA-TGFβRDN, and P-
 5 PSMA-101;
- Glypican-3(GPC3), such as TT-16, and GLYCAR;
- Hemoglobin, such as PGN-236;
- Hepatocyte growth factor receptor, such as anti-cMet RNA CAR T;
- Human papillomavirus E7 protein, such as KITE-439;
- 10 Immunoglobulin gamma Fc receptor III, such as ACTR087;
- IL-12, such as DC-RTS-IL-12;
- IL-12 agonist/mucin 16, such as JCAR-020;
- IL-13 alpha 2, such as MB-101;
- IL-2, such as CST-101;
- 15 K-Ras GTPase, such as anti-KRAS G12V mTCR cell therapy;
- Neural cell adhesion molecule L1 L1CAM (CD171), such as JCAR-023;
- Latent membrane protein 1/Latent membrane protein 2, such as Ad5f35-LMPd1-2-transduced
 autologous dendritic cells;
- Melanoma associated antigen 10, such as MAGE-A10C796T MAGE-A10 TCR;
- 20 Melanoma associated antigen 3/ Melanoma associated antigen 6 (MAGE A3/A6) such as KITE-
 718;
- Mesothelin, such as CSG-MESO, and TC-210;
- NKG2D, such as NKR-2;
- Ntrkr1 tyrosine kinase receptor, such as JCAR-024;
- 25 T cell receptors, such as BPX-701, and IMCgp100;

T-lymphocyte, such as TT-12;

Tumor infiltrating lymphocytes, such as LN-144, and LN-145;

Wilms tumor protein, such as JTCR-016, and WT1-CTL;

Subjects

5 Any of the methods of treatment provided may be used to treat a subject (*e.g.*, human) who has been diagnosed with or is suspected of having cancer. As used herein, a subject refers to a mammal, including, for example, a human.

In some embodiments, the subject may be a human who exhibits one or more symptoms associated with cancer or hyperproliferative disease. In some embodiments, the subject may be a human
10 who exhibits one or more symptoms associated with cancer. In some embodiments, the subject is at an early stage of a cancer. In other embodiments, the subject is at an advanced stage of cancer.

In certain, the subject may be a human who is at risk, or genetically or otherwise predisposed (*e.g.*, risk factor) to developing cancer or hyperproliferative disease who has or has not been diagnosed. As used herein, an “at risk” subject is a subject who is at risk of developing cancer. The subject may or
15 may not have detectable disease, and may or may not have displayed detectable disease prior to the treatment methods described herein. An at risk subject may have one or more so-called risk factors, which are measurable parameters that correlate with development of cancer, which are described herein. A subject having one or more of these risk factors has a higher probability of developing cancer than an individual without these risk factor(s). These risk factors may include, for example, age, sex, race, diet,
20 history of previous disease, presence of precursor disease, genetic (*e.g.*, hereditary) considerations, and environmental exposure. In some embodiments, the subjects at risk for cancer include, for example, those having relatives who have experienced the disease, and those whose risk is determined by analysis of genetic or biochemical markers.

In addition, the subject may be a human who is undergoing one or more standard therapies, such
25 as chemotherapy, radiotherapy, immunotherapy, surgery, or combination thereof. Accordingly, one or more kinase inhibitors may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, surgery or combination thereof.

In certain embodiments, the subject may be a human who is (i) substantially refractory to at least one chemotherapy treatment, or (ii) is in relapse after treatment with chemotherapy, or both (i) and (ii).
30 In some of embodiments, the subject is refractory to at least two, at least three, or at least four chemotherapy treatments (including standard or experimental chemotherapies).

As used herein, a “therapeutically effective amount” means an amount sufficient to modulate a specific pathway, and thereby treat a subject (such as a human) suffering an indication, or to alleviate the existing symptoms of the indication. Determination of a therapeutically effective amount is within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. In some embodiments, a therapeutically effective amount of a JAK inhibitor, such as Compound A or ruxolitinib or pharmaceutically acceptable salt thereof, and a therapeutically effective amount of PI3K inhibitor, such as Compound B, Compound C, Compound D, or Compound E and pharmaceutically acceptable salt thereof, may (i) reduce the number of diseased cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent, and preferably stop the diseased cell infiltration into peripheral organs; (iv) inhibit (*e.g.*, slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of a tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with cancer or myeloproliferative disease. In other embodiments, a therapeutically effective amount of Compound B or Compound C and a therapeutically effective amount of obinutuzumab may (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent, and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (*e.g.*, slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of a tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer. In various embodiments, the amount is sufficient to ameliorate, palliate, lessen, and/or delay one or more of symptoms of cancer.

In some embodiments, the cancer is Burkitt’s lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma (NHL), indolent non-Hodgkin’s lymphoma (iNHL), refractory iNHL, multiple myeloma (MM), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), B-cell ALL, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), mantle cell lymphoma (MCL), follicular lymphoma (FL), Waldstrom’s macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), or marginal zone lymphoma (MZL). In one embodiment, the cancer is minimal residual disease (MRD). In additional embodiment, the cancer is selected from Hodgkin’s lymphoma, non-Hodgkin’s lymphoma (NHL), indolent non-Hodgkin’s lymphoma (iNHL), and refractory iNHL. In certain embodiment, the cancer is indolent non-Hodgkin’s lymphoma (iNHL). In some embodiment, the cancer is refractory iNHL. In one embodiment, the cancer is chronic lymphocytic leukemia (CLL). In other embodiment, the cancer is diffuse large B-cell lymphoma (DLBCL).

In certain embodiments, the cancer is a solid tumor is selected from the group consisting of pancreatic cancer; bladder cancer; colorectal cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; kidney or renal cancer, including, *e.g.*, metastatic renal cell carcinoma; hepatocellular cancer; lung cancer, including, *e.g.*, non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and

adenocarcinoma of the lung; ovarian cancer, including, *e.g.*, progressive epithelial or primary peritoneal cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer, including, *e.g.*, squamous cell carcinoma of the head and neck; melanoma; neuroendocrine cancer, including metastatic neuroendocrine tumors; brain tumors, including, *e.g.*, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; bone cancer; and soft tissue sarcoma, hepatic carcinoma, rectal cancer, penile carcinoma, vulval cancer, thyroid cancer, salivary gland carcinoma, endometrial or uterine carcinoma, hepatoma, hepatocellular cancer, liver cancer, gastric or stomach cancer including gastrointestinal cancer, cancer of the peritoneum, squamous carcinoma of the lung, gastroesophageal cancer, biliary tract cancer, gall bladder cancer, colorectal/appendiceal cancer, squamous cell cancer (*e.g.*, epithelial squamous cell cancer).

Any of the methods of treatment provided may be used to treat cancer at various stages. By way of example, the cancer stage includes but is not limited to early, advanced, locally advanced, remission, refractory, reoccurred after remission and progressive.

Lymphoma or Leukemia Combination Therapy: Some chemotherapy agents are suitable for treating lymphoma or leukemia. These agents include aldesleukin, alvocidib, amifostine trihydrate, aminocamptothecin, antineoplaston A10, antineoplaston AS2-1, anti-thymocyte globulin, arsenic trioxide, Bcl-2 family protein inhibitor ABT-263, beta alethine, BMS-345541, bortezomib (VELCADE[®]), bortezomib (VELCADE[®], PS-341), bryostatatin 1, bulsulfan, campath-1H, carboplatin, carfilzomib (Kyprolis[®]), carmustine, caspofungin acetate, CC-5103, chlorambucil, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), cisplatin, cladribine, clofarabine, curcumin, CVP (cyclophosphamide, vincristine, and prednisone), cyclophosphamide, cyclosporine, cytarabine, denileukin diftitox, dexamethasone, docetaxel, dolastatin 10, doxorubicin, doxorubicin hydrochloride, DT-PACE (dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide), enzastaurin, epoetin alfa, etoposide, everolimus (RAD001), FCM (fludarabine, cyclophosphamide, and mitoxantrone), FCR (fludarabine, cyclophosphamide, and rituximab), fenretinide, filgrastim, flavopiridol, fludarabine, FR (fludarabine and rituximab), geldanamycin (17-AAG), hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine), ICE (ifosfamide, carboplatin, and etoposide), ifosfamide, irinotecan hydrochloride, interferon alpha-2b, ixabepilone, lenalidomide (REVLIMID[®], CC-5013), lymphokine-activated killer cells, MCP (mitoxantrone, chlorambucil, and prednisolone), melphalan, mesna, methotrexate, mitoxantrone hydrochloride, motexafin gadolinium, mycophenolate mofetil, nelarabine, obatoclax (GX15-070), oblimersen, octreotide acetate, omega-3 fatty acids, Omr-IgG-am (WNIG, Omrix), oxaliplatin, paclitaxel, palbociclib (PD0332991), pegfilgrastim, PEGylated liposomal doxorubicin hydrochloride, perifosin, prednisolone, prednisone, recombinant flt3 ligand, recombinant human thrombopoietin, recombinant interferon alfa, recombinant interleukin-11, recombinant interleukin-12, rituximab, R-CHOP (rituximab and CHOP), R-CVP (rituximab and CVP), R-FCM (rituximab and FCM), R-ICE (rituximab and ICE), and R-MCP (rituximab and MCP), R-

roscovitine (seliciclib, CYC202), sargramostim, sildenafil citrate, simvastatin, sirolimus, styryl sulphones, tacrolimus, tanespimycin, temsirolimus (CCI-779), thalidomide, therapeutic allogeneic lymphocytes, thiotepa, tipifarnib, vincristine, vincristine sulfate, vinorelbine ditartrate, SAHA (suberanilohydroxamic acid, or suberoyl, anilide, and hydroxamic acid), vemurafenib (Zelboraf®),
 5 venetoclax (ABT-199).

One modified approach is radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as indium-111, yttrium-90, and iodine-131. Examples of combination therapies include, but are not limited to, iodine-131 tositumomab (BEXXAR®), yttrium-90 ibritumomab tiuxetan (ZEVALIN®), and BEXXAR® with CHOP.

10 The abovementioned therapies can be supplemented or combined with stem cell transplantation or treatment. Therapeutic procedures include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, *in vitro*-treated peripheral blood stem cell transplantation, umbilical cord
 15 blood transplantation, immunoenzyme technique, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Non-Hodgkin's Lymphomas Combination Therapy: Treatment of non-Hodgkin's lymphomas (NHL), especially those of B cell origin, includes using monoclonal antibodies, standard chemotherapy
 20 approaches (*e.g.*, CHOP, CVP, FCM, MCP, and the like), radioimmunotherapy, and combinations thereof, especially integration of an antibody therapy with chemotherapy.

Examples of unconjugated monoclonal antibodies for the treatment of NHL/B-cell cancers include rituximab, alemtuzumab, human or humanized anti-CD20 antibodies, lumiliximab, anti-TNF-related apoptosis-inducing ligand (anti-TRAIL), bevacizumab, galiximab, epratuzumab, SGN-40, and
 25 anti-CD74.

Examples of experimental antibody agents used in treatment of NHL/B-cell cancers include ofatumumab, ha20, PRO131921, alemtuzumab, galiximab, SGN-40, CHIR-12.12, epratuzumab, lumiliximab, apolizumab, milatuzumab, and bevacizumab.

Examples of standard regimens of chemotherapy for NHL/B-cell cancers include CHOP, FCM,
 30 CVP, MCP, R-CHOP, R-FCM, R-CVP, and R-MCP.

Examples of radioimmunotherapy for NHL/B-cell cancers include yttrium-90 ibritumomab tiuxetan (ZEVALIN®) and iodine-131 tositumomab (BEXXAR®).

Mantle Cell Lymphoma Combination Therapy: Therapeutic treatments for mantle cell lymphoma (MCL) include combination chemotherapies such as CHOP, hyperCVAD, and FCM. These regimens can also be supplemented with the monoclonal antibody rituximab to form combination therapies R-CHOP, hyperCVAD-R, and R-FCM. Any of the abovementioned therapies may be combined with stem cell transplantation or ICE in order to treat MCL.

An alternative approach to treating MCL is immunotherapy. One immunotherapy uses monoclonal antibodies like rituximab. Another uses cancer vaccines, such as GTOP-99, which are based on the genetic makeup of an individual patient's tumor.

A modified approach to treat MCL is radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as iodine-131 tositumomab (BEXXAR[®]) and yttrium-90 ibritumomab tiuxetan (ZEVALIN[®]). In another example, BEXXAR[®] is used in sequential treatment with CHOP.

Other approaches to treating MCL include autologous stem cell transplantation coupled with high-dose chemotherapy, administering proteasome inhibitors such as bortezomib (VELCADE[®] or PS-341), or administering antiangiogenesis agents such as thalidomide, especially in combination with rituximab.

Another treatment approach is administering drugs that lead to the degradation of Bcl-2 protein and increase cancer cell sensitivity to chemotherapy, such as oblimersen, in combination with other chemotherapeutic agents.

A further treatment approach includes administering mTOR inhibitors, which can lead to inhibition of cell growth and even cell death. Non-limiting examples are sirolimus, temsirolimus (TORISEL[®], CCI-779), CC-115, CC-223, SF-1126, PQR-309 (bimiralisib), voxtalisib, GSK-2126458, and temsirolimus in combination with RITUXAN[®], VELCADE[®], or other chemotherapeutic agents.

Other recent therapies for MCL have been disclosed. Such examples include flavopiridol, palbociclib (PD0332991), R-roscovitine (seliciclib, CYC202), styryl sulphones, obatoclax (GX15-070), TRAIL, Anti-TRAIL death receptors DR4 and DR5 antibodies, temsirolimus (TORISEL[®], CCI-779), everolimus (RAD001), BMS-345541, curcumin, SAHA, thalidomide, lenalidomide (REVLIMID[®], CC-5013), and geldanamycin (17-AAG).

Waldenstrom's Macroglobulinemia Combination Therapy: Therapeutic agents used to treat Waldenstrom's Macroglobulinemia (WM) include aldesleukin, alemtuzumab, alvocidib, amifostine trihydrate, aminocamptothecin, antineoplaston A10, antineoplaston AS2-1, anti-thymocyte globulin, arsenic trioxide, autologous human tumor-derived HSPPC-96, Bcl-2 family protein inhibitor ABT-263, beta alethine, bortezomib (VELCADE[®]), bryostatin 1, busulfan, campath-1H, carboplatin, carmustine,

casprofungin acetate, CC-5103, cisplatin, clofarabine, cyclophosphamide, cyclosporine, cytarabine, denileukin diftitox, dexamethasone, docetaxel, dolastatin 10, doxorubicin hydrochloride, DT-PACE, enzastaurin, epoetin alfa, epratuzumab (hLL2- anti-CD22 humanized antibody), etoposide, everolimus, fenretinide, filgrastim, fludarabine, ifosfamide, indium-111 monoclonal antibody MN-14, iodine-131
5 tositumomab, irinotecan hydrochloride, ixabepilone, lymphokine-activated killer cells, melphalan, mesna, methotrexate, mitoxantrone hydrochloride, monoclonal antibody CD19 (such as tisagenlecleucel-T, CART-19, CTL-019), monoclonal antibody CD20, motexafin gadolinium, mycophenolate mofetil, nelarabine, oblimersen, octreotide acetate, omega-3 fatty acids, oxaliplatin, paclitaxel, pegfilgrastim, PEGylated liposomal doxorubicin hydrochloride, pentostatin, perifosine, prednisone, recombinant flt3
10 ligand, recombinant human thrombopoietin, recombinant interferon alfa, recombinant interleukin-11, recombinant interleukin-12, rituximab, sargramostim, sildenafil citrate (VIAGRA®), simvastatin, sirolimus, tacrolimus, tanespimycin, thalidomide, therapeutic allogeneic lymphocytes, thiotepa, tipifarnib, tositumomab, veltuzumab, vincristine sulfate, vinorelbine ditartrate, vorinostat, WT1 126-134 peptide vaccine, WT-1 analog peptide vaccine, yttrium-90 ibritumomab tiuxetan, yttrium-90 humanized
15 epratuzumab, and any combination thereof.

Examples of therapeutic procedures used to treat WM include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, *in vitro*-treated peripheral blood
20 stem cell transplantation, umbilical cord blood transplantation, immunoenzyme techniques, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Diffuse Large B-cell Lymphoma Combination Therapy: Therapeutic agents used to treat diffuse large B-cell lymphoma (DLBCL) include cyclophosphamide, doxorubicin, vincristine, prednisone, anti-
25 CD20 monoclonal antibodies, etoposide, bleomycin, many of the agents listed for WM, and any combination thereof, such as ICE and R-ICE.

Chronic Lymphocytic Leukemia Combination Therapy: Examples of therapeutic agents used to treat chronic lymphocytic leukemia (CLL) include chlorambucil, cyclophosphamide, fludarabine, pentostatin, cladribine, doxorubicin, vincristine, prednisone, prednisolone, alemtuzumab, many of the
30 agents listed for WM, and combination chemotherapy and chemoimmunotherapy, including the following common combination regimens: CVP, R-CVP, ICE, R-ICE, FCR, and FR.

Myelofibrosis Combination Therapy: Myelofibrosis inhibiting agents include, but are not limited to, hedgehog inhibitors, histone deacetylase (HDAC) inhibitors, and tyrosine kinase inhibitors. Non-limiting examples of hedgehog inhibitors are saridegib and vismodegib. Examples of HDAC inhibitors

include, but are not limited to, pracinostat and panobinostat. Non-limiting examples of tyrosine kinase inhibitors are lestaurtinib, bosutinib, imatinib, gilteritinib, radotinib, and cabozantinib.

Hyperproliferative Disorder Combination Therapy: Gemcitabine, nab-paclitaxel, and gemcitabine/nab-paclitaxel may be used with a JAK inhibitor and/or PI3K δ inhibitor to treat hyperproliferative disorders.

Bladder cancer combination therapy: Therapeutic agents used to treat bladder cancer include atezolizumab, carboplatin, cisplatin, docetaxel, doxorubicin, fluorouracil (5-FU), gemcitabine, idosfamide, Interferon alfa-2b, methotrexate, mitomycin, nab-paclitaxel, paclitaxel, pemetrexed, thiotepa, vinblastine, and any combination thereof.

Breast cancer combination therapy: Therapeutic agents used to treat breast cancer include albumin-bound paclitaxel, anastrozole, capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, epirubicin, everolimus, exemestane, fluorouracil, fulvestrant, gemcitabine, Ixabepilone, lapatinib, Letrozole, methotrexate, mitoxantrone, paclitaxel, pegylated liposomal doxorubicin, pertuzumab, tamoxifen, toremifene, trastuzumab, vinorelbine, and any combinations thereof.

Triple negative breast cancer combination therapy: Therapeutic agents used to treat triple negative breast cancer include cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil, paclitaxel, and combinations thereof.

Colorectal cancer combination therapy: Therapeutic agents used to treat colorectal cancer include bevacizumab, capecitabine, cetuximab, fluorouracil, irinotecan, leucovorin, oxaliplatin, panitumumab, ziv-aflibercept, and any combinations thereof.

Castration-resistant prostate cancer combination therapy: Therapeutic agents used to treat castration-resistant prostate cancer include abiraterone, cabazitaxel, docetaxel, enzalutamide, prednisone, sipuleucel-T, and any combinations thereof.

Esophageal and esophagogastric junction cancer combination therapy: Therapeutic agents used to treat esophageal and esophagogastric junction cancer include capecitabine, carboplatin, cisplatin, docetaxel, epirubicin, fluoropyrimidine, fluorouracil, irinotecan, leucovorin, oxaliplatin, paclitaxel, ramucirumab, trastuzumab, and any combinations thereof.

Gastric cancer combination therapy: Therapeutic agents used to treat gastric cancer include capecitabine, carboplatin, cisplatin, docetaxel, epirubicin, fluoropyrimidine, fluorouracil, Irinotecan, leucovorin, mitomycin, oxaliplatin, paclitaxel, ramucirumab, trastuzumab, and any combinations thereof.

Head & neck cancer combination therapy: Therapeutic agents used to treat head & neck cancer include afatinib, bleomycin, capecitabine, carboplatin, cetuximab, cisplatin, docetaxel, fluorouracil,

gemcitabine, hydroxyurea, methotrexate, nivolumab, paclitaxel, pembrolizumab, vinorelbine, and any combinations thereof.

Hepatobiliary cancer combination therapy: Therapeutic agents used to treat hepatobiliary cancer include capecitabine, cisplatin, fluoropyrimidine, 5-fluorourcil, gemcitabine, oxaliplatin, sorafenib, and any combinations thereof.

Hepatocellular carcinoma combination therapy: Therapeutic agents used to treat hepatocellular carcinoma include capecitabine, doxorubicin, gemcitabine, sorafenib, and any combinations thereof.

Non-small cell lung cancer combination therapy: Therapeutic agents used to treat non-small cell lung cancer (NSCLC) include afatinib, albumin-bound paclitaxel, alectinib, bevacizumab, bevacizumab, cabozantinib, carboplatin, cisplatin, crizotinib, dabrafenib, docetaxel, erlotinib, etoposide, gemcitabine, nivolumab, paclitaxel, pembrolizumab, pemetrexed, ramucirumab, trametinib, trastuzumab, vandetanib, vemurafenib, vinblastine, vinorelbine, and any combinations thereof.

Small cell lung cancer combination therapy: Therapeutic agents used to treat small cell lung cancer (SCLC) include bendamustine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, gemcitabine, ipilimumab, irinotecan, nivolumab, paclitaxel, temozolomide, topotecan, vincristine, vinorelbine, and any combinations thereof.

Melanoma combination therapy: Therapeutic agents used to treat melanoma cancer include albumin bound paclitaxel, carboplatin, cisplatin, cobimetinib, dabrafenib, dacrabazine, IL-2, imatinib, interferon alfa-2b, ipilimumab, nitrosourea, nivolumab, paclitaxel, pembrolizumab, pilimumab, temozolomide, trametinib, vemurafenib, vinblastine, and any combinations thereof.

Ovarian cancer combination therapy: Therapeutic agents used to treat ovarian cancer include 5-flourouracil, albumin bound paclitaxel, altretamine, anastrozole, bevacizumab, capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, exemestane, gemcibabine, ifosfamide, irinotecan, letrozole, leuprolide acetate, liposomal doxorubicin, megestrol acetate, melphalan, olaparib, oxaliplatin, paclitaxel, Pazopanib, pemetrexed, tamoxifen, topotecan, vinorelbine, and any combinations thereof.

Pancreatic cancer combination therapy: Therapeutic agents used to treat pancreatic cancer include 5-fluorourcil, albumin-bound paclitaxel, capecitabine, cisplatin, docetaxel, erlotinib, fluoropyrimidine, gemcitabine, irinotecan, leucovorin, oxaliplatin, paclitaxel, and any combinations thereof.

Renal cell carcinoma combination therapy: Therapeutic agents used to treat renal cell carcinoma include axitinib, bevacizumab, cabozantinib, erlotinib, everolimus, levantinib, nivolumab, pazopanib, sorafenib, sunitinib, temsirolimus, and any combinations thereof.

In one embodiment, the compound of formula (I) is useful for the treatment of cancer in combination with a standard of care in the treatment of the respective cancer. One of skill in the art is aware of the standard of care as of a given date in the particular field of cancer therapy or with respect to a given cancer.

5 Certain embodiments of the present application include or use one or more additional therapeutic agent. The one or more additional therapeutic agent may be an agent useful for the treatment of cancer, inflammation, autoimmune disease and/or related conditions. The one or more additional therapeutic agent may be a chemotherapeutic agent, an anti-angiogenic agent, an antifibrotic agent, an anti-inflammatory agent, an immune modulating agent, an immunotherapeutic agent, a therapeutic antibody, a
10 radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti-proliferation agent, or any combination thereof. In some embodiments, the compound(s) described herein may be used or combined with a chemotherapeutic agent, an anti-angiogenic agent, an anti-fibrotic agent, an anti-inflammatory agent, an immune modulating agent, an immunotherapeutic agent, a therapeutic antibody, a
15 radiotherapeutic agent, an antineoplastic agent or an anti-cancer agent, an anti-proliferation agent, or any combination thereof.

In one embodiment, a compound(s) of formula (I) optionally in combination with an additional anticancer agent described herein, may be used or combined with an anti-neoplastic agent or an anti-cancer agent, anti-fibrotic agent, an anti-anti-inflammatory agent, or an immune modulating agent.

In one embodiment, provided are kits comprising a pharmaceutical composition comprising a
20 compound of formula (I) or a pharmaceutically acceptable salt, or a compound of formula (I) and at least one additional anticancer agent, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. In one embodiment, the kit comprises instructions for use in the treatment of cancer or inflammatory conditions. In one embodiment, the instructions in the kit are directed to use of the pharmaceutical composition for the treatment of cancer selected from pancreatic
25 cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer and colon cancer.

The application also provides method for treating a subject who is undergoing one or more
30 standard therapies, such as chemotherapy, radiotherapy, immunotherapy, surgery, or combination thereof comprising administering or co-administering a compound of formula (I) to said subject. Accordingly, one or more compound(S) of formula (I), or pharmaceutically acceptable salt thereof, may be administered before, during, or after administration of a chemotherapy, radiotherapy, immunotherapy, surgery or combination thereof.

35 In one embodiment, the subject may be a human who is (i) substantially refractory to at least one chemotherapy treatment, or (ii) in relapse after treatment with chemotherapy, or both (i) and (ii). In some

of embodiments, the subject is refractory to at least two, at least three, or at least four chemotherapy treatments (including standard or experimental chemotherapies).

In one embodiment, the subject is refractory to at least one, at least two, at least three, or at least four chemotherapy treatment (including standard or experimental chemotherapy) selected from
 5 fludarabine, rituximab, obinutuzumab, alkylating agents, alemtuzumab and other chemotherapy treatments such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone); R-CHOP (rituximab-CHOP); hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine); R-hyperCVAD (rituximab-hyperCVAD); FCM (fludarabine, cyclophosphamide, mitoxantrone); R-FCM (rituximab, fludarabine, cyclophosphamide, mitoxantrone);
 10 bortezomib and rituximab; temsirolimus and rituximab; temsirolimus and Velcade[®]; Iodine-131 tositumomab (Bexxar[®]) and CHOP; CVP (cyclophosphamide, vincristine, prednisone); R-CVP (rituximab-CVP); ICE (iphoosphamide, carboplatin, etoposide); R-ICE (rituximab-ICE); FCR (fludarabine, cyclophosphamide, rituximab); FR (fludarabine, rituximab); and D.T. PACE (dexamethasone, thalidomide, cisplatin, Adriamycin[®], cyclophosphamide, etoposide).

15 Other examples of chemotherapy treatments (including standard or experimental chemotherapies) are described below. In addition, treatment of certain lymphomas is reviewed in Cheson, B.D., Leonard, J.P., "Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma" *The New England Journal of Medicine* 2008, 359(6), p. 613-626; and Wierda, W.G., "Current and Investigational Therapies for Patients with CLL" *Hematology* 2006, p. 285-294. Lymphoma incidence
 20 patterns in the United States is profiled in Morton, L.M., *et al.* "Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992-2001" *Blood* 2006, 107(1), p. 265-276.

Examples of immunotherapeutic agents treating lymphoma or leukemia include, but are not limited to, rituximab (such as Rituxan), alemtuzumab (such as Campath, MabCampath), anti-CD19
 25 antibodies, anti-CD20 antibodies, anti-MN-14 antibodies, anti-TRAIL, Anti-TRAIL DR4 and DR5 antibodies, anti-CD74 antibodies, apolizumab, bevacizumab, CHIR-12.12, epratuzumab (hLL2- anti-CD22 humanized antibody), galiximab, ha20, ibritumomab tiuxetan, lumiliximab, milatuzumab, ofatumumab, PRO131921, SGN-40, WT-1 analog peptide vaccine, WT1 126-134 peptide vaccine, tositumomab, autologous human tumor-derived HSPPC-96, and veltuzumab. Additional immunotherapy agents includes using cancer vaccines based upon the genetic makeup of an individual patient's tumor,
 30 such as lymphoma vaccine example is GTOP-99 (MyVax[®]).

Examples of chemotherapy agents for treating lymphoma or leukemia include aldesleukin, alvocidib, antineoplaston AS2-1, antineoplaston A10, anti-thymocyte globulin, amifostine trihydrate, aminocamptothecin, arsenic trioxide, beta alethine, Bcl-2 family protein inhibitor ABT-263, BMS-345541, bortezomib (Velcade[®]), bryostatin 1, busulfan, carboplatin, campath-1H, CC-5103, carmustine,
 35 caspofungin acetate, clofarabine, cisplatin, Cladribine (Leustarin), Chlorambucil (Leukeran), Curcumin, cyclosporine, Cyclophosphamide (Cyloxan, Endoxan, Endoxana, Cyclostin), cytarabine, denileukin diftitox, dexamethasone, DT PACE, docetaxel, dolastatin 10, Doxorubicin (Adriamycin[®], Adriblastine),

doxorubicin hydrochloride, enzastaurin, epoetin alfa, etoposide, Everolimus (RAD001), fenretinide, filgrastim, melphalan, mesna, Flavopiridol, Fludarabine (Fludara), Geldanamycin (17-AAG), ifosfamide, irinotecan hydrochloride, ixabepilone, Lenalidomide (Revlimid[®], CC-5013), lymphokine-activated killer cells, melphalan, methotrexate, mitoxantrone hydrochloride, motexafin gadolinium, mycophenolate mofetil, nelarabine, oblimersen (Genasense) Obatoclox (GX15-070), oblimersen, octreotide acetate, omega-3 fatty acids, oxaliplatin, paclitaxel, PD0332991, PEGylated liposomal doxorubicin hydrochloride, pegfilgrastim, Pentstatin (Nipent), perifosine, Prednisolone, Prednisone, R-roscovitine (Selicilib, CYC202), recombinant interferon alfa, recombinant interleukin-12, recombinant interleukin-11, recombinant flt3 ligand, recombinant human thrombopoietin, rituximab, sargramostim, sildenafil citrate, simvastatin, sirolimus, Styryl sulphones, tacrolimus, tanespimycin, Temsirolimus (CCI-779), Thalidomide, therapeutic allogeneic lymphocytes, thiotepa, tipifarnib, Velcade[®] (bortezomib or PS-341), Vincristine (Oncovin), vincristine sulfate, vinorelbine ditartrate, Vorinostat (SAHA), vorinostat, and FR (fludarabine, rituximab), CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CVP (cyclophosphamide, vincristine and prednisone), FCM (fludarabine, cyclophosphamide, mitoxantrone), FCR (fludarabine, cyclophosphamide, rituximab), hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), ICE (iphosphamide, carboplatin and etoposide), MCP (mitoxantrone, chlorambucil, and prednisolone), R-CHOP (rituximab plus CHOP), R-CVP (rituximab plus CVP), R-FCM (rituximab plus FCM), R-ICE (rituximab-ICE), and R-MCP (Rituximab-MCP).

In some embodiments, the cancer is melanoma. Suitable agents for use in combination with the compounds described herein include, without limitation, dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the “Dartmouth regimen,” which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC, temozolomide or YERVOY[™]. Compounds disclosed herein may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in the treatment of melanoma.

Compounds described here may also be used in combination with vaccine therapy in the treatment of melanoma. Anti-melanoma vaccines are, in some ways, similar to the anti-virus vaccines which are used to prevent diseases caused by viruses such as polio, measles, and mumps. Weakened melanoma cells or parts of melanoma cells called antigens may be injected into a patient to stimulate the body's immune system to destroy melanoma cells.

Melanomas that are confined to the arms or legs may also be treated with a combination of agents including one or more compounds described herein, using for example, a hyperthermic isolated limb perfusion technique. This treatment protocol temporarily separates the circulation of the involved limb from the rest of the body and injects high doses of chemotherapy into the artery feeding the limb, thus providing high doses to the area of the tumor without exposing internal organs to these doses that might otherwise cause severe side effects. Usually the fluid is warmed to 102° to 104° F. Melphalan is the

drug most often used in this chemotherapy procedure. This can be given with another agent called tumor necrosis factor (TNF) and optionally in combination with a compound of formula (I).

The therapeutic treatments can be supplemented or combined with any of the aforementioned therapies with stem cell transplantation or treatment. One example of modified approach is
5 radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as indium In 111, yttrium Y 90, iodine I-131. Examples of combination therapies include, but are not limited to, Iodine-131 tositumomab (Bexxar[®]), Yttrium-90 ibritumomab tiuxetan (Zevalin[®]), Bexxar[®] with CHOP.

Other therapeutic procedures useful in combination with treatment with a compound of formula
10 (I) include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, *in vitro*-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, pharmacological study, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional
15 surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.

In some embodiments, the application provides pharmaceutical compositions comprising a compound of formula (I) in combination with an MMP9 binding protein and/or one or more additional therapeutic agent, and a pharmaceutically acceptable diluent, carrier or excipient. In one embodiment, the pharmaceutical compositions comprise an MMP9 binding protein, one or more additional therapeutic
20 agent, and a pharmaceutically acceptable excipient, carrier or diluent. In some embodiments, the pharmaceutical compositions comprise the compound of formula (I) and anti-MMP9 antibody AB0045.

In one embodiment, the pharmaceutical compositions comprise the compound of formula (I), anti-MMP9 antibody AB0045, at least one additional therapeutic agent that is an immunomodulating agent, and a pharmaceutically acceptable diluent, carrier or excipient. In certain other embodiments, the
25 pharmaceutical compositions comprise the anti-MMP9 antibody AB0045, at least one additional therapeutic agent that is an anti-inflammatory agent, and a pharmaceutically acceptable diluent, carrier or excipient. In certain other embodiments, the pharmaceutical compositions comprise compound of formula (I), the anti-MMP9 antibody AB0045, at least one additional therapeutic agent that is an antineoplastic agent or anti-cancer agent, and a pharmaceutically acceptable diluent, carrier or excipient.
30 In one embodiment, MMP9 compounds useful for combination treatment with a compound of formula (I) include but are not limited to marimastat (BB-2516), cipemastat (Ro 32-3555) and those described in WO 2012/027721 (Gilead Biologics).

In one embodiment, the one or more additional therapeutic agent is an immune modulating agent, e.g., an immunostimulant or an immunosuppressant. In certain other embodiments, an immune
35 modulating agent is an agent capable of altering the function of immune checkpoints, including the CTLA-4, LAG-3, B7-H3, B7-H4, Tim3, BTLA, KIR, A2aR, CD200 and/or PD-1 pathways. In other

embodiments, the immune modulating agent is immune checkpoint modulating agents. Exemplary immune checkpoint modulating agents include anti-CTLA-4 antibody (e.g., ipilimumab), anti-LAG-3 antibody, anti-B7-H3 antibody, anti-B7-H4 antibody, anti-Tim3 antibody, anti-BTLA antibody, anti-KIR antibody, anti-A2aR antibody, anti CD200 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-
5 CD28 antibody, anti- CD80 or - CD86 antibody, anti-B7RP1 antibody, anti-B7-H3 antibody, anti-HVEM antibody, anti-CD137 or -CD137L antibody, anti-OX40 or -OX40L antibody, anti-CD40 or -CD40L antibody, anti-GAL9 antibody, anti-IL-10 antibody and A2aR drug. For certain such immune pathway gene products, the use of either antagonists or agonists of such gene products is contemplated, as are small molecule modulators of such gene products. In one embodiment, the immune modulatory agent is
10 an anti-PD-1 or anti-PD-L1 antibody. In some embodiments, immune modulating agents include those agents capable of altering the function of mediators in cytokine mediated signaling pathways.

In some embodiments, the one or more additional therapy or anti-cancer agent is cancer gene therapy or cell therapy. Cancer gene therapy and cell therapy include the insertion of a normal gene into cancer cells to replace a mutated or altered gene; genetic modification to silence a mutated gene; genetic
15 approaches to directly kill the cancer cells; including the infusion of immune cells designed to replace most of the patient's own immune system to enhance the immune response to cancer cells, or activate the patient's own immune system (T cells or Natural Killer cells) to kill cancer cells, or find and kill the cancer cells; genetic approaches to modify cellular activity to further alter endogenous immune responsiveness against cancer. Non limiting examples are Algenpantucel-L (2 pancreatic cell lines),
20 Sipuleucel-T, SGT-53 liposomal nanodelivery (scL) of gene p53; T-cell therapy, such as CD19 CAR-T tisagenlecleucel-T (CTL019) WO2012079000, WO2017049166, axicabtagene ciloleucel (KTE-C19) US7741465, US6319494, JCAR-015 US7446190, JCAR-014, JCAR-020, JCAR-024, JCAR-023, JTCR-016, JCAR-018 WO2016090190, JCAR-017, (WO2016196388, WO2016033570, WO2015157386), BPX-501 US9089520, WO2016100236, AU-105, UCART-22, ACTR-087, P-BCMA-101; activated
25 allogeneic natural killer cells CNDO-109-AANK, FATE-NK100, LFU-835 hematopoietic stem cells.

In one embodiment, the one or more additional therapeutic agent is an immune checkpoint inhibitor. Tumors subvert the immune system by taking advantage of a mechanism known as T-cell exhaustion, which results from chronic exposure to antigens and is characterized by the up-regulation of inhibitory receptors. These inhibitory receptors serve as immune checkpoints in order to prevent
30 uncontrolled immune reactions.

PD-1 and co-inhibitory receptors such as cytotoxic T-lymphocyte antigen 4 (CTLA-4, B and T Lymphocyte Attenuator (BTLA; CD272), T cell Immunoglobulin and Mucin domain-3 (Tim-3), Lymphocyte Activation Gene-3 (Lag-3; CD223), and others are often referred to as a checkpoint
35 intracellular signaling processes should proceed based upon extracellular information.

In addition to specific antigen recognition through the T-cell receptor (TCR), T-cell activation is regulated through a balance of positive and negative signals provided by costimulatory receptors. These

surface proteins are typically members of either the TNF receptor or B7 superfamilies. Agonistic antibodies directed against activating co-stimulatory molecules and blocking antibodies against negative co-stimulatory molecules may enhance T-cell stimulation to promote tumor destruction.

5 Programmed Cell Death Protein 1, (PD-1 or CD279), a 55-kD type 1 transmembrane protein, is a member of the CD28 family of T cell co-stimulatory receptors that include immunoglobulin superfamily member CD28, CTLA-4, inducible co-stimulator (ICOS), and BTLA. PD-1 is highly expressed on activated T cells and B cells. PD-1 expression can also be detected on memory T-cell subsets with variable levels of expression. Two ligands specific for PD-1 have been identified: programmed death- ligand 1 (PD-L1, also known as B7-H1 or CD274) and PD-L2 (also known as B7-DC or CD273). PD-L1 and PD-L2 have been shown to down-regulate T cell activation upon binding to PD-1 in both mouse and human systems (Okazaki et al., *Int. Immunol.*, 2007; 19: 813-824). The interaction of PD-1 with its ligands, PD-L1 and PD-L2, which are expressed on antigen-presenting, cells (APCs) and dendritic cells (DCs), transmits negative regulatory stimuli to down-modulate the activated T cell immune response. Blockade of PD-1 suppresses this negative signal and amplifies T cell responses. 15 Numerous studies indicate that the cancer microenvironment manipulates the PD-L1/PD-1 signaling pathway and that induction of PD-L1 expression is associated with inhibition of immune responses against cancer, thus permitting cancer progression and metastasis. The PD-L1/ PD-1 signaling pathway is a primary mechanism of cancer immune evasion for several reasons. This pathway is involved in negative regulation of immune responses of activated T effector cells found in the periphery. PD-L1 is up-regulated in cancer microenvironments, while PD-1 is also up-regulated on activated tumor 20 infiltrating T cells, thus possibly potentiating a vicious cycle of inhibition. This pathway is also intricately involved in both innate and adaptive immune regulation through bi-directional signaling. These factors make the PD-1/PD-L1 complex a central point through which cancer can manipulate immune responses and promote its own progression.

25 The first immune-checkpoint inhibitor to be tested in a clinical trial was ipilimumab (Yervoy, Bristol-Myers Squibb), a CTLA-4 mAb. CTLA-4 belongs to the immunoglobulin superfamily of receptors, which also includes PD-1, BTLA, TIM-3, and V-domain immunoglobulin suppressor of T cell activation (VISTA). Anti-CTLA-4 mAb is a powerful checkpoint inhibitor which removes “the break” from both naive and antigen-experienced cells.

30 Therapy enhances the antitumor function of CD8⁺ T cells, increases the ratio of CD8⁺ T cells to Foxp3⁺ T regulatory cells, and inhibits the suppressive function of T regulatory cells. TIM-3 has been identified as another important inhibitory receptor expressed by exhausted CD8⁺ T cells. In mouse models of cancer, it has been shown that the most dysfunctional tumor-infiltrating CD8⁺ T cells actually co-express PD-1 and LAG-3. LAG-3 is another recently identified inhibitory receptor that acts to limit 35 effector T-cell function and augment the suppressive activity of T regulatory cells. It has recently been revealed that PD-1 and LAG-3 are extensively co-expressed by tumor-infiltrating T cells in mice, and

that combined blockade of PD-1 and LAG-3 provokes potent synergistic antitumor immune responses in mouse models of cancer.

Thus in one embodiment, the present disclosure provides the use of immune checkpoint inhibitors of formula (I) disclosed herein in combination with one or more additional immune checkpoint inhibitors. In one embodiment, the present disclosure provides the use of immune checkpoint inhibitors of formula (I) disclosed herein in combination with one or more additional immune checkpoint inhibitors and an anti-MMP9 antibody or antigen binding fragment thereof to treat or prevent cancer. In some embodiments, the immune checkpoint inhibitors may be an anti-PD-1 and/or an anti-PD-L1 antibody or an anti PD-1/PD-L1 interaction inhibitor. In some embodiments, the anti-PD-L1 antibody may be B7-H1 antibody, BMS 936559 antibody, MPDL3280A (atezolizumab) antibody, MEDI-4736 antibody, MSB0010718C antibody or combinations thereof. According to another embodiment, the anti-PD-1 antibody may be nivolumab antibody, pembrolizumab antibody, pidilizumab antibody or combinations thereof.

In addition, PD-1 may also be targeted with AMP-224, which is a PD-L2-IgG recombinant fusion protein. Additional antagonists of inhibitory pathways in the immune response include IMP321, a soluble LAG-3 Ig fusion protein and MHC class II agonist, which is used to increase an immune response to tumors. Lirilumab is an antagonist to the KIR receptor and BMS 986016 is an antagonist of LAG3. The TIM-3-Galectin-9 pathway is another inhibitory checkpoint pathway that is also a promising target for checkpoint inhibition. RX518 targets and activates the glucocorticoid-induced tumor necrosis factor receptor (GITR), a member of the TNF receptor superfamily that is expressed on the surface of multiple types of immune cells, including regulatory T cells, effector T cells, B cells, natural killer (NK) cells, and activated dendritic cells. Thus, in one embodiment, the compound(s) of formula (I) may be used in combination with IMP321, Lirilumab and/or BMS 986016.

Anti-PD-1 antibodies that may be used in the compositions and methods described herein include but are not limited to: Nivolumab /MDX-1106/BMS-936558/ONO1152, a fully human IgG4 anti-PD-1 monoclonal antibody; pidilizumab (MDV9300/CT-011), a humanized IgG1 monoclonal antibody; pembrolizumab (MK-3475/ pembrolizumab /lambrolizumab), a humanized monoclonal IgG4 antibody; durvalumab (MEDI-4736) and atezolizumab. Anti-PD-L1 antibodies that may be used in compositions and methods described herein include but are not limited to: avelumab; BMS-936559, a fully human IgG4 antibody; atezolizumab (MPDL3280A/RG-7446), a human monoclonal antibody; MEDI4736; MSB0010718C, and MDX1105-01.

In one embodiment, the compound of formula (I) is administered in combination with the anti-PD-1 antibody nivolumab, pembrolizumab, and/or pidilizumab to a patient in need thereof. In one embodiment, the anti-PD-L1 antibody useful for combination treatment with a compound of formula (I) is BMS-936559, atezolizumab, or avelumab. In one embodiment, the immune modulating agent inhibits an immune checkpoint pathway. In another embodiment, the immune checkpoint pathway is selected from CTLA-4, LAG-3, B7-H3, B7-H4, Tim3, BTLA, KIR, A2aR, CD200 and PD-1. Additional

antibodies that may be used in combination with a compound of formula (I) in compositions and methods described herein include the anti-PD-1 and anti-PD-L1 antibodies disclosed in U.S. Patent Nos. 8,008,449 and 7,943,743, respectively.

In one embodiment, the one or more additional therapeutic agent is an anti-inflammatory agent.

5 In certain other embodiments, the anti-inflammatory agent is a tumor necrosis factor alpha (TNF- α) inhibitor. As used herein, the terms "TNF alpha," "TNF- α ," and "TNF α ," are interchangeable. TNF- α is a pro-inflammatory cytokine secreted primarily by macrophages but also by a variety of other cell types including lymphoid cells, mast cells, endothelial cells, cardiac myocytes, adipose tissue, fibroblasts, and neuronal tissue. TNF- α is also known as endotoxin-induced factor in serum, cachectin, and
10 differentiation inducing factor. The tumor necrosis factor (TNF) family includes TNF alpha, TNF beta, CD40 ligand (CD40L), Fas ligand (FasL), TNF-related apoptosis inducing ligand (TRAIL), and LIGHT (homologous to lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), some of the most important cytokines involved in, among other physiological processes, systematic inflammation, tumor lysis, apoptosis and initiation of
15 the acute phase reaction.

The above therapeutic agents when employed in combination with a compound(s) disclosed herein, may be used, for example, in those amounts indicated in the referenced manuals e.g., Physicians Desk Reference or in amounts generally known to a qualified care giver, i.e., one of ordinary skill in the art. In the methods of the present disclosure, such other therapeutic agent(s) may be administered prior
20 to, simultaneously with, or following the administration of the compound(s) of formula (I). Certain other therapeutic agents may be combined into a single formulation or kit when amenable to such. For example, tablet, capsule or liquid formulations may be combined with other tablet, capsule or liquid formulations into one fixed or combined dose formulation or regimen. Other combinations may be given separately, contemporaneously or otherwise.

25 *Combination Therapy for HBV*

In certain embodiments, a method for treating or preventing an HBV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or
30 two, one to three, or one to four) additional therapeutic agents. In one embodiment, a method for treating an HBV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents.

35 In certain embodiments, the present disclosure provides a method for treating an HBV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound

disclosed herein or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents which are suitable for treating an HBV infection.

5 In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four, or more additional therapeutic agents. In certain
embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined
with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further
embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined
10 with four additional therapeutic agents. The one, two, three, four, or more additional therapeutic agents
can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be
selected from different classes of therapeutic agents.

Administration of HBV Combination Therapy

15 In certain embodiments, when a compound disclosed herein is combined with one or more additional therapeutic agents as described above, the components of the composition are administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.

Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and
20 one or more additional therapeutic agents, such that therapeutically effective amounts of each agent are present in the body of the patient.

Co-administration includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents. The
compound disclosed herein may be administered within seconds, minutes, or hours of the administration
25 of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound disclosed herein is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound disclosed herein within seconds or minutes. In some embodiments, a unit dose of a
30 compound disclosed herein is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound disclosed herein.

35 In certain embodiments, a compound disclosed herein is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.

In certain embodiments a compound of Formula (I) is formulated as a tablet, which may optionally contain one or more other compounds useful for treating hepatitis B virus (HBV). In certain embodiments, the tablet can contain another active ingredient for treating hepatitis B virus (HBV).

In certain embodiments, such tablets are suitable for once daily dosing.

5 The compounds described herein may be used or combined with one or more of a chemotherapeutic agent, an immunomodulator, an immunotherapeutic agent, a therapeutic antibody, a therapeutic vaccine, a bispecific antibody and “antibody-like” therapeutic protein (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs®, Fab derivatives), an antibody-drug conjugate (ADC), gene modifiers or gene editors (such as CRISPR Cas9, zinc finger nucleases, homing endonucleases, synthetic nucleases, TALENs), cell therapies such as CAR-T (chimeric antigen receptor T-cell), and TCR-T (an engineered T cell receptor) agent or any combination thereof.

In the above embodiments, the additional therapeutic agent may be an anti-HBV agent. For example, the additional therapeutic agent may be selected from the group consisting of HBV combination drugs, other drugs for treating hepatitis B virus (HBV), 3-dioxygenase (IDO) inhibitors, 15 antisense oligonucleotide targeting viral mRNA, Apolipoprotein A1 modulator, arginase inhibitors, B- and T-lymphocyte attenuator inhibitors, Bruton’s tyrosine kinase (BTK) inhibitors, CCR2 chemokine antagonist, CD137 inhibitors, CD160 inhibitors, CD305 inhibitors, CD4 agonist and modulator, compounds targeting HBcAg, compounds targeting hepatitis B core antigen (HBcAg), covalently closed circular DNA (cccDNA) inhibitors, cyclophilin inhibitors, cytokines, cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors, DNA polymerase inhibitor, Endonuclease modulator, epigenetic modifiers, 20 Farnesoid X receptor agonist, gene modifiers or editors, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV antibodies, HBV DNA polymerase inhibitors, HBV replication inhibitors, HBV RNase inhibitors, HBV vaccines, HBV viral entry inhibitors, HBx inhibitors, Hepatitis B large envelope protein modulator, Hepatitis B large envelope protein stimulator, Hepatitis B structural protein modulator, 25 hepatitis B surface antigen (HBsAg) inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, hepatitis B virus E antigen inhibitors, hepatitis B virus replication inhibitors, Hepatitis virus structural protein inhibitor, HIV-1 reverse transcriptase inhibitor, Hyaluronidase inhibitor, IAPs inhibitors, IL-2 agonist, IL-7 agonist, Immunoglobulin agonist, Immunoglobulin G modulator, immunomodulators, indoleamine-2, inhibitors of ribonucleotide reductase, Interferon agonist, Interferon alpha 1 ligand, Interferon alpha 2 ligand, Interferon alpha 5 ligand modulator, Interferon alpha ligand, 30 Interferon alpha ligand modulator, interferon alpha receptor ligands, Interferon beta ligand, Interferon ligand, Interferon receptor modulator, Interleukin-2 ligand, ipi4 inhibitors, lysine demethylase inhibitors, histone demethylase inhibitors, KDM5 inhibitors, KDM1 inhibitors, killer cell lectin-like receptor subfamily G member 1 inhibitors, lymphocyte-activation gene 3 inhibitors, lymphotoxin beta receptor activators, microRNA (miRNA) gene therapy agents, modulators of Axl, modulators of B7-H3, 35 modulators of B7-H4, modulators of CD160, modulators of CD161, modulators of CD27, modulators of CD47, modulators of CD70, modulators of GITR, modulators of HEVEM, modulators of ICOS,

modulators of Mer, modulators of NKG2A, modulators of NKG2D, modulators of OX40, modulators of SIRPalpha, modulators of TIGIT, modulators of Tim-4, modulators of Tyro, Na⁺-taurocholate cotransporting polypeptide (NTCP) inhibitors, natural killer cell receptor 2B4 inhibitors, NOD2 gene stimulator, Nucleoprotein inhibitor, nucleoprotein modulators, PD-1 inhibitors, PD-L1 inhibitors, PEG-
5 Interferon Lambda, Peptidylprolyl isomerase inhibitor, phosphatidylinositol-3 kinase (PI3K) inhibitors, recombinant scavenger receptor A (SRA) proteins, recombinant thymosin alpha-1, Retinoic acid-inducible gene 1 stimulator, Reverse transcriptase inhibitor, Ribonuclease inhibitor, RNA DNA polymerase inhibitor, short interfering RNAs (siRNA), short synthetic hairpin RNAs (sshRNAs), SLC10A1 gene inhibitor, SMAC mimetics, Src tyrosine kinase inhibitor, stimulator of interferon gene
10 (STING) agonists, stimulators of NOD1, T cell surface glycoprotein CD28 inhibitor, T-cell surface glycoprotein CD8 modulator, Thymosin agonist, Thymosin alpha 1 ligand, Tim-3 inhibitors, TLR-3 agonist, TLR-7 agonist, TLR-9 agonist, TLR9 gene stimulator, toll-like receptor (TLR) modulators, Viral ribonucleotide reductase inhibitor, zinc finger nucleases or synthetic nucleases (TALENs), and combinations thereof.

15 In some embodiments, provided herein is a method for treating hepatitis B virus (HBV) in a patient in need thereof, comprising administering an effective amount of a compound described herein in combination with an effective amount of one or more anti-HCV agents, such as a NS5A inhibitor, a NS5B inhibitor, a NS3 inhibitor, or a combination thereof.

In some embodiments, provided is a method of treating hepatitis B virus (HBV) infection in a
20 human in need thereof, comprising administering to the patient an effective amount of a compound described herein in combination with an effective amount of a NS5A inhibitor. In some embodiments, the NS5A inhibitor is ledipasvir or velpatasvir. In some embodiments, is provided a method of treating hepatitis B virus (HBV) infection in a human in need thereof, comprising administering to the patient an effective amount of a compound described herein in combination with an effective amount of a NS5B
25 inhibitor. In some embodiments, the NS5B inhibitor is sofosbuvir or mericitabine. In some embodiments, is provided a method of treating hepatitis B virus (HBV) infection in a human in need thereof, comprising administering to the patient an effective amount of a compound described herein in combination with an effective amount of a NS3 inhibitor. In some embodiments, the NS3 inhibitor is voxilaprevir.

30 In some embodiments, the patient is administered an effective amount of a compound described herein in combination with an effective amount of both an effective amount of a NS5A inhibitor and an effective amount of a NS5B inhibitor. In some embodiments, the NS5A inhibitor is ledipasvir and the NS5B inhibitor is sofosbuvir. In some embodiments, the patient is administered an effective amount of a compound described herein in combination with an effective amount of a fixed dose combination of a
35 NS5A inhibitor and a NS5B inhibitor. In some embodiments, the patient is administered an effective amount of a compound described herein in combination with an effective amount of a fixed dose combination of ledipasvir and sofosbuvir.

In some embodiments, the patient is administered an effective amount of a compound of Table 1 in combination with an effective amount of both an effective amount of a NS5A inhibitor and an effective amount of a NS5B inhibitor. In some embodiments, the NS5A inhibitor is ledipasvir and the NS5B inhibitor is sofosbuvir. In some embodiments, the patient is administered an effective amount of a compound of Table 1 in combination with an effective amount of a fixed dose combination of a NS5A inhibitor and a NS5B inhibitor. In some embodiments, the patient is administered an effective amount of a compound of Table 1 in combination with an effective amount of a fixed dose combination of ledipasvir and sofosbuvir (e.g., ledipasvir 90 mg/sofosbuvir 400 mg). In some embodiments, the patient is administered an effective amount of a compound of Table 1 in combination with an effective amount of Harvoni®. In some embodiments, the patient is administered an effective amount of a compound of Table 1 in combination with an effective amount of a fixed dose combination of velpatasvir and sofosbuvir (e.g., velpatasvir 100 mg/sofosbuvir 400 mg). In some embodiments, the patient is administered an effective amount of a compound of Table 1 in combination with an effective amount of Epclusa®.

In some embodiments, the patient is administered an effective amount of compound 139 in combination with an effective amount of both an effective amount of a NS5A inhibitor and an effective amount of a NS5B inhibitor. In some embodiments, the NS5A inhibitor is ledipasvir and the NS5B inhibitor is sofosbuvir. In some embodiments, the patient is administered an effective amount of compound 139 in combination with an effective amount of a fixed dose combination of a NS5A inhibitor and a NS5B inhibitor. In some embodiments, the patient is administered an effective amount of compound 139 in combination with an effective amount of a fixed dose combination of ledipasvir and sofosbuvir (e.g., ledipasvir 90 mg/sofosbuvir 400 mg). In some embodiments, the patient is administered an effective amount of compound 139 in combination with an effective amount of Harvoni®. In some embodiments, the patient is administered an effective amount of compound 139 in combination with an effective amount of a fixed dose combination of velpatasvir and sofosbuvir (e.g., velpatasvir 100 mg/sofosbuvir 400 mg). In some embodiments, the patient is administered an effective amount of compound 139 in combination with an effective amount of Epclusa®.

In some embodiments, the patient is administered an effective amount of a compound described herein in combination with an effective amount of both an effective amount of a NS5A inhibitor and an effective amount of a NS5B inhibitor, and optionally a NS3 inhibitor. In some embodiments, the patient is administered an effective amount of a compound described herein in combination with an effective amount of sofosbuvir, velpatasvir, and voxilaprevir (e.g., sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg). In some embodiments, the patient is administered an effective amount of a compound described herein (e.g., compound 139) in combination with an effective amount of Vosevi™.

In certain embodiments, a compound of Formula (I) is formulated as a tablet, which may optionally contain one or more other compounds useful for treating hepatitis B virus (HBV). In certain embodiments, the tablet can contain another active ingredient for treating hepatitis B virus (HBV), such

as 3-dioxygenase (IDO) inhibitors, Apolipoprotein A1 modulator, arginase inhibitors, B- and T-lymphocyte attenuator inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, CCR2 chemokine antagonist, CD137 inhibitors, CD160 inhibitors, CD305 inhibitors, CD4 agonist and modulator, compounds targeting HBcAg, compounds targeting hepatitis B core antigen (HBcAg), core protein allosteric modulators, covalently closed circular DNA (cccDNA) inhibitors, cyclophilin inhibitors, cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors, DNA polymerase inhibitor, Endonuclease modulator, epigenetic modifiers, Farnesoid X receptor agonist, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV DNA polymerase inhibitors, HBV replication inhibitors, HBV RNase inhibitors, HBV viral entry inhibitors, HBx inhibitors, Hepatitis B large envelope protein modulator, Hepatitis B large envelope protein stimulator, Hepatitis B structural protein modulator, hepatitis B surface antigen (HBsAg) inhibitors, hepatitis B surface antigen (HBsAg) secretion or assembly inhibitors, hepatitis B virus E antigen inhibitors, hepatitis B virus replication inhibitors, Hepatitis virus structural protein inhibitor, HIV-1 reverse transcriptase inhibitor, Hyaluronidase inhibitor, IAPs inhibitors, IL-2 agonist, IL-7 agonist, immunomodulators, indoleamine-2 inhibitors, inhibitors of ribonucleotide reductase, Interleukin-2 ligand, ipi4 inhibitors, lysine demethylase inhibitors, histone demethylase inhibitors, KDM1 inhibitors, KDM5 inhibitors, killer cell lectin-like receptor subfamily G member 1 inhibitors, lymphocyte-activation gene 3 inhibitors, lymphotoxin beta receptor activators, modulators of Axl, modulators of B7-H3, modulators of B7-H4, modulators of CD160, modulators of CD161, modulators of CD27, modulators of CD47, modulators of CD70, modulators of GITR, modulators of HEVEM, modulators of ICOS, modulators of Mer, modulators of NKG2A, modulators of NKG2D, modulators of OX40, modulators of SIRPalpha, modulators of TIGIT, modulators of Tim-4, modulators of Tyro, Na⁺-taurocholate cotransporting polypeptide (NTCP) inhibitors, natural killer cell receptor 2B4 inhibitors, NOD2 gene stimulator, Nucleoprotein inhibitor, nucleoprotein modulators, PD-1 inhibitors, PD-L1 inhibitors, Peptidylprolyl isomerase inhibitor, phosphatidylinositol-3 kinase (PI3K) inhibitors, Retinoic acid-inducible gene 1 stimulator, Reverse transcriptase inhibitor, Ribonuclease inhibitor, RNA DNA polymerase inhibitor, SLC10A1 gene inhibitor, SMAC mimetics, Src tyrosine kinase inhibitor, stimulator of interferon gene (STING) agonists, stimulators of NOD1, T cell surface glycoprotein CD28 inhibitor, T-cell surface glycoprotein CD8 modulator, Thymosin agonist, Thymosin alpha 1 ligand, Tim-3 inhibitors, TLR-3 agonist, TLR-7 agonist, TLR-9 agonist, TLR9 gene stimulator, toll-like receptor (TLR) modulators, Viral ribonucleotide reductase inhibitor, and combinations thereof.

In certain embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents selected from HBV combination drugs, HBV vaccines, HBV DNA polymerase inhibitors, immunomodulators toll-like receptor (TLR) modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, hepatitis b surface antigen (HBsAg) inhibitors, cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors, cyclophilin inhibitors, HBV viral entry inhibitors, antisense oligonucleotide targeting viral mRNA, short interfering RNAs (siRNA) and ddRNAi endonuclease modulators, ribonucleotide reductase inhibitors, HBV E antigen inhibitors, covalently closed circular DNA (cccDNA) inhibitors, farnesoid X receptor agonists,

HBV antibodies, CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein modulators, retinoic acid-inducible gene 1 stimulators, NOD2 stimulators, phosphatidylinositol 3-kinase (PI3K) inhibitors, indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors, PD-1 inhibitors, PD-L1 inhibitors, recombinant thymosin alpha-1, bruton's tyrosine kinase (BTK) inhibitors, KDM inhibitors, HBV replication inhibitors, arginase inhibitors, and other HBV drugs.

HBV Combination Drugs

Examples of combination drugs for the treatment of HBV include TRUVADA[®] (tenofovir disoproxil fumarate and emtricitabine); ABX-203, lamivudine, and PEG-IFN-alpha; ABX-203 adefovir, and PEG-IFNalpha; and INO-1800 (INO-9112 and RG7944).

Other HBV Drugs

Examples of other drugs for the treatment of HBV include alpha-hydroxytropolones, amdoxovir, beta-hydroxycytosine nucleosides, AL-034, CCC-0975, elvucitabine, ezetimibe, cyclosporin A, gentiopiricin (gentiopicroside), JNJ-56136379, nitazoxanide, birinapant, NJK14047, NOV-205 (molixan, BAM-205), oligotide, mivotilate, feron, GST-HG-131, levamisole, Ka Shu Ning, alloferon, WS-007, Y-101 (Ti Fen Tai), rSIFN-co, PEG-IIFNm, KW-3, BP-Inter-014, oleanolic acid, HepB-nRNA, cTP-5 (rTP-5), HSK-II-2, HEISCO-106-1, HEISCO-106, Hepbarna, IBPB-006IA, Hepuyinfe, DasKloster 0014-01, ISA-204, Jiangantai (Ganxikang), MIV-210, OB-AI-004, PF-06, picoside, DasKloster-0039, hepulantai, IMB-2613, TCM-800B, reduced glutathione, RO-6864018, RG-7834, UB-551, and ZH-2N, and the compounds disclosed in US20150210682, (Roche), US 2016/0122344 (Roche), WO2015173164, WO2016023877, US2015252057A (Roche), WO16128335A1 (Roche), WO16120186A1 (Roche), US2016237090A (Roche), WO16107833A1 (Roche), WO16107832A1 (Roche), US2016176899A (Roche), WO16102438A1 (Roche), WO16012470A1 (Roche), US2016220586A (Roche), and US2015031687A (Roche).

HBV Vaccines

HBV vaccines include both prophylactic and therapeutic vaccines. Examples of HBV prophylactic vaccines include Vaxelis, Hexaxim, Heplisav, Mosquirix, DTwP-HBV vaccine, Bio-Hep-B, D/T/P/HBV/M (LBVP-0101; LBVW-0101), DTwP-Hepb-Hib-IPV vaccine, Heberpenta L, DTwP-HepB-Hib, V-419, CVI-HBV-001, Tetrabay, hepatitis B prophylactic vaccine (Advax Super D), Hepatrol-07, GSK-223192A, ENGERIX B[®], recombinant hepatitis B vaccine (intramuscular, Kangtai Biological Products), recombinant hepatitis B vaccine (Hansensual polymorpha yeast, intramuscular, Hualan Biological Engineering), recombinant hepatitis B surface antigen vaccine, Bimmugen, Euforavac, Eutravac, anrix-DTaP-IPV-Hep B, HBAI-20, Infanrix-DTaP-IPV-Hep B-Hib, Pentabio Vaksin DTP-HB-Hib, Comvac 4, Twinrix, Euvax-B, Tritanrix HB, Infanrix Hep B, Comvac, DTP-Hib-HBV vaccine, DTP-HBV vaccine, Yi Tai, Heberbiovac HB, Trivac HB, GerVax, DTwP-Hep B-Hib vaccine, Bilive, Hepavax-Gene, SUPERVAX, Comvac5, Shanvac-B, Hebsulin, Recombivax HB, Revac B mcf, Revac

B+, Fendrix, DTwP-HepB-Hib, DNA-001, Shan5, Shan6, rhHBsAG vaccine, HBI pentavalent vaccine, LBVD, Infanrix HeXa, and DTaP-rHB-Hib vaccine.

Examples of HBV therapeutic vaccines include HBsAG-HBIG complex, ARB-1598, Bio-Hep-B, NASVAC, abi-HB (intravenous), ABX-203, Tetrabhay, GX-110E, GS-4774, peptide vaccine
 5 (epsilonPA-44), Hepatrol-07, NASVAC (NASTERAP), IMP-321, BEVAC, Revac B mcf, Revac B+, MGN-1333, KW-2, CVI-HBV-002, AltraHepB, VGX-6200, FP-02, FP-02.2, TG-1050, NU-500, HBVax, im/TriGrid/antigen vaccine, Mega-CD40L-adjuvanted vaccine, HepB-v, RG7944 (INO-1800), recombinant VLP-based therapeutic vaccine (HBV infection, VLP Biotech), AdTG-17909, AdTG-17910 AdTG-18202, ChronVac-B, TG-1050, and Lm HBV.

10 *HBV DNA Polymerase Inhibitors*

Examples of HBV DNA polymerase inhibitors include adefovir (HEPSERA[®]), emtricitabine (EMTRIVA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir dipivoxil, tenofovir dipivoxil fumarate, tenofovir octadecyloxyethyl ester, CMX-157, besifovir, entecavir
 15 (BARACLUDE[®]), entecavir maleate, telbivudine (TYZEKA[®]), pradevovir, clevudine, ribavirin, lamivudine (EPIVIR-HBV[®]), phosphazide, famciclovir, fusolin, metacavir, SNC-019754, FMCA, AGX-1009, AR-II-04-26, HIP-1302, tenofovir disoproxil aspartate, tenofovir disoproxil orotate, and HS-10234.

Immunomodulators

Examples of immunomodulators include rintatolimod, imidol hydrochloride, ingaron, dermaVir, plaquenil (hydroxychloroquine), proleukin, hydroxyurea, mycophenolate mofetil (MPA) and its ester
 20 derivative mycophenolate mofetil (MMF), WF-10, ribavirin, IL-12, INO-9112, polymer polyethyleneimine (PEI), Gepon, VGV-1, MOR-22, BMS-936559, RO-7011785, RO-6871765, AIC-649, and IR-103.

Toll-like Receptor (TLR) Modulators

25 TLR modulators include modulators of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13. Examples of TLR3 modulators include rintatolimod, poly-ICLC, RIBOXXON[®], Apoxsim, RIBOXXIM[®], IPH-33, MCT-465, MCT-475, GS-9688 and ND-1.1.

Examples of TLR7 modulators include GS-9620, GSK-2245035, imiquimod, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X,
 30 TMX-202, RG-7863, RG-7795, RG-7854, and the compounds disclosed in US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), and US20090047249 (Gilead Sciences).

Examples of TLR8 modulators include motolimod, resiquimod, 3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463, and the compounds disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189
 35 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma),

US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics).

- 5 Examples of TLR9 modulators include BB-001, BB-006, CYT-003, IMO-2055, IMO-2125, IMO-3100, IMO-8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, leftolimod (MGN-1703), litenimod, and CYT-003-QbG10.

Interferon Alpha Receptor Ligands

- Examples of interferon alpha receptor ligands include interferon alpha-2b (INTRON A[®]),
 10 pegylated interferon alpha-2a (PEGASYS[®]), PEGylated interferon alpha-1b, interferon alpha 1b (HAPGEN[®]), Veldona, Infradure, Roferon-A, YPEG-interferon alfa-2a (YPEG-rhIFNalpha-2a), P-1101, Algeron, Alfarona, Ingaron (interferon gamma), rSIFN-co (recombinant super compound interferon), Ypeginterferon alfa-2b (YPEG-rhIFNalpha-2b), MOR-22, peginterferon alfa-2b (PEG-INTRON[®]), Bioferon, Novaferon, Inmutag (Inferon), MULTIFERON[®], interferon alfa-n1 (HUMOFERON[®]),
 15 interferon beta-1a (AVONEX[®]), Shaferon, interferon alfa-2b (Axxo), Alfaferone, interferon alfa-2b (BioGeneric Pharma), interferon-alpha 2 (CJ), Laferonum, VIPEG, BLAUFERON-A, BLAUFERON-B, Intermax Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), interferon alfa 2a, Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Amege),
 20 interferon alfa-2b (Virchow), ropeginterferon alfa-2b, rHSA-IFN alpha-2a (recombinant human serum albumin interfereferon alpha 2a fusion protein), rHSA-IFN alpha 2b, recombinant human interferon alpha- (1b, 2a, 2b), peginterferon alfa-2b (Amege), peginterferon alfa-2a, Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, Layfferon, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai, Pegstat, rHSA-IFN alpha-2b, SFR-
 25 9216, and Interapo (Interapa).

Hyaluronidase Inhibitors

Examples of hyaluronidase inhibitors include astodimer.

Hepatitis B Surface Antigen (HBsAg) Inhibitors

- Examples of HBsAg inhibitors include HBF-0259, PBHBV-001, PBHBV-2-15, PBHBV-2-1,
 30 REP-9AC, REP-9C, REP-9, REP-2139, REP-2139-Ca, REP-2165, REP-2055, REP-2163, REP-2165, REP-2053, REP-2031 and REP-006, and REP-9AC'.

Examples of HBsAg secretion inhibitors include BM601.

Cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors

- Examples of Cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors include AGEN-2041,
 35 AGEN-1884, ipilumimab, belatacept, PSI-001, PRS-010, Probody mAbs, tremelimumab, and JHL-1155.

Cyclophilin Inhibitors

Examples of cyclophilin inhibitors include CPI-431-32, EDP-494, OCB-030, SCY-635, NVP-015, NVP-018, NVP-019, STG-175, and the compounds disclosed in US8513184 (Gilead Sciences), US20140030221 (Gilead Sciences), US20130344030 (Gilead Sciences), and US20130344029 (Gilead Sciences).

HBV Viral Entry Inhibitors

Examples of HBV viral entry inhibitors include Myrcludex B.

Antisense Oligonucleotide Targeting Viral mRNA

Examples of antisense oligonucleotide targeting viral mRNA include ISIS-HBVRx, IONIS-HBVRx, IONIS-GSK6-LRx, GSK-3389404, RG-6004.

Short Interfering RNAs (siRNA) and ddRNAi.

Examples of siRNA include TKM-HBV (TKM-HepB), ALN-HBV, SR-008, HepB-nRNA, and ARC-520, ARC-521, ARB-1740, ARB-1467.

Examples of DNA-directed RNA interference (ddRNAi) include BB-HB-331.

Endonuclease Modulators

Examples of endonuclease modulators include PGN-514.

Ribonucleotide Reductase Inhibitors

Examples of inhibitors of ribonucleotide reductase include Trimidox.

HBV E Antigen Inhibitors

Examples of HBV E antigen inhibitors include wogonin.

Covalently Closed Circular DNA (cccDNA) Inhibitors

Examples of cccDNA inhibitors include BSBI-25, and CHR-101.

Farnesoid X receptor agonist

Example of farnesoid x receptor agonist such as EYP-001.

HBV Antibodies

Examples of HBV antibodies targeting the surface antigens of the hepatitis B virus include GC-1102, XTL-17, XTL-19, KN-003, IV Hepabulin SN, and fully human monoclonal antibody therapy (hepatitis B virus infection, Humabs BioMed). Examples of HBV antibodies, including monoclonal antibodies and polyclonal antibodies, include Zutectra, Shang Sheng Gan Di, Uman Big (Hepatitis B Hyperimmune), Omri-Hep-B, Nabi-HB, Hepatect CP, HepaGam B, igantibe, Niuliva, CT-P24, hepatitis

B immunoglobulin (intravenous, pH4, HBV infection, Shanghai RAAS Blood Products), and Fovepta (BT-088). Fully human monoclonal antibodies such as HBC-34.

CCR2 Chemokine Antagonists

Examples of CCR2 chemokine antagonists include propagermanium.

5 *Thymosin Agonists*

Examples of thymosin agonists include Thymalfasin, recombinant thymosin alpha 1 (GeneScience).

Cytokines

10 Examples of cytokines include recombinant IL-7, CYT-107, interleukin-2 (IL-2, Immunex), recombinant human interleukin-2 (Shenzhen Neptunus), IL-15, IL-21, IL-24, and celmoleukin.

Nucleoprotein modulators

Nucleoprotein modulators may be either HBV core or capsid protein inhibitors. Examples of nucleoprotein modulators include AB-423, AT-130, GLS4, NVR-1221, NVR-3778, BAY 41-4109, morphothiadine mesilate, JNJ-379, RG-7907, ABI-H0731, ABI-H2158 and DVR-23.

15 Examples of capsid inhibitors include the compounds disclosed in US20140275167 (Novira Therapeutics), US20130251673 (Novira Therapeutics), US20140343032 (Roche), WO2014037480 (Roche), US20130267517 (Roche), WO2014131847 (Janssen), WO2014033176 (Janssen), WO2014033170 (Janssen), WO2014033167 (Janssen), WO2015/059212 (Janssen), WO2015118057 (Janssen), WO2015011281 (Janssen), WO2014184365 (Janssen), WO2014184350 (Janssen),
20 WO2014161888 (Janssen), WO2013096744 (Novira), US20150225355 (Novira), US20140178337 (Novira), US20150315159 (Novira), US20150197533 (Novira), US20150274652 (Novira), US20150259324, (Novira), US20150132258 (Novira), US9181288 (Novira), WO2014184350 (Janssen), WO2013144129 (Roche).

Retinoic Acid-inducible Gene 1 Stimulators

25 Examples of stimulators of retinoic acid-inducible gene 1 include SB-9200, SB-40, SB-44, ORI-7246, ORI-9350, ORI-7537, ORI-9020, ORI-9198, and ORI-7170, RGT-100.

NOD2 Stimulators

Examples of stimulators of NOD2 include SB-9200.

Phosphatidylinositol 3-kinase (PI3K) Inhibitors

30 Examples of PI3K inhibitors include idelalisib, ACP-319, AZD-8186, AZD-8835, buparlisib, CDZ-173, CLR-457, pictilisib, neratinib, rigosertib, rigosertib sodium, EN-3342, TGR-1202, alpelisib, duvelisib, IPI-549, UCB-5857, taselisib, XL-765, gedatolisib, ME-401, VS-5584, copanlisib, CAI orotate, perifosine, RG-7666, GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458,

CUDC-907, PQR-309, INCB-40093, pilaralisib, BAY-1082439, puquitinib mesylate, SAR-245409, AMG-319, RP-6530, ZSTK-474, MLN-1117, SF-1126, RV-1729, sonolisib, LY-3023414, SAR-260301, TAK-117, HMPL-689, tenalisib, voxalisib, and CLR-1401.

Indoleamine-2, 3-dioxygenase (IDO) Pathway Inhibitors

5 Examples of IDO inhibitors include epacadostat (INCB24360), resminostat (4SC-201), indoximod, F-001287, SN-35837, NLG-919, GDC-0919, GBV-1028, GBV-1012, NKTR-218, and the compounds disclosed in US20100015178 (Incyte), US2016137652 (Flexus Biosciences, Inc.), WO2014073738 (Flexus Biosciences, Inc.), and WO2015188085 (Flexus Biosciences, Inc.).

PD-1 Inhibitors

10 Examples of PD-1 inhibitors include nivolumab, pembrolizumab, pidilizumab, BGB-108, SHR-1210, PDR-001, PF-06801591, IBI-308, GB-226, STI-1110, and mDX-400.

PD-L1 Inhibitors

15 Examples of PD-L1 inhibitors include atezolizumab, avelumab, AMP-224, MEDI-0680, RG-7446, GX-P2, durvalumab, KY-1003, KD-033, MSB-0010718C, TSR-042, ALN-PDL, STI-A1014, CX-072, and BMS-936559.

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with compounds such as those disclosed in WO2018026971, US20180044329, US20180044305, US20180044304, US20180044303, US20180044350, US20180057455, US20180057486, US20180045142, WO20180044963, WO2018044783, WO2018009505, 20 WO20180044329, WO2017066227, WO2017087777, US20170145025, WO2017079669, WO2017070089, US2017107216, WO2017222976, US20170262253, WO2017205464, US20170320875, WO2017192961, WO2017112730, US20170174679, WO2017106634, WO2017202744, WO2017202275, WO2017202273, WO2017202274, WO2017202276, WO2017180769, WO2017118762, WO2016041511, WO2016039749, WO2016142835, 25 WO2016142852, WO2016142886, WO2016142894, and WO2016142833.

Recombinant Thymosin Alpha-1

Examples of recombinant thymosin alpha-1 include NL-004 and PEGylated thymosin alpha-1.

Bruton's Tyrosine Kinase (BTK) Inhibitors

30 Examples of BTK inhibitors include ABBV-105, acalabrutinib (ACP-196), ARQ-531, BMS-986142, dasatinib, ibrutinib, GDC-0853, PRN-1008, SNS-062, ONO-4059, BGB-3111, ML-319, MSC-2364447, RDX-022, X-022, AC-058, RG-7845, spebrutinib, TAS-5315, TP-0158, TP-4207, HM-71224, KBP-7536, M-2951, TAK-020, AC-0025, and the compounds disclosed in US20140330015 (Ono Pharmaceutical), US20130079327 (Ono Pharmaceutical), and US20130217880 (Ono Pharmaceutical).

KDM Inhibitors

Examples of KDM5 inhibitors include the compounds disclosed in WO2016057924 (Genentech/Constellation Pharmaceuticals), US20140275092 (Genentech/Constellation Pharmaceuticals), US20140371195 (Epitherapeutics) and US20140371214 (Epitherapeutics),
 5 US20160102096 (Epitherapeutics), US20140194469 (Quantice), US20140171432, US20140213591 (Quantice), US20160039808 (Quantice), US20140275084 (Quantice), WO2014164708 (Quantice).

Examples of KDM1 inhibitors include the compounds disclosed in US9186337B2 (Oryzon Genomics), and GSK-2879552, RG-6016, ORY-2001.

HBV Replication Inhibitors

10 Examples of hepatitis B virus replication inhibitors include isothiafludine, IQP-HBV, RM-5038, and Xingantie.

Arginase inhibitors

Examples of Arginase inhibitors include CB-1158, C-201, and resminostat.

Gene Therapy and Cell Therapy

15 Gene Therapy and Cell Therapy including the genetic modification to silence a gene; genetic approaches to directly kill the infected cells; the infusion of immune cells designed to replace most of the patient's own immune system to enhance the immune response to infected cells, or activate the patient's own immune system to kill infected cells, or find and kill the infected cells; genetic approaches to modify cellular activity to further alter endogenous immune responsiveness against the infection.

Gene Editors

The genome editing system is selected from the group consisting of: a CRISPR/Cas9 system, a zinc finger nuclease system, a TALEN system, a homing endonucleases system, and a meganuclease system; e.g., cccDNA elimination via targeted cleavage, and altering one or more of the hepatitis B virus (HBV) viral genes. Altering (e.g., knocking out and/or knocking down) the *PreC*, *C*, *X*, *PreS1*, *PreS2*, *S*,
 25 *P* or *SP* gene refers to (1) reducing or eliminating *PreC*, *C*, *X*, *PreS1*, *PreS2*, *S*, *P* or *SP* gene expression, (2) interfering with Precore, Core, X protein, Long surface protein, middle surface protein, S protein (also known as HBs antigen and HBsAg), polymerase protein, and/or Hepatitis B spliced protein function (HBe, HBc, HBx, PreS1, PreS2, S, Pol, and/or HBSP or (3) reducing or eliminating the intracellular, serum and/or intraparenchymal levels of HBe, HBc, HBx, LHBS, MHBS, SHBS, Pol, and/or HBSP
 30 proteins. Knockdown of one or more of the *PreC*, *C*, *X*, *PreS1*, *PreS2*, *S*, *P* and/or *SP* gene(s) is performed by targeting the gene(s) within HBV cccDNA and/or integrated HBV DNA.

CAR-T cell therapy

A population of immune effector cells engineered to express a chimeric antigen receptor (CAR), wherein the CAR comprises an HBV antigen-binding domain. The immune effector cell is a T cell or an

NK cell. In some embodiments, the T cell is a CD4⁺ T cell, a CD8⁺ T cell, or a combination thereof. Cells can be autologous or allogeneic.

TCR-T cell therapy

T cells expressing HBV-specific T cell receptors. TCR-T cells are engineered to target HBV
5 derived peptides presented on the surface of virus-infected cells.

T-Cells expressing HBV surface antigen (HBsAg)-specific TCR.

TCR-T therapy directed to treatment of HBV, such as LTCR-H2-1

HBV Combination Therapy

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt
10 thereof, is combined with one, two, three, or four additional therapeutic agent selected from the group
consisting of adefovir (HEPSERA®), tenofovir disoproxil fumarate (VIREAD®), tenofovir alafenamide,
tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
entecavir (BARACLUDE®), telbivudine (TYZEKA®), or lamivudine (EPIVIR-HBV®). In a particular
embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined
15 with a first additional therapeutic agent selected from the group consisting of adefovir (HEPSERA®),
tenofovir disoproxil fumarate (VIREAD®), tenofovir alafenamide, tenofovir, tenofovir disoproxil,
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE®),
telbivudine (TYZEKA®), or lamivudine (EPIVIR-HBV®). In one embodiment, pharmaceutical
compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in
20 combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four)
additional therapeutic agents and a pharmaceutically acceptable carrier, diluent, or excipient are
provided.

HBV DNA Polymerase Inhibitor Combination Therapy

In a specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt
25 thereof, is combined with an HBV DNA polymerase inhibitor. In another specific embodiment, a
compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV
DNA polymerase inhibitor and at least one additional therapeutic agent selected from the group
consisting of: immunomodulators, TLR modulators, interferon alpha receptor ligands, hyaluronidase
inhibitors, recombinant IL-7, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, compounds
30 targeting HBcAg, cyclophilin inhibitors, HBV vaccines, HBV viral entry inhibitors, NTCP inhibitors,
antisense oligonucleotide targeting viral mRNA, siRNA, miRNA gene therapy agents, endonuclease
modulators, inhibitors of ribonucleotide reductase, hepatitis B virus E antigen inhibitors, recombinant
SRA proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, sshRNAs, HBV antibodies
including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies
35 and “antibody-like” therapeutic proteins (such as DARTs®, DUOBODIES®, BITES®, XmAbs®,

TandAbs[®], Fab derivatives, or TCR-like antibodies), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein modulators (HBV core or capsid protein modulators), stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, stimulators of NOD2, stimulators of NOD1, Arginase inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, natural killer cell receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors, CD137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PEG-Interferon Lambda, recombinant thymosin alpha-1, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha, modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, epigenetic modifiers, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), IAPs inhibitors, SMAC mimetics, KDM5 inhibitors, IDO inhibitors, and hepatitis B virus replication inhibitors.

In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor, one or two additional therapeutic agents selected from the group consisting of immunomodulators, TLR modulators, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and “antibody-like” therapeutic proteins (such as DARTs[®], DUOBODIES[®], BITES[®], XmAbs[®], TandAbs[®], Fab derivatives, or TCR-like antibodies), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, PD-1 inhibitors, PD-L1 inhibitors, Arginase inhibitors, PI3K inhibitors, IDO inhibitors, and stimulators of NOD2, and one or two additional therapeutic agents selected from the group consisting of HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, siRNA, miRNA gene therapy agents, sshRNAs, KDM5 inhibitors, and nucleoprotein modulators (HBV core or capsid protein modulators).

In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor and at least a second additional therapeutic agent selected from the group consisting of: immunomodulators, TLR modulators, HBsAg inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and “antibody-like” therapeutic proteins (such as DARTs[®], DUOBODIES[®], BITES[®], XmAbs[®], TandAbs[®], Fab derivatives, or TCR-like antibodies), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, PD-1 inhibitors, PD-L1 inhibitors, Arginase inhibitors, PI3K inhibitors, IDO inhibitors, and stimulators of NOD2.

In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor and at least a second additional therapeutic agent selected from the group consisting of: HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, siRNA, miRNA gene therapy agents, sshRNAs, KDM5 inhibitors, and nucleoprotein modulators (HBV core or capsid protein inhibitors).

HBV Drug Combination Therapy

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of adefovir (HEPSERA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE[®]), telbivudine (TYZEKA[®]), or lamivudine (EPIVIR-HBV[®]), and at least a second additional therapeutic agent selected from the group consisting of immunomodulators, TLR modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, siRNA, miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, hepatitis B virus E antigen inhibitors, recombinant SRA proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, sshRNAs, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and “antibody-like” therapeutic proteins (such as DARTs[®], DUOBODIES[®], BITES[®], XmAbs[®], TandAbs[®], Fab derivatives, and TCR-like antibodies), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein modulators (HBV core or capsid protein modulators), stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, stimulators of NOD2, stimulators of NOD1, IDO inhibitors, recombinant thymosin alpha-1, Arginase inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, natural killer cell receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors, ipi4 inhibitors, CD137 inhibitors, killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, epigenetic modifiers, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PEG-Interferon Lambda, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha, modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), IAPs inhibitors, SMAC mimetics, KDM5 inhibitors, and hepatitis B virus replication inhibitors.

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of

adefovir (HEPSERA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE[®]), telbivudine (TYZEKA[®]) or lamivudine (EPIVIR-HBV[®]) and at least a second additional therapeutic agent selected from the group consisting of peginterferon alfa-2b (PEG-
5 INTRON[®]), MULTIFERON[®], interferon alpha 1b (HAPGEN[®]), interferon alpha-2b (INTRON A[®]), pegylated interferon alpha-2a (PEGASYS[®]), interferon alfa-n1 (HUMOFERON[®]), ribavirin, interferon beta-1a (AVONEX[®]), Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A, Oligotide, Zutectra, Shaferon, interferon alfa-2b (AXXO), Alfaferone, interferon alfa-2b (BioGeneric Pharma), Feron, interferon-alpha 2 (CJ), BEVAC, Laferonum, VIPEG, BLAUFERON-B, BLAUFERON-A, Intermax
10 Alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma), alfainterferona 2b, Kalferon, Pignano, Feronsure, PegiHep, interferon alfa 2b (Zydus-Cadila), Optipeg A, Realfa 2B, Reliferon, interferon alfa-2b (Ameqa), interferon alfa-2b (Virchow), peginterferon alfa-2b (Ameqa), Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alfa-2b (Changchun Institute of Biological Products), Anterferon, Shanferon, MOR-22, interleukin-2 (IL-2, Immunex), recombinant
15 human interleukin-2 (Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, INTEFEN, SINOGEN, Fukangtai, Alloferon, and celmoleukin.

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of adefovir (HEPSERA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir,
20 tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE[®]), telbivudine (TYZEKA[®]), or lamivudine (EPIVIR-HBV[®]), and at least a second additional therapeutic agent selected from the group consisting of immunomodulators, TLR modulators, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies
25 and “antibody-like” therapeutic proteins (such as DARTs[®], DUOBODIES[®], BITES[®], XmAbs[®], TandAbs[®], Fab derivatives, or TCR-like antibodies), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, Arginase inhibitors, PI3K inhibitors, PD-1 inhibitors, PD-L1 inhibitors, IDO inhibitors, and stimulators of NOD2.

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of:
30 adefovir (HEPSERA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE[®]), telbivudine (TYZEKA[®]), or lamivudine (EPIVIR-HBV[®]), and at least a second additional therapeutic agent selected from the group consisting of HBV viral entry inhibitors, NTCP
35 inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, siRNA, miRNA gene therapy agents, sshRNAs, KDM5 inhibitors, and nucleoprotein modulators (HBV core or capsid protein modulators).

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of adefovir (HEPSERA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE[®]), telbivudine (TYZEKA[®]), or lamivudine (EPIVIR-HBV[®]); one, two, or three
5 additional therapeutic agents selected from the group consisting of immunomodulators, TLR modulators, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and “antibody-like” therapeutic proteins (such as DARTs[®], DUOBODIES[®], BITES[®], XmAbs[®],
10 TandAbs[®], Fab derivatives, or TCR-like antibodies), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, PD-1 inhibitors, PD-L1 inhibitors, Arginase inhibitors, PI3K inhibitors, IDO inhibitors, and stimulators of NOD2; and one or two additional therapeutic agents selected from the group consisting of HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B
15 virus, siRNA, miRNA gene therapy agents, sshRNAs, KDM5 inhibitors, and nucleoprotein modulators (HBV core or capsid protein modulators).

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of adefovir (HEPSERA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir,
20 tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE[®]), telbivudine (TYZEKA[®]), or lamivudine (EPIVIR-HBV[®]); one or two additional therapeutic agents selected from the group consisting of immunomodulators, TLR modulators, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and
25 “antibody-like” therapeutic proteins (such as DARTs[®], DUOBODIES[®], BITES[®], XmAbs[®], TandAbs[®], Fab derivatives, or TCR-like antibodies), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, PD-1 inhibitors, PD-L1 inhibitors, Arginase inhibitors, PI3K inhibitors, IDO inhibitors, and stimulators of NOD2; and one or two additional therapeutic agents selected from the group consisting of HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV antibodies targeting the surface antigens of the hepatitis B virus, siRNA,
30 miRNA gene therapy agents, sshRNAs, KDM5 inhibitors, and nucleoprotein modulators (HBV core or capsid protein modulators).

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with a first additional therapeutic agent selected from the group consisting of adefovir (HEPSERA[®]), tenofovir disoproxil fumarate (VIREAD[®]), tenofovir alafenamide, tenofovir,
35 tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, entecavir (BARACLUDE[®]), telbivudine (TYZEKA[®]), or lamivudine (EPIVIR-HBV[®]); and one, two, three, or four

additional therapeutic agents selected from the group consisting of immunomodulators, TLR7 modulators, TLR8 modulators, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and “antibody-like” therapeutic proteins (such as DARTs[®], DUOBODIES[®], BITES[®], XmAbs[®], TandAbs[®], Fab derivatives, or TCR-like antibodies), cyclophilin inhibitors, stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, PD-1 inhibitors, PD-L1 inhibitors, Arginase inhibitors, PI3K inhibitors, IDO inhibitors, stimulators of NOD2 HBV viral entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, siRNA, miRNA gene therapy agents, sshRNAs, KDM5 inhibitors, and nucleoprotein modulators (HBV core or capsid protein modulators).

In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with compounds such as those disclosed in U.S. Publication No. 2010/0143301 (Gilead Sciences), U.S. Publication No. 2011/0098248 (Gilead Sciences), U.S. Publication No. 2009/0047249 (Gilead Sciences), U.S. Patent No. 8722054 (Gilead Sciences), U.S. Publication No. 2014/0045849 (Janssen), U.S. Publication No. 2014/0073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), U.S. Publication No. 2014/0350031 (Janssen), WO2014/023813 (Janssen), U.S. Publication No. 2008/0234251 (Array Biopharma), U.S. Publication No. 2008/0306050 (Array Biopharma), U.S. Publication No. 2010/0029585 (Ventirx Pharma), U.S. Publication No. 2011/0092485 (Ventirx Pharma), US2011/0118235 (Ventirx Pharma), U.S. Publication No. 2012/0082658 (Ventirx Pharma), U.S. Publication No. 2012/0219615 (Ventirx Pharma), U.S. Publication No. 2014/0066432 (Ventirx Pharma), U.S. Publication No. 2014/0088085 (Ventirx Pharma), U.S. Publication No. 2014/0275167 (Novira Therapeutics), U.S. Publication No. 2013/0251673 (Novira Therapeutics), U.S. Patent No. 8513184 (Gilead Sciences), U.S. Publication No. 2014/0030221 (Gilead Sciences), U.S. Publication No. 2013/0344030 (Gilead Sciences), U.S. Publication No. 2013/0344029 (Gilead Sciences), US20140275167 (Novira Therapeutics), US20130251673 (Novira Therapeutics), U.S. Publication No. 2014/0343032 (Roche), WO2014037480 (Roche), U.S. Publication No. 2013/0267517 (Roche), WO2014131847 (Janssen), WO2014033176 (Janssen), WO2014033170 (Janssen), WO2014033167 (Janssen), WO2015/059212 (Janssen), WO2015118057 (Janssen), WO2015011281 (Janssen), WO2014184365 (Janssen), WO2014184350 (Janssen), WO2014161888 (Janssen), WO2013096744 (Novira), US20150225355 (Novira), US20140178337 (Novira), US20150315159 (Novira), US20150197533 (Novira), US20150274652 (Novira), US20150259324 (Novira), US20150132258 (Novira), US9181288 (Novira), WO2014184350 (Janssen), WO2013144129 (Roche), US20100015178 (Incyte), US2016137652 (Flexus Biosciences, Inc.), WO2014073738 (Flexus Biosciences, Inc.), WO2015188085 (Flexus Biosciences, Inc.), U.S. Publication No. 2014/0330015 (Ono Pharmaceutical), U.S. Publication No. 2013/0079327 (Ono Pharmaceutical), U.S. Publication No. 2013/0217880 (Ono pharmaceutical), WO2016057924 (Genentech/Constellation Pharmaceuticals), US20140275092 (Genentech/Constellation Pharmaceuticals), US20140371195 (Epitherapeutics) and US20140371214 (Epitherapeutics), US20160102096 (Epitherapeutics), US20140194469 (Quantice),

US20140171432, US20140213591 (Quantice), US20160039808 (Quantice), US20140275084 (Quantice), WO2014164708 (Quantice), US9186337B2 (Oryzon Genomics), and other drugs for treating hepatitis B virus (HBV), and combinations thereof.

5 In certain embodiments, a compound as disclosed herein (e.g., any compound of Formula I) may be combined with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents in any dosage amount of the compound of Formula (I) (e.g., from 10 mg to 1000 mg of compound).

10 In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 5-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 5-10; 5-15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 10 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 25 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. A compound as disclosed herein (e.g., a compound of Formula I) may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.

20 In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 100-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 100 mg to 150 mg; 100 mg to 200 mg; 100 mg to 250 mg; 100 mg to 300 mg; 100 mg to 350 mg; 150 mg to 200 mg; 150 mg to 250 mg; 150 mg to 300 mg; 150 mg to 350 mg; 150 mg to 400 mg; 200 mg to 250 mg; 200 mg to 300 mg; 200 mg to 350 mg; 200 mg to 400 mg; 250 mg to 350 mg; 250 mg to 400 mg; 350 mg to 400 or 300 mg to 400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 300 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 250 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 150 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil. A compound as disclosed herein (e.g., a compound of Formula I) may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.

In one embodiment, kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents are provided.

Any pharmaceutical composition provided in the present disclosure may be used in the kits, the same as if each and every composition were specifically and individually listed for use in a kit.

Synthesis

The compounds of the disclosure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein.

The synthesis of typical compounds of formula (I), or a pharmaceutically acceptable salt thereof, e.g., compounds having structures described by one or more of formula (I), or other formulas or compounds disclosed herein, may be accomplished as described in the following examples.

General Syntheses

Typical embodiments of compounds in accordance with the present disclosure may be synthesized using the general reaction schemes and/or examples described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Starting materials are typically obtained from commercial sources or synthesized using published methods for synthesizing compounds which are embodiments of the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. Group labels (e.g., R¹, R^a, R^b) used in the reaction schemes herein are for illustrative purposes only and unless otherwise specified do not necessarily match by name or function the labels used elsewhere to describe compounds of formula (I) or aspects or fragments thereof.

Synthetic Reaction Parameters

The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable

protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) *Protecting Groups in Organic Synthesis*, 3rd Edition, Wiley, New York, and references cited therein.

5 Furthermore, the compounds of this disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting
10 materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.

The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting
15 materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989) organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's
20 Advanced Organic Chemistry, (John Wiley, and Sons, 5th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).


The terms "solvent," "inert organic solvent" or "inert solvent" refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene
25 chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like). Unless specified to the contrary, the solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.

The term "q.s." means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).

30 Compounds as provided herein may be synthesized according to the general schemes provided below. In the Schemes below, it should be appreciated that each of the compounds shown therein may have protecting groups as required present at any step. Standard protecting groups are well within the purview of one skilled in the art.


Scheme 1 shows exemplary synthetic routes for the synthesis of compounds of Formula (I). In
35 Scheme 1, Q, R^E, R^W, Z¹, Z³, n, m, are as defined herein, each R⁵⁰ is independently C₁₋₆ alkyl or two R⁵⁰

together with the atom to which they are attached form a ring, X is halo, and each FG is independently a functional group capable of forming a covalent bond with compound **105**.



5 In Scheme 1, compound **100** is coupled with compound **101** under standard metal-catalyzed coupling conditions (e.g., using a palladium(0) catalyst) in a suitable solvent (e.g., DMF) under an inert atmosphere to provide compound **102**. Compounds of Formula (I) are then provided by contacting compound **102** with appropriately substituted compound **106** under standard metal-catalyzed coupling conditions. Alternatively, compound **102** is contacted with compound **103** under standard metal-catalyzed coupling conditions to provide compound **104**. Compound **104** is then reacted with compound **105** under conditions suitable to provide compounds of Formula (I). Exemplary conditions include, but are not limited to, reductive amination (FG is an aldehyde and compound **105** comprises a primary or secondary amine).

15 Symmetric compounds as provided herein, such as those of Formula (Id), may be synthesized according to Scheme 2 below. In Scheme 2, Q, R^E, R^W, Z¹, Z², n, m, are as defined herein, each R⁵⁰ is independently C₁₋₆ alkyl or two R⁵⁰ together with the atom to which they are attached form a ring, X is halo, and FG is a functional group capable of forming a covalent bond with compound **105**.



In Scheme 2, symmetric compounds of Formula (Id) can be provided by coupling compound **100** with at least a two-fold excess of appropriately substituted compound **101** under standard metal-catalyzed coupling conditions (e.g., using a palladium(0) catalyst) in a suitable solvent (e.g., DMF) under an inert atmosphere. Alternatively, compound **100** is contacted with compound **200** under standard metal-catalyzed coupling conditions to provide compound **201**. Compound **201** is then reacted with compound **105** under conditions suitable to provide compounds of Formula (Id). Exemplary conditions include, but are not limited to, reductive amination (FG is an aldehyde and compound **105** comprises a primary or secondary amine).

Suitably substituted compounds **100**, **101**, **103**, **106** and **105** for use in the methods provided herein can be purchased from commercial sources or synthesized by known methods. Resolution of the isomers of Formula (I) can be performed as needed using standard chiral separation/resolution conditions (e.g., chromatography, crystallization, etc.).

Examples


The compounds were named using the IUPAC naming convention or using ChemBioDraw Ultra Version 14.0. Structures are drawn ChemBioDraw.

When production of starting materials is not particularly described, the compounds are known or may be prepared analogously to methods known in the art or as disclosed in the Examples. One of skill in the art will appreciate that synthetic methodologies described herein are only representative of methods for preparation of the compounds described herein, and that other known methods and variants of methods described herein may be used. The methods or features described in various Examples may

be combined or adapted in various ways to provide additional ways of making the compounds described herein.

Exemplary procedures for select intermediates:

Lactam intermediates:




To the appropriate alcohol (above), as can be obtained as in PCT Int. Appl. WO 2015/150995, was added triethylamine (2.0 equiv.) and dichloromethane (0.1 M) at room temperature. The mixture was cooled to 0 °C, and mesyl chloride (1.1 equiv.) was added dropwise. The mixture was stirred at 0 °C for 1 hour before being quenched with water. The organic layer was separated and washed once with brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography. The mesylate was dissolved in dimethylformamide (0.5M) at room temperature, and sodium azide (5.0 equiv.) was added. The mixture was heated to 85 °C overnight. After cooling to room temperature, the mixture was diluted with ethyl acetate and water. The organic layer was then washed once with brine, dried over magnesium sulfate, filtered, and concentrated. The azide was used without further purification. To an oven-dried 40 mL vial was added the azide in ethyl acetate at room temperature. The vessel was purged with nitrogen, and Palladium on carbon was added (10 mol %). The vessel was then purged with hydrogen. After stirring for 4 hours, the contents were filtered through celite and concentrated. The crude amine was dissolved in ether and precipitated by the addition of 1.0 equiv. of HCl in dioxane. The solid HCl salt was isolated by filtration.

10

15

20

Pyrazine intermediate:


A 30 percent w/w solution of NaOMe in MeOH (168 mL, 896 mmol) was added to a stirring suspension of 3,5-dibromopyrazin-2-amine (200 g, 791 mmol) in dry MeOH (900 mL). The reaction mixture was heated to reflux and stirred for 3 h. The reaction mixture was allowed to cool to room temperature and concentrated to 1/3 volume. The resulted mixture was then partitioned between dichloromethane (DCM) and saturated aqueous NaHCO₃ solution. The layers were separated and the organic phase was washed with saturated aqueous NaHCO₃ solution. The combined aqueous portions were extracted with DCM. The combined organic portions were washed with brine, dried over Na₂SO₄, filtered and concentrated to give 5-bromo-3-methoxypyrazin-2-amine. ¹H NMR: (400 MHz, CDCl₃) δ 7.64 (s, 1H), 4.79 (s, 2H), 4.00 (s, 3H).

A mixture of 5-bromo-3-methoxypyrazin-2-amine (20 g, 98 mmol), 55 % aqueous HI (55%, 200 mL, 1462 mmol) and acetonitrile (200 mL) in water (300 mL) was stirred at 0 °C for 0.5 h. And a solution of sodium nitrite (120 g, 1740 mmol) in H₂O (200 mL) was added in a dropwise fashion. The reaction mixture warm to 23 °C, and then stirred for 20 h at 50 °C. After cooling, the solution was poured into 20 % aqueous NaOH and extracted with ethyl acetate (2 x200 mL). The combined organic layers were washed with saturated aqueous sodium metabisulfite (200 mL) and brine (200 mL), dried over Na₂SO₄, filtered and concentrated under vacuum to give the crude product. The crude product was purified by column chromatography on silica gel (CH₂Cl₂/hexanes=1:1) to give the desired product 5-bromo-2-iodo-3-methoxypyrazine. ¹H NMR: (400 MHz, DMSO) δ 8.07 (s, 1H), 4.04 (s, 3H).

Isopropylmagnesium chloride lithium chloride complex solution (1.3 M in tetrahydrofuran, 59.22 mL, 75.6 mmol) was added via syringe over 5 min to a stirred solution of 5-bromo-2-iodo-3-methoxypyrazine (21 g, 66.69 mmol) in anhydrous tetrahydrofuran (147 mL) under an atmosphere of dry nitrogen at -40 °C. After 25 min, anhydrous *N,N*-dimethylformamide (15.54 mL, 200.34 mmol) was added via syringe over 2 min, and the resulting mixture was allowed to warm to -18 °C over 25 min. Aqueous citric acid solution (5% w/v, 200 mL) was added slowly, and the resulting heterogeneous mixture was stirred vigorously and warmed to room temperature. After 10 min, ethyl acetate (450 mL) was added. The organic layer was washed with water (2 x 300 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure. The residue was purified

by flash column chromatography on silica gel (0 to 10% ethyl acetate in hexanes) to provide 5-bromo-3-methoxypyrazine-2-carbaldehyde. ¹H NMR: (400 MHz, CDCl₃) δ 10.21 (s, 1H), 8.43 (s, 1H), 4.14 (s, 3H).

2,2'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane):



5

A mixture of 3-bromo-2-chlorophenol (73.5 g, 0.355 mol, 1.0 eq), B₂Pin₂ (98 g, 0.391 mol, 1.1 eq), KOAc (96.7 g, 0.987 mol, 2.78 eq) and Pd(dppf)Cl₂-DCM (25.97 g, 35.5 mmol, 0.1 eq) were suspended in dioxane (1.2 L) was stirred at 80 °C for 15 h under positive pressure of nitrogen. The resulting mixture was cooled to ambient temperature and filtered. The filter cake was washed with dioxane (500 mL). The filtrates were combined.


3-bromo-2-chlorophenol (73.5 g, 0.355 mol, 1.0 eq), K₂CO₃ (122 g, 0.888 mol, 2.5 eq) and Pd(dppf)Cl₂-DCM (8.8 g, 10.65 mmol, 0.03 eq) were added to the filtrate prepared above. The reaction was stirred at 80 °C for 8 h under positive pressure of nitrogen. The resulting mixture was cooled to ambient temperature and filtered. The filter cake was washed with dioxane (500 mL). The filtrate were combined and concentrated. The residue was dissolved with ethyl acetate (2 L). The solution was washed with water, brine, dried over sodium sulfate and concentrated. The crude was purified by silica gel chromatography (PE:EA = 5:1) to give 2,2'-dichloro-[1,1'-biphenyl]-3,3'-diol.

To a solution of 2,2'-dichloro-[1,1'-biphenyl]-3,3'-diol (63.8 g, 0.251 mol, 1.0 eq) and DIPEA (121.5 g, 0.944 mol, 3.76 eq) in DCM (2 L) at 0 °C was added Tf₂O (166 g, 0.590 mol, 2.35 eq) dropwise slowly. Then the reaction was warmed to rt and stirred for 2 h. The pH of the reaction solution was greater than 7. Water (2 L) was added. The layers were separated, and the organic phase was washed with aqueous solution NaHCO₃, and brine, and dried over anhydrous sodium sulfate and concentrated. The crude was purified by silica gel chromatography, eluting with PE/DCM/EtOAc (1:1:0 - 1:1:0.2) to give 2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl bis(trifluoromethanesulfonate).

A mixture of 2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl bis(trifluoromethanesulfonate) (150 g, 0.289 mol, 1.0 eq), Bin₂Pin₂ (180 g, 0.722 mol, 2.5 eq) KOAc (113 g, 1.156 mol, 4.0 eq) and Pd(dppf)Cl₂-DCM

(31.72 g, 0.0434 mol, 0.15 eq) in dioxane (1.5 L) was stirred at 80 °C for 15 h under positive pressure of nitrogen. The resulting mixture was cooled to ambient temperature. DCM (1.5 L) was added, and the mixture was stirred for 15 min at rt. The mixture was filtered and the filter cake was washed with DCM (500 mL). The filtrates were combined and concentrated. The crude was purified by silica gel chromatography (PE:EA, 10:1 - 5:1) to give 2,2'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.63 (d, *J* = 6.7 Hz, 2H), 7.46 – 7.30 (m, 4H), 1.34 (s, 24H).

6-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxypyridine



To a solution of aldehyde (3.5 g, 20.4 mmol) in 60 mL DCM at 0°C was added ethylenediamine (1.50 mL, 22.44 mmol) dropwise. The solution was stirred at 0°C for 30 minutes, then N-bromosuccinimide (3.99 g, 22.44 mmol) was added in one portion, and the reaction mixture was stirred for 16 hours with gradual warming to ambient temperature. Reaction was taken up in DCM and stirred vigorously with 1:1 sat. sodium thiosulfate and sat sodium carbonate for 15 min. The organic later was dried with MgSO₄, filtered and conc to provide 6-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxypyridine.

General reductive amination procedures:

Procedure A – Reductive Amination with DMF / TEA; NaBH(OAc)₃

Aldehyde (1 equiv) was suspended in DMF (0.025 M) and to this was added (3S)-4-Amino-3-hydroxybutanoic acid (6 equiv) followed by triethylamine (6 equiv) and the reaction stirred at room temperature for 90 minutes. To this was added sodium triacetoxyborohydride (6 equiv) and the reaction stirred an additional 4 hours. At this point TFA was added slowly dropwise to the reaction until the solution went clear. Reaction was diluted with 2 mL of water, filtered and purified by reverse phase HPLC (0.1% trifluoroacetic acid in acetonitrile/water) providing the final compound upon lyophilization as the bis-TFA salt.

Procedure B – Reductive Amination with DMF / aq NaOH; NaBH(OAc)₃

A solution of aldehyde (1 equiv) in DMF (0.014 M) was added to a solution of the (S)-4-amino-3-hydroxybutanoic acid in 1N NaOH (10 equiv). After 2h sodium triacetoxyborohydride (10 equiv) was added. After 30 min the reaction was complete and TFA was added. Solids were removed by filtration and rinsed with MeOH. Organic phase was removed under reduced pressure, and the crude subjected to purification by reverse phase HPLC (0.1% trifluoroacetic acid in acetonitrile/water) providing the final compound upon lyophilization as the bis-TFA salt.

Procedure C – Reductive amination with DMF / AcOH; NaCNBH₃ + NaBH(OAc)₃

To a stirred mixture of aldehyde (1 equiv) and (*S*)-3-aminobutanoic acid (15 equiv) in a 6:1 mixture of DMF/AcOH (0.02 M) at room temperature was added sequentially sodium cyanoborohydride (9 equiv) and sodium triacetoxyborohydride (9 equiv). After 15 min, trifluoroacetic acid was added until the solution went clear. The resulting mixture was purified by reverse phase HPLC (0.1% trifluoroacetic acid in acetonitrile/water) providing the final compound upon lyophilization as the bis-TFA salt.

Procedure D – Reductive amination with DMSO / AcOH; NaBH(OAc)₃

To a stirred mixture of aldehyde (1 equiv) and (*1R,2R*)-2-aminocyclopentane-1-carboxylic acid (15 equiv) in 5:1 mixture of DMSO/AcOH (0.008 M) at room temperature was added sodium triacetoxyborohydride (9 equiv). After 1 h, TFA was added until the solution went clear. The resulting homogeneous mixture was purified by reverse phase HPLC (0.1% trifluoroacetic acid in acetonitrile/water) providing the final compound upon lyophilization as the bis-TFA salt.

Procedure E – Reductive Amination with MeOH/AcOH; 2-methylpyridine borane

Aldehyde A (1 equiv) was suspended in a 10:1 mixture of MeOH/AcOH (0.01M) and to this was added (*3S*)-4-amino-3-hydroxybutyric acid (3 equiv) at room temperature. Mixture was stirred at room temperature under argon for 1 hour. To this solution was added 2-methylpyridine borane (3 equiv) at room temperature and the reaction was stirred for an additional 2 hours. At this point, TFA was added dropwise to the reaction mixture until the solution went clear. Reaction was filtered and purified by reverse phase HPLC (0.1% trifluoroacetic acid in acetonitrile/water) providing the final compound upon lyophilization as the bis-TFA salt.

Procedure F – Reductive Amination with DMF/MeOH/AcOH ; 2-methylpyridine borane

Aldehyde (1 equiv) was suspended in a 6:3:1 mixture of DMF/MeOH/AcOH (0.01 M) and to this was added (*3S*)-4-amino-3-hydroxybutyric acid (10 equiv) at room temperature. Mixture was stirred at room temperature under argon for 1 hour. To this solution was added 2-methylpyridine borane (10 equiv) at room temperature and the reaction was stirred for an additional 2 hours. At this point, TFA was added dropwise to the reaction mixture until the solution goes clear. Reaction was filtered and purified by reverse phase HPLC (0.1% trifluoroacetic acid in acetonitrile/water) providing the final compound upon lyophilization as the bis-TFA salt.

Procedure G - Reductive Amination with DCM / EtOH / KOH ; Na(OAc)₃BH





To aldehyde in DCM (0.05M) was added a pre-sonicated 0.1M solution of KOH (10 equiv) and (*3S*)-4-amino-3-hydroxybutanoic acid (10 equiv) in EtOH. The reaction was stirred for 1 hour at rt before Na(OAc)₃BH (10 equiv) and AcOH (10 equiv) were added. The cloudy reaction was sonicated for 1 min, and stirred at rt for 2h. The reaction was quenched with the addition of 1M HCl until the solution clears. The solution was concentrated in-vacuo, diluted with a mixture of MeCN/H₂O/ DMF (1:1:1), and

purified by reverse phase HPLC (0.1% trifluoroacetic acid in acetonitrile/water) providing the final compound upon lyophilization as the bis-TFA salt.

Procedure H - Reductive Amination with DCM / DMF /DIPEA; Na(OAc)₃BH

The di aldehyde 6,6'-(((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(methylene))bis(oxy))bis(5-chloro-2-methoxynicotinaldehyde) (50 mg, 1equiv) was taken in a vial and dissolved in DCM (1.5 mL). The (2S,4R)-4-hydroxypiperidine-2-carboxylic acid (125 mg, 10equiv) was dissolved in mixture of DMF(3 mL), and DIPEA (0.15 mL, 10equiv) in a another vial. These two solutions were mixed together and sonicated for 5 min, and allowed to stir for 1h at room temperature. To well stirred mixture was added Na(OAc)₃BH at once and sonicated for 5 min to bring everything in to solution and allowed to stirred for overnight. The solution was concentrated under reduced pressure. The crude product was diluted with a mixture of MeCN/H₂O/ (2:1, with 0.1% TFA), solids were removed by filtration and purified by reverse phase HPLC (0.1% trifluoroacetic acid in acetonitrile/water) providing the final compound as the bis-TFA salt.

Procedure 1:



15

A 40 mL reaction vial, fitted with a stir bar, was charged with aryl-boronic acid (16 mmol), aryl-bromide (16 mmol), Pd(dppf) (0.8 mmol) and potassium carbonate (32 mmol). DriSolv 1,4-Dioxane (27 mL) and distilled water (3 mL) were then added by syringe, and the mixture de-gassed by bubbling argon for 5 min while mixing. The reaction vial was then sealed with a septum cap and the reaction heated to 85 °C using a heating block, the reaction was monitored by LC/MS. Upon complete consumption of starting material, saturated NaCl in water was added and the reaction mixture was extracted three times with ethyl acetate. The organic layers were collected, volatiles removed and crude mixture purified by silica gel column chromatography. The desired product eluted at ~ 27 % EtOAc/Hexanes.

A 100 mL round bottom flask fitted with a stir bar, was charged with Aryl-alcohol (10.37 mmol), N,N-diisopropylethylamine (41 mmol), dichloromethane (100 mL), placed under an atmosphere of argon and cooled to 0 °C with an ice water bath. While mixing triflic anhydride (26 mmol) was added by syringe dropwise and allowed to mix 1 h. The reaction was then quenched with a saturated solution of sodium bicarbonate and extracted three times with ethyl acetate. The organic layers were collected, volatiles removed and crude mixture purified by silica gel column chromatography. The desired product eluted at ~ 14 % EtOAc/Hexanes.


A 40 mL screw cap vial, fitted with a stir bar, was charged with aryl-triflate (6.87 mmol), bis(pinacolato)diboron (17.17 mmol), potassium acetate (27.46 mmol) and Pd(dppf) (1.03 mmol). DriSolv 1,4-Dioxane (27 mL) was then added by syringe, and the mixture was de-gassed by bubbling argon through for 5 min while mixing. The vial was then sealed and the mixture heated to 85 °C for 5 h. The reaction was quenched with saturated NaCl in water and extracted three times with ethyl acetate. The organic layers were collected, volatiles removed and crude mixture purified by silica gel column chromatography.

A 40 mL reaction vial, fitted with a stir bar, was charged with aryl-bromide (0.97 mmol), aryl-Bpin (0.46 mmol), Pd(PPh₃)₄ (23 μmol) and potassium carbonate (1 mmol). DriSolv 1,4-Dioxane (3.6 mL) and distilled water (0.9 mL) were then added by syringe, the mixture was de-gassed by bubbling argon through for 5 min while mixing. The reaction vial was then sealed with a septum cap and the reaction heated to 85° C using a heating block, the reaction was then monitored by LC/MS. Upon complete consumption of starting material, the reaction was quenched with saturated solution of NaCl in water and extracted three times with ethyl acetate. The organic layers were collected, volatiles removed and product isolated by crashing out of diethyl ether.

A 20 mL reaction vial, fitted with a stir bar, was charged with dialdehyde (0.14 mmol), amine salt (0.5 mmol), trimethylamine (0.57 mmol) and dimethylformamide (1.4 mL) and allotted to mix for 0.5 h. Sodium triacetoxy-borohydride (0.57 mmol) was then added and the reaction allowed to mix overnight. The next day the reaction was quenched with trifluoroacetic acid (0.65 mmol), filtered, diluted with a 1:4 solution DMF/water and purified by HPLC. ¹H NMR (400 MHz, Methanol-d₄) δ 8.70 (d, J =

2.1 Hz, 1H), 8.52 (s, 1H), 8.21 (s, 1H), 7.74 (d, J = 7.4 Hz, 1H), 7.68 - 7.44 (m, 4H), 4.82 - 4.03 (m, 16H), 2.58 (d, J = 8.2 Hz, 4H), 2.46 (d, J = 8.0 Hz, 4H). ES/MS m/z: 699.200 M+1

Procedure 2: (S)-5-((((5-(3'-(5-(((1-acetylazetid-3-yl)amino)methyl)-6-methoxypyrazin-2-yl)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)amino)methyl)pyrrolidin-2-one




A solution of (S)-5-(aminomethyl)pyrrolidin-2-one (3.29 g, 2.8 mmol) and 5-bromo-3-methoxypyrazine-2-carbaldehyde (5.0 g, 2.3 mmol) in dimethylformamide (10 ml) was stirred for 90 minutes. Sodium triacetoxyborohydride (5.59 g, 3.1 mmol), acetic acid (1.78 ml, 3.1 mmol) and dimethylformamide (10 ml) were added. After 16 hours di-*tert*-butyl dicarbonate (7.54 g, 3.5 mmol) and trimethylamine (8.42 ml, 6.0 mmol) were added. After 2 hours the reaction was partitioned with water (100 mL) and ethyl acetate (100 ml). The aqueous phase was extracted with ethyl acetate (2 x 75 mL). The combined organic phases were washed with brine (2 x 25 mL) and dried over sodium sulfate. The solvent was removed under reduced pressure. The residue was subjected to flash chromatography (0-20 % methanol / dichloromethane). The fractions containing product were combined and the solvent was

removed under reduced pressure providing *tert*-butyl (S)-((5-bromo-3-methoxypyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate.

A mixture of 2,2'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (2.29 g, 4.8 mmol), *tert*-butyl (S)-((5-bromo-3-methoxypyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (2.00 g, 4.8 mmol), 5-bromo-3-methoxypyrazine-2-carbaldehyde (1.05 g, 4.8 mmol), tetrakis(triphenylphosphine)palladium(0) (1.1 g, 0.96 mmol), potassium carbonate (2.00 g, 14.4 mmol) in dimethylformamide (40 ml) and water (6 ml) was degassed with argon of 10 minutes. The mixture was heated at 100 °C for 2h. The mixture was portioned with water (50 ml) and ethyl acetate (200 ml). The organic phase was washed with 5% lithium chloride (2 x 50 ml) and brine (50 ml). The organic phase was dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was subjected to flash chromatography (0-20 % methanol / dichloromethane). The fractions containing product were combined and the solvent was removed under reduced pressure, providing *tert*-butyl (S)-((5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate.

A solution of *tert*-butyl (S)-((5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (10 mg, 0.014 mmol), 1-(3-aminoazetidin-1-yl)ethan-1-one hydrochloride (6.6 mg, 0.058 mmol) and *N,N*-diisopropylethylamine (12.6 µL, 0.072 mmol) in dichloromethane (1 mL) and ethanol (1mL) was stirred at room temperature for 10 minutes. Sodium triacetoxyborohydride (30.6 mg, 0.144 mmol) and acetic acid (1 drop) were added. After 30m the solvent was removed under reduced pressure. The residue was taken up in dichloromethane (2 mL) and trifluoroacetic acid (1 mL) were added. After 15 minutes the solvent was removed under reduced pressure. The residue was taken up in methanol (1 mL), water (0.75 mL). The solution was subjected to preparative HPLC (eluant 0.1% trifluoroacetic acid in water / 0.1% trifluoroacetic acid in acetonitrile at a gradient of 20-100%). The clean fractions were combined and subjected to lyophilization, providing (S)-5-(((5-(3'-(5-(((1-acetylazetidin-3-yl)amino)methyl)-6-methoxypyrazin-2-yl)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)amino)methyl)pyrrolidin-2-one.


Procedure 3: (5*S*,5'*S*)-5,5'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(pyrrolidin-2-one)



A vigorously stirred mixture of 2,2'-((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane)) (3.50 g, 7.37 mmol), 5-bromo-3-methoxypyrazine-2-carbaldehyde (3.52 g, 16.2 mmol), tetrakis(triphenylphosphine)palladium(0) (596 mg, 0.516 mmol), potassium carbonate (5.09 g, 36.8 mmol), water (5.0 mL), and 1,4-dioxane (24 mL) was heated to 100 °C. After 40 min, the resulting mixture was cooled to room temperature. Ethyl acetate (125 mL) was added, and the organic layer was washed with a mixture of water and brine (1:1 v:v, 100 mL), was dried over anhydrous sodium sulfate, was filtered through celite, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 50% ethyl acetate in hexanes) to give 5,5'-((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-2-carbaldehyde)) contaminated with pinacol. Dichloromethane (50 mL) was added, and the resulting mixture was stirred at room temperature. (S)-5-(Aminomethyl)pyrrolidin-2-one (2.52 g, 22.1 mmol) was added. After 15 min, acetic acid (1.05 mL, 18.4 mmol) was added via syringe. After 1 min, sodium triacetoxyborohydride (7.81 g, 36.9 mmol) was added. After 75 min, aqueous sodium hydroxide solution (2 M, 63 mL) was added, and the resulting biphasic mixture was stirred vigorously. After 10 min, saturated aqueous sodium carbonate solution (40 mL) was added. After 5 min, water (80 mL) and dichloromethane (40 mL) were added sequentially. The resulting biphasic mixture was agitated, and the layers were separated. The aqueous layer was extracted with dichloromethane (3 × 125 mL). The combined organic layers were dried over anhydrous sodium sulfate, were filtered through celite, and were concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 20% methanol in dichloromethane) to give (5*S*,5'*S*)-5,5'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(pyrrolidin-2-one). Acetonitrile (15 mL) and methanol (15 mL) were added sequentially to dissolve the gel. Trifluoroacetic acid (1.0 mL) was added, and the resulting mixture was swirled vigorously. After 1 min, the resulting mixture was concentrated

under reduced pressure. The residue was lyophilized from a mixture of acetonitrile and water (1:1 v:v, 30 mL) to give (5S,5'S)-5,5'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(pyrrolidin-2-one) bis(2,2,2-trifluoroacetate). A portion of this material (2.1 g) was dissolved in 10% acetonitrile in water (15 mL) and was further purified by reverse phase preparative HPLC (0.1% trifluoroacetic acid in acetonitrile/water) to give (5S,5'S)-5,5'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(pyrrolidin-2-one) bis(2,2,2-trifluoroacetate). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.53 (s, 2H), 7.72 (dd, J = 7.6, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.58 – 4.47 (m, 4H), 4.18 – 4.07 (m, 2H), 4.12 (s, 6H), 3.42 – 3.27 (m, 4H), 2.54 – 2.25 (m, 6H), 2.08 – 1.83 (m, 2H); LRMS (ESI-TOF) Calc'd for C₃₄H₃₆Cl₂N₈O₄ [M+H]⁺: 691.2; found 691.3.

Procedure 4: (1R,1'R,3R,3'R)-3,3'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-(methylamino)pyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(cyclobutan-1-ol)




A vigorously stirred mixture of 2,2'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (750 mg, 1.58 mmol), 3,5-dichloropyrazine-2-carbaldehyde (3.52 g, 16.2 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (92 mg, 0.13 mmol), cesium carbonate (3.09 g, 9.47 mmol), water (1.8 mL), and 1,4-dioxane (11 mL) was heated to 100 °C. After 60 min, the resulting mixture was cooled to room temperature, was filtered through celite, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 70% ethyl acetate in hexanes) to give 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-chloropyrazine-2-carbaldehyde).

A stirred mixture of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-chloropyrazine-2-carbaldehyde) (55.0 mg, 0.019 mmol) and methylamine solution (2.0 M in tetrahydrofuran, 6.0 mL, 12 mmol) was heated to 70 °C. After 60 min, acetic acid (0.5 mL) and water (2.0 mL) were sequentially added. After 30 min, the resulting mixture was cooled to room temperature. Ethyl acetate (15 ml) was

added, and the organic layer was washed with water (2×15 mL), was dried over anhydrous sodium sulfate, was filtered, and was concentrated under reduced pressure. The residue was dissolved in dimethylsulfoxide (1.5 mL) and acetic acid (0.15 mL) and stirred at room temperature. (1*r*,3*r*)-3-(Aminomethyl)cyclobutan-1-ol hydrochloride (41.8 mg, 0.304 mmol), *N,N*-diisopropylethylamine (79.4 μ L, 0.456 mmol), and sodium triacetoxyborohydride (64.4 mg, 0.304 mmol) were added sequentially, and the resulting mixture was heated to 57 °C. After 60 min, the resulting mixture was cooled to room temperature and was purified by reverse phase preparative HPLC (0.1% trifluoroacetic acid in acetonitrile/water) to give (1*r*,1'*r*,3*r*,3'*r*)-3,3'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-(methylamino)pyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(cyclobutan-1-ol).


10 **Procedure 5: 1,1'-(((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(pyrazine-5,2-diyl))bis(methylene))bis(azetidin-3-ol)**



A vigorously stirred mixture of 2,2'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (150 mg, 0.316 mmol), 5-chloropyrazine-2-carbaldehyde (135 mg, 0.947 mmol), tetrakis(triphenylphosphine)palladium(0) (26 mg, 0.022 mmol), potassium carbonate (218 mg, 1.58 mmol), water (5 mL), and 1,4-dioxane (24 mL) was heated to 100 °C. After 60 min, the resulting mixture was cooled to room temperature, was filtered through celite, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 70% ethyl acetate in hexanes) to give 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(pyrazine-2-carbaldehyde).

Sodium triacetoxyborohydride (82.8 mg, 0.391 mmol) was added to a stirred mixture of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(pyrazine-2-carbaldehyde) (17 mg, 0.039 mmol), 3-hydroxyazetidine hydrochloride (42.8 mg, 0.391 mmol), *N,N*-diisopropylethylamine (102 μ L, 0.586 mmol), acetic acid (0.15 mL), and dimethylsulfoxide (1.5 mL) at 57 °C. After 60 min, the resulting mixture was cooled to room temperature and was purified by reverse phase preparative HPLC (0.1% trifluoroacetic acid in acetonitrile/water) to give 1,1'-(((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(pyrazine-5,2-diyl))bis(methylene))bis(azetidin-3-ol).

Procedure 6: 1,1'-((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-ethylpyrazine-5,2-diyl))bis(methylene))bis(azetidin-3-ol)




A stirred mixture of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-chloropyrazine-2-carbaldehyde) (84.2 mg, 0.167 mmol), tributyl(vinyl)stannane (390 μ L, 1.336 mmol), and tetrakis(triphenylphosphine)palladium(0) (39 mg, 0.033 mmol) in toluene (2.0 mL) was heated to 110 $^{\circ}$ C. After 37 min, the resulting mixture was cooled to room temperature and was purified by flash column chromatography on silica gel (0 to 35% ethyl acetate in hexanes) to give 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-vinylpyrazine-2-carbaldehyde).

A mixture of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-vinylpyrazine-2-carbaldehyde) (53.8 mg, 0.110 mmol) and palladium on carbon (10% wt, 23.5 mg, 0.022 mmol) in ethanol (2.0 mL) and tetrahydrofuran (1.0 mL) was stirred under one atmosphere of hydrogen gas at room temperature. After 90 min, the reaction mixture was filtered through celite and was concentrated under reduced pressure to give 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-ethylpyrazine-2-carbaldehyde).

Sodium triacetoxyborohydride (43.1 mg, 0.204 mmol) was added to a stirred mixture of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-ethylpyrazine-2-carbaldehyde) (10 mg, 0.020 mmol), 3-hydroxyazetidine hydrochloride (22.3 mg, 0.204 mmol), *N,N*-diisopropylethylamine (53.2 μ L, 0.305 mmol), acetic acid (0.15 mL), and dimethylsulfoxide (1.5 mL) at 57 $^{\circ}$ C. After 60 min, the resulting mixture was cooled to room temperature and was purified by reverse phase preparative HPLC (0.1% trifluoroacetic acid in acetonitrile/water) to give 1,1'-((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-ethylpyrazine-5,2-diyl))bis(methylene))bis(azetidin-3-ol).


Procedure 7: 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(2-((3-methoxyazetid-1-yl)methyl)-3-(methylthio)pyrazine)



Sodium methanethiolate (72.3 mg, 1.03 mmol) was added to a stirred mixture of 5,5'-(2,2'-
 5 dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-chloropyrazine-2-carbaldehyde) (104 mg, 0.206 mmol), in *N,N*-
 dimethylformamide (2.0 mL) at room temperature. After 20 min, diethyl ether (20 mL) and ethyl acetate
 (20 mL) were added. The organic layer was washed sequentially with aqueous sodium hydroxide
 solution (0.2 M, 30 mL) and water (30 mL), was dried over anhydrous magnesium sulfate, was filtered,
 and was concentrated under reduced pressure to give 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-
 10 (methylthio)pyrazine-2-carbaldehyde).

5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(2-((3-methoxyazetid-1-yl)methyl)-3-
 (methylthio)pyrazine) was synthesized in a manner similar to Procedure 6 using 5,5'-(2,2'-dichloro-[1,1'-
 biphenyl]-3,3'-diyl)bis(3-(methylthio)pyrazine-2-carbaldehyde) in place of 5,5'-(2,2'-dichloro-[1,1'-
 biphenyl]-3,3'-diyl)bis(3-ethylpyrazine-2-carbaldehyde) and using 3-methoxyazetidine hydrochloride in
 15 place of 3-hydroxyazetidine hydrochloride.


Procedure 8: 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(2-((3-methoxyazetid-1-yl)methyl)-3-methylpyrazine)



A vigorously stirred mixture of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-chloropyrazine-
 20 2-carbaldehyde) (60 mg, 0.12 mmol), tetramethyltin (165 μ L, 1.19 mmol), and [1,1'-
 bis(diphenylphosphino)ferrocene]dichloropalladium(II) (8.7 mg, 0.012 mmol) in *N,N*-
 dimethylformamide (2.0 mL) was heated to 110 °C. After 60 min, the resulting mixture was cooled to
 room temperature. An aliquot of the reaction mixture (0.4 mL) was removed via syringe and was added
 to a stirred mixture of 3-methoxyazetidine hydrochloride (26.7 mg, 0.216 mmol) and *N,N*-
 25 diisopropylethylamine (56.4 μ L, 0.324 mmol) in *N,N*-dimethylformamide (1.5 mL) and acetic acid (0.15
 mL) at 57 °C. Sodium triacetoxyborohydride (45.7 mg, 0.217 mmol) was added. After 60 min, the
 resulting mixture was cooled to room temperature and was purified by reverse phase preparative HPLC

(0.1% trifluoroacetic acid in acetonitrile/water) to give 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(2-((3-methoxyazetid-1-yl)methyl)-3-methylpyrazine).

Procedure 9: 1,1'-(((2,2'-dibromo-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(azetid-3-ol)




5

A stirred mixture of 2-chloro-6-methoxypyrazine (2.00 g, 13.8 mmol), hexabutylditin (8.74 mL, 17.3 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (304 mg, 0.415 mmol) in toluene (22 mL) was heated to 115 °C. After 18 h, the resulting mixture was cooled to room temperature, was filtered through celite, and was concentrated under reduced pressure. The residue was purified by
 10 flash column chromatography on silica gel (0 to 10% ethyl acetate in hexanes) to give 2-methoxy-6-(tributylstannyl)pyrazine.


Lithium diisopropylamide solution (2.0 M in tetrahydrofuran/heptane/ethylbenzene, 2.4 mL, 4.8 mmol) was added over 2 min via syringe to a stirred solution of 2-methoxy-6-(tributylstannyl)pyrazine (872 mg, 2.19 mmol) in tetrahydrofuran (18 mL) at -78 °C. After 100 min, *N,N*-dimethylformamide
 15 (846 μ L, 10.9 mmol) was added via syringe. After 45 min, saturated aqueous ammonium chloride solution (20 mL) and water (20 mL) were sequentially added, and the resulting biphasic mixture was warmed to room temperature with vigorous stirring. Diethyl ether (125 mL) was added, and the organic layer was washed sequentially with water (50 mL) and a mixture of water and saturated aqueous ammonium chloride solution (1:1 v:v, 100 mL), was dried over anhydrous magnesium sulfate, was
 20 filtered, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 10% ethyl acetate in hexanes) to give 3-methoxy-5-(tributylstannyl)pyrazine-2-carbaldehyde.

Iodine (79.1 mg, 0.312 mmol) was added to a stirred solution of give 3-methoxy-5-(tributylstannyl)pyrazine-2-carbaldehyde (133 mg, 0.312 mmol) in tetrahydrofuran (2 mL) at room
 25 temperature in the dark. After 15 h, sodium thiosulfate (20 mg) was added, and the resulting mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 20% methanol in dichloromethane) to give 5-iodo-3-methoxypyrazine-2-carbaldehyde.



n -Butyl lithium solution (1.94 M in cyclohexane, 19.8 mL, 38.5 mmol) was added over 2 min via syringe to a stirred solution of 2,2,6,6-tetramethylpiperidine (6.49 mL, 38.5 mmol) in tetrahydrofuran (64 mL) at 0 °C. After 10 min, the resulting mixture was cooled to -78 °C over 15 min. Triisopropyl borate (14.8 mL, 64.1 mmol) was added over 2 min via syringe. After 8 min, a solution of 2,2'-dibromo-1,1'-biphenyl (2.00 g, 6.41 mmol) in tetrahydrofuran (15 mL) at -78 °C was added over 5 min via cannula. After 3.5 h, triisopropyl borate (7.40 mL, 32.1 mmol) was added over 5 min via syringe, and the resulting mixture was allowed to warm to -45 °C over 15.5 h. Aqueous hydrogen chloride solution (1 M, 100 mL) was added, and the resulting biphasic mixture was warmed to rt. The aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were extracted with aqueous sodium hydroxide solution (4 × 100 mL). Concentrated hydrochloric acid was added to the combined basic aqueous layers until the combined layers had a pH of 1, and the resulting combined aqueous layers were extracted with ethyl acetate (3 × 250 mL). The combined organic layers from this extraction were dried over anhydrous sodium sulfate, were filtered, and were concentrated under reduced pressure to give (2,2'-dibromo-[1,1'-biphenyl]-3,3'-diyl)diboronic acid.

A stirred mixture of (2,2'-dibromo-[1,1'-biphenyl]-3,3'-diyl)diboronic acid (40 mg, 0.100 mmol), 5-iodo-3-methoxypyridazine-2-carbaldehyde (52.9 mg, 0.200 mmol), tetrakis(triphenylphosphine)palladium(0) (12 mg, 0.010 mmol), and saturated aqueous sodium carbonate solution (400 μL) in 1,2-dimethoxyethane (2.0 mL) was heated to 100 °C. After 2 h, the resulting mixture was cooled to room temperature. Ethyl acetate (30 mL) was added. The organic layer was washed with brine (20 mL), was dried over anhydrous sodium sulfate, was filtered, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 35% ethyl acetate in hexanes) to give 5,5'-((2,2'-dibromo-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyridazine-2-carbaldehyde)).




25

1,1'-(((2,2'-dibromo-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyridazine-5,2-diyl))bis(methylene))bis(azetidin-3-ol) was synthesized in a manner similar to Procedure 6 using 5,5'-

(2,2'-dibromo-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-2-carbaldehyde) in place of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-ethylpyrazine-2-carbaldehyde).

Procedure 10: 2-((5-(2,2'-dichloro-3'-(5-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy)pyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy)pyrazin-2-yl)methyl)-2,6-diazaspiro[3.4]octan-7-one



5

A vigorously stirred mixture of 5-(2,2'-dichloro-3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy)pyrazine-2-carbaldehyde (35 mg, 0.072 mmol), 6-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxy)pyridine (32 mg, 0.15 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (3 mg, 0.004 mmol), and saturated aqueous sodium carbonate solution (180 μ L), in 1,4-dioxane (1.5 mL) was heated to 105 $^{\circ}$ C. After 60 min, the resulting mixture was cooled to room temperature. Ethyl acetate (30 mL) was added, and the organic layer was washed with brine (20 mL), was dried over anhydrous sodium sulfate, was filtered, and was concentrated under reduced pressure to give 5-(2,2'-dichloro-3'-(5-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy)pyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy)pyrazine-2-carbaldehyde.


10

15

2-((5-(2,2'-dichloro-3'-(5-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy)pyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy)pyrazin-2-yl)methyl)-2,6-diazaspiro[3.4]octan-7-one was synthesized in a manner similar to Procedure 6 using 5-(2,2'-dichloro-3'-(5-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy)pyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy)pyrazine-2-carbaldehyde in place of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-ethylpyrazine-2-carbaldehyde) and using 2,6-diazaspiro[3.4]octan-7-one hydrochloride in place of 3-hydroxyazetidone hydrochloride.

20

Procedure 11: (5*S*,5'*S*)-5,5'-((((2,2'-dichloro-5-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(azanediy))bis(methylene))bis(pyrrolidin-2-one)




A stirred mixture of 1,3-dibromo-2-chloro-5-fluorobenzene (1.08 g, 3.75 mmol), (3-bromo-2-chlorophenyl)boronic acid (0.420 g, 1.79 mmol), aqueous sodium carbonate solution (2.0 M, 5.35 mL, 10.71 mmol), and tetrakis(triphenylphosphine)palladium(0) (103.15 mg, 0.089 mmol) in 1,4-dioxane (7 mL) was heated to 105 °C in a heating block. After 60 min, the resulting mixture was allowed to cool to room temperature. Ethyl acetate (30 mL) was added, and the organic layer was washed with brine (20 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 10% ethyl acetate in hexane) to give 3,3'-dibromo-2,2'-dichloro-5-fluoro-1,1'-biphenyl.

A stirred mixture of 3,3'-dibromo-2,2'-dichloro-5-fluoro-1,1'-biphenyl (0.443 g, 1.11 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (0.705 g, 2.78 mmol), potassium acetate (0.545 g, 5.55 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.041 g, 0.056 mmol) in dioxane (4 mL) was heated to 100 °C in a heating block. After 90 min, the resulting mixture was allowed to cool to room temperature and filtered through a pad of celite, was rinsed with EtOAc (10 mL), and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 50% ethyl acetate in hexane) to give 2,2'-(2,2'-dichloro-5-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane).

A stirred mixture of 2,2'-(2,2'-dichloro-5-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (53 mg, 0.107 mmol), 5-bromo-3-methoxypyrazine-2-carbaldehyde (49 mg, 0.226 mmol), aqueous sodium carbonate solution (2.0 M, 323 μ L, 0.645 mmol), and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (4 mg, 0.005 mmol) in 1,4-dioxane (0.5 mL) was heated to 105 $^{\circ}$ C in a heating block. After 60 min, the resulting mixture was allowed to cool to room temperature. Ethyl acetate (5 mL) was added, and the organic layer was washed with brine (2 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure to give 5,5'-(2,2'-dichloro-5-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-2-carbaldehyde).


N,N-diisopropylethylamine (76 μ L, 0.430 mmol) was added via syringe to a stirred mixture of 5,5'-(2,2'-dichloro-5-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-2-carbaldehyde). (15 mg, 0.029 mmol) and (*S*)-5-(aminomethyl)pyrrolidin-2-one hydrochloride (44 mg, 0.290 mmol) in dimethylsulfoxide (1 mL) at room temperature. After 10 min, sodium triacetoxyborohydride (62 mg, 0.290 mmol) was added as a solid, and the resulting mixture was heated to 60 $^{\circ}$ C in a heating block. After 30 min, the resulting mixture was allowed to cool to room temperature. The mixture was filtered and was purified by reverse phase preparative HPLC (0.1% trifluoroacetic acid in acetonitrile/water) to give (*5S,5'S*)-5,5'-((((2,2'-dichloro-5-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(azanediy))bis(methylene))bis(pyrrolidin-2-one).

Procedure 12: 2-((5-(2,2'-dichloro-3''-methoxy-4''-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)-[1,1':3',1''-terphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)-2,6-diazaspiro[3.4]octan-7-one



2-((5-(2,2'-dichloro-3''-methoxy-4''-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)-[1,1':3',1''-terphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)-2,6-diazaspiro[3.4]octan-7-one was synthesized in a manner similar to 2-((5-(2,2'-dichloro-3'-(5-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxypyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)-2,6-diazaspiro[3.4]octan-7-one (Procedure 10) using 4-bromo-2-methoxybenzaldehyde in place of 6-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxypyridine.

Procedure 13: (S)-2',2''-dichloro-3''-(6-methoxy-5-(((5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-4-((6-oxo-2,5-diazaspiro[3.4]octan-2-yl)methyl)-[1,1':3',1''-terphenyl]-3-carbonitrile




5 2,2'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (302 mg, 0.64 mmol) and tert-butyl (S)-((5-bromo-3-methoxy-2-pyrazinyl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (220 mg, 0.53 mmol) were suspended in 1,4-dioxane (2 mL) and H₂O (0.3 mL), added potassium carbonate (95 mg, 0.69 mmol) and tetrakis(triphenylphosphine)palladium(0) (61 mg, 0.05 mmol). The mixture was heated at 85 °C. After 90 min, LCMS showed almost complete
10 conversion. The mixture was filtered through a short be of celite, washed with EtOAc. The filtrate was partitioned between EtOAc and brine. The organic layer was concentrated in vacuo. The residue was purified by silica gel chromatography using Hexanes / EtOAc as the eluent to afford tert-butyl (S)-((5-(2,2'-dichloro-3''-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-2-pyrazinyl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate.

15 tert-butyl (S)-((5-(2,2'-dichloro-3''-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-2-pyrazinyl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (100 mg, 0.15 mmol) and 5-bromo-2-formylbenzonitrile (53 mg, 0.25 mmol) were suspended in 1,4-dioxane (5 mL) and H₂O (0.5 mL), added potassium carbonate (22.3 mg, 0.16 mmol) and tetrakis(triphenylphosphine)palladium(0) (34.3 mg, 0.03 mmol). The mixture was heated at 85 °C. After 20 min, LCMS showed almost complete
20 conversion. The mixture was filtered through a short be of celite, washed with EtOAc. The filtrate was partitioned between EtOAc and brine. The organic layer was concentrated in vacuo. The residue was purified by silica gel chromatography using Hexanes / EtOAc as the eluent to afford tert-butyl (S)-((5-(2,2'-dichloro-3''-cyano-4''-formyl-[1,1':3',1''-terphenyl]-3-yl)-3-methoxy-2-pyrazinyl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate.

The title compound was synthesized according to general reductive amination procedure G.

Procedure 14: (S)-5-((((5-(2, 2'-dichloro-3'-(5-((3-(hydroxymethyl)-3-methylazetididin-1-yl)methyl)-6-methoxypyridin-2-yl)-[1, 1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)amino)methyl)pyrrolidin-2-one



5

2,2'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (3.32 g, 7.00 mmol) and 6-chloro-2-methoxynicotinaldehyde (1 g, 5.83 mmol) were suspended in 1,4-dioxane (18 mL) and H₂O (2.4 mL), added potassium carbonate (1.05 g, 7.58 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.67 g, 0.58 mmol). The mixture was heated at 84 °C. After 90min, LCMS showed almost complete conversion. The mixture was filtered through a short be of celite, washed with EtOAc. The filtrate was partitioned between EtOAc and brine. The organic layer was concentrated in vacuo. The residue was purified by silica gel chromatography using Hexanes / EtOAc as the eluent to afford 6-(2, 2'-dichloro-3'-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)-[1, 1'-biphenyl]-3-yl)-2-methoxynicotinaldehyde.

10

15


6-(2, 2'-dichloro-3'-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)-[1, 1'-biphenyl]-3-yl)-2-methoxynicotinaldehyde (423 mg, 0.87 mmol) and tert-butyl (S)-((5-bromo-3-methoxypyrazin-2-yl)methyl)amino)methyl)pyrrolidin-2-one) (330 mg, 0.79 mmol) were suspended in 1,4-dioxane (3 mL) and H₂O (0.6 mL), added potassium carbonate(132 mg, 0.95 mmol) and tetrakis(triphenylphosphine)palladium(0) (92 mg, 0.08 mmol). The mixture was heated at 84 °C. After 90min, LCMS showed almost complete conversion. The mixture was filtered through a short be of celite, washed with EtOAc. The filtrate was partitioned between EtOAc and brine. The organic layer was concentrated in vacuo. The residue was purified by silica gel chromatography using Hexanes / EtOAc as

20

the eluent to afford tert-butyl (S)-((5-(2, 2'-dichloro-3'-(5-formyl-6-methoxypyridin-2-yl)-[1, 1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate.

The title compound was synthesized according to general reductive amination procedure G followed by standard Boc deprotection with TFA.

5 **Procedure 15: (S)-5-(((5-(3'-(5-((R)-1-aminoethyl)-6-methoxypyrazin-2-yl)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)amino)methyl)pyrrolidin-2-one**



To an oven-dried 40 mL vial was added 5-bromo-3-methoxypyridine-2-carbaldehyde, dichloromethane (0.5M), and (R)-2-methylpropane-2-sulfonamide (1.0 equiv.) at room temperature. To the vial was then added titanium tetraethoxide (2.0 equiv.). The mixture was stirred overnight before being diluted with sodium bicarbonate solution. The contents of the vial were filtered through celite, and the filtrate was washed once with water and once with brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography

using hexanes/ethyl acetate gradient to yield (R,E)-N-((5-bromo-3-methoxypyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide.


To an oven-dried 40 mL vial was added (R,E)-N-((5-bromo-3-methoxypyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide and dichloromethane (0.1M) at room temperature. The mixture was cooled to -78 °C, and methyl magnesium iodide (1M in tetrahydrofuran, 1.6 equiv.) was added dropwise. The mixture was slowly warmed to room temperature and quenched with aqueous ammonium chloride solution, washed once with water, and washed once with brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using hexanes/ethyl acetate gradient to yield (R)-N-((R)-1-(5-bromo-3-methoxypyrazin-2-yl)ethyl)-2-methylpropane-2-sulfinamide and (R)-N-((S)-1-(5-bromo-3-methoxypyrazin-2-yl)ethyl)-2-methylpropane-2-sulfinamide.

To an oven-dried 40 mL vial was added (R)-N-((R)-1-(5-bromo-3-methoxypyrazin-2-yl)ethyl)-2-methylpropane-2-sulfinamide, 5-(2,2'-dichloro-3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde (1.0 equiv.), potassium carbonate (2.0 equiv.), Pd(dppf)Cl₂ (10 mol %), dimethylformamide (0.2M), and water (10 vol %). The contents of the vial were sparged with nitrogen for 30 seconds then heated to 90 °C for 45 minutes. After cooling to room temperature, the mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed once with water and once with brine before being dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography with a methanol/dichloromethane gradient to yield (R)-N-((R)-1-(5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)ethyl)-2-methylpropane-2-sulfinamide.

(S)-5-(aminomethyl)pyrrolidin-2-one (3 equiv.) was reacted with (R)-N-((R)-1-(5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)ethyl)-2-methylpropane-2-sulfinamide following reductive amination procedure C to yield (R)-N-((R)-1-(5-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)ethyl)-2-methylpropane-2-sulfinamide.

To an oven-dried 20 mL vial was added (R)-N-((R)-1-(5-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)ethyl)-2-methylpropane-2-sulfinamide, methanol and 4M HCl in dioxane (2.0 equiv.). The mixture was stirred at room temperature for 30 minutes before being concentrated and purified by HPLC to yield (S)-5-(((5-(3'-(5-((R)-1-aminoethyl)-6-methoxypyrazin-2-yl)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)amino)methyl)pyrrolidin-2-one.

Procedure 16: (S)-5-(((5-(2,2'-dichloro-3'-(5-((2,5-dimethyl-1H-pyrrol-1-yl)methyl)-6-methoxy-pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-pyrazin-2-yl)methyl)amino)methyl)pyrrolidin-2-one




5 tert-butyl (S)-((5-(2,2'-dichloro-3'-(5-formyl-6-methoxy-pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-pyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate was reacted with (2R,5R)-2,5-dimethylpyrrolidine (3.0 equiv.) following reductive amination procedure C to obtain the undesired tert-butyl (S)-((5-(2,2'-dichloro-3'-(5-((2,5-dimethyl-1H-pyrrol-1-yl)methyl)-6-methoxy-pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-pyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate.

10 To an oven-dried 40 mL vial was added tert-butyl (S)-((5-(2,2'-dichloro-3'-(5-((2,5-dimethyl-1H-pyrrol-1-yl)methyl)-6-methoxy-pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-pyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate, dichloromethane (0.5M), and trifluoroacetic acid (10 equiv.) at room temperature. The mixture was stirred for 30 minutes before being concentrated and purified by HPLC to furnish (S)-5-(((5-(2,2'-dichloro-3'-(5-((2,5-dimethyl-1H-pyrrol-1-yl)methyl)-6-methoxy-pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-pyrazin-2-yl)methyl)amino)methyl)pyrrolidin-2-one.


15

Procedure 17: 2,2'-(((2-bromo-2'-chloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(2,6-diazaspiro[3.4]octan-7-one)



2,2'-(((2-bromo-2'-chloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(2,6-diazaspiro[3.4]octan-7-one) was synthesized in a manner similar to Procedure 18 using (2-chlorophenyl)boronic acid in place of (2-fluorophenyl)boronic acid.

Procedure 18: 2,2'-(((2-bromo-2'-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(2,6-diazaspiro[3.4]octan-7-one)




10 A stirred mixture of 1-bromo-2-iodobenzene (0.6 g, 4.29 mmol), (2-fluorophenyl)boronic acid (1.213 g, 4.29 mmol), potassium carbonate (1.48 g, 10.72 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.149 g, 0.129 mmol) in dimethoxyethane (12.88 mL) and water (1.72 mL) was heated to 95 °C in a heating block. After 60 min, the resulting mixture was allowed to cool to room temperature. Ethyl acetate (50 mL) was added, and the organic layer was washed with
15 brine (25 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 10% ethyl acetate in hexane) to give 2-bromo-2'-fluoro-1,1'-biphenyl.

N-Butyllithium solution (3.42 mL, 2.5 M in hexane, 8.56 mmol) was added via syringe to a stirred 2,2,6,6-tetramethylpiperidine (1.44 mL, 8.56 mmol) in anhydrous tetrahydrofuran (10.70 mL) at 0 °C. The resulting mixture was stirred for 10 min and cooled to -78 °C. Triisopropyl borate (3.29 mL, 14.27 mmol) was added and stirred for 8 min. 2-bromo-2'-fluoro-1,1'-biphenyl was added via syringe and the mixture was slowly warmed to room temperature overnight. 1M HCl (25 mL) was added, was extracted with ethyl acetate (3 x 25 mL), was extracted with 1M NaOH (25 mL), 0.5 N NaOH twice, was acidified with concentrated HCl to pH 1, was extracted with ethyl acetate (3 x 35 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure to give (2-bromo-2'-fluoro-[1,1'-biphenyl]-3,3'-diyl)diboronic acid.

A stirred mixture of (2-bromo-2'-fluoro-[1,1'-biphenyl]-3,3'-diyl)diboronic acid (0.263 g, 0.776 mmol), 5-bromo-3-methoxypyrazine-2-carbaldehyde (0.506 g, 2.33 mmol), potassium carbonate (1.48 g, 10.72 mmol), aqueous sodium carbonate solution (2.0 M, 3.16 mL, 6.21 mmol) and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.031 g, 0.039 mmol) in dimethoxyethane (4 mL) was heated to 100 °C in a heating block. After 60 min, the resulting mixture was allowed to cool to room temperature. Ethyl acetate (40 mL) was added, and the organic layer was washed with brine (20 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 50% ethyl acetate in hexane) to give 5,5'-(2-bromo-2'-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-2-carbaldehyde).


N,N-diisopropylethylamine (79 µL, 0.453 mmol) was added via syringe to a stirred mixture of 5,5'-(2-bromo-2'-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-2-carbaldehyde) (15.8 mg, 0.030 mmol) and 2,6-diazaspiro[3.4]octan-7-one 4-methylbenzenesulfonate (90 mg, 0.302 mmol) in dimethylsulfoxide (1 mL) at room temperature. After 10 min, sodium triacetoxyborohydride (64 mg, 0.302 mmol) was added as a solid, and the resulting mixture was heated to 60 °C in a heating block. After 30 min, the resulting mixture was allowed to cool to room temperature. The mixture was filtered and was purified by reverse phase preparative HPLC (0.1% trifluoroacetic acid in acetonitrile/water) to give 2,2'-(((2-bromo-2'-fluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(2,6-diazaspiro[3.4]octan-7-one).

Procedure 19: (5*S*,5'*S*)-5,5'-((((2,2'-dichloro-5,5'-difluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxypyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(pyrrolidin-2-one)



(5*S*,5'*S*)-5,5'-((((2,2'-dichloro-5,5'-difluoro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxy-pyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(pyrrolidin-2-one) was synthesized in a manner similar to Procedure 11 using 2-(3-bromo-2-chloro-5-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in place of (3-bromo-2-chlorophenyl)boronic acid.


5 **Procedure 20: (5*S*,5'*S*)-5,5'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-(methylamino)pyrazine-5,2-diyl))bis(methylene))bis(methylazanediyl))bis(methylene))bis(pyrrolidin-2-one)**



To an oven-dried 40 mL vial was added (5*S*,5'*S*)-5,5'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-(methylamino)pyrazine-5,2-diyl))bis(methylene))bis(azanediyl))bis(methylene))bis(pyrrolidin-2-one), paraformaldehyde (10 equiv.), magnesium sulfate (2.0 equiv.), dimethylformamide (0.2 M), and acetic acid (10 equiv.) at room temperature. The mixture was stirred vigorously for 30 minutes before sodium triacetoxyborohydride (10 equiv.) was added. After 30 minutes, sodium borohydride (1.0 equiv.) was added, and the mixture was stirred for an additional 1 hour. The mixture was purified by HPLC to yield (5*S*,5'*S*)-5,5'-((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-(methylamino)pyrazine-5,2-diyl))bis(methylene))bis(methylazanediyl))bis(methylene))bis(pyrrolidin-2-one).

10
15


Procedure 21: ((5-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl(((S)-5-oxopyrrolidin-2-yl)methyl)sulfamic acid



- 5 Sodium triacetoxyborohydride (122 mg, 0.577 mmol) was added to a stirred mixture of tert-butyl (S)-((5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (200 mg, 0.288 mmol), (S)-5-
- (aminomethyl)pyrrolidin-2-one hydrochloride (87 mg, 0.58 mmol), *N,N*-diisopropylethylamine (200 μ L, 1.2 mmol), and acetic acid (33 μ L, 0.58 mmol) in dichloromethane (4.0 mL) at room temperature. After
- 10 75 min, aqueous sodium hydroxide solution (2 M, 1.5 mL) was added, and the resulting mixture was stirred vigorously. After 10 min, saturated aqueous sodium carbonate solution (3.0 mL), water (10 mL), and dichloromethane (15 mL) were added sequentially. The biphasic mixture was agitated, and the layers were separated. The aqueous layer was extracted with dichloromethane (3 \times 15 mL), and the combined organic layers were dried over anhydrous sodium sulfate, were filtered, and were concentrated under
- 15 reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 15% methanol in dichloromethane) to give tert-butyl ((S)-((5-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl(((S)-5-oxopyrrolidin-2-yl)methyl)sulfamate.


Chlorosulfonic acid (9.6 μL , 0.060 mmol) was added via syringe to a stirred mixture of tert-butyl ((5-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-pyrazin-2-yl)methyl)(((S)-5-oxopyrrolidin-2-yl)methyl)carbamate (43 mg, 0.055 mmol) and triethylamine (27 μL , 0.19 mmol) in dichloromethane (1.0 mL) at 0 °C. After 5 min, the resulting mixture was warmed to room temperature. After 40 min, trifluoroacetic acid (1.0 mL) was added. After 30 min, the resulting mixture was concentrated under reduced pressure and was purified by reverse phase preparative HPLC (0.1% trifluoroacetic acid in acetonitrile/water) to give ((5-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-pyrazin-2-yl)methyl)(((S)-5-oxopyrrolidin-2-yl)methyl)sulfamic acid.

10 **Procedure 22: 2,2'-((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxy-pyrazine-5,2-diyl))bis(5,5-difluoro-1,4,5,6-tetrahydropyrimidine)**



2,2-Difluoropropane-1,3-diamine dihydrochloride (22.2 mg, 0.121 mmol) was added to a vigorously stirred mixture of 5,5'-((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxy-pyrazine-2-carbaldehyde) (10 mg, 0.020 mmol) and potassium carbonate (33.5 mg, 0.242 mmol) in tetrahydrofuran (0.7 mL) and ethanol (1.3 mL) at room temperature, and the resulting mixture was heated to 80 °C. After 20 min, the resulting mixture was cooled to room temperature over 5 min, and *N*-bromosuccinimide (28.8 mg, 0.162 mmol) was added. After 45 min, the resulting mixture was filtered and was purified by reverse phase preparative HPLC (0.1% trifluoroacetic acid in acetonitrile/water) to give 2,2'-((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-methoxy-pyrazine-5,2-diyl))bis(5,5-difluoro-1,4,5,6-tetrahydropyrimidine).

Procedure 23: (S)-5-(((6-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-2-methoxypyridin-3-yl)methyl)amino)methyl)pyrrolidin-2-one




5 A vigorously stirred mixture of 6-(2,2'-dichloro-3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-3-yl)-2-methoxynicotinaldehyde (1.00 g, 2.07 mmol), 5-bromo-3-methoxypyrazine-2-carbaldehyde (672 mg, 3.10 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (81.3 mg, 0.103 mmol), and saturated aqueous sodium carbonate solution (5.16 mL) in 1,4-dioxane (15 mL) was heated to 85 °C. After 60 min, the
10 resulting mixture was cooled to room temperature, and ethyl acetate (100 mL) was added. The organic layer was washed with brine (60 mL), was dried over anhydrous sodium sulfate, was filtered, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 50% ethyl acetate in hexanes) to give 5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde.

15 Sodium triacetoxyborohydride (1.21 g, 5.71 mmol) was added to a vigorously stirred mixture of 5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde (565 mg, 1.14 mmol), (S)-5-(aminomethyl)pyrrolidin-2-one (392 mg, 3.431 mmol), and acetic acid (65 μ L, 1.1 mmol) in dichloromethane (25 mL) at room temperature. After 60 min, aqueous sodium hydroxide solution (2 M, 10 mL) was added, and the resulting biphasic mixture was stirred
20 vigorously. After 2 min, saturated aqueous sodium carbonate solution (8 mL), water (50 mL), and brine (20 mL) were added sequentially. The aqueous layer was extracted with dichloromethane (2 \times 100 mL), and the combined organic layers were dried over anhydrous sodium sulfate, were filtered through celite, and were concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 20% methanol in dichloromethane) to give (S)-5-(((6-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-2-methoxypyridin-3-yl)methyl)amino)methyl)pyrrolidin-2-one. Acetonitrile (15 mL) and methanol (15 mL) were added sequentially to dissolve the gel. Trifluoroacetic acid (0.4 mL) was added, and the
25

resulting mixture was swirled vigorously. After 1 min, the resulting mixture was concentrated under reduced pressure. The residue was lyophilized from a mixture of acetonitrile and water (1:1 v:v, 30 mL) to give (S)-5-((((6-(2,2'-dichloro-3'-(6-methoxy-5-(((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-2-methoxypyridin-3-yl)methyl)amino)methyl)pyrrolidin-2-one as its bis(2,2,2-trifluoroacetate) salt.

Procedure 24: 2-((5-(2,2'-dichloro-3'-(6-(methylamino)-5-((6-oxo-2,5-diazaspiro[3.4]octan-2-yl)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)-2,5-diazaspiro[3.4]octan-6-one



10

A vigorously stirred mixture of 5-(2,2'-dichloro-3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde (526 mg, 1.08 mmol), 3,5-dichloropyrazine-2-carbaldehyde (288 mg, 1.63 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (63 mg, 0.087 mmol), and cesium carbonate (1.06 g, 3.25 mmol), in 1,4-dioxane (11 mL) and water (1.8 mL) was heated to 100 °C. After 60 min, the resulting mixture was cooled to room temperature, was filtered through celite, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 70% ethyl acetate in hexanes) to give 3-chloro-5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyrazin-2-yl)-[1,1'-biphenyl]-3-yl)pyrazine-2-carbaldehyde.


15

A stirred mixture of 3-chloro-5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyrazin-2-yl)-[1,1'-biphenyl]-3-yl)pyrazine-2-carbaldehyde (81.0 mg, 0.162 mmol) and methylamine solution (2.0 M in tetrahydrofuran, 3.0 mL, 6.0 mmol) was heated to 70 °C. After 60 min, acetic acid (0.4 mL) and water (1.0 mL) were added sequentially, and the resulting biphasic mixture was stirred vigorously. After 15 min, the biphasic mixture was cooled to room temperature, and ethyl acetate (15 mL) was added. The organic layer was washed sequentially with water (15 mL) and a mixture of saturated aqueous sodium bicarbonate solution and brine (1:1 v:v, 15 mL), was dried over anhydrous sodium sulfate, was filtered, and was concentrated under reduced pressure to give 5-(2,2'-dichloro-3'-(5-formyl-6-(methylamino)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde.

25

2-((5-(2,2'-Dichloro-3'-(6-(methylamino)-5-((6-oxo-2,5-diazaspiro[3.4]octan-2-yl)methyl)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazin-2-yl)methyl)-2,5-diazaspiro[3.4]octan-6-one was synthesized in a manner similar to Procedure 6 using 5-(2,2'-dichloro-3'-(5-formyl-6-(methylamino)pyrazin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde in place of 5,5'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(3-ethylpyrazine-2-carbaldehyde) and using 2,5-diazaspiro[3.4]octan-6-one hydrochloride in place of 3-hydroxyazetidine hydrochloride.

Procedure 26: 5-(2,2'-dichloro-3'-(6-methoxy-5-((3-methoxyazetidin-1-yl)methyl)pyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-2-((3-methoxyazetidin-1-yl)methyl)pyrazine



10

A stirred mixture of 2,2'-(2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (1.24 g, 2.54 mmol), 5-bromo-3-methoxypyrazine-2-carbaldehyde (0.500 g, 2.30 mmol), aqueous sodium carbonate solution (2.0 M, 4.61 mL, 9.22 mmol), and tetrakis(triphenylphosphine)palladium(0) (133 mg, 0.115 mmol) in 1,4-dioxane (6 mL) was heated to 105 °C in a heating block. After 60 min, the resulting mixture was allowed to cool to room temperature. Ethyl acetate (30 mL) was added, and the organic layer was washed with brine (20 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 40% ethyl acetate in hexane) to give 5-(2,2'-dichloro-3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde.

20

A stirred mixture of 5-(2,2'-dichloro-3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde (50 mg, 0.103 mmol), 5-chloro-3-methoxypyridine-2-carbaldehyde (22.1 mg, 0.129 mmol), aqueous sodium carbonate solution (2.0 M, 206 μL, 0.412 mmol), and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (4.1 mg, 0.005 mmol) in 1,4-dioxane (0.5 mL) was heated to 105 °C in a heating block. After 60 min, the resulting mixture was allowed to cool to room temperature. Ethyl acetate (5 mL) was added, and the organic layer was washed with brine (2 mL), was dried over anhydrous

25

magnesium sulfate, was filtered, and was concentrated under reduced pressure to give 5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde.







N,N-diisopropylethylamine (42 μ L, 0.243 mmol) was added via syringe to a stirred mixture of 5-(2,2'-dichloro-3'-(5-formyl-6-methoxypyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxypyrazine-2-carbaldehyde (8 mg, 0.016 mmol) and 3-methoxyazetidine hydrochloride (20 mg, 0.162 mmol) in dimethylsulfoxide (1 mL) at room temperature. After 10 min, sodium triacetoxyborohydride (34.3 mg, 0.162 mmol) was added as a solid, and the resulting mixture was heated to 60 °C in a heating block. After 30 min, the resulting mixture was allowed to cool to room temperature. The mixture was filtered and was purified by reverse phase preparative hplc (0.1% trifluoroacetic acid in acetonitrile/water) to give 5-(2,2'-dichloro-3'-(6-methoxy-5-((3-methoxyazetidin-1-yl)methyl)pyridin-2-yl)-[1,1'-biphenyl]-3-yl)-3-methoxy-2-((3-methoxyazetidin-1-yl)methyl)pyrazine. ¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (s, 1H), 7.92 (d, J = 7.6 Hz, 2H), 7.72 (ddd, J = 12.2, 7.7, 1.7 Hz, 2H), 7.60 (q, J = 7.6 Hz, 3H), 7.53 – 7.43 (m, 2H), 7.41 (d, J = 7.5 Hz, 2H), 4.76 (s, 2H), 4.52 (s, 2H), 4.15 (s, 3H), 4.12 (d, J = 1.4 Hz, 5H), 3.41 (s, 3H), 3.40 (s, 4H).






The following compounds were prepared according to the procedures described herein (and indicated in Table 1 under Procedure) using the appropriate starting material(s) and appropriate protecting group chemistry as needed.







Table 1

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
1		699.2	1
2		593.2	1

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
3		621.2	1
4		727.292	1
5		570.2	1
6		675.2	1
7		685.11	2
8		690.06	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
9		673.19	2
10		659.18	2
11		680.12	2
12		660.19	2
13		676.14	2
14		717.2	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
15		728.16	2
16		664.16	2
17		719.3	2
18		719.3	2
19		705.3	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
20		705.1	2
21		692.3	2
22		692.3	2
23		678.2	2
24		678.2	2
25		681.2	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
26		718.2	2
27		688.2	2
28		675.1	2
29		687.2	3
30		685.2	3
31		713.2	3
32		703.2	2
33		689.2	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
34		688.2	2
35		675.2	2
36		691.2	2
37		758.1	2
38		706	2
39		677.2	2
40		696.1	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
41		677.1	2
42		702.2	2
43		701.3	2
44		680.1	2
45		665.1	2
46		622.1	2
47		706.1	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
48		716.1	2
49		688.1	2
50		705.1	2
51		665.1	2
52		690.2	2
53		690.2	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
54		692.2	2
55		692.2	2
56		721.2	2
57		663.2	4
58		495.2	4
59		742.2	24

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
60		608.2	24
61		714.2	24
62		714.2	24
63		690.1	24
64		793.3 (M+Na) +	21
65		769.2	4

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
66		635.2	4
67		741.3	4
68		371.2 (M+2H) 2+	4
69		611.2	4
70		603.2	4

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
71		551.2	4
72		288.1 (M+2H) 2+	4
73		549.2	4
74		523.2	4
75		635.3	4
76		741.3	4







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
77		607.2	4
78		713.3	4
79		713.3	4
80		689.2	4
81		549.1	5
82		605.2	6
83		711.3	6







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
84		711.3	6
85		687.3	6
86		629.2	3
87		669.2	7
88		641.1	7
89		747.2	7







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
90		747.2	7
91		723.2	7
92		605.2	8
93		577.2	8
94		683.2	8
95		683.2	8
96		659.3	8







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
97		663.3	4
98		654.3	4 (byproduct)
99		635.2	4
100		626.1	4 (byproduct)
101		741.3	4
102		732.3	4 (byproduct)







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
103		741.2	4
104		732.3	4 (byproduct)
105		717.2	4
106		708.3	4 (byproduct)
107		645.1	4
108		617.1	4







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
109		723.2	4
110		723.2	4
111		699.1	4
112		697.2	9
113		779.2	9
114		644.2	10








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
115		644.2	10
116		591.2	10
117		632.2	10
118		613.2	3
119		675.3	22
120		715.3	3









No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
121		603.3	22
122		495.2	12
123		713.2	12
124		713.2	12
125		689.3	12
126		690.2	23

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
127		631.4	22
128		635.2	22
129		603.3	22
130		637.3	3
131		609.2	3
132		637.4	3







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
133		635.1	22
134		635.1	22
135		497.3	3
136		715.2	3
137		701.2	3
138		691.2	3









No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
139		691.3	3
140		585.2	3
141		575.2	22
142		665.174	3
143		637.064	3
144		637.054	3








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
145		637.141	3
146		665.107	3
147		637.089	3
148		665.169	3
149		665.105	3
150		665.13	3
151		696.151	13







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
169		675.991	14
170		663.107	14
171		663	14
172		678.078	2
173		664.044	2
174		678.077	2
175		678.143	2
176		664.136	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
177		680.043	2
178		651.916	2
179		648.076	2
180		683.908	2
181		685.985	2
182		700.069	2
183		657.987	2
184		633.983	2






No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
185		692.17	2
186		692.18	2
187		690.19	2
188		721.19	2
189		719.26	3
190		771.27	3







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
191		691.35	2
192		717.3	2
193		717.2	2
194		705.16	2
195		733.48	2
196		691.13	2
197		717.3	2
198		705.2	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
199		677.08	2
200		677.1	2
201		688.32	2
202		731.33	2
203		731.21	2
204		705.28	2
205		719.25	2
206		719.34	2









No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
207		704.22	2
208		731.25	2
209		743.16	3
210		707.23	2
211		706.24	2
212		714.25	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
213		687.24	2
214		702.25	2
215		692.25	2
216		704.25	2
217		705.25	2
218		726.2	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
219		725.25	2
220		687.24	2
221		692.25	2
222		724.22	2
223		692.25	2
224		708.25	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
225		692.25	2
226		692.25	2
227		719.26	2
228		692.25	2
229		692.25	2
230		718.27	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
231		692.25	2
232		718.23	2
233		692.25	2
234		690.24	2
235		705.25	2
236		692.25	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
237		692.25	2
238		692.25	2
239		673.09	3
240		669.17	3
241		665.14	3
242		665.2	3
243		665.16	3
244		747.21	3

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
245		719.16	2
246		693.15	2
247		684.15	2
248		670.16	2
249		719.99	2
250		677.27	2
251		677.27	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
252		682.28	2
253		680.2	2
254		663.28	2
255		663.32	2
256		691.16	2
257		680.12	2
258		720.01	2
259		703.18	2









No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
260		710.05	2
261		710.11	2
262		705.09	2
263		696.1	2
264		696.07	2
265		682.09	2
266		689.05	2
267		698.08	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
268		663.95	2
269		703.2	2
270		680.12	2
271		698.05	2
272		712.1	2
273		674.13	2
274		678.1	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
275		678.12	2
276		663.81	2
277		696.25	2
278		696.17	2
279		696.13	2
280		696.04	2
281		693.14	2
282		698.15	2
283		666.06	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
284		684.05	2
285		719.2	2
286		742.2	2
287		703.16	2
288		665.12	2
289		690.17	2
290		746.09	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
291		744.15	2
292		732.13	2
293		746.06	2
294		746.05	2
295		678.22	2
296		678.05	2
297		678.07	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
298		718.19	2
299		678.23	2
300		708.2	2
301		724.11	2
302		651.04	2
303		705.15	2
304		681.1	2
305		715.08	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
306		727.03	2
307		704.65	2
308		758.14	2
309		678.17	2
310		678.17	2
311		712.08	2
312		703.14	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
313		708.08	2
314		705.15	2
315		608.2	15
316		608.2	15
317		719.7	3
318		594.2	2
319		717.3	20

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
320		689.3	4
321		791.2	3
322		666.2	2
323		652.2	2
324		715.2	3
325		781.3	2
326		719.3	3

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
327		719.3	3
328		799.3	3
329		744.3	2
330		855.2	3
331		743.3	3
332		692.2	2
333		719.3	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
334		694.2	2
335		694.2	2
336		694.2	2
337		769.2	2
338		701.2	2
339		694.2	2
340		652.2	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
341		678.2	2
342		664.2	2
343		664.2	2
344		652.2	2
345		652.2	2
346		652.2	2
347		652.2	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
348		705.2	2
349		711.2	2
350		710.2	2
351		719.3	2
352		672.2	16
353		678.2	2
354		678.2	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
355		678.2	2
356		678.2	2
357		726.2	2
358		726.2	2
359		664.2	2
360		664.2	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
361		705.2	2
362		705.2	2
363		738.2	2
364		678.2	2
365		678.2	2
366		706.3	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
367		724.2	2
368		703.2	2
369		691.2	2
370		715.2	2
371		703.2	2
372		705.2	2
373		679.2	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
374		638.2	2
375		707.3	2
376		707.3	2
377		666.2	2
378		666.2	2
379		650.2	2
380		664.2	2
381		678.2	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
382		641.2	3
383		665.2	3
384		641.2	3
385		525.2	15
386		525.2	15
387		717.299	2
388		765.483 (m/z M+Na ⁺)	3

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
389		761.156	17
390		761.161	17
391		653.12	17
392		736.104	17
393		743.096	18
394		743.268	18








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
395		637.69	18
396		717.045	18
397		727.327	19
398		709.596	11
399		627.114	11
400		637.4	3








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
401		553.308	3
402		525.282	3
403		705.2	2
404		726.2	2
405		725.2	2
406		725.2	2
407		703.2	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
408		726.3	2
409		718.3	2
410		725.2	2
411		718.4	2
412		715.2	2
413		721.3	2
414		727.1	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
415		771.3	2
416		705	2
417		699.1	2
418		685.1	2
419		752.2	2
420		686.1	2
421		711.2	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
422		685.1	2
423		694.2	2
424		711.2	2
425		685.1	2
426		664.1	2
427		678.2	2
428		698.2	2
429		673	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
430		678.2	2
431		664.2	2
432		696.0	2
433		680.1	2
434		719.20	3
435		691.2	2
436		496.3	26








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
437		714.3	26
438		636.226	26
439		608.242	26
440		660.1	26
441		714.3	2
442		692.2	2
443		692.198	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
444		676.16	2
445		676.14	2
446		664.16	2
447		690.09	2
448		651.13	2
449		611.16	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
450		737.2	12
451		765.2	12
452		719.2	2
453		692.2	2
454		671.2	3
455		745.2	3
456		657.2	3






No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
457		706.2	2
458		687.2	2
459		692.2	2
460		753.2	3
461		689.1	2
462		715.1	2
463		722.1	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
464		691.1	2
465		691.1	2
466		749.2	3
467		749.1	3
468		719.2	3
469		662.2	2








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
470		720.1	2
471		720.1	2
472		705.2	2
473		705.1	2
474		661.2	3
475		691.2	3
476		693.2	3

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
477		689.2	3
478		693.2	3
479		665.2	3
480		691.2	3
481		691.2	2
482		690.2	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
483		706.2	2
484		692.2	2
485		676.2	2
486		678.2	2
487		678.2	2
488		716.3	13








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
493		737.2	12
494		737.2	12
495		713.2	12
496		659.2	4
497		698.139	26

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
498		674.085	26
499		721.151	3
500		721.142	3
501		706.114	2
502		706.132	2
508		705.16	2
509		678.133	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
510		678.119	2
511		678.164	2
512		665.2	2
513		691.2	2
514		691.14	2
515		714.23	2
516		678.22	2









No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
517		691.25	2
518		709.15	3
519		669.23	3
520		700.16	2
521		700.25	2
522		682.1	2
523		694.18	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
524		680.14	2
525		773.26	3
526		669.21	3
527		663.63	3
528		732.22	2
529		680.48	2
530		722.38	2
531		747.32	3







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
532		691.15	3
533		693.18	3
534		719.45	2
535		691.21	2
536		714.07	2
537		743.2	3
538		720.31	3









No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
539		705.22	2
540		720.19	3
541		705.2	2
542		717.19	2
543		705.3	2
544		689.13	3










No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
545		690.1	2
546		791.12	3
547		741.17	2
548		689.17	3
549		690.19	2
550		659.14	3
551		674.14	2
552		692.21	2









No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
553		696.07	2
554		721.14	3
555		691.18	3
556		763.11	3
557		706.19	2
558		691.19	2
559		727.13	2
560		698.11	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
561		665.12	3
562		693.14	3
563		693.13	3
564		678.12	2
565		692.12	2
566		692.12	2
567		692.13	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
568		763.03	3
569		763.03	3
570		819.11	3
571		764.92	3
572		715.01	2
573		741.14	2
574		712.12	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
575		739.06	3
576		763.1	3
577		715.06	2
578		679.12	2
579		665.13	3
580		705.18	2
581		693.1	2
582		535.1	10

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
583		535.1	10
584		536.1	10
585		594.9	2
586		567.2	2
587		567.2	2
588		670.1	3
589		680.9	2
590		772.3	3
591		607.1	2







No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
592		581.2	2
593		596.2	2
594		553	2
595		607	2
596		567	2
597		620.2	2
598		706	2
599		706	2

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
600		695.1	2
601		719.2	3
602		740.216	13
603		701.2	13
604		740.201	13
605		726.2	13








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
606		714.2	13
607		738.198	12
608		780.2	12
609		752.198	12
610		752.2	12
611		646.12	12








No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
612		766.2	12
613		738.14	12
614		674.1	26
615		568.0	26
616		648.2	26
617		726.2	26
618		698.1	26
619		592.0	26

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
620		715.0	2
621		635.1	3
622		663.2	2
623		691.1	2
624		665.2	3
625		678.2	2
626		665.3	3
627		678.2	2
628		704.1	13


No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
629		623.11	2
630		593.2	14
631		663.1	14
632		716.1	14
633		702.1	14
634		725.2	3

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
635		718.2	26
636		740.2	26
637		740.2	26
638		716.3	26
639		690.2	14
640		677.2	14

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
641		644.168	10
642		605.182	10
643		646.196	10
644		646.211	10
645		632.19	10
646		647.195	10
647		647.209	10

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
648		692.175	2
649		698.096	26
650		712.055	26
651		712.082	26
652		691.07	13
653		730.12	13
654		760.96	13

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
655		745.1	13
656		677.33	14
657		723.1	3
658		691.14	2
659		705.17	2
660		719.8	3
661		691.16	3
662		723.389	1

No.	Structure	ES/MS (m/z, M+H ⁺)	Procedure
663		747.2	3

NMR data for select compounds is shown below in Table 2.

Table 2

No.	NMR
1	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.70 (d, J = 2.1 Hz, 1H), 8.52 (s, 1H), 8.21 (s, 1H), 7.74 (d, J = 7.4 Hz, 1H), 7.68 - 7.44 (m, 4H), 4.82 - 4.03 (m, 16H), 2.58 (d, J = 8.2 Hz, 4H), 2.46 (d, J = 8.0 Hz, 4H).
2	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.67 (d, J = 2.3 Hz, 1H), 8.49 (s, 1H), 8.19 (td, J = 7.2, 2.7 Hz, 1H), 7.71 (dd, J = 7.3, 2.2 Hz, 1H), 7.65 - 7.42 (m, 4H), 4.72 (s, 9H), 4.34 (d, J = 34.3 Hz, 1H), 4.14 (d, J = 21.4 Hz, 9H).
3	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.67 (s, 1H), 8.49 (s, 1H), 8.19 (s, 1H), 7.71 (d, J = 7.1 Hz, 1H), 7.65 - 7.41 (m, 4H), 4.72 (s, 6H), 4.39 (s, 6H), 4.14 (d, J = 21.3 Hz, 8H), 3.37 (s, 6H).
4	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.66 (s, 1H), 8.49 (s, 1H), 8.20 (d, J = 7.2 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.66 - 7.43 (m, 4H), 4.79 - 4.02 (m, 24H), 1.86 (s, 6H).
5	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.77 - 8.66 (m, 1H), 8.53 (s, 1H), 8.26 - 8.14 (m, 1H), 7.80 - 7.67 (m, 1H), 7.66 - 7.43 (m, 4H), 4.49 (d, J = 6.5 Hz, 4H), 4.18 (s, 3H), 4.13 (s, 3H), 3.95 - 3.83 (m, 4H).
6	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.80 - 8.66 (m, 1H), 8.62 - 8.51 (m, 1H), 8.31 - 8.11 (m, 1H), 7.83 - 7.40 (m, 5H), 4.66 - 4.43 (m, 4H), 4.23 - 4.05 (m, 7H), 3.05 (d, J = 6.2 Hz, 2H), 2.52 - 2.32 (m, 5H), 1.97 (d, J = 8.9 Hz, 2H).
7	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.25 (s, 1H), 9.15 (s, 1H), 8.57 (d, J = 0.8 Hz, 1H), 8.50 (s, 1H), 7.75 (dt, J = 7.6, 1.6 Hz, 2H), 7.63 (dq, J = 7.6, 4.0 Hz, 3H), 7.55 (ddd, J = 7.5, 5.7, 1.8 Hz, 2H), 4.46 (s, 2H), 4.22 (d, J = 7.0 Hz, 2H), 4.01 (d, J = 7.8 Hz, 6H), 3.93 (m, 1H), 3.20 (s, 2H), 2.48 - 2.42 (m, 5H), 2.25 - 2.09 (m, 3H), 1.81 (m, 1H), 1.78 (s, 1H).

No.	NMR
8	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.23 (s, 1H), 8.56 (d, J = 7.4 Hz, 2H), 7.76 (dt, J = 7.7, 2.0 Hz, 2H), 7.68 - 7.59 (m, 3H), 7.56 (dd, J = 7.9, 1.8 Hz, 2H), 4.46 (s, 2H), 4.33 (s, 2H), 4.02 (s, 6H), 3.94 (t, J = 6.9 Hz, 1H), 3.22 (s, 3H), 3.17 (s, 1H), 2.25 - 2.13 (m, 2H), 2.14 (s, 6H), 1.80 (dd, J = 11.9, 6.3 Hz, 1H).
9	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.26 (s, 1H), 9.14 (s, 1H), 8.57 (s, 1H), 8.48 (s, 1H), 7.74 (ddd, J = 8.6, 7.6, 1.8 Hz, 2H), 7.68 - 7.58 (m, 3H), 7.55 (ddd, J = 7.6, 5.1, 1.8 Hz, 2H), 4.68 (s, 2H), 4.55 (s, 2H), 4.46 (s, 2H), 4.01 (d, J = 9.2 Hz, 6H), 3.94 (s, 1H), 3.19 (s, 2H), 2.24 - 2.09 (m, 3H), 1.85 - 1.74 (m, 1H), 1.69 (s, 3H).
10	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.24 (s, 1H), 9.12 (s, 1H), 8.57 (s, 1H), 8.48 (s, 1H), 7.74 (ddd, J = 9.2, 7.6, 1.8 Hz, 2H), 7.68 - 7.51 (m, 6H), 4.65 (s, 2H), 4.46 (s, 2H), 4.40 (s, 2H), 4.02 (s, 2H), 3.99 (s, 3H), 3.94 (s, 2H), 3.20 (s, 2H), 2.25 - 2.09 (m, 4H), 1.78 (s, 1H).
11	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.54 (s, 2H), 9.21 (s, 2H), 8.57 (d, J = 2.4 Hz, 2H), 7.75 (dd, J = 7.7, 1.8 Hz, 2H), 7.68 - 7.59 (m, 3H), 7.56 (dd, J = 7.6, 1.8 Hz, 2H), 5.62 (s, 1H), 4.47 (s, 5H), 4.09 - 3.95 (m, 6H), 3.96 - 3.83 (m, 2H), 3.70 (s, 1H), 3.50 (dd, J = 9.4, 3.8 Hz, 1H), 3.19 (s, 2H), 2.24 - 2.09 (m, 3H), 1.78 (s, 1H).
12	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.90 (s, 2H), 9.21 (s, 2H), 8.56 (d, J = 7.1 Hz, 2H), 7.76 (dt, J = 7.6, 1.9 Hz, 2H), 7.68 - 7.59 (m, 3H), 7.56 (dd, J = 7.6, 1.8 Hz, 2H), 4.46 (s, 2H), 4.32 (s, 2H), 4.02 (s, 6H), 3.94 (s, 1H), 3.19 (s, 2H), 2.67 (s, 1H), 2.26 - 2.09 (m, 3H), 2.03 (s, 3H), 1.85 - 1.75 (m, 1H).
13	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.25 (s, 2H), 9.14 (s, 1H), 8.55 (d, J = 16.1 Hz, 2H), 7.79 - 7.52 (m, 9H), 4.46 (s, 3H), 4.32 (s, 1H), 4.01 (m, 6H), 3.43 (s, 1H), 3.25 (d, J = 6.7 Hz, 2H), 2.52 (s, 1H), 2.25 - 2.19 (m, 2H), 2.23 - 2.09 (m, 3H), 1.80 (dd, J = 11.8, 6.3 Hz, 1H).
14	¹ H NMR (400 MHz, DMSO-d ₆) δ 10.48 (s, 1H), 9.23 (s, 1H), 9.13 (s, 1H), 8.57 (s, 1H), 8.50 (s, 1H), 7.74 (td, J = 7.4, 1.8 Hz, 2H), 7.68 - 7.56 (m, 3H), 7.56 (ddd, J = 7.6, 3.0, 1.8 Hz, 2H), 5.04 (s, 1H), 4.88 (d, J = 8.4 Hz, 1H), 4.78 (d, J = 14.9 Hz, 2H), 4.59 (s, 1H), 4.44 (d, J = 18.7 Hz, 5H), 4.35 (s, 1H), 4.02 (s, 2H), 3.94 (s, 1H), 3.92 (d, J = 6.7 Hz, 1H), 3.52 (t, J = 7.1 Hz, 1H), 3.29-3.10 (m, 2H) 2.29 - 2.09 (m, 5H), 1.94 (dd, J = 14.1, 7.1 Hz, 2H), 1.80 (dd, J = 12.1, 6.5 Hz, 1H).
15	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.22 (s, 1H), 9.11 (s, 1H), 8.57 (s, 1H), 8.50 (s, 1H), 7.75 (dd, J = 7.6, 1.8 Hz, 2H), 7.68 - 7.51 (m, 6H), 4.46 (s, 2H), 4.22 (s, 2H), 4.02 (s, 3), 3.99 (s, 3H), 3.94 (t, J = 5.7 Hz, 1H), 3.20 (s, 2H), 2.25 - 2.09 (m, 8H), 1.80 (dd, J = 11.7, 6.4 Hz, 1H).

No.	NMR
16	¹ H NMR (400 MHz, DMSO-d ₆) δ 10.50 (s, 1H), 9.23 (s, 1H), 9.12 (s, 1H), 8.57 (s, 1H), 8.51 (d, J = 1.7 Hz, 1H), 7.74 (td, J = 7.4, 1.8 Hz, 2H), 7.68 - 7.52 (m, 5H), 6.07 (s, 1H), 4.75 - 4.67 (m, 2H), 4.46 (s, 2H), 4.12 (dd, J = 25.4, 6.6 Hz, 2H), 4.02 (d, J = 4.9 Hz, 6H), 3.94 (t, J = 6.2 Hz, 1H), 3.20 (s, 2H), 2.25 - 2.09 (m, 3H), 1.80 (dd, J = 11.8, 6.5 Hz, 1H), 1.44 (d, J = 18.5 Hz, 3H).
17	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.54 (s, 1H), 8.52 (s, 1H), 7.72 (ddd, J = 7.7, 1.8, 0.9 Hz, 2H), 7.58 (td, J = 7.6, 1.3 Hz, 2H), 7.49 (ddd, J = 7.6, 2.5, 1.8 Hz, 2H), 4.53 (d, J = 4.0 Hz, 2H), 4.51 - 4.38 (m, 3H), 4.12 (d, J = 3.1 Hz, 7H), 3.69 - 3.56 (m, 2H), 3.41 - 3.33 (m, 4H), 2.50 - 2.35 (m, 3H), 2.22 (dt, J = 12.9, 7.8 Hz, 1H), 2.14 (s, 3H), 2.10 - 1.92 (m, 3H), 1.88 - 1.77 (m, 1H).
21	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 8.55 (s, 1H), 7.73 (ddd, J = 7.7, 3.3, 1.7 Hz, 2H), 7.63 - 7.56 (m, 2H), 7.50 (dd, J = 7.8, 1.8 Hz, 2H), 4.90 (s, 1H), 4.61 - 4.48 (m, 3H), 4.16 - 4.07 (m, 7H), 4.04 - 3.93 (m, 1H), 3.88 - 3.76 (m, 2H), 3.67 (dd, J = 11.1, 7.2 Hz, 1H), 3.37 (d, J = 12.9 Hz, 5H), 2.51 - 2.28 (m, 5H), 2.25 - 2.15 (m, 1H), 2.09 (dd, J = 14.4, 7.3 Hz, 1H), 2.02 - 1.86 (m, 3H).
23	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 8.54 (s, 1H), 7.73 (ddd, J = 7.7, 4.3, 1.7 Hz, 2H), 7.59 (t, J = 7.7 Hz, 2H), 7.49 (dd, J = 7.7, 1.7 Hz, 2H), 4.94 (d, J = 15.4 Hz, 1H), 4.62 - 4.55 (m, 1H), 4.54 (d, J = 3.9 Hz, 2H), 4.13 (d, J = 0.8 Hz, 7H), 3.99 (dd, J = 11.7, 3.3 Hz, 1H), 3.92 - 3.77 (m, 3H), 3.44 - 3.33 (m, 3H), 2.51 - 2.37 (m, 3H), 2.36 - 1.89 (m, 7H).
24	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 8.54 (s, 1H), 7.73 (ddd, J = 7.7, 4.4, 1.7 Hz, 2H), 7.59 (t, J = 7.6 Hz, 2H), 7.49 (dd, J = 7.6, 1.7 Hz, 2H), 4.94 (d, J = 15.4 Hz, 1H), 4.62 - 4.55 (m, 1H), 4.53 (d, J = 3.9 Hz, 2H), 4.13 (s, 7H), 3.99 (dd, J = 11.7, 3.2 Hz, 1H), 3.91 - 3.77 (m, 3H), 3.44 - 3.33 (m, 4H), 2.51 - 2.36 (m, 3H), 2.36 - 1.89 (m, 6H).
28	¹ H (MeOH-d ₄ , 400 MHz, d): 8.58 (s, 1H); 8.56 (s, 1H); 8.55 (s, 1H); 7.74 (dd, 2H); 7.61 (td, 2H); 7.50 (dt, 2H); 4.61 (d, 2H); 4.56 (dd, 2H); 4.14 (s, 3H); 4.13 (s, 3H); 3.37 (m, 2H); 2.50 - 2.38 (m, 3H); 2.02 (d, 2H); 2.00 (m, 2H).
30	¹ H (MeOH-d ₄ , 400 MHz, d): 8.54 (s, 2H); 7.74 (dd, 2H); 7.68 (d, 2H); 7.61 (t, 2H); 7.50 (dd, 2H); 6.46 (d, 2H); 4.49 (s, 4H); 4.41 (s, 4H); 4.13 (s, 6H); 3.94 (s, 6H).
32	¹ H (MeOH-d ₄ , 400 MHz, d): 8.58 (s, 1H); 8.56 (s, 1H); 8.17 (s, 1H); 7.75 (dd, 2H); 7.62 (td, 2H); 7.48 (dt, 2H); 4.60 - 4.45 (m, 8H); 4.14 (s, 3H); 4.13 (s, 3H); 4.20 - 4.08 (m, 1H); 3.38 (m, 2H); 2.60 - 2.40 (m, 3H); 2.00 - 1.85 (m, 1H); 1.55 (t, 3H).
33	¹ H (MeOH-d ₄ , 400 MHz, d): 8.57 (s, 1H); 8.55 (s, 1H); 7.79 (s, 1H); 7.75 (dd, 2H); 7.62 (td, 2H); 7.48 (dt, 2H); 4.60 (broad s, 4H), 4.15 (broad s, 6H); 4.17 - 4.12 (m, 2H); 3.60 (t, 2H); 3.38 (t, 1H); 3.28 (t, 2H); 2.50 - 2.38 (m, 3H); 2.05 - 1.95 (m, 2H).

No.	NMR
35	¹ H (MeOH- <i>d</i> ₄ , 400 MHz, d): 8.52 (s, 1H); 8.51 (s, 1H); 7.98 (s, 1H); 7.72 (dd, 2H); 7.57 (td, 2H); 7.48 (dt, 2H); 4.58 (s, 2H); 4.52 (broad s, 4H), 4.11 (s, 3H); 4.10 (s, 3H); 4.17 - 4.12 (m, 2H); 3.38 (m, 2H); 2.50 - 2.38 (m, 3H); 2.05 - 1.95 (m, 2H).
43	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 3.1 Hz, 2H), 7.71 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.57 (t, <i>J</i> = 7.6 Hz, 2H), 7.47 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.63 - 4.43 (m, 4H), 4.11 (s, 7H), 3.71 (td, <i>J</i> = 6.8, 1.1 Hz, 2H), 3.61 (td, <i>J</i> = 6.7, 1.1 Hz, 2H), 3.36 (h, <i>J</i> = 5.4 Hz, 2H), 2.53 - 2.26 (m, 3H), 2.05 - 1.89 (m, 1H).
44	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.20 (d, <i>J</i> = 46.7 Hz, 4H), 8.55 (d, <i>J</i> = 13.3 Hz, 2H), 7.75 (dt, <i>J</i> = 7.6, 1.6 Hz, 2H), 7.69 - 7.59 (m, 3H), 7.56 (dt, <i>J</i> = 7.6, 2.2 Hz, 2H), 6.36 (t, <i>J</i> = 5.7 Hz, 1H), 5.81 (s, 2H), 4.43 (dd, <i>J</i> = 14.8, 8.9 Hz, 5H), 4.02 (d, <i>J</i> = 4.5 Hz, 7H), 3.93 (d, <i>J</i> = 6.9 Hz, 1H), 3.33 (q, <i>J</i> = 5.7 Hz, 2H), 3.27 - 3.02 (m, 5H), 2.27 - 2.09 (m, 3H), 1.79 (tt, <i>J</i> = 11.1, 5.5 Hz, 1H).
45	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.19 (d, <i>J</i> = 49.3 Hz, 5H), 8.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.75 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 7.69 - 7.50 (m, 7H), 7.12 (s, 1H), 4.62 - 4.34 (m, 5H), 4.02 (d, <i>J</i> = 3.7 Hz, 7H), 3.93 (d, <i>J</i> = 6.3 Hz, 1H), 3.34 - 3.08 (m, 6H), 2.58 (t, <i>J</i> = 7.0 Hz, 3H), 2.28 - 2.06 (m, 3H), 1.90 - 1.67 (m, 1H).
46	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (d, <i>J</i> = 11.8 Hz, 2H), 7.72 (ddd, <i>J</i> = 7.7, 5.9, 1.7 Hz, 2H), 7.58 (td, <i>J</i> = 7.7, 1.0 Hz, 2H), 7.48 (dt, <i>J</i> = 7.6, 1.5 Hz, 2H), 4.59 (s, 2H), 4.52 (d, <i>J</i> = 3.8 Hz, 2H), 4.12 (s, 7H), 3.36 (h, <i>J</i> = 5.5 Hz, 2H), 3.05 (s, 6H), 2.52 - 2.29 (m, 3H), 2.04 - 1.90 (m, 1H).
47	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 2.3 Hz, 2H), 7.75 - 7.67 (m, 2H), 7.57 (t, <i>J</i> = 7.7 Hz, 2H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.63 - 4.45 (m, 6H), 4.11 (d, <i>J</i> = 1.0 Hz, 7H), 3.64 - 3.32 (m, 5H), 2.53 - 2.23 (m, 3H), 2.06 - 1.88 (m, 1H).
49	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (s, 1H), 8.51 (s, 1H), 7.74 - 7.67 (m, 4H), 7.57 (td, <i>J</i> = 7.7, 0.7 Hz, 2H), 7.47 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.52 (d, <i>J</i> = 3.8 Hz, 2H), 4.48 (s, 2H), 4.11 (d, <i>J</i> = 3.8 Hz, 7H), 3.50 - 3.39 (m, 2H), 3.39 - 3.32 (m, 2H), 3.05 (t, <i>J</i> = 7.8 Hz, 2H), 2.52 - 2.30 (m, 3H), 2.05 - 1.88 (m, 1H).
50	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (s, 1H), 8.48 (s, 1H), 7.70 (ddd, <i>J</i> = 7.7, 4.2, 1.7 Hz, 2H), 7.57 (td, <i>J</i> = 7.7, 1.5 Hz, 2H), 7.47 (dd, <i>J</i> = 7.6, 1.8 Hz, 2H), 4.80 (s, 2H), 4.70 (s, 4H), 4.52 (d, <i>J</i> = 3.8 Hz, 2H), 4.11 (d, <i>J</i> = 2.3 Hz, 7H), 3.90 (s, 2H), 3.42 - 3.33 (m, 2H), 3.05 (s, 1H), 2.52 - 2.30 (m, 3H), 2.07 - 1.86 (m, 1H).
72	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.01 (s, 2H), 7.63 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.51 (t, <i>J</i> = 7.7 Hz, 2H), 7.41 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.52 - 4.42 (m, 4H), 4.45 (s, 4H), 4.18 (q, <i>J</i> = 10.0, 9.5 Hz, 4H), 3.02 (s, 6H), 2.76 - 2.63 (m, 2H), 2.63 - 2.48 (m, 2H).

No.	NMR
73	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.05 (s, 1H), 8.01 (s, 1H), 7.68 - 7.59 (m, 2H), 7.56 - 7.47 (m, 2H), 7.45 - 7.38 (m, 2H), 4.53 - 4.42 (m, 2H), 4.46 (s, 2H), 4.23 - 4.13 (m, 2H), 4.21 (s, 2H), 3.02 (s, 3H), 3.02 (s, 3H), 2.88 (s, 3H), 2.75 - 2.62 (m, 1H), 2.60 - 2.50 (m, 1H).
74	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.05 (s, 2H), 7.64 (dd, J = 7.7, 1.7 Hz, 2H), 7.52 (t, J = 7.6 Hz, 2H), 7.42 (dd, J = 7.6, 1.7 Hz, 2H), 4.21 (s, 4H), 3.02 (s, 6H), 2.88 (s, 6H).
76	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.01 (s, 2H), 7.62 (dd, J = 7.6, 1.8 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.41 (dd, J = 7.6, 1.7 Hz, 2H), 4.77 - 4.07 (m, 20H), 3.01 (s, 6H), 1.86 (s, 6H).
77	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.02 (s, 2H), 7.63 (dd, J = 7.7, 1.7 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.41 (dd, J = 7.6, 1.7 Hz, 2H), 4.81 - 3.88 (m, 14H), 3.01 (s, 6H).
78	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.02 (s, 2H), 7.62 (dd, J = 7.6, 1.8 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.41 (dd, J = 7.6, 1.8 Hz, 2H), 4.73 - 4.13 (m, 12H), 3.91 - 3.59 (m, 4H), 3.02 (s, 6H), 2.90 - 2.67 (m, 4H).
79	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.02 (s, 2H), 7.64 - 7.60 (m, 2H), 7.52 (t, J = 7.6 Hz, 2H), 7.41 (dd, J = 7.6, 1.7 Hz, 2H), 4.94 - 4.06 (m, 12H), 3.02 (s, 6H), 2.57 (t, J = 7.9 Hz, 4H), 2.42 (t, J = 7.9 Hz, 4H).
82	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.75 (s, 2H), 7.67 (dd, J = 7.6, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.49 (dd, J = 7.6, 1.7 Hz, 2H), 4.97 - 3.83 (m, 14), 2.92 (q, J = 7.5 Hz, 4H), 1.38 (t, J = 7.5 Hz, 6H).
83	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.76 (s, 2H), 7.71 - 7.66 (m, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.49 (dd, J = 7.4, 1.8 Hz, 2H), 4.88 (s, 4H), 4.64 - 4.29 (m, 8H), 3.90 - 3.60 (m, 4H), 2.97 - 2.72 (m, 8H), 1.39 (t, J = 7.5 Hz, 6H).
84	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.77 (s, 2H), 7.68 (dd, J = 7.6, 1.7 Hz, 2H), 7.59 (t, J = 7.6 Hz, 2H), 7.50 (dd, J = 7.6, 1.7 Hz, 2H), 4.88 (s, 4H), 4.78 - 4.23 (m, 8H), 2.92 (q, J = 7.5 Hz, 4H), 2.58 (t, J = 7.9 Hz, 4H), 2.42 (t, J = 7.8 Hz, 4H), 1.40 (t, J = 7.5 Hz, 6H).
88	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.60 (s, 2H), 7.73 (dd, J = 7.7, 1.8 Hz, 2H), 7.59 (t, J = 7.6 Hz, 2H), 7.50 (dd, J = 7.6, 1.7 Hz, 2H), 4.83 - 3.91 (m, 14), 2.69 (s, 6H).
89	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.60 (s, 2H), 7.73 (dd, J = 7.7, 1.7 Hz, 2H), 7.59 (t, J = 7.6 Hz, 2H), 7.50 (dd, J = 7.6, 1.7 Hz, 2H), 4.73 (s, 4H), 4.68 - 4.27 (m, 8H), 3.88 - 3.55 (m, 4H), 2.93 - 2.71 (m, 4H), 2.70 (s, 6H).
90	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.60 (s, 2H), 7.73 (dd, J = 7.7, 1.7 Hz, 2H), 7.59 (t, J = 7.7 Hz, 2H), 7.50 (dd, J = 7.7, 1.7 Hz, 2H), 4.73 (s, 4H), 4.72 - 4.18 (m, 8H), 2.70 (s, 6H), 2.57 (t, J = 7.9 Hz, 4H), 2.42 (t, J = 7.9 Hz, 4H).

No.	NMR
93	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.75 (s, 2H), 7.65 (dd, J = 7.7, 1.8 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.49 (dd, J = 7.6, 1.8 Hz, 2H), 4.85 – 4.63 (m, 8H), 4.46 – 4.22 (m, 4H), 4.09 – 4.00 (m, 2H), 2.63 (s, 6H).
100	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.94 (s, 1H), 8.34 (s, 1H), 7.74 - 7.64 (m, 2H), 7.64 - 7.49 (m, 3H), 7.45 (dd, J = 7.6, 1.7 Hz, 1H), 4.97 - 3.93 (m, 14H), 3.05 (s, 6H).
101	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.33 (s, 2H), 7.65 (dd, J = 7.7, 1.7 Hz, 2H), 7.53 (t, J = 7.6 Hz, 2H), 7.43 (dd, J = 7.6, 1.7 Hz, 2H), 4.81 (s, 4H), 4.57 - 4.17 (m, 8H), 3.86 - 3.59 (m, 4H), 3.05 (s, 12H), 2.90 - 2.66 (m, 4H).
102	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.94 (s, 1H), 8.34 (s, 1H), 7.73 - 7.65 (m, 2H), 7.65 - 7.48 (m, 3H), 7.45 (d, J = 6.6 Hz, 1H), 4.95 (s, 2H), 4.81 (s, 2H), 4.62 - 4.12 (m, 8H), 3.90 - 3.58 (m, 2H), 3.06 (s, 6H), 2.90 - 2.65 (m, 2H).
103	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.34 (s, 2H), 7.66 (dd, J = 7.7, 1.8 Hz, 2H), 7.54 (t, J = 7.6 Hz, 2H), 7.44 (dd, J = 7.6, 1.7 Hz, 2H), 4.82 (s, 4H), 4.75 - 4.11 (m, 8H), 3.06 (s, 12H), 2.60 - 2.49 (m, 4H), 2.47 - 2.32 (m, 4H).
104	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.94 (s, 1H), 8.35 (s, 1H), 7.73 - 7.66 (m, 2H), 7.65 - 7.49 (m, 3H), 7.49 - 7.41 (m, 1H), 4.95 (s, 2H), 4.87 - 4.17 (m, 10H), 3.06 (s, 6H), 2.61 - 2.51 (m, 4H), 2.46 - 2.35 (m, 4H).
112	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.43 (s, 2H), 7.63 – 7.57 (m, 4H), 7.43 (dd, J = 5.2, 4.1 Hz, 2H), 4.83 – 4.00 (m, 14H), 4.10 (s, 6H).
113	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.48 (s, 2H), 7.65 – 7.59 (m, 4H), 7.44 (dd, J = 5.8, 3.5 Hz, 2H), 4.60 – 4.43 (m, 4H), 4.18 – 4.05 (m, 2H), 4.12 (s, 6H), 3.37 – 3.30 (m, 4H), 2.54 – 2.34 (m, 6H), 2.06 – 1.93 (m, 2H).
114	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.48 (s, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.81 – 7.40 (m, 7H), 4.74 (s, 2H), 4.61 – 4.29 (m, 4H), 4.18 (s, 4H), 4.10 (s, 6H), 3.83 – 3.65 (m, 2H), 2.89 – 2.59 (m, 2H).
116	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.48 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.81 – 7.40 (m, 7H), 4.83 – 4.21 (m, 7H), 4.18 (s, 4H), 4.10 (s, 6H).
120	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.48 (s, 2H), 7.70 (dd, J = 7.7, 1.7 Hz, 2H), 7.57 (t, J = 7.7 Hz, 2H), 7.47 (dd, J = 7.5, 1.7 Hz, 2H), 4.74 (s, 4H), 4.69 – 4.19 (m, 8H), 4.11 (s, 6H), 3.89 – 3.60 (m, 4H), 2.97 – 2.54 (m, 4H).
121	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.82 (s, 2H), 7.83 (dd, J = 7.6, 1.7 Hz, 2H), 7.65 (t, J = 7.7 Hz, 2H), 7.57 (dd, J = 7.6, 1.7 Hz, 2H), 4.64 – 4.51 (m, 2H), 4.32 – 4.23 (m, 2H), 4.26 (s, 6H), 3.73 (dd, J = 11.7, 8.0 Hz, 2H), 1.50 (d, J = 6.4 Hz, 6H).
122	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.47 (s, 1H), 7.79 – 7.03 (m, 9H), 4.56 (s, 2H), 4.15 (s, 2H), 4.10 (s, 3H), 3.95 (s, 3H).

No.	NMR
123	¹ H NMR (400 MHz, Methanol-d4) δ 8.47 (s, 1H), 7.68 (dd, J = 7.6, 1.7 Hz, 1H), 7.59 – 7.40 (m, 5H), 7.37 (dd, J = 7.4, 1.9 Hz, 1H), 7.18 (s, 1H), 7.16 – 7.10 (m, 1H), 4.74 (s, 2H), 4.61 – 4.19 (m, 10H), 4.11 (s, 3H), 3.96 (s, 3H), 3.85 – 3.60 (m, 4H), 2.92 – 2.66 (m, 4H).
124	¹ H NMR (400 MHz, Methanol-d4) δ 8.48 (s, 1H), 7.68 (dd, J = 7.8, 1.8 Hz, 1H), 7.61 – 7.41 (m, 5H), 7.38 (dd, J = 7.3, 1.9 Hz, 1H), 7.20 (s, 1H), 7.14 (d, J = 7.7 Hz, 1H), 4.83 – 4.23 (m, 12H), 4.11 (s, 3H), 3.97 (s, 3H), 2.63 – 2.33 (m, 8H).
125	¹ H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 7.72 – 7.66 (m, 1H), 7.62 – 7.42 (m, 5H), 7.38 (dd, J = 7.4, 2.1 Hz, 1H), 7.20 (s, 1H), 7.14 (d, J = 7.8 Hz, 1H), 4.58 – 4.44 (m, 2H), 4.41 – 4.26 (m, 2H), 4.12 (s, 3H), 4.12 – 4.01 (m, 2H), 3.98 (s, 3H), 3.39 – 3.17 (m, 4H), 2.51 – 2.27 (m, 6H), 2.08 – 1.72 (m, 2H).
126	¹ H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 7.89 (d, J = 7.5 Hz, 1H), 7.70 (dd, J = 7.6, 1.7 Hz, 1H), 7.66 (dd, J = 7.6, 1.7 Hz, 1H), 7.60 – 7.50 (m, 2H), 7.47 (dd, J = 7.6, 1.7 Hz, 1H), 7.42 (dd, J = 7.6, 1.7 Hz, 1H), 7.37 (d, J = 7.4 Hz, 1H), 4.60 – 4.43 (m, 2H), 4.41 – 4.26 (m, 2H), 4.12 – 4.00 (m, 2H), 4.12 (s, 3H), 4.10 (s, 3H), 3.38 – 3.20 (m, 4H), 2.54 – 2.24 (m, 6H), 2.10 – 1.76 (m, 2H).
130	¹ H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 2H), 7.72 (dd, J = 7.7, 1.8 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.75 - 4.55 (m, 6H), 4.11 (s, 6H), 4.06 - 3.28 (m, 8H), 2.49 - 2.00 (m, 4H).
131	¹ H NMR (400 MHz, Methanol-d4) δ 8.48 (s, 2H), 7.70 (dd, J = 7.7, 1.7 Hz, 2H), 7.57 (t, J = 7.6 Hz, 2H), 7.47 (dd, J = 7.6, 1.7 Hz, 2H), 4.81 - 3.95 (m, 14H), 4.10 (s, 6H).
133	¹ H NMR (400 MHz, Methanol-d4) δ 8.82 (s, 2H), 7.83 (dd, J = 7.7, 1.8 Hz, 2H), 7.65 (t, J = 7.6 Hz, 2H), 7.57 (dd, J = 7.6, 1.8 Hz, 2H), 4.59 – 4.49 (m, 2H), 4.26 (s, 6H), 4.22 (t, J = 11.9 Hz, 2H), 4.05 (dd, J = 11.8, 7.5 Hz, 2H), 3.85 (dd, J = 11.8, 3.6 Hz, 2H), 3.72 (dd, J = 11.8, 3.6 Hz, 2H).
134	¹ H NMR (400 MHz, Methanol-d4) δ 8.82 (s, 2H), 7.83 (dd, J = 7.6, 1.8 Hz, 2H), 7.65 (t, J = 7.6 Hz, 2H), 7.57 (dd, J = 7.7, 1.8 Hz, 2H), 4.63 – 4.43 (m, 2H), 4.26 (s, 6H), 4.22 (t, J = 11.9 Hz, 2H), 4.11 – 4.01 (m, 2H), 3.85 (dd, J = 11.8, 3.7 Hz, 2H), 3.72 (dd, J = 11.8, 3.6 Hz, 2H).
136	¹ H NMR (400 MHz, Methanol-d4) δ 8.49 (s, 2H), 7.70 (dd, J = 7.7, 1.8 Hz, 2H), 7.57 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.74 (s, 4H), 4.69 – 4.18 (m, 8H), 4.12 (s, 6H), 2.63 – 2.52 (m, 2H), 2.42 (t, J = 7.7 Hz, 2H).
137	¹ H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 2H), 7.71 (dd, J = 7.7, 1.8 Hz, 2H), 7.57 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.49 (s, 4H), 4.40 (ddd, J = 9.8, 6.3, 2.9 Hz, 2H), 4.11 (s, 6H), 3.41 (dd, J = 12.7, 3.1 Hz, 2H), 3.21 (dd, J = 12.6, 9.8 Hz, 2H), 2.59 (d, J = 6.3 Hz, 4H).

No.	NMR
138	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (s, 2H), 7.72 (dd, J = 7.7, 1.8 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.60 – 4.45 (m, 4H), 4.18 – 4.07 (m, 2H), 4.12 (s, 6H), 3.39 – 3.31 (m, 4H), 2.53 – 2.25 (m, 6H), 2.08 – 1.81 (m, 2H).
139	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (s, 2H), 7.72 (dd, J = 7.6, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.58 – 4.47 (m, 4H), 4.18 – 4.07 (m, 2H), 4.12 (s, 6H), 3.42 – 3.27 (m, 4H), 2.54 – 2.25 (m, 6H), 2.08 – 1.83 (m, 2H).
140	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.52 (s, 2H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.57 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.7, 1.7 Hz, 2H), 4.49 (s, 6H), 4.11 (s, 8H), 3.91 – 3.87 (m, 4H), 3.37 – 3.27 (m, 4H).
141	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.82 (s, 2H), 7.83 (dd, J = 7.7, 1.7 Hz, 2H), 7.65 (t, J = 7.7 Hz, 2H), 7.57 (dd, J = 7.7, 1.7 Hz, 2H), 4.26 (s, 6H), 4.15 (s, 8H).
156	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.89 (d, J = 7.5 Hz, 1H), 7.78 - 7.30 (m, 7H), 4.60 - 4.40 (m, 4H), 4.30 - 3.87 (m, 11H), 3.63 - 3.36 (m, 4H), 2.57 - 2.29 (m, 3H), 2.05 - 1.89 (m, 1H), 1.32 (d, J = 10.3 Hz, 3H).
157	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.90 (s, 1H), 7.78 - 7.34 (m, 7H), 4.62 - 4.04 (m, 15H), 3.38 (d, J = 4.3 Hz, 5H), 2.53 - 2.33 (m, 3H), 2.06 - 1.88 (m, 1H).
158	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.81 - 7.34 (m, 7H), 4.63 - 4.44 (m, 2H), 4.41 (s, 2H), 4.20-4.05 (m, 7H), 3.50 - 3.35 (m, 6H), 2.53 - 2.31 (m, 3H), 2.10 - 1.72 (m, 5H), 1.31 (s, 3H).
159	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.77 - 7.67 (m, 2H), 7.63 - 7.34 (m, 5H), 4.61 - 4.35 (m, 4H), 4.13 (d, J = 13.6 Hz, 7H), 3.92 - 3.11 (m, 6H), 2.52 - 1.92 (m, 6H), 1.48 (s, 3H).
160	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.72 (ddd, J = 10.6, 7.7, 1.7 Hz, 2H), 7.65 - 7.36 (m, 5H), 4.62 - 4.49 (m, 2H), 4.39 (s, 2H), 4.20-4.04(m, 7H), 3.62 (d, J = 11.8 Hz, 2H), 3.51 - 3.43 (m, 2H), 3.37 (dd, J = 6.2, 5.1 Hz, 2H), 3.21 - 3.07 (m, 2H), 2.55 - 2.34 (m, 3H), 2.12 - 1.44 (m, 6H).
161	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.71 (ddd, J = 16.8, 7.7, 1.8 Hz, 2H), 7.66 - 7.31 (m, 5H), 4.64 - 4.50 (m, 2H), 4.46 (s, 2H), 4.37 (s, 2H), 4.20-4.04 (m, 7H), 3.37 (dd, J = 6.2, 5.0 Hz, 2H), 2.55 - 2.33 (m, 3H), 2.06 - 1.97 (m, 1H).
162	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.79 - 7.32 (m, 7H), 4.63 - 4.46 (m, 2H), 4.33 (s, 2H), 4.13 (d, J = 12.1 Hz, 9H), 3.50 (td, J = 12.1, 2.1 Hz, 3H), 3.37 (dd, J = 6.2, 5.2 Hz, 2H), 2.60 - 2.32 (m, 3H), 2.15 (dd, J = 12.0, 3.9 Hz, 2H), 2.08 - 1.90 (m, 1H), 1.76 (qd, J = 12.2, 4.7 Hz, 2H).

No.	NMR
163	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.72 (ddd, J = 10.3, 7.7, 1.7 Hz, 2H), 7.66 - 7.35 (m, 5H), 4.62 - 4.48 (m, 2H), 4.43 (d, J = 21.3 Hz, 2H), 4.21-4.04 (m, 7H), 3.66 (d, J = 12.3 Hz, 2H), 3.50 - 3.35 (m, 2H), 3.23 - 3.10 (m, 2H), 2.75 - 1.85 (m, 9H).
164	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.81 - 7.30 (m, 7H), 4.82 - 4.29 (m, 7H), 4.13 (d, J = 15.8 Hz, 9H), 3.44 - 3.36 (m, 2H), 2.57 - 2.30 (m, 3H), 2.07 - 1.87 (m, 1H).
165	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.93 (d, J = 7.5 Hz, 1H), 7.79 - 7.33 (m, 7H), 4.65 - 4.50 (m, 3H), 4.48 - 4.30 (m, 2H), 4.27 - 4.06 (m, 9H), 4.02 (dd, J = 11.0, 3.2 Hz, 1H), 3.73 (dt, J = 5.7, 2.8 Hz, 1H), 3.63 (dd, J = 9.8, 4.4 Hz, 1H), 3.37 (dd, J = 6.2, 5.2 Hz, 2H), 2.56 - 2.31 (m, 3H), 2.12 - 1.90 (m, 1H).
166	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.77 - 7.33 (m, 7H), 4.63 - 4.48 (m, 2H), 4.35 (s, 2H), 4.26 (tt, J = 8.5, 4.4 Hz, 1H), 4.14 (d, J = 8.2 Hz, 7H), 3.90 (dd, J = 11.7, 7.6 Hz, 1H), 3.61 (dd, J = 11.7, 4.0 Hz, 1H), 3.37 (dd, J = 6.2, 5.1 Hz, 2H), 2.93 (dd, J = 17.8, 8.8 Hz, 1H), 2.59 (dd, J = 17.8, 4.7 Hz, 1H), 2.54 - 2.30 (m, 3H), 2.00 (ddd, J = 13.1, 5.7, 3.5 Hz, 1H).
167	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.79 - 7.35 (m, 7H), 4.63 - 4.47 (m, 2H), 4.35 (s, 2H), 4.26 (dt, J = 8.2, 4.2 Hz, 1H), 4.14 (d, J = 8.2 Hz, 7H), 3.90 (dd, J = 11.6, 7.6 Hz, 1H), 3.61 (dd, J = 11.6, 3.9 Hz, 1H), 3.37 (dd, J = 6.2, 5.2 Hz, 2H), 2.93 (dd, J = 17.8, 8.8 Hz, 1H), 2.59 (dd, J = 17.8, 4.7 Hz, 1H), 2.54 - 2.36 (m, 3H), 2.07 - 1.94 (m, 1H).
168	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.80 - 7.37 (m, 7H), 4.62 - 4.33 (m, 9H), 4.13 (d, J = 12.3 Hz, 6H), 3.83 (s, 2H), 3.37 (dd, J = 6.2, 5.1 Hz, 2H), 2.58 - 2.35 (m, 3H), 2.07 - 1.97 (m, 1H).
169	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.92 (d, J = 7.5 Hz, 1H), 7.79 - 7.30 (m, 7H), 4.61 - 4.48 (m, 3H), 4.38 (d, J = 13.2 Hz, 1H), 4.22 (dd, J = 10.6, 8.6 Hz, 1H), 4.13 (d, J = 11.1 Hz, 7H), 3.54 - 3.41 (m, 2H), 3.41 - 3.35 (m, 2H), 2.66 (ddt, J = 8.7, 6.5, 3.3 Hz, 1H), 2.54 - 2.35 (m, 3H), 2.33 - 2.18 (m, 1H), 2.06 - 1.96 (m, 1H).
170	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.77 - 7.31 (m, 7H), 4.65 - 4.46 (m, 2H), 4.31 (s, 2H), 4.20 - 3.97 (m, 10H), 3.88 (dd, J = 10.8, 5.7 Hz, 1H), 3.84 - 3.71 (m, 1H), 3.38 (dd, J = 6.2, 5.3 Hz, 2H), 2.56 - 2.34 (m, 4H), 2.22 - 1.96 (m, 2H).
171	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.71 (ddd, J = 19.1, 7.7, 1.7 Hz, 2H), 7.63 - 7.33 (m, 5H), 4.62 - 4.48 (m, 2H), 4.31 (s, 2H), 4.22 - 3.96 (m, 10H), 3.88 (dd, J = 10.8, 5.7 Hz, 1H), 3.83 - 3.70 (m, 1H), 3.37 (dd, J = 6.2, 5.2 Hz, 2H), 2.57 - 2.37 (m, 4H), 2.21 - 1.96 (m, 2H).

No.	NMR
172	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (d, J = 7.5 Hz, 2H), 7.74 (dt, J = 7.7, 1.6 Hz, 2H), 7.61 (td, J = 7.7, 1.1 Hz, 2H), 7.51 (dt, J = 7.6, 1.6 Hz, 2H), 4.62 - 4.48 (m, 2H), 4.45 (s, 2H), 4.24 - 4.05 (m, 8H), 3.43 - 3.35 (m, 2H), 3.27 (d, J = 7.4 Hz, 2H), 2.66 - 2.14 (m, 6H), 2.05 - 1.97 (m, 1H), 1.85 - 1.67 (m, 2H).
173	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 8.51 (s, 1H), 7.74 (ddd, J = 7.5, 5.6, 1.7 Hz, 2H), 7.60 (td, J = 7.7, 2.7 Hz, 2H), 7.51 (dt, J = 7.6, 1.7 Hz, 2H), 4.75 (d, J = 9.9 Hz, 4H), 4.64 - 4.49 (m, 2H), 4.41 (s, 3H), 4.27-4.03 (m, 7H), 3.39 (t, J = 5.3 Hz, 5H), 2.57 - 2.34 (m, 3H), 2.04 - 1.97 (m, 1H).
174	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (d, J = 2.2 Hz, 2H), 7.75 (dt, J = 7.7, 1.6 Hz, 2H), 7.61 (td, J = 7.6, 0.9 Hz, 2H), 7.51 (dt, J = 7.6, 1.5 Hz, 2H), 4.81 (d, J = 8.6 Hz, 1H), 4.71 (s, 1H), 4.62 - 4.47 (m, 2H), 4.19-4.04 (m, 7H), 4.07 - 3.47 (m, 3H), 3.42 - 3.34 (m, 2H), 3.29-3.11 (m, 1H), 2.57 - 1.97 (m, 6H), 1.49 (d, J = 1.6 Hz, 3H).
175	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 8.50 (d, J = 2.5 Hz, 1H), 7.73 (tt, J = 6.3, 1.6 Hz, 2H), 7.60 (td, J = 7.6, 3.0 Hz, 2H), 7.50 (dt, J = 7.6, 2.0 Hz, 2H), 4.70 (d, J = 19.7 Hz, 2H), 4.55 (d, J = 4.0 Hz, 2H), 4.53 - 4.43 (m, 1H), 4.26 - 4.06 (m, 9H), 4.02 (d, J = 10.7 Hz, 1H), 3.62 (s, 1H), 3.45 (s, 1H), 3.37 (dd, J = 6.2, 5.0 Hz, 2H), 2.60 - 2.35 (m, 3H), 2.13 - 1.93 (m, 1H), 1.35 (d, J = 32.2 Hz, 3H).
176	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 8.50 (s, 1H), 7.74 (ddd, J = 7.2, 5.3, 1.7 Hz, 2H), 7.60 (td, J = 7.7, 3.0 Hz, 2H), 7.50 (dt, J = 7.6, 2.0 Hz, 2H), 4.71 (d, J = 3.2 Hz, 2H), 4.59 - 4.22 (m, 6H), 4.19-4.07 (m, 7H), 3.79 (d, J = 4.3 Hz, 1H), 3.67 (d, J = 3.8 Hz, 1H), 3.43 - 3.37 (m, 2H), 3.27 - 3.03 (m, 1H), 2.60 - 2.33 (m, 3H), 2.04 - 1.94 (m, 1H).
177	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (d, J = 4.4 Hz, 2H), 7.74 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H), 5.25 (d, J = 53.4 Hz, 1H), 4.56 (d, J = 3.9 Hz, 2H), 4.50 (s, 2H), 4.22-4.10 (m, 7H), 4.03 - 3.85 (m, 1H), 3.45-3.35 (m, 2H), 2.71 - 1.78 (m, 10H).
178	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (d, J = 2.5 Hz, 2H), 7.75 (dd, J = 7.9, 1.7 Hz, 2H), 7.61 (t, J = 7.6 Hz, 2H), 7.51 (d, J = 7.5 Hz, 2H), 5.14-4.97 (m, 1H), 4.63 (d, J = 5.9 Hz, 2H), 4.55 (d, J = 3.8 Hz, 2H), 4.15 (s, 7H), 3.45-3.35 (m, 2H), 3.11-2.99 (m, 1H), 2.44 (q, J = 11.9, 10.7 Hz, 3H), 1.99 (d, J = 8.9 Hz, 1H), 1.64 - 1.24 (m, 2H).
179	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (d, J = 4.5 Hz, 2H), 7.75 (dd, J = 7.7, 1.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (dt, J = 7.6, 1.7 Hz, 2H), 4.64 - 4.44 (m, 4H), 4.21-4.08(m, 7H), 3.38 (t, J = 5.7 Hz, 2H), 3.13 (d, J = 7.6 Hz, 2H), 2.52 - 2.33 (m, 3H), 1.98 (dd, J = 11.8, 6.5 Hz, 1H), 1.29 - 1.12 (m, 1H), 0.84 - 0.71 (m, 2H), 0.49 (d, J = 5.0 Hz, 2H).

No.	NMR
185	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (s, 1H), 8.56 (s, 1H), 7.75 (t, J = 1.7 Hz, 1H), 7.73 (t, J = 1.7 Hz, 1H), 7.61 (t, J = 7.7 Hz, 2H), 7.52 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 1.7 Hz, 1H), 4.61 – 4.49 (m, 2H), 4.36 (s, 2H), 4.15 (m, 7H), 3.83 (s, 2H), 3.47 (s, 3H), 3.40 – 3.34 (m, 2H), 2.53 – 2.36 (m, 5H), 2.29 – 2.17 (m, 2H), 2.03 (dtd, J = 23.7, 9.1, 4.9 Hz, 3H).</p>
186	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (s, 1H), 8.55 (s, 1H), 7.75 (d, J = 1.7 Hz, 1H), 7.73 (d, J = 1.7 Hz, 1H), 7.61 (td, J = 7.6, 1.3 Hz, 2H), 7.52 (t, J = 2.0 Hz, 1H), 7.50 (t, J = 1.9 Hz, 1H), 4.55 (d, J = 4.1 Hz, 2H), 4.50 (d, J = 2.0 Hz, 2H), 4.15 (s, 3H), 4.14 (s, 5H), 3.95 (q, J = 7.4 Hz, 1H), 3.43 – 3.35 (m, 2H), 3.25 (m, 2H), 2.53 – 2.36 (m, 3H), 2.17 (dq, J = 15.7, 7.8 Hz, 1H), 2.02 (ddtd, J = 17.9, 13.6, 9.8, 9.2, 4.4 Hz, 3H), 1.85 (ddd, J = 13.2, 9.4, 5.0 Hz, 1H), 1.78 – 1.68 (m, 1H), 1.68 – 1.55 (m, 1H), 1.45 – 1.33 (m, 1H).</p>
187	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (s, 1H), 8.55 (s, 1H), 7.75 (t, J = 1.4 Hz, 1H), 7.73 (d, J = 1.5 Hz, 1H), 7.61 (td, J = 7.7, 1.1 Hz, 2H), 7.52 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 1.7 Hz, 1H), 4.74 (m, 1H), 4.66 – 4.49 (m, 2H), 4.19 (m, 1H), 4.15 (s, 3H), 4.13 (s, 3H), 4.00 (m, 2H), 3.84 (m, 1H), 3.69 (s, 1H), 3.41 – 3.34 (m, 2H), 2.53 – 2.36 (m, 3H), 1.99 (ddt, J = 14.3, 10.3, 4.7 Hz, 2H), 1.85 (td, J = 7.9, 4.2 Hz, 1H), 1.30 (m, 1H), 1.05 (m, 1H), 0.97 (m, 1H), 0.85 (m, 1H).</p>
188	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (s, 2H), 7.76 (t, J = 2.0 Hz, 1H), 7.74 (t, J = 2.0 Hz, 1H), 7.61 (t, J = 7.6 Hz, 2H), 7.52 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 1.7 Hz, 1H), 4.73 (s, 2H), 4.61 – 4.49 (m, 2H), 4.38 (s, 1H), 4.15 (s, 3H), 4.14 (s, 4H), 4.12 (d, J = 9.8 Hz, 1H), 4.05 (m, 1H), 3.93 (d, J = 23.2 Hz, 1H), 3.69 (s, 3H), 3.45 (m, 1H), 3.41 – 3.36 (m, 2H), 2.56 (m, 1H), 2.53 – 2.35 (m, 3H), 2.17 (s, 1H), 2.06 – 1.91 (m, 1H).</p>
189	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (s, 2H), 7.78 – 7.72 (m, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.56 – 7.46 (m, 2H), 4.53 (s, 4H), 4.44 (t, J = 8.8 Hz, 2H), 4.20 (t, J = 9.4 Hz, 2H), 4.15 (s, 6H), 4.06 (dd, J = 9.1, 5.5 Hz, 2H), 3.86 (dd, J = 10.3, 5.6 Hz, 2H), 3.54 (d, J = 7.5 Hz, 4H), 3.21 – 3.08 (m, 2H), 1.89 (s, 6H).</p>
190	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.54 (s, 2H), 7.74 (dd, J = 7.9, 1.8 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 7.7, 1.7 Hz, 2H), 4.37 (s, 4H), 4.32 (s, 2H), 4.23 (s, 2H), 4.14 (s, 6H), 4.08 (s, 2H), 3.99 (s, 2H), 3.93 (q, J = 8.2 Hz, 2H), 2.74 (dt, J = 12.6, 9.9 Hz, 4H), 2.53 (t, J = 10.8 Hz, 4H), 1.92 – 1.84 (m, 6H).</p>
191	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.57 (s, 1H), 8.56 (s, 1H), 7.75 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.52 (dd, J = 7.4, 1.7 Hz, 2H), 4.62 (d, J = 9.4 Hz, 2H), 4.56 (d, J = 3.9 Hz, 2H), 4.52 (s, 2H), 4.46 – 4.32 (m, 3H), 4.15 (s, 7H), 3.38 (d, J = 4.7 Hz, 2H), 2.44 (h, J = 7.4, 6.9 Hz, 3H), 2.06 – 1.97 (m, 1H), 1.95 (s, 3H).</p>

No.	NMR
192	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (s, 1H), 8.51 (s, 1H), 7.74 (t, J = 6.9 Hz, 2H), 7.61 (td, J = 7.6, 2.0 Hz, 2H), 7.56 – 7.47 (m, 2H), 4.73 (s, 2H), 4.62 (d, J = 17.1 Hz, 1H), 4.56 (d, J = 3.9 Hz, 2H), 4.49 (m, 2H), 4.28 (s, 1H), 4.15 (m, 5H), 4.14 (m, 5H), 3.39 (d, J = 4.7 Hz, 2H), 2.55 – 2.33 (m, 3H), 1.99 (q, J = 10.0 Hz, 1H), 1.89 (s, 3H).</p>
193	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.57 (d, J = 2.3 Hz, 2H), 7.75 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.52 (d, J = 7.6 Hz, 2H), 4.78 (d, J = 4.7 Hz, 2H), 4.56 (d, J = 3.8 Hz, 2H), 4.15 (s, 7H), 4.00 (s, 2H), 3.54 (m, 3H), 3.38 (m, 2H), 2.63 (d, J = 17.4 Hz, 1H), 2.55 – 2.34 (m, 3H), 2.27 (m, 3H), 1.99 (d, J = 8.1 Hz, 1H).</p>
194	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (d, J = 2.8 Hz, 2H), 7.78 – 7.71 (m, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H), 4.65 – 4.46 (m, 4H), 4.26 – 4.02 (m, 8H), 3.93 (dd, J = 13.1, 7.3 Hz, 1H), 3.79 (dd, J = 16.3, 10.4 Hz, 1H), 3.71 (t, J = 7.6 Hz, 1H), 3.37 (d, J = 2.5 Hz, 3H), 2.70 – 2.55 (m, 1H), 2.55 – 2.42 (m, 3H), 2.42 – 2.19 (m, 1H), 2.12 (d, J = 3.9 Hz, 3H), 1.99 (d, J = 9.4 Hz, 1H).</p>
195	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.57 (s, 1H), 8.55 (s, 1H), 7.75 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (d, J = 7.7 Hz, 2H), 4.56 (d, J = 3.9 Hz, 2H), 4.51 (s, 2H), 4.15 (s, 7H), 3.69 (s, 1H), 3.38 (d, J = 4.6 Hz, 2H), 2.44 (q, J = 11.8, 10.7 Hz, 3H), 2.31 (d, J = 12.5 Hz, 2H), 2.10 (d, J = 12.8 Hz, 2H), 1.99 (d, J = 8.0 Hz, 1H), 1.95 (s, 3H), 1.64 (q, J = 12.7 Hz, 2H), 1.39 (q, J = 15.5, 14.2 Hz, 3H).</p>
196	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.57 (s, 2H), 7.78 – 7.71 (m, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H), 4.56 (d, J = 4.0 Hz, 2H), 4.54 (s, 2H), 4.15 (s, 7H), 3.67 (dd, J = 10.3, 8.1 Hz, 1H), 3.38 (d, J = 4.1 Hz, 2H), 3.30 – 3.21 (m, 1H), 3.01 (p, J = 7.4 Hz, 1H), 2.63 (dd, J = 16.9, 8.8 Hz, 1H), 2.47 (td, J = 17.7, 16.9, 9.4 Hz, 3H), 2.32 (dd, J = 16.9, 7.5 Hz, 1H), 1.99 (d, J = 8.4 Hz, 1H).</p>
197	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.57 (d, J = 2.9 Hz, 2H), 7.75 (d, J = 7.6 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.52 (d, J = 7.7 Hz, 2H), 4.78 (s, 2H), 4.56 (d, J = 3.9 Hz, 2H), 4.21 – 4.11 (m, 7H), 4.02 (s, 5H), 3.38 (s, 1H), 2.46 (dd, J = 12.0, 7.4 Hz, 4H), 2.41 – 2.21 (m, 1H), 2.00 (d, J = 11.7 Hz, 1H).</p>
198	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.57 (s, 2H), 7.75 (d, J = 7.8 Hz, 2H), 7.61 (t, J = 7.8 Hz, 2H), 7.52 (d, J = 7.6 Hz, 2H), 4.73 (s, 1H), 4.55 (d, J = 3.7 Hz, 2H), 4.15 (d, J = 2.1 Hz, 7H), 3.37 (s, 1H), 2.45 (s, 3H), 2.18 (s, 1H), 2.01 (m, 5H).</p>
199	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.57 (s, 1H), 8.56 (s, 1H), 7.75 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.55 – 7.48 (m, 2H), 4.56 (d, J = 3.3 Hz, 4H), 4.35 (m, 1H), 4.21 – 4.04 (m, 7H), 3.92 (dd, J = 11.5, 7.7 Hz, 1H), 3.65 (dd, J = 11.6, 4.0 Hz, 1H), 3.38 (d, J = 4.6 Hz, 2H), 2.94 (dd, J = 17.7, 8.8 Hz, 1H), 2.66 (dd, J = 17.7, 4.9 Hz, 1H), 2.54 – 2.36 (m, 3H), 2.06 – 1.92 (m, 1H).</p>

No.	NMR
200	^1H NMR (400 MHz, Methanol- d_4) δ 8.57 (s, 1H), 8.56 (s, 1H), 7.75 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H), 4.62 – 4.50 (m, 4H), 4.35 (s, 1H), 4.15 (m, 7H), 3.92 (dd, J = 11.5, 7.7 Hz, 1H), 3.70 – 3.59 (m, 1H), 3.38 (d, J = 4.7 Hz, 2H), 2.93 (dd, J = 17.6, 8.7 Hz, 1H), 2.66 (dd, J = 17.7, 4.9 Hz, 1H), 2.55 – 2.34 (m, 3H), 2.00 (d, J = 12.4 Hz, 1H).
201	^1H NMR (400 MHz, Methanol- d_4) δ 8.56 (s, 1H), 8.54 (s, 1H), 7.79 – 7.71 (m, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.57 – 7.48 (m, 4H), 4.58 (s, 2H), 4.56 (d, J = 4.0 Hz, 2H), 4.15 (d, J = 1.9 Hz, 7H), 3.72 (t, J = 7.7 Hz, 2H), 3.59 (t, J = 7.7 Hz, 2H), 3.38 (t, J = 5.8 Hz, 2H), 2.55 – 2.34 (m, 3H), 2.02 (dd, J = 19.7, 9.9 Hz, 1H).
202	^1H NMR (400 MHz, Methanol- d_4) δ 8.56 (s, 1H), 8.55 (s, 1H), 7.75 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 7.3, 1.7 Hz, 2H), 4.56 (d, J = 3.9 Hz, 2H), 4.48 (s, 2H), 4.15 (m, 7H), 3.92 (s, 1H), 3.47 – 3.35 (m, 5H), 2.53 – 2.40 (m, 5H), 2.35 (dd, J = 15.0, 6.8 Hz, 1H), 1.97 (q, J = 12.1, 10.3 Hz, 2H), 1.88 (dd, J = 13.0, 8.8 Hz, 1H).
203	^1H NMR (400 MHz, Methanol- d_4) δ 8.61 (s, 1H), 8.57 (s, 1H), 7.76 (t, J = 6.8 Hz, 2H), 7.62 (t, J = 7.7 Hz, 2H), 7.52 (d, J = 7.6 Hz, 2H), 4.63 (s, 2H), 4.56 (d, J = 3.9 Hz, 2H), 4.15 (s, 6H), 3.77 (s, 2H), 3.38 (m, 2H), 2.53 – 2.37 (m, 5H), 2.21 (s, 1H), 2.09 (s, 8H), 1.98 (m, J = 9.0 Hz, 1H).
204	^1H NMR (400 MHz, Methanol- d_4) δ 8.57 (s, 2H), 7.75 (d, J = 7.3 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.56 – 7.48 (m, 2H), 4.74 (s, 1H), 4.56 (d, J = 3.9 Hz, 2H), 4.45 (s, 1H), 4.15 (d, J = 2.0 Hz, 6H), 4.06 (m, 1H), 4.00 – 3.77 (m, 1H), 3.59 (m, 1H), 3.38 (t, J = 5.6 Hz, 2H), 2.60 (s, 1H), 2.44 (q, J = 11.7, 10.6 Hz, 3H), 2.19 (s, 1H), 2.06 – 1.93 (m, 4H).
205	^1H NMR (400 MHz, Methanol- d_4) δ 8.56 (d, J = 3.3 Hz, 2H), 7.75 (dd, J = 7.7, 1.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H), 4.61 (d, J = 5.0 Hz, 1H), 4.58 (s, 2H), 4.56 (d, J = 3.8 Hz, 2H), 4.44 (d, J = 11.1 Hz, 1H), 4.30 (t, J = 14.4 Hz, 1H), 4.15 (d, J = 2.0 Hz, 6H), 3.78 (d, J = 13.9 Hz, 1H), 3.48 – 3.36 (m, 3H), 2.54 – 2.40 (m, 3H), 2.36 (d, J = 18.0 Hz, 2H), 2.20 (s, 1H), 2.17 (s, 3H), 2.08 – 1.94 (m, 1H), 1.90 (d, J = 11.9 Hz, 3H), 1.78 – 1.55 (m, 1H).
206	^1H NMR (400 MHz, Methanol- d_4) δ 8.56 (s, 1H), 8.56 (s, 1H), 7.75 (dd, J = 7.7, 1.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 7.6, 1.7 Hz, 2H), 4.72 (d, J = 14.2 Hz, 1H), 4.64 – 4.48 (m, 4H), 4.15 (d, J = 1.8 Hz, 8H), 3.67 – 3.54 (m, 1H), 3.38 (t, J = 5.7 Hz, 2H), 3.24 (t, J = 13.2 Hz, 1H), 2.72 (dd, J = 14.4, 11.7 Hz, 1H), 2.55 – 2.36 (m, 3H), 2.30 (t, J = 15.4 Hz, 2H), 2.16 (s, 3H), 1.99 (q, J = 10.1 Hz, 1H), 1.73 (tt, J = 12.2, 6.1 Hz, 1H), 1.65 – 1.54 (m, 1H).

No.	NMR
207	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.57 (s, 1H), 8.52 (s, 1H), 7.74 (t, J = 6.3 Hz, 2H), 7.66 – 7.58 (m, 2H), 7.51 (d, J = 7.6 Hz, 2H), 4.78 (s, 2H), 4.69 (s, 1H), 4.56 (d, J = 3.9 Hz, 2H), 4.39 (s, 1H), 4.15 (d, J = 1.8 Hz, 7H), 3.90 (s, 2H), 3.38 (d, J = 4.5 Hz, 2H), 2.53 – 2.32 (m, 3H), 2.06 – 1.93 (m, 1H).
208	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.57 (s, 1H), 8.54 (s, 1H), 7.74 (d, J = 7.5 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 8.0, 1.7 Hz, 2H), 4.56 (d, J = 3.9 Hz, 2H), 4.38 (s, 2H), 4.32 (s, 1H), 4.23 (s, 1H), 4.15 (s, 3H), 4.14 (s, 4H), 4.08 (s, 1H), 3.99 (s, 1H), 3.98 – 3.88 (m, 1H), 3.38 (d, 1H), 2.74 (m, 2H), 2.59 – 2.47 (m, 1H), 2.47 – 2.37 (m, 2H), 2.01 (m, 1H), 1.90 – 1.84 (m, 3H).
209	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.51 (s, 2H), 7.73 (d, J = 7.7 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H), 4.73 (s, 4H), 4.65 (s, 4H), 4.47 (m 8H), 4.23 (m, 4H), 4.14 (s, 6H), 1.89 (s, 6H).
221	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.55 (d, J = 8.4 Hz, 2H), 7.74 (dt, J = 7.7, 1.8 Hz, 2H), 7.61 (td, J = 7.6, 1.1 Hz, 2H), 7.51 (dt, J = 7.6, 1.5 Hz, 2H), 4.62 – 4.48 (m, 2H), 4.36 (s, 2H), 4.14 (d, J = 3.9 Hz, 6H), 3.85 (q, J = 8.1 Hz, 1H), 3.47 – 3.33 (m, 7H), 2.58 – 2.33 (m, 5H), 2.17 – 2.07 (m, 4H), 2.05 – 1.93 (m, 1H).
222	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.59 – 8.51 (m, 2H), 7.78 – 7.70 (m, 2H), 7.60 (td, J = 7.7, 1.5 Hz, 2H), 7.51 (dt, J = 7.6, 1.8 Hz, 2H), 4.62 – 4.45 (m, 4H), 4.15 (d, J = 1.2 Hz, 6H), 3.95 (q, J = 6.6, 6.1 Hz, 1H), 3.91 – 3.78 (m, 1H), 3.48 – 3.33 (m, 5H), 2.79 – 2.54 (m, 3H), 2.53 – 2.07 (m, 6H), 2.08 – 1.93 (m, 2H).
224	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.58 (d, J = 9.2 Hz, 2H), 7.75 (ddd, J = 7.3, 5.4, 1.7 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.55 – 7.48 (m, 2H), 5.02 (d, J = 15.6 Hz, 1H), 4.69 – 4.58 (m, 1H), 4.55 (d, J = 4.0 Hz, 2H), 4.15 (d, J = 3.1 Hz, 7H), 4.06 (d, J = 12.4 Hz, 1H), 4.02 – 3.87 (m, 3H), 3.51 – 3.45 (m, 1H), 3.40 – 3.34 (m, 4H), 2.63 – 2.47 (m, 2H), 2.50 – 2.36 (m, 4H), 2.05 – 1.94 (m, 2H).
225	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (s, 1H), 8.50 (d, J = 1.8 Hz, 1H), 7.74 (ddd, J = 7.4, 5.5, 1.8 Hz, 2H), 7.60 (td, J = 7.6, 2.9 Hz, 2H), 7.50 (dt, J = 7.6, 1.8 Hz, 2H), 4.76 (s, 1H), 4.67 (s, 1H), 4.62 – 4.44 (m, 3H), 4.31 – 4.23 (m, 2H), 4.14 (d, J = 7.7 Hz, 7H), 4.08 – 3.98 (m, 2H), 3.51 – 3.33 (m, 5H), 3.20 – 3.07 (m, 1H), 2.54 – 2.36 (m, 4H), 2.08 – 1.90 (m, 3H).
227	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (d, J = 1.0 Hz, 2H), 7.75 (dd, J = 7.7, 1.7 Hz, 2H), 7.61 (t, J = 7.6 Hz, 2H), 7.55 – 7.47 (m, 2H), 4.63 – 4.48 (m, 4H), 4.15 (d, J = 1.0 Hz, 6H), 3.90 – 3.53 (m, 4H), 3.49 – 3.33 (m, 3H), 3.28 – 3.18 (m, 1H), 2.85 – 2.65 (m, 1H), 2.54 – 2.36 (m, 4H), 2.28 (ddd, J = 24.7, 12.2, 5.2 Hz, 1H), 2.09 (d, J = 3.4 Hz, 3H), 2.08 – 1.96 (m, 1H), 1.99 – 1.76 (m, 1H).

No.	NMR
228	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (d, <i>J</i> = 7.3 Hz, 2H), 7.74 (dt, <i>J</i> = 7.6, 1.4 Hz, 2H), 7.61 (td, <i>J</i> = 7.7, 1.1 Hz, 2H), 7.51 (dt, <i>J</i> = 7.6, 1.6 Hz, 2H), 4.62 – 4.48 (m, 2H), 4.46 (s, 2H), 4.14 (d, <i>J</i> = 3.3 Hz, 7H), 3.87 (p, <i>J</i> = 7.2 Hz, 1H), 3.44 – 3.33 (m, 2H), 3.28 (d, <i>J</i> = 10.8 Hz, 5H), 2.63 – 2.21 (m, 6H), 2.08 – 1.93 (m, 1H), 1.82 – 1.69 (m, 2H).
229	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.58 (d, <i>J</i> = 13.1 Hz, 2H), 7.75 (ddd, <i>J</i> = 5.7, 4.6, 2.5 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.52 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.63 – 4.52 (m, 3H), 4.50 (d, <i>J</i> = 15.9 Hz, 1H), 4.14 (d, <i>J</i> = 3.0 Hz, 6H), 3.93 (s, 1H), 3.70 (d, <i>J</i> = 12.2 Hz, 1H), 3.62 (d, <i>J</i> = 12.2 Hz, 1H), 3.44 – 3.33 (m, 3H), 3.27 (d, <i>J</i> = 12.3 Hz, 2H), 2.54 – 2.33 (m, 3H), 2.15 – 1.93 (m, 2H), 1.86 (s, 1H), 1.72 (d, <i>J</i> = 14.3 Hz, 1H), 1.08 (d, <i>J</i> = 6.7 Hz, 3H).
231	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.58 (d, <i>J</i> = 15.0 Hz, 2H), 7.75 (ddd, <i>J</i> = 7.3, 5.4, 1.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.6 Hz, 2H), 7.51 (ddd, <i>J</i> = 7.6, 1.8, 0.8 Hz, 2H), 4.63 – 4.48 (m, 4H), 4.14 (d, <i>J</i> = 2.8 Hz, 7H), 3.78 (d, <i>J</i> = 12.5 Hz, 1H), 3.67 (d, <i>J</i> = 12.6 Hz, 1H), 3.49 – 3.33 (m, 3H), 2.99 (t, <i>J</i> = 12.5 Hz, 1H), 2.54 – 2.36 (m, 4H), 2.23 – 2.15 (m, 1H), 2.08 – 1.80 (m, 3H), 1.11 (d, <i>J</i> = 6.5 Hz, 3H).
232	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.57 (d, <i>J</i> = 4.2 Hz, 2H), 7.75 (dt, <i>J</i> = 7.6, 1.8 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 4.82 (d, <i>J</i> = 9.3 Hz, 2H), 4.63 – 4.48 (m, 2H), 4.49 – 4.37 (m, 2H), 4.15 (s, 6H), 3.74 – 3.64 (m, 5H), 3.44 – 3.32 (m, 4H), 2.55 – 2.35 (m, 4H), 2.08 – 1.93 (m, 2H).
234	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 1H), 8.51 (s, 1H), 7.74 (ddd, <i>J</i> = 7.5, 5.5, 1.8 Hz, 2H), 7.60 (td, <i>J</i> = 7.7, 2.2 Hz, 2H), 7.55 – 7.47 (m, 2H), 4.76 (d, <i>J</i> = 10.4 Hz, 3H), 4.62 – 4.45 (m, 4H), 4.34 (t, <i>J</i> = 10.9 Hz, 2H), 4.14 (d, <i>J</i> = 4.1 Hz, 6H), 4.03 (s, 1H), 3.94 (s, 1H), 3.90 – 3.82 (m, 2H), 3.41 – 3.33 (m, 3H), 2.52 – 2.36 (m, 3H), 2.31 (s, 1H), 2.05 – 1.93 (m, 1H).
235	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (d, <i>J</i> = 5.3 Hz, 2H), 7.74 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (ddd, <i>J</i> = 7.6, 1.7, 0.8 Hz, 2H), 4.62 – 4.48 (m, 4H), 4.15 (d, <i>J</i> = 1.4 Hz, 6H), 3.61 (dd, <i>J</i> = 10.0, 7.7 Hz, 1H), 3.44 – 3.33 (m, 3H), 3.26 (t, <i>J</i> = 8.1 Hz, 2H), 3.13 (d, <i>J</i> = 10.0 Hz, 1H), 2.68 – 2.45 (m, 3H), 2.50 – 2.34 (m, 2H), 2.25 – 2.07 (m, 1H), 2.07 – 1.90 (m, 3H).
236	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (d, <i>J</i> = 9.4 Hz, 2H), 7.74 (ddd, <i>J</i> = 7.7, 1.7, 0.9 Hz, 2H), 7.61 (td, <i>J</i> = 7.6, 1.3 Hz, 2H), 7.51 (dt, <i>J</i> = 7.6, 1.8 Hz, 2H), 4.62 – 4.48 (m, 2H), 4.48 (d, <i>J</i> = 1.7 Hz, 2H), 4.14 (d, <i>J</i> = 2.5 Hz, 7H), 4.15 – 3.91 (m, 2H), 3.80 (td, <i>J</i> = 7.9, 6.4 Hz, 1H), 3.44 – 3.33 (m, 4H), 2.54 – 2.33 (m, 4H), 2.21 – 1.87 (m, 5H), 1.61 (dq, <i>J</i> = 12.1, 7.9 Hz, 1H)

No.	NMR
237	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (d, <i>J</i> = 10.7 Hz, 2H), 7.74 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.61 (td, <i>J</i> = 7.7, 1.2 Hz, 2H), 7.51 (dt, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.69 (d, <i>J</i> = 16.2 Hz, 1H), 4.62 – 4.48 (m, 3H), 4.15 (d, <i>J</i> = 2.2 Hz, 6H), 3.97 (dt, <i>J</i> = 10.1, 5.0 Hz, 1H), 3.86 (ddd, <i>J</i> = 10.6, 8.3, 4.6 Hz, 1H), 3.45 – 3.33 (m, 2H), 2.94 – 2.83 (m, 1H), 2.68 (s, 1H), 2.54 – 2.33 (m, 3H), 2.18 – 2.03 (m, 1H), 2.05 – 1.93 (m, 1H), 1.18 – 1.05 (m, 1H), 0.86 (s, 2H), 0.91 – 0.75 (m, 1H), 0.67 (dq, <i>J</i> = 8.8, 4.7 Hz, 1H), 0.45 (dq, <i>J</i> = 10.2, 4.7 Hz, 1H).
261	8.57 (s, 1H), 8.52 (s, 1H), 7.72 (td, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.58 (td, <i>J</i> = 7.7, 1.5 Hz, 2H), 7.48 (dt, <i>J</i> = 7.6, 1.6 Hz, 2H), 4.63 (d, <i>J</i> = 7.3 Hz, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.12 (d, <i>J</i> = 1.2 Hz, 7H), 3.99 (s, 1H), 3.79 – 3.53 (m, 3H), 3.35 (t, <i>J</i> = 5.9 Hz, 2H), 2.52 – 1.64 (m, 7H), 1.37 (dd, <i>J</i> = 6.7, 3.6 Hz, 2H).
265	δ 8.53 (d, <i>J</i> = 7.1 Hz, 2H), 7.72 (ddd, <i>J</i> = 7.7, 3.0, 1.7 Hz, 2H), 7.58 (t, <i>J</i> = 7.6 Hz, 2H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 5.20 (d, <i>J</i> = 50.4 Hz, 1H), 4.79 (d, <i>J</i> = 2.5 Hz, 2H), 4.63 – 4.45 (m, 4H), 4.11 (d, <i>J</i> = 2.2 Hz, 7H), 3.35 (t, <i>J</i> = 5.9 Hz, 2H), 2.56 – 2.30 (m, 3H), 2.03 – 1.88 (m, 1H).
270	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.57 (s, 1H), 8.52 (s, 1H), 7.72 (td, <i>J</i> = 7.5, 1.7 Hz, 2H), 7.58 (td, <i>J</i> = 7.6, 1.5 Hz, 2H), 7.48 (dt, <i>J</i> = 7.6, 1.8 Hz, 2H), 5.08 (d, <i>J</i> = 45.1 Hz, 1H), 4.71 – 4.55 (m, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.12 (d, <i>J</i> = 0.8 Hz, 8H), 3.93 (s, 0H), 3.67 (s, 1H), 3.35 (t, <i>J</i> = 5.9 Hz, 2H), 2.54 – 2.32 (m, 3H), 2.21 (dd, <i>J</i> = 30.9, 17.5 Hz, 2H), 2.03 – 1.81 (m, 3H).
274	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 5.6 Hz, 2H), 7.71 (dt, <i>J</i> = 7.7, 1.5 Hz, 2H), 7.57 (td, <i>J</i> = 7.7, 0.6 Hz, 2H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.35 (s, 2H), 4.11 (d, <i>J</i> = 2.3 Hz, 7H), 3.67 – 3.56 (m, 1H), 3.43 – 3.33 (m, 2H), 2.59 – 2.26 (m, 7H), 2.05 – 1.88 (m, 1H), 1.39 (s, 3H).
275	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 4.3 Hz, 2H), 7.71 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.57 (td, <i>J</i> = 7.7, 0.7 Hz, 2H), 7.48 (ddd, <i>J</i> = 7.6, 1.7, 0.7 Hz, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.44 (s, 2H), 4.37 (td, <i>J</i> = 6.6, 6.1, 1.0 Hz, 1H), 4.11 (d, <i>J</i> = 2.1 Hz, 8H), 3.41 – 3.32 (m, 2H), 2.69 (tt, <i>J</i> = 8.6, 4.4 Hz, 1H), 2.51 – 2.33 (m, 3H), 2.31 – 2.12 (m, 4H), 2.03 – 1.89 (m, 1H), 1.36 (dd, <i>J</i> = 6.7, 3.5 Hz, 1H).
283	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.53 (d, 2H), 7.71 (dt, <i>J</i> = 7.7, 1.5 Hz, 2H), 7.58 (t, <i>J</i> = 7.7 Hz, 2H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 5.35 (t, <i>J</i> = 4.7 Hz, 1H), 5.21 (t, <i>J</i> = 4.7 Hz, 1H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.39 (s, 2H), 4.27 – 4.17 (m, 1H), 4.12 (d, <i>J</i> = 2.3 Hz, 6H), 3.35 (d, <i>J</i> = 4.6 Hz, 2H), 2.79 – 2.60 (m, 4H), 2.51 – 2.34 (m, 3H), 2.02 – 1.86 (m, 1H).
286	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (d, <i>J</i> = 3.0 Hz, 2H), 7.72 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.58 (t, <i>J</i> = 7.7 Hz, 2H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.53 (t, <i>J</i> = 1.9 Hz, 4H), 4.12 (s, 6H), 3.55 – 3.24 (m, 10H), 2.52 – 2.31 (m, 4H), 2.03 – 1.90 (m, 2H). ¹⁹ F NMR (376 MHz, Methanol- <i>d</i> ₄) δ -77.66

No.	NMR
287	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.54 (d, J = 9.1 Hz, 2H), 7.73 (ddd, J = 9.0, 7.7, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.80 (d, J = 14.9 Hz, 1H), 4.69 (d, J = 9.2 Hz, 1H), 4.60 – 4.46 (m, 2H), 4.12 (d, J = 3.3 Hz, 6H), 3.78 (s, 1H), 3.67 (dd, J = 10.7, 7.4 Hz, 1H), 3.59 (s, 1H), 3.46 – 3.31 (m, 3H), 3.27 (dd, J = 10.6, 1.7 Hz, 1H), 2.64 – 2.50 (m, 1H), 2.52 – 2.31 (m, 3H), 2.07 – 1.90 (m, 2H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.67</p>
288	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 – 8.47 (m, 2H), 7.71 (ddd, J = 7.7, 3.2, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 2.2 Hz, 2H), 7.48 (ddd, J = 7.6, 2.9, 1.7 Hz, 2H), 4.60 – 4.44 (m, 3H), 4.34 (s, 2H), 4.12 (d, J = 3.4 Hz, 6H), 3.98 (s, 2H), 3.42 – 3.31 (m, 2H), 2.82 (s, 2H), 2.52 – 2.31 (m, 3H), 2.03 – 1.90 (m, 2H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.60 (d, J = 5.2 Hz).</p>
289	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (s, 1H), 8.47 (s, 1H), 7.70 (ddd, J = 8.1, 6.6, 1.7 Hz, 2H), 7.57 (td, J = 7.7, 2.6 Hz, 2H), 7.51 – 7.44 (m, 2H), 4.65 (s, 2H), 4.60 – 4.36 (m, 4H), 4.27 – 4.15 (m, 2H), 4.18 – 4.07 (m, 7H), 3.42 – 3.31 (m, 2H), 2.79 – 2.71 (m, 2H), 2.65 – 2.57 (m, 2H), 2.52 – 2.31 (m, 3H), 2.28 – 2.12 (m, 2H), 2.05 – 1.90 (m, 2H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.70</p>
290	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (d, J = 19.7 Hz, 2H), 7.73 (ddd, J = 8.4, 6.8, 1.7 Hz, 2H), 7.59 (td, J = 7.7, 1.9 Hz, 2H), 7.49 (dt, J = 7.6, 2.0 Hz, 2H), 4.63 (s, 2H), 4.60 – 4.46 (m, 4H), 4.13 (d, J = 3.4 Hz, 4H), 3.89 (dd, J = 12.6, 5.0 Hz, 2H), 3.42 – 3.31 (m, 2H), 2.52 – 2.33 (m, 4H), 2.14 (s, 2H), 2.03 – 1.90 (m, 2H), 0.09 (s, 2H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.55.</p>
291	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (d, J = 6.2 Hz, 2H), 7.72 (dt, J = 7.7, 2.0 Hz, 2H), 7.58 (td, J = 7.7, 1.9 Hz, 2H), 7.48 (dt, J = 7.5, 1.4 Hz, 2H), 4.51 (dd, J = 14.8, 5.7 Hz, 4H), 4.11 (d, J = 8.2 Hz, 7H), 3.55 (d, J = 12.4 Hz, 1H), 3.45 – 3.31 (m, 4H), 2.52 – 2.33 (m, 3H), 2.30 (d, J = 18.8 Hz, 2H), 2.22 (d, J = 12.3 Hz, 2H), 2.11 (s, 2H), 2.03 – 1.88 (m, 2H), 1.78 (d, J = 13.5 Hz, 2H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.66</p>
292	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.54 (d, J = 2.4 Hz, 2H), 7.72 (dt, J = 7.7, 1.8 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.79 (d, J = 1.4 Hz, 2H), 4.64 – 4.46 (m, 2H), 4.12 (d, J = 0.7 Hz, 6H), 4.02 (s, 1H), 3.87 (s, 2H), 3.78 (s, 1H), 3.65 (s, 1H), 3.42 – 3.31 (m, 2H), 2.66 (dt, J = 14.3, 7.2 Hz, 1H), 2.52 – 2.31 (m, 4H), 2.05 – 1.90 (m, 1H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.66.</p>
293	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (d, J = 3.2 Hz, 2H), 7.72 (ddd, J = 7.6, 4.6, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 1.8 Hz, 2H), 7.48 (dt, J = 7.6, 2.1 Hz, 2H), 4.53 (d, J = 3.9 Hz, 3H), 4.12 (d, J = 4.6 Hz, 7H), 3.67 (s, 2H), 3.45 – 3.31 (m, 5H), 2.52 – 2.31 (m, 3H), 2.09 (s, 3H), 2.03 – 1.89 (m, 2H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.60</p>

No.	NMR
294	<p>1H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 1.2 Hz, 2H), 7.72 (dt, J = 7.7, 1.4 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.7, 1.7 Hz, 2H), 4.79 (s, 2H), 4.60 – 4.46 (m, 2H), 4.12 (d, J = 1.0 Hz, 7H), 4.00 (s, 1H), 3.88 (s, 2H), 3.75 (s, 2H), 3.42 – 3.31 (m, 3H), 2.99 (s, 3H), 2.64 (dt, J = 14.3, 7.2 Hz, 1H), 2.52 – 2.31 (m, 2H), 2.03 – 1.90 (m, 2H). ¹⁹F NMR (376 MHz, Methanol-d4) δ -77.57</p>
295	<p>1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 2H), 7.72 (dd, J = 7.7, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.60 – 4.49 (m, 3H), 4.51 – 4.40 (m, 1H), 4.12 (d, J = 2.8 Hz, 7H), 4.12 – 4.00 (m, 1H), 3.97 (dq, J = 8.6, 4.7, 3.8 Hz, 1H), 3.82 – 3.68 (m, 1H), 3.42 – 3.31 (m, 3H), 2.56 – 2.31 (m, 2H), 2.30 – 2.16 (m, 1H), 2.03 – 1.90 (m, 1H), 1.47 (d, J = 6.6 Hz, 2H). ¹⁹F NMR (376 MHz, Methanol-d4) δ -77.55.</p>
296	<p>1H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 2.4 Hz, 2H), 7.75 – 7.68 (m, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (ddd, J = 7.6, 2.0, 0.8 Hz, 2H), 4.60 – 4.43 (m, 4H), 4.12 (dd, J = 1.3, 0.6 Hz, 7H), 3.97 – 3.87 (m, 2H), 3.84 – 3.73 (m, 1H), 3.62 (dd, J = 9.0, 5.7 Hz, 1H), 3.42 – 3.15 (m, 4H), 2.71 (hept, J = 7.0 Hz, 1H), 2.52 – 2.31 (m, 3H), 2.23 (dtd, J = 12.9, 7.9, 5.0 Hz, 1H), 2.03 – 1.90 (m, 1H), 1.76 (dq, J = 14.0, 7.3 Hz, 1H). ¹⁹F NMR (376 MHz, Methanol-d4) δ -77.54.</p>
297	<p>1H NMR (400 MHz, Methanol-d4) δ 8.55 (d, J = 14.9 Hz, 2H), 7.73 (ddd, J = 7.6, 5.8, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 1.6 Hz, 2H), 7.49 (dt, J = 7.6, 2.0 Hz, 2H), 4.59 (d, J = 9.5 Hz, 2H), 4.55 – 4.46 (m, 3H), 4.29 (ddt, J = 12.0, 8.7, 2.7 Hz, 2H), 4.22 – 4.06 (m, 5H), 3.92 – 3.80 (m, 2H), 3.73 (q, J = 8.4 Hz, 2H), 3.42 – 3.31 (m, 4H), 2.99 (s, 3H), 2.52 – 2.27 (m, 3H), 2.03 – 1.90 (m, 1H). Multiplet Report ¹⁹F NMR (376 MHz, Methanol-d4) δ -77.54.</p>
298	<p>1H NMR (400 MHz, Methanol-d4) δ 8.54 (d, J = 4.5 Hz, 2H), 7.72 (dt, J = 7.6, 2.0 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.49 (dd, J = 7.5, 1.7 Hz, 2H), 4.70 – 4.57 (m, 2H), 4.53 (d, J = 3.9 Hz, 2H), 4.38 (dd, J = 11.0, 6.4 Hz, 1H), 4.18 – 4.06 (m, 6H), 3.96 (d, J = 11.8 Hz, 1H), 3.90 – 3.73 (m, 1H), 3.52 (dd, J = 11.2, 6.1 Hz, 2H), 3.42 – 3.32 (m, 1H), 3.36 – 3.20 (m, 3H), 2.54 – 2.38 (m, 1H), 2.40 – 2.19 (m, 1H), 2.18 – 2.07 (m, 0H), 2.07 – 1.91 (m, 2H). ¹⁹F NMR (376 MHz, Methanol-d4) δ -77.31 (d, J = 7.5 Hz), -77.59</p>
299	<p>1H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 2.4 Hz, 2H), 7.75 – 7.68 (m, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (ddd, J = 7.6, 2.0, 0.8 Hz, 2H), 4.60 – 4.43 (m, 4H), 4.12 (dd, J = 1.3, 0.6 Hz, 7H), 3.97 – 3.87 (m, 2H), 3.84 – 3.73 (m, 1H), 3.62 (dd, J = 9.0, 5.7 Hz, 1H), 3.42 – 3.15 (m, 4H), 2.71 (hept, J = 7.0 Hz, 1H), 2.52 – 2.31 (m, 3H), 2.23 (dtd, J = 12.9, 7.9, 5.0 Hz, 1H), 2.03 – 1.90 (m, 1H), 1.76 (dq, J = 14.0, 7.3 Hz, 1H). ¹⁹F NMR (376 MHz, Methanol-d4) δ -77.54.</p>

No.	NMR
300	<p>¹H (400 MHz, Methanol-d₄) δ 8.55 (d, J = 14.9 Hz, 2H), 7.73 (ddd, J = 7.6, 5.8, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 1.6 Hz, 2H), 7.49 (dt, J = 7.6, 2.0 Hz, 2H), 4.59 (d, J = 9.5 Hz, 2H), 4.55 – 4.46 (m, 2H), 4.29 (ddt, J = 12.0, 8.7, 2.7 Hz, 2H), 4.22 – 4.06 (m, 5H), 3.92 – 3.80 (m, 4H), 3.73 (q, J = 8.4 Hz, 3H), 3.42 – 3.31 (m, 2H), 2.99 (s, 3H), 2.52 – 2.27 (m, 2H), 2.03 – 1.90 (m, 1H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.54.</p>
301	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.51 (d, J = 16.6 Hz, 2H), 7.71 (ddd, J = 7.7, 4.2, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 2.0 Hz, 2H), 7.48 (ddd, J = 7.6, 1.7, 0.7 Hz, 2H), 4.89 (d, J = 12.5 Hz, 2H), 4.76 (s, 2H), 4.65 (d, J = 12.5 Hz, 2H), 4.60 – 4.46 (m, 2H), 4.17 – 4.06 (m, 8H), 3.42 – 3.31 (m, 3H), 2.57 – 2.48 (m, 2H), 2.52 – 2.31 (m, 3H), 2.03 – 1.90 (m, 1H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.56.</p>
302	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (d, J = 5.5 Hz, 2H), 7.72 (ddd, J = 7.6, 1.8, 0.8 Hz, 2H), 7.58 (td, J = 7.7, 1.2 Hz, 2H), 7.48 (dt, J = 7.6, 1.7 Hz, 2H), 4.59 – 4.45 (m, 4H), 4.12 (d, J = 3.9 Hz, 6H), 4.01 (s, 2H), 3.65 (s, 2H), 3.34 (s, 2H), 2.49 – 2.35 (m, 2H), 1.29 (s, 0H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.47.</p>
303	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.54 (d, J = 2.0 Hz, 2H), 7.72 (dt, J = 7.7, 1.8 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.49 (dd, J = 7.6, 1.7 Hz, 2H), 4.60 – 4.46 (m, 4H), 4.13 (d, J = 1.4 Hz, 7H), 3.53 (dd, J = 12.9, 3.2 Hz, 1H), 3.46 – 3.31 (m, 4H), 2.90 (s, 3H), 2.58 – 2.45 (m, 1H), 2.42 (ddtt, J = 17.2, 13.8, 6.8, 3.2 Hz, 5H), 2.14 – 1.90 (m, 2H), 1.31 (d, J = 16.8 Hz, 1H). Multiplet Report ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.60.</p>
304	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (d, J = 5.8 Hz, 2H), 7.72 (dd, J = 7.7, 1.7 Hz, 2H), 7.58 (td, J = 7.6, 1.5 Hz, 2H), 7.48 (dt, J = 7.7, 2.1 Hz, 2H), 4.53 (d, J = 3.9 Hz, 3H), 4.28 – 4.17 (m, 1H), 4.12 (d, J = 4.7 Hz, 6H), 4.02 (dd, J = 12.0, 5.6 Hz, 1H), 3.41 – 3.31 (m, 3H), 2.50 – 2.33 (m, 3H), 2.03 – 1.90 (m, 1H), 1.29 (s, 1H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.58.</p>
305	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (d, J = 9.4 Hz, 2H), 7.81 – 7.67 (m, 2H), 7.58 (td, J = 7.7, 1.4 Hz, 2H), 7.48 (dt, J = 7.7, 2.0 Hz, 4H), 6.43 (t, J = 6.9 Hz, 2H), 4.60 – 4.45 (m, 2H), 4.31 (s, 3H), 4.12 (d, J = 6.7 Hz, 9H), 3.61 (s, 4H), 3.35 (q, J = 3.7, 3.3 Hz, 4H), 2.50 – 2.33 (m, 4H), 2.03 – 1.90 (m, 3H). Multiplet Report ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.58.</p>
306	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (d, J = 5.0 Hz, 2H), 7.72 (dd, J = 7.7, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 1.0 Hz, 2H), 7.48 (dt, J = 7.6, 1.7 Hz, 2H), 4.60 – 4.44 (m, 4H), 4.12 (d, J = 0.9 Hz, 8H), 3.44 – 3.31 (m, 4H), 3.28 (d, J = 2.5 Hz, 1H), 3.05 (ddd, J = 12.8, 11.0, 9.0 Hz, 1H), 2.73 (dtd, J = 13.5, 8.8, 2.5 Hz, 1H), 2.52 – 2.33 (m, 3H), 2.21 – 2.04 (m, 1H), 2.03 – 1.90 (m, 1H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.57.</p>

No.	NMR
307	<p>1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 8.48 (s, 1H), 7.71 (ddd, J = 8.1, 6.5, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 2.8 Hz, 2H), 7.48 (dt, J = 7.6, 1.5 Hz, 2H), 4.66 (s, 2H), 4.55 (d, J = 16.5 Hz, 1H), 4.55 – 4.41 (m, 3H), 4.31 – 4.22 (m, 4H), 4.11 (d, J = 8.0 Hz, 8H), 3.42 – 3.31 (m, 3H), 2.52 – 2.27 (m, 6H), 2.05 – 1.90 (m, 2H). 19F NMR (376 MHz, Methanol-d4) δ -77.81.</p>
308	<p>1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 8.48 (s, 1H), 7.71 (ddd, J = 7.7, 6.1, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 2.7 Hz, 2H), 7.48 (ddd, J = 7.6, 1.8, 1.0 Hz, 2H), 4.67 (s, 2H), 4.60 – 4.43 (m, 4H), 4.33 (d, J = 10.4 Hz, 1H), 4.11 (d, J = 7.8 Hz, 6H), 3.42 – 3.31 (m, 2H), 2.86 (d, J = 13.7 Hz, 1H), 2.77 (d, J = 14.0 Hz, 2H), 2.55 (d, J = 13.9 Hz, 2H), 2.52 – 2.32 (m, 3H), 2.05 – 1.90 (m, 2H). 19F NMR (376 MHz, Methanol-d4) δ -77.81, -86.45.</p>
309	<p>1H NMR (400 MHz, Methanol-d4) δ 8.52 (d, J = 13.9 Hz, 2H), 7.71 (ddd, J = 7.7, 3.2, 1.8 Hz, 2H), 7.58 (td, J = 7.7, 1.3 Hz, 2H), 7.48 (dt, J = 7.6, 1.2 Hz, 2H), 4.79 – 4.61 (m, 2H), 4.60 – 4.46 (m, 2H), 4.35 (td, J = 10.0, 5.4 Hz, 1H), 4.12 (d, J = 3.9 Hz, 7H), 3.82 – 3.66 (m, 2H), 3.42 (s, 3H), 3.42 – 3.31 (m, 2H), 2.63 – 2.52 (m, 1H), 2.54 – 2.41 (m, 2H), 2.45 – 2.31 (m, 2H), 2.05 – 1.90 (m, 2H). Multiplet Report 19F NMR (376 MHz, Methanol-d4) δ -77.82.</p>
310	<p>1H NMR (400 MHz, Methanol-d4) δ 8.52 (d, J = 13.9 Hz, 2H), 7.71 (ddd, J = 7.7, 3.2, 1.8 Hz, 2H), 7.58 (td, J = 7.7, 1.3 Hz, 2H), 7.48 (dt, J = 7.6, 1.2 Hz, 2H), 4.79 – 4.61 (m, 2H), 4.60 – 4.46 (m, 2H), 4.35 (td, J = 10.0, 5.4 Hz, 1H), 4.12 (d, J = 3.9 Hz, 7H), 3.82 – 3.66 (m, 2H), 3.42 (s, 3H), 3.42 – 3.31 (m, 2H), 2.63 – 2.52 (m, 1H), 2.54 – 2.41 (m, 2H), 2.45 – 2.31 (m, 2H), 2.05 – 1.90 (m, 2H). Multiplet Report 19F NMR (376 MHz, Methanol-d4) δ -77.82.</p>
311	<p>1H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 2.0 Hz, 2H), 7.72 (dd, J = 7.7, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.8 Hz, 2H), 4.60 – 4.46 (m, 4H), 4.45 – 4.34 (m, 2H), 4.15 – 4.03 (m, 8H), 3.58 (d, J = 7.5 Hz, 2H), 3.42 – 3.31 (m, 2H), 3.12 – 2.99 (m, 2H), 2.50 – 2.33 (m, 2H), 2.05 – 1.90 (m, 2H). 19F NMR (376 MHz, Methanol-d4) δ -77.83</p>
312	<p>1H NMR (400 MHz, Methanol-d4) δ 8.54 (d, J = 5.1 Hz, 2H), 7.72 (dt, J = 7.7, 2.0 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.49 (dt, J = 7.6, 1.5 Hz, 2H), 4.71 (s, 2H), 4.53 (d, J = 3.9 Hz, 2H), 4.12 (d, J = 2.5 Hz, 7H), 3.73 (s, 2H), 3.44 (s, 1H), 3.35 (dd, J = 6.2, 5.1 Hz, 2H), 2.78 (dd, J = 18.0, 10.2 Hz, 1H), 2.52 – 2.40 (m, 1H), 2.42 (s, 2H), 2.44 – 2.32 (m, 2H), 2.05 – 1.90 (m, 2H). 19F NMR (376 MHz, Methanol-d4) δ -77.71.</p>
313	<p>1H NMR (400 MHz, Methanol-d4) δ 8.51 (d, J = 18.6 Hz, 2H), 7.71 (ddd, J = 7.7, 4.0, 1.7 Hz, 2H), 7.58 (td, J = 7.7, 1.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.84 (s, 6H), 4.60 – 4.46 (m, 2H), 4.12 (d, J = 2.0 Hz, 4H), 3.35 (dd, J = 6.2, 5.2 Hz, 1H), 2.52 – 2.31 (m, 2H), 2.05 – 1.90 (m, 1H). Multiplet Report 19F NMR (376 MHz, Methanol-d4) δ -77.85.</p>

No.	NMR
314	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (d, J = 4.4 Hz, 2H), 7.72 (ddd, J = 7.7, 1.7, 0.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.7, 1.7 Hz, 2H), 4.60 – 4.46 (m, 4H), 4.12 (d, J = 0.8 Hz, 2H), 3.78 (q, J = 6.6 Hz, 2H), 3.42 – 3.31 (m, 2H), 3.26 (dd, J = 10.2, 6.4 Hz, 4H), 2.52 – 2.28 (m, 4H), 2.09 – 1.90 (m, 4H), 1.87 – 1.76 (m, 2H), 1.28 (s, 1H). Multiplet Report 19F NMR (376 MHz, Methanol-d ₄) δ -77.68.
315	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.55 (d, J = 7.1 Hz, 2H), 7.74 (dt, J = 7.8, 1.7 Hz, 2H), 7.60 (td, J = 7.6, 1.3 Hz, 2H), 7.51 (dt, J = 7.6, 1.7 Hz, 2H), 4.82 (d, J = 6.8 Hz, 1H), 4.54 (d, J = 4.0 Hz, 2H), 4.15 (s, 6H), 3.36 (s, 1H), 2.51 – 2.32 (m, 5H), 1.99 (d, J = 7.8 Hz, 1H), 1.66 (d, J = 6.8 Hz, 3H).
316	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (d, J = 7.0 Hz, 2H), 7.74 (dt, J = 7.8, 1.7 Hz, 2H), 7.58 (td, J = 7.6, 1.3 Hz, 2H), 7.50 (dt, J = 7.6, 1.8 Hz, 2H), 4.82 (d, J = 6.8 Hz, 1H), 4.54 (d, J = 4.0 Hz, 2H), 4.16 (s, 6H), 3.37 (s, 1H), 2.51 – 2.31 (m, 5H), 2.01 (d, J = 7.7 Hz, 1H), 1.66 (d, J = 6.8 Hz, 3H).
317	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.54 (s, 2H), 7.74 (dd, J = 7.7, 1.7 Hz, 2H), 7.60 (t, J = 7.6 Hz, 2H), 7.50 (dd, J = 7.6, 1.8 Hz, 2H), 4.15 – 4.06 (m, 6H), 3.50 (t, J = 1.7 Hz, 2H), 3.37 (s, 6H), 3.15 (t, J = 1.7 Hz, 2H), 2.44 – 2.36 (m, 4H), 2.03 (s, 4H), 1.35 (d, J = 6.6 Hz, 4H).
318	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.54 (d, J = 14.3 Hz, 2H), 7.74 (ddd, J = 7.7, 3.4, 1.7 Hz, 2H), 7.60 (td, J = 7.7, 2.3 Hz, 2H), 7.50 (ddd, J = 7.6, 3.3, 1.7 Hz, 2H), 4.55 (d, J = 4.1 Hz, 2H), 4.37 (s, 2H), 4.14 (d, J = 3.7 Hz, 6H), 3.37 (d, J = 6.7 Hz, 1H), 3.01 (s, 1H), 2.88 (d, J = 0.7 Hz, 1H), 2.72 (s, 1H), 2.46 – 2.42 (m, 2H), 1.99 (d, J = 7.9 Hz, 1H).
319	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.07 (s, 2H), 7.69 (dd, J = 7.7, 1.8 Hz, 2H), 7.52 (t, J = 7.6 Hz, 2H), 7.40 (dd, J = 7.6, 1.8 Hz, 2H), 4.39 – 4.26 (m, 4H), 4.19 – 3.99 (m, 2H), 3.38 – 3.26 (m, 4H), 3.15 (s, 6H), 3.03 (s, 6H), 2.52 – 2.29 (m, 6H), 2.07 – 1.92 (m, 2H).
320	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.07 (s, 2H), 7.64 (dd, J = 7.7, 1.8 Hz, 2H), 7.52 (t, J = 7.6 Hz, 2H), 7.42 (dd, J = 7.6, 1.8 Hz, 2H), 4.39 – 4.24 (m, 4H), 4.19 – 3.99 (m, 2H), 3.38 – 3.26 (m, 4H), 3.03 (s, 6H), 2.52 – 2.29 (m, 6H), 2.07 – 1.92 (m, 2H).
321	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.55 (s, 2H), 7.74 (dd, J = 7.7, 1.8 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 7.6, 1.7 Hz, 2H), 4.52 (d, J = 3.4 Hz, 4H), 4.15 (s, 7H), 3.77 (dd, J = 11.2, 6.8 Hz, 2H), 3.68 – 3.57 (m, 4H), 3.44 (dt, J = 10.1, 7.7 Hz, 3H), 2.98 (s, 6H), 2.61 – 2.52 (m, 2H), 2.27 (dd, J = 13.8, 6.7 Hz, 2H).
322	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.58 – 8.50 (m, 2H), 7.75 – 7.69 (m, 2H), 7.61 – 7.55 (m, 2H), 7.48 (d, J = 7.4 Hz, 2H), 4.50 (d, J = 12.2 Hz, 2H), 4.20 – 4.09 (m, 7H), 3.96 (s, 2H), 3.89 (t, J = 5.2 Hz, 2H), 3.49 – 3.45 (m, 1H), 3.33 (d, J = 8.2 Hz, 3H), 3.12 (d, J = 1.7 Hz, 1H), 3.08 (s, 2H), 2.44 – 2.31 (m, 4H), 2.01 – 1.80 (m, 3H).

No.	NMR
323	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (d, <i>J</i> = 12.2 Hz, 2H), 7.72 (ddd, <i>J</i> = 7.7, 6.0, 1.7 Hz, 2H), 7.62 – 7.55 (m, 2H), 7.52 – 7.46 (m, 2H), 4.76 (s, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.12 (s, 6H), 4.11 – 4.05 (m, 1H), 4.00 – 3.93 (m, 2H), 3.53 (d, <i>J</i> = 8.2 Hz, 1H), 3.37 – 3.32 (m, 2H), 3.09 (s, 3H), 2.50 – 2.33 (m, 4H), 1.96 (d, <i>J</i> = 7.8 Hz, 1H).
324	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 1H), 7.75 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.61 (t, <i>J</i> = 7.7 Hz, 1H), 7.51 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.59 – 4.54 (m, 2H), 4.15 (s, 3H), 3.98 (t, <i>J</i> = 5.4 Hz, 1H), 3.47 – 3.36 (m, 2H), 2.13 – 2.08 (m, 1H), 2.00 – 1.95 (m, 1H), 1.33 (td, <i>J</i> = 8.1, 4.7 Hz, 1H), 0.77 (q, <i>J</i> = 4.1 Hz, 1H).
325	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.57 (s, 1H), 8.49 (s, 1H), 7.73 (ddd, <i>J</i> = 12.7, 7.7, 1.7 Hz, 2H), 7.63 – 7.56 (m, 2H), 7.55 – 7.26 (m, 7H), 4.55 (d, <i>J</i> = 4.0 Hz, 2H), 4.30 – 4.19 (m, 2H), 4.15 (s, 4H), 4.05 (s, 2H), 3.50 (t, <i>J</i> = 1.7 Hz, 1H), 3.42 – 3.34 (m, 4H), 3.15 (t, <i>J</i> = 1.7 Hz, 1H), 2.51 – 2.39 (m, 3H), 2.32 (s, 3H), 2.04 – 1.90 (m, 2H), 1.87 – 1.72 (m, 2H).
326	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 1H), 7.74 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.61 (t, <i>J</i> = 7.7 Hz, 1H), 7.51 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.54 (d, <i>J</i> = 4.2 Hz, 2H), 4.15 (s, 3H), 4.06 (dq, <i>J</i> = 8.0, 2.6 Hz, 1H), 3.36 (d, <i>J</i> = 5.1 Hz, 2H), 2.69 – 2.59 (m, 1H), 2.30 – 2.23 (m, 1H), 2.14 – 2.06 (m, 1H), 1.22 (d, <i>J</i> = 7.2 Hz, 3H).
327	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.60 (s, 1H), 7.76 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.62 (t, <i>J</i> = 7.7 Hz, 1H), 7.52 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 4.70 (s, 2H), 4.26 (q, <i>J</i> = 6.4 Hz, 1H), 4.15 (s, 3H), 3.45 (s, 2H), 3.15 (s, 3H), 2.52 – 2.33 (m, 3H), 1.96 (s, 1H).
328	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.59 (s, 1H), 7.76 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.65 (t, <i>J</i> = 7.7 Hz, 1H), 7.51 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 4.70 (s, 2H), 4.26 (q, <i>J</i> = 6.4 Hz, 1H), 4.12 (s, 3H), 3.45 (s, 2H), 3.15 (s, 3H), 2.52 – 2.33 (m, 3H), 2.01 – 1.97 (m, 4H), 1.96 (s, 1H).
329	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.60 (s, 1H), 8.56 (s, 1H), 7.76 (td, <i>J</i> = 7.8, 1.7 Hz, 2H), 7.61 (td, <i>J</i> = 7.7, 1.4 Hz, 2H), 7.51 (dt, <i>J</i> = 7.6, 1.6 Hz, 2H), 4.84 – 4.70 (m, 2H), 4.55 (d, <i>J</i> = 4.1 Hz, 2H), 4.31 – 4.23 (m, 1H), 4.15 (d, <i>J</i> = 4.5 Hz, 7H), 3.58 – 3.35 (m, 6H), 2.52 – 2.36 (m, 6H), 2.04 – 1.91 (m, 2H), 1.24 (s, 1H), 0.82 (d, <i>J</i> = 7.7 Hz, 2H), 0.52 (s, 2H).
330	HPLC retention time = 4.89 min.
331	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 1H), 7.75 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.51 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.57 – 4.55 (m, 2H), 4.15 (s, 3H), 3.98 (t, <i>J</i> = 5.4 Hz, 1H), 3.47 – 3.36 (m, 2H), 2.13 – 1.95 (m, 2H), 1.35 (td, <i>J</i> = 8.1, 4.7 Hz, 1H), 0.77 (q, <i>J</i> = 4.1 Hz, 1H).
332	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.61 (s, 1H), 8.56 (s, 1H), 7.76 (t, <i>J</i> = 7.3 Hz, 2H), 7.61 (t, <i>J</i> = 7.6 Hz, 2H), 7.52 (d, <i>J</i> = 7.6 Hz, 2H), 4.53 (s, 2H), 4.16 (d, <i>J</i> = 6.1 Hz, 7H), 4.05 – 3.71 (m, 7H), 3.50 (s, 1H), 3.15 (s, 1H), 2.45 (s, 4H), 1.99 (d, <i>J</i> = 17.9 Hz, 2H), 1.45 (s, 5H).

No.	NMR
333	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (d, <i>J</i> = 7.2 Hz, 2H), 7.75 (d, <i>J</i> = 7.5 Hz, 2H), 7.61 (t, <i>J</i> = 7.6 Hz, 2H), 7.51 (d, <i>J</i> = 8.0 Hz, 2H), 4.80 (t, <i>J</i> = 6.7 Hz, 2H), 4.65 (d, <i>J</i> = 6.6 Hz, 2H), 4.56 (d, <i>J</i> = 4.0 Hz, 2H), 4.49 (d, <i>J</i> = 4.2 Hz, 2H), 4.11 – 4.00 (m, 2H), 3.83 (s, 2H), 3.50 (d, <i>J</i> = 3.4 Hz, 3H), 3.17 – 3.06 (m, 3H), 2.85 (d, <i>J</i> = 7.2 Hz, 2H), 2.62 – 2.52 (m, 2H), 2.47 – 2.38 (m, 3H), 2.19 – 2.07 (m, 2H), 2.06 – 1.96 (m, 2H).
334	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 2H), 7.75 (d, <i>J</i> = 7.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.6 Hz, 2H), 4.61 (s, 2H), 4.51 (s, 2H), 4.15 (s, 7H), 4.00 (dd, <i>J</i> = 10.8, 5.1 Hz, 2H), 3.81 (d, <i>J</i> = 5.1 Hz, 2H), 3.52 – 3.37 (m, 3H), 3.17 (t, <i>J</i> = 10.2 Hz, 2H), 2.45 (t, <i>J</i> = 9.6 Hz, 3H), 2.24 (d, <i>J</i> = 13.2 Hz, 1H), 2.02 – 1.96 (m, 1H).
335	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 2H), 7.75 (d, <i>J</i> = 7.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.6 Hz, 2H), 4.61 (s, 2H), 4.51 (s, 2H), 4.15 (s, 7H), 4.00 (dd, <i>J</i> = 10.8, 5.1 Hz, 2H), 3.81 (d, <i>J</i> = 5.1 Hz, 2H), 3.52 – 3.37 (m, 3H), 3.17 (t, <i>J</i> = 10.2 Hz, 2H), 2.45 (t, <i>J</i> = 9.6 Hz, 3H), 2.24 (d, <i>J</i> = 13.2 Hz, 1H), 2.02 – 1.96 (m, 1H).
336	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 2H), 7.75 (d, <i>J</i> = 7.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.6 Hz, 2H), 4.61 (s, 2H), 4.51 (s, 2H), 4.15 (s, 7H), 4.00 (dd, <i>J</i> = 10.8, 5.1 Hz, 2H), 3.81 (d, <i>J</i> = 5.1 Hz, 2H), 3.52 – 3.37 (m, 3H), 3.17 (t, <i>J</i> = 10.2 Hz, 2H), 2.45 (t, <i>J</i> = 9.6 Hz, 3H), 2.24 (d, <i>J</i> = 13.2 Hz, 1H), 2.02 – 1.96 (m, 1H).
337	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (d, <i>J</i> = 6.2 Hz, 2H), 7.74 (d, <i>J</i> = 7.9 Hz, 2H), 7.61 (t, <i>J</i> = 7.0 Hz, 3H), 7.51 (d, <i>J</i> = 7.6 Hz, 2H), 7.32 (s, 1H), 4.64 (s, 2H), 4.53 (s, 2H), 4.47 (s, 2H), 4.14 (d, <i>J</i> = 7.7 Hz, 6H), 3.50 (s, 1H), 3.15 (s, 1H), 2.44 (d, <i>J</i> = 6.7 Hz, 3H), 2.18 (s, 1H), 2.08 – 1.96 (m, 2H).
338	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (d, <i>J</i> = 6.2 Hz, 2H), 7.74 (d, <i>J</i> = 7.9 Hz, 2H), 7.61 (t, <i>J</i> = 7.0 Hz, 4H), 7.49 (d, <i>J</i> = 7.4 Hz, 2H), 7.32 (s, 1H), 4.60 (s, 2H), 4.53 (s, 2H), 4.47 (s, 2H), 4.13 (d, <i>J</i> = 7.4 Hz, 6H), 3.50 (s, 1H), 3.15 (s, 1H), 2.44 (d, <i>J</i> = 6.7 Hz, 3H), 2.18 (s, 1H), 2.08 – 1.96 (m, 2H).
339	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 2H), 7.75 (d, <i>J</i> = 7.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.6 Hz, 2H), 4.61 (s, 2H), 4.51 (s, 2H), 4.15 (s, 7H), 4.00 (dd, <i>J</i> = 10.8, 5.1 Hz, 2H), 3.81 (d, <i>J</i> = 5.1 Hz, 2H), 3.52 – 3.37 (m, 3H), 3.17 (t, <i>J</i> = 10.2 Hz, 2H), 2.45 (t, <i>J</i> = 9.6 Hz, 3H), 2.24 (d, <i>J</i> = 13.2 Hz, 1H), 2.02 – 1.96 (m, 1H).
340	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.58 – 8.50 (m, 2H), 7.75 – 7.69 (m, 2H), 7.61 – 7.55 (m, 2H), 7.48 (d, <i>J</i> = 7.4 Hz, 2H), 4.50 (d, <i>J</i> = 12.2 Hz, 2H), 4.20 – 4.09 (m, 7H), 3.96 (s, 2H), 3.89 (t, <i>J</i> = 5.2 Hz, 2H), 3.49 – 3.45 (m, 1H), 3.35 – 3.21 (m, 3H), 3.18 (d, <i>J</i> = 1.7 Hz, 1H), 3.16 (s, 2H), 2.44 – 2.23 (m, 4H).

No.	NMR
341	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.55 (d, J = 2.9 Hz, 2H), 7.74 (dt, J = 7.7, 1.6 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 7.4, 1.7 Hz, 2H), 4.52 (dd, J = 16.1, 3.8 Hz, 3H), 4.38 (s, 2H), 4.17 – 4.07 (m, 7H), 3.54 – 3.46 (m, 1H), 3.19 – 3.10 (m, 1H), 2.60 (dd, J = 13.8, 6.9 Hz, 2H), 2.56 – 2.49 (m, 2H) 2.46 – 2.38 (m, 4H), 2.17 (s, 2H), 2.04 – 1.91 (m, 2H).
342	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.55 (d, J = 2.9 Hz, 2H), 7.74 (dt, J = 7.7, 1.6 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 7.4, 1.7 Hz, 2H), 4.52 (dd, J = 16.1, 3.8 Hz, 3H), 4.38 (s, 2H), 4.17 – 4.07 (m, 7H), 3.54 – 3.46 (m, 1H), 3.19 – 3.10 (m, 1H), 2.60 (dd, J = 13.8, 6.9 Hz, 2H), 2.46 – 2.38 (m, 4H), 2.17 (s, 2H), 2.04 – 1.91 (m, 2H).
343	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.55 (d, J = 2.9 Hz, 2H), 7.74 (dt, J = 7.7, 1.6 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 7.4, 1.7 Hz, 2H), 4.52 (dd, J = 16.1, 3.8 Hz, 3H), 4.38 (s, 2H), 4.17 – 4.07 (m, 7H), 3.54 – 3.46 (m, 1H), 3.19 – 3.10 (m, 1H), 2.60 (dd, J = 13.8, 6.9 Hz, 2H), 2.46 – 2.38 (m, 4H), 2.17 (s, 2H), 2.04 – 1.91 (m, 2H).
344	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.51 (d, J = 5.9 Hz, 2H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.62 – 7.54 (m, 2H), 7.48 (dt, J = 7.5, 1.7 Hz, 2H), 4.54 – 4.45 (m, 4H), 4.12 (d, J = 2.0 Hz, 7H), 3.93 – 3.34 (m, 5H), 2.48 – 2.39 (m, 5H), 2.00 – 1.92 (m, 2H).
345	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.51 (d, J = 5.9 Hz, 2H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.62 – 7.54 (m, 2H), 7.48 (dt, J = 7.5, 1.7 Hz, 2H), 4.54 – 4.45 (m, 4H), 4.12 (d, J = 2.0 Hz, 7H), 3.93 – 3.34 (m, 5H), 2.48 – 2.39 (m, 5H), 2.00 – 1.92 (m, 2H).
346	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.51 (d, J = 5.9 Hz, 2H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.62 – 7.54 (m, 2H), 7.48 (dt, J = 7.5, 1.7 Hz, 2H), 4.54 – 4.45 (m, 4H), 4.06 (d, J = 2.0 Hz, 7H), 3.92 – 3.34 (m, 5H), 2.48 – 2.39 (m, 5H), 2.00 – 1.92 (m, 2H).
347	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.51 (d, J = 5.9 Hz, 2H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.62 – 7.54 (m, 2H), 7.48 (dt, J = 7.5, 1.7 Hz, 2H), 4.54 – 4.45 (m, 4H), 4.06 (d, J = 2.0 Hz, 7H), 3.92 – 3.34 (m, 5H), 2.48 – 2.39 (m, 5H), 2.00 – 1.92 (m, 2H).
348	HPLC retention time = 3.81 min.
349	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.74 (s, 1H), 8.54 (d, J = 12.9 Hz, 2H), 7.82 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 7.9 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.51 (d, J = 7.5 Hz, 2H), 7.38 (d, J = 8.3 Hz, 2H), 4.52 (s, 4H), 4.33 (s, 2H), 4.15 (d, J = 5.4 Hz, 7H), 3.50 (s, 1H), 3.44 – 3.35 (m, 2H), 3.15 (s, 1H), 2.43 (d, J = 6.9 Hz, 3H), 2.06 – 1.94 (m, 2H).
350	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.54 (d, J = 4.6 Hz, 2H), 7.74 (d, J = 7.5 Hz, 2H), 7.60 (t, J = 7.6 Hz, 2H), 7.53 – 7.48 (m, 2H), 7.45 (d, J = 4.4 Hz, 3H), 7.37 (s, 2H), 4.72 (d, J = 16.1 Hz, 2H), 4.50 – 4.33 (m, 5H), 4.17 – 3.98 (m, 7H), 3.50 (s, 1H), 3.16 (s, 1H), 2.42 (d, J = 5.5 Hz, 3H), 2.05 (d, J = 8.7 Hz, 3H).

No.	NMR
351	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (d, <i>J</i> = 19.5 Hz, 2H), 7.73 (d, <i>J</i> = 7.2 Hz, 2H), 7.61 (t, <i>J</i> = 8.0 Hz, 2H), 7.51 (d, <i>J</i> = 7.8 Hz, 2H), 4.75 (s, 2H), 4.54 (s, 2H), 4.41 – 4.29 (m, 2H), 4.14 (d, <i>J</i> = 3.5 Hz, 6H), 3.75 (s, 3H), 3.50 (s, 1H), 3.15 (s, 1H), 2.43 (d, <i>J</i> = 20.9 Hz, 7H), 2.01 (d, <i>J</i> = 23.5 Hz, 3H), 1.35 – 1.20 (m, 2H).
352	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.57 (s, 2H), 7.78 (d, <i>J</i> = 29.3 Hz, 4H), 7.57 (d, <i>J</i> = 35.0 Hz, 4H), 4.55 (s, 3H), 4.18 (d, <i>J</i> = 19.1 Hz, 8H), 3.50 (s, 1H), 3.15 (s, 1H), 2.44 (s, 4H), 2.06 – 1.90 (m, 4H), 1.51 (d, <i>J</i> = 6.6 Hz, 2H).
353	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (s, 2H), 7.74 (d, <i>J</i> = 7.6 Hz, 2H), 7.60 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.7 Hz, 2H), 4.50 – 4.39 (m, 5H), 4.15 (d, <i>J</i> = 3.8 Hz, 7H), 3.90 – 3.85 (m, 1H), 3.50 (s, 1H), 3.26 (d, <i>J</i> = 16.0 Hz, 2H), 3.16 (s, 1H), 2.42 (d, <i>J</i> = 5.4 Hz, 3H), 2.27 (s, 2H), 1.96 (d, <i>J</i> = 25.8 Hz, 3H).
354	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (s, 2H), 7.74 (d, <i>J</i> = 7.6 Hz, 2H), 7.60 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.7 Hz, 2H), 4.50 – 4.39 (m, 5H), 4.15 (d, <i>J</i> = 3.8 Hz, 7H), 3.90 – 3.85 (m, 1H), 3.50 (s, 1H), 3.26 (d, <i>J</i> = 16.0 Hz, 2H), 3.19 (s, 1H), 2.42 (d, <i>J</i> = 5.4 Hz, 3H), 2.27 (s, 2H), 1.96 (d, <i>J</i> = 25.8 Hz, 3H).
355	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (s, 2H), 7.74 (d, <i>J</i> = 7.6 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.7 Hz, 2H), 4.50 – 4.39 (m, 5H), 4.15 (d, <i>J</i> = 3.8 Hz, 7H), 3.90 – 3.85 (m, 1H), 3.50 (s, 1H), 3.26 (d, <i>J</i> = 16.0 Hz, 2H), 3.17 (s, 1H), 2.42 (d, <i>J</i> = 5.4 Hz, 3H), 2.27 (s, 2H), 1.96 (d, <i>J</i> = 25.8 Hz, 3H).
356	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (s, 2H), 7.74 (d, <i>J</i> = 7.6 Hz, 2H), 7.60 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.7 Hz, 2H), 4.50 – 4.39 (m, 5H), 4.15 (d, <i>J</i> = 3.8 Hz, 7H), 3.90 – 3.83 (m, 1H), 3.49 (s, 1H), 3.26 (d, <i>J</i> = 16.0 Hz, 2H), 3.16 (s, 1H), 2.42 (d, <i>J</i> = 5.4 Hz, 3H), 2.27 (s, 2H), 1.96 (d, <i>J</i> = 25.8 Hz, 3H).
357	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (d, <i>J</i> = 6.9 Hz, 2H), 7.74 (d, <i>J</i> = 7.6 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.7 Hz, 2H), 4.52 (d, <i>J</i> = 3.6 Hz, 2H), 4.40 (s, 2H), 4.15 (d, <i>J</i> = 2.1 Hz, 7H), 3.97 (d, <i>J</i> = 11.0 Hz, 1H), 3.50 (s, 1H), 3.16 (s, 1H), 3.00 (s, 3H), 2.92 (s, 2H), 2.80 (s, 2H), 2.43 (d, <i>J</i> = 6.9 Hz, 2H).
358	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (d, <i>J</i> = 6.9 Hz, 2H), 7.74 (d, <i>J</i> = 7.6 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.7 Hz, 2H), 4.52 (d, <i>J</i> = 3.6 Hz, 2H), 4.40 (s, 2H), 4.15 (d, <i>J</i> = 2.1 Hz, 7H), 3.97 (d, <i>J</i> = 11.0 Hz, 1H), 3.50 (s, 1H), 3.16 (s, 1H), 3.00 (s, 3H), 2.92 (s, 2H), 2.80 (s, 2H), 2.43 (d, <i>J</i> = 6.9 Hz, 2H).
359	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (s, 2H), 7.74 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.60 (t, <i>J</i> = 7.6 Hz, 2H), 7.53 – 7.48 (m, 2H), 4.49 (d, <i>J</i> = 1.5 Hz, 3H), 4.15 – 4.07 (m, 8H), 3.94 – 3.88 (m, 2H), 3.84 – 3.75 (m, 2H), 3.50 (t, <i>J</i> = 1.7 Hz, 1H), 3.15 (d, <i>J</i> = 1.7 Hz, 1H), 2.46 – 2.38 (m, 3H), 2.17 (s, 2H), 2.04 – 1.95 (m, 2H).

No.	NMR
360	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (s, 2H), 7.74 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.60 (t, <i>J</i> = 7.6 Hz, 2H), 7.53 – 7.48 (m, 2H), 4.49 (d, <i>J</i> = 1.5 Hz, 3H), 4.15 – 4.07 (m, 8H), 3.94 – 3.88 (m, 2H), 3.84 – 3.75 (m, 2H), 3.50 (t, <i>J</i> = 1.7 Hz, 1H), 3.15 (d, <i>J</i> = 1.7 Hz, 1H), 2.46 – 2.38 (m, 3H), 2.17 (s, 2H), 2.04 – 1.95 (m, 2H).
361	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (s, 2H), 7.74 (d, <i>J</i> = 8.0 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.4 Hz, 2H), 4.45 (s, 2H), 4.39 (s, 2H), 4.14 (s, 7H), 3.51 (s, 1H), 3.15 (s, 1H), 2.69 (s, 2H), 2.47 (d, <i>J</i> = 31.2 Hz, 5H), 2.05 (d, <i>J</i> = 8.8 Hz, 3H), 1.98 (s, 3H).
362	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.55 (s, 2H), 7.74 (d, <i>J</i> = 8.0 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.4 Hz, 2H), 4.45 (s, 2H), 4.39 (s, 2H), 4.14 (s, 7H), 3.51 (s, 1H), 3.15 (s, 1H), 2.69 (s, 2H), 2.47 (d, <i>J</i> = 31.2 Hz, 5H), 2.05 (d, <i>J</i> = 8.8 Hz, 3H), 1.98 (s, 3H).
363	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (d, <i>J</i> = 4.2 Hz, 2H), 7.74 (d, <i>J</i> = 7.6 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 2H), 7.51 (d, <i>J</i> = 7.8 Hz, 2H), 4.48 (s, 2H), 4.36 (s, 2H), 4.29 (s, 2H), 4.24 (s, 2H), 4.14 (s, 6H), 4.04 – 3.94 (m, 2H), 3.16 (s, 1H), 2.81 (t, <i>J</i> = 10.0 Hz, 2H), 2.64 (t, <i>J</i> = 10.8 Hz, 2H), 2.43 (d, <i>J</i> = 6.7 Hz, 2H), 2.39 (s, 1H), 2.05 (d, <i>J</i> = 8.5 Hz, 1H), 1.97 (s, 1H).
364	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 9.1 Hz, 2H), 7.71 (dt, <i>J</i> = 7.6, 2.2 Hz, 2H), 7.61 – 7.54 (m, 2H), 7.50 – 7.45 (m, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.36 (s, 2H), 4.12 (d, <i>J</i> = 3.4 Hz, 7H), 3.80 (t, <i>J</i> = 7.0 Hz, 1H), 3.59 (d, <i>J</i> = 8.1 Hz, 1H), 3.48 (d, <i>J</i> = 7.0 Hz, 1H), 3.38 – 3.32 (m, 2H), 2.84 – 2.75 (m, 2H), 2.41 (dd, <i>J</i> = 7.8, 4.4 Hz, 2H), 2.19 – 2.11 (m, 2H), 2.00 (s, 4H).
365	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 9.1 Hz, 2H), 7.71 (dt, <i>J</i> = 7.6, 2.2 Hz, 2H), 7.63 – 7.54 (m, 2H), 7.50 – 7.45 (m, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.36 (s, 2H), 4.12 (d, <i>J</i> = 3.4 Hz, 7H), 3.80 (t, <i>J</i> = 7.0 Hz, 1H), 3.59 (d, <i>J</i> = 8.1 Hz, 1H), 3.48 (d, <i>J</i> = 7.0 Hz, 1H), 3.38 – 3.32 (m, 2H), 2.84 – 2.75 (m, 2H), 2.42 (dd, <i>J</i> = 7.8, 4.4 Hz, 2H), 2.19 – 2.10 (m, 2H), 2.00 (s, 4H).
366	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 7.6 Hz, 2H), 7.71 (dt, <i>J</i> = 7.7, 1.9 Hz, 2H), 7.61 – 7.54 (m, 2H), 7.51 – 7.45 (m, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.33 (s, 2H), 4.12 (d, <i>J</i> = 3.2 Hz, 7H), 3.92 – 3.84 (m, 1H), 3.34 (d, <i>J</i> = 6.7 Hz, 2H), 2.52 – 2.28 (m, 9H), 1.99 – 1.93 (m, 1H), 1.16 (s, 6H).
367	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.53 (s, 1H), 8.47 (s, 1H), 7.71 (ddd, <i>J</i> = 7.3, 5.4, 1.7 Hz, 2H), 7.57 (td, <i>J</i> = 7.7, 2.2 Hz, 2H), 7.48 (ddd, <i>J</i> = 7.6, 1.8, 0.9 Hz, 2H), 4.70 (s, 2H), 4.58 (s, 3H), 4.51 (d, <i>J</i> = 8.5 Hz, 6H), 4.11 (d, <i>J</i> = 6.2 Hz, 6H), 3.34 (d, <i>J</i> = 4.6 Hz, 2H), 2.48 – 2.31 (m, 4H), 2.01 – 1.90 (m, 2H), 1.28 (s, 1H), 1.23 (t, <i>J</i> = 7.1 Hz, 1H), 0.93 – 0.82 (m, 2H).

No.	NMR
368	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.51 (d, <i>J</i> = 20.3 Hz, 2H), 7.71 (ddd, <i>J</i> = 7.5, 5.7, 1.7 Hz, 2H), 7.57 (td, <i>J</i> = 7.7, 2.0 Hz, 2H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.74 (s, 2H), 4.52 (d, <i>J</i> = 3.8 Hz, 3H), 4.38 (s, 1H), 4.11 (d, <i>J</i> = 3.8 Hz, 7H), 3.82 – 3.64 (m, 3H), 3.37 – 3.32 (m, 2H), 2.87 – 2.69 (m, 3H), 2.45 – 2.32 (m, 3H), 1.96 (d, <i>J</i> = 8.1 Hz, 1H).
369	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.50 (d, <i>J</i> = 19.8 Hz, 2H), 7.73 – 7.68 (m, 2H), 7.57 (td, <i>J</i> = 7.6, 2.2 Hz, 2H), 7.47 (d, <i>J</i> = 7.6 Hz, 2H), 4.73 (s, 2H), 4.48 (s, 2H), 4.11 (d, <i>J</i> = 2.8 Hz, 7H), 2.40 (d, <i>J</i> = 6.6 Hz, 3H), 2.00 (s, 4H), 1.28 (s, 4H), 0.90 (d, <i>J</i> = 6.6 Hz, 4H).
370	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.53 (s, 1H), 8.47 (s, 1H), 7.73 – 7.65 (m, 3H), 7.63 – 7.54 (m, 4H), 7.50 – 7.45 (m, 2H), 6.63 (d, <i>J</i> = 9.1 Hz, 1H), 6.47 (t, <i>J</i> = 6.6 Hz, 1H), 4.49 (s, 4H), 4.46 – 4.42 (m, 2H), 4.11 (d, <i>J</i> = 5.0 Hz, 8H), 3.62 – 3.57 (m, 2H), 2.43 – 2.36 (m, 3H), 1.98 – 1.90 (m, 2H).
371	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.50 (d, <i>J</i> = 19.0 Hz, 2H), 7.72 – 7.68 (m, 2H), 7.60 – 7.54 (m, 2H), 7.47 (d, <i>J</i> = 8.4 Hz, 2H), 4.48 (s, 2H), 4.11 (d, <i>J</i> = 3.3 Hz, 7H), 3.47 (d, <i>J</i> = 1.9 Hz, 1H), 3.39 – 3.31 (m, 4H), 3.12 (s, 1H), 2.53 (d, <i>J</i> = 8.1 Hz, 3H), 2.41 (t, <i>J</i> = 6.7 Hz, 5H), 1.96 (d, <i>J</i> = 17.8 Hz, 2H).
372	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 6.9 Hz, 2H), 7.74 – 7.68 (m, 2H), 7.61 – 7.54 (m, 2H), 7.48 (d, <i>J</i> = 7.6 Hz, 2H), 4.50 (d, <i>J</i> = 5.1 Hz, 4H), 4.12 (d, <i>J</i> = 1.2 Hz, 7H), 3.71 (t, <i>J</i> = 5.6 Hz, 2H), 3.55 (t, <i>J</i> = 7.1 Hz, 2H), 3.48 (d, <i>J</i> = 6.9 Hz, 1H), 3.42 (t, <i>J</i> = 5.6 Hz, 2H), 2.45 – 2.34 (m, 5H), 2.15 – 2.09 (m, 2H), 1.96 (t, <i>J</i> = 11.3 Hz, 2H).
373	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 9.9 Hz, 2H), 7.74 – 7.68 (m, 2H), 7.58 (td, <i>J</i> = 7.7, 1.3 Hz, 2H), 7.51 – 7.46 (m, 2H), 4.52 (d, <i>J</i> = 3.9 Hz, 2H), 4.48 (s, 2H), 4.12 (d, <i>J</i> = 2.9 Hz, 7H), 3.58 (t, <i>J</i> = 5.7 Hz, 2H), 3.38 – 3.32 (m, 4H), 2.48 – 2.38 (m, 3H), 2.00 (s, 4H).
374	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 5.9 Hz, 2H), 7.71 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.61 – 7.54 (m, 2H), 7.48 (dt, <i>J</i> = 7.5, 1.7 Hz, 2H), 4.54 – 4.46 (m, 4H), 4.12 (d, <i>J</i> = 2.0 Hz, 7H), 3.93 – 3.86 (m, 2H), 3.34 (s, 3H), 2.48 – 2.38 (m, 3H), 2.00 – 1.92 (m, 2H).
375	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.51 (d, <i>J</i> = 3.7 Hz, 2H), 7.71 (d, <i>J</i> = 7.7 Hz, 2H), 7.57 (t, <i>J</i> = 7.8 Hz, 2H), 7.50 – 7.45 (m, 2H), 4.50 (s, 2H), 4.11 (d, <i>J</i> = 6.6 Hz, 6H), 3.51 (s, 2H), 3.47 (s, 2H), 3.32 (d, <i>J</i> = 2.3 Hz, 3H), 3.12 (s, 1H), 2.39 (d, <i>J</i> = 3.6 Hz, 3H), 2.01 (d, <i>J</i> = 3.2 Hz, 3H), 1.45 (s, 6H).
376	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 4.8 Hz, 2H), 7.74 – 7.68 (m, 2H), 7.58 (dd, <i>J</i> = 8.0, 7.3 Hz, 2H), 7.51 – 7.45 (m, 2H), 4.49 (d, <i>J</i> = 3.9 Hz, 2H), 4.45 (s, 2H), 4.12 (d, <i>J</i> = 1.5 Hz, 7H), 3.43 (s, 2H), 3.39 – 3.32 (m, 2H), 2.44 – 2.35 (m, 3H), 1.99 (s, 4H), 1.45 (s, 6H).

No.	NMR
377	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 5.2 Hz, 2H), 7.71 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 7.61 – 7.55 (m, 2H), 7.47 (dd, <i>J</i> = 7.5, 1.7 Hz, 2H), 4.43 (s, 4H), 4.12 (d, <i>J</i> = 5.3 Hz, 7H), 3.68 (s, 2H), 2.39 (d, <i>J</i> = 5.5 Hz, 4H), 1.97 – 1.87 (m, 2H), 1.43 (s, 6H).
378	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (d, <i>J</i> = 7.1 Hz, 2H), 7.71 (d, <i>J</i> = 7.9 Hz, 2H), 7.57 (t, <i>J</i> = 7.7 Hz, 2H), 7.50 – 7.45 (m, 2H), 4.47 (s, 2H), 4.41 (s, 2H), 4.11 (d, <i>J</i> = 2.5 Hz, 7H), 3.22 (s, 1H), 3.17 (s, 2H), 2.42 – 2.33 (m, 3H), 1.97 – 1.86 (m, 2H), 1.35 (s, 6H).
379	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.49 (d, <i>J</i> = 9.1 Hz, 2H), 7.72 – 7.67 (m, 2H), 7.60 – 7.53 (m, 2H), 7.47 (d, <i>J</i> = 7.6 Hz, 2H), 4.71 (d, <i>J</i> = 17.2 Hz, 4H), 4.53 (s, 1H), 4.39 (d, <i>J</i> = 11.7 Hz, 2H), 4.10 (s, 8H), 3.23 – 3.15 (m, 2H), 2.39 (d, <i>J</i> = 18.4 Hz, 3H), 1.90 (s, 2H).
380	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.50 (d, <i>J</i> = 9.1 Hz, 2H), 7.72 – 7.67 (m, 2H), 7.60 – 7.53 (m, 2H), 7.48 (d, <i>J</i> = 7.6 Hz, 2H), 4.71 (d, <i>J</i> = 17.2 Hz, 4H), 4.52 (s, 1H), 4.39 (d, <i>J</i> = 11.7 Hz, 2H), 4.10 (s, 8H), 3.20 – 3.15 (m, 4H), 2.39 (d, <i>J</i> = 18.4 Hz, 3H), 1.90 (s, 2H).
381	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (s, 2H), 7.71 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.57 (t, <i>J</i> = 7.7 Hz, 2H), 7.48 (dd, <i>J</i> = 7.5, 1.7 Hz, 2H), 4.53 – 4.37 (m, 5H), 4.12 (s, 7H), 3.61 (d, <i>J</i> = 5.0 Hz, 1H), 3.48 (q, <i>J</i> = 7.1 Hz, 1H), 2.46 – 2.36 (m, 3H), 2.17 (d, <i>J</i> = 14.5 Hz, 1H), 1.94 – 1.69 (m, 4H), 1.20 (dt, <i>J</i> = 24.4, 7.1 Hz, 3H).
382	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.53 (s, 1H), 7.72 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.57 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.48 (s, 2H), 4.11 (s, 3H), 3.18 (s, 2H), 1.35 (s, 6H).
383	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (s, 1H), 7.71 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.57 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.46 (d, <i>J</i> = 5.5 Hz, 2H), 4.40 (d, <i>J</i> = 6.4 Hz, 1H), 4.11 (s, 3H), 3.60 (d, <i>J</i> = 5.0 Hz, 1H), 2.16 (d, <i>J</i> = 8.4 Hz, 1H), 1.98 – 1.78 (m, 4H), 1.73 – 1.64 (m, 1H).
384	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.52 (s, 1H), 7.71 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.57 (t, <i>J</i> = 7.6 Hz, 1H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.43 (s, 2H), 4.12 (s, 3H), 3.68 (s, 2H), 1.43 (s, 6H).
385	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.51 (s, 1H), 7.71 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.57 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.79 (t, <i>J</i> = 6.8 Hz, 1H), 4.12 (s, 3H), 1.63 (d, <i>J</i> = 6.8 Hz, 3H).
386	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.51 (s, 1H), 7.71 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.57 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.79 (t, <i>J</i> = 6.8 Hz, 1H), 4.12 (s, 3H), 1.63 (d, <i>J</i> = 6.8 Hz, 3H).
387	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.53 (s, 2H), 7.71 (d, <i>J</i> = 7.5 Hz, 2H), 7.58 (t, <i>J</i> = 7.6 Hz, 2H), 7.48 (d, <i>J</i> = 7.9 Hz, 2H), 4.50 (s, 4H), 4.37 (s, 1H), 4.12 (d, <i>J</i> = 3.0 Hz, 7H), 3.34 (s, 2H), 2.72 (dd, <i>J</i> = 17.9, 10.6 Hz, 1H), 2.46 – 2.35 (m, 2H), 2.15 (s, 2H), 2.08 – 1.87 (m, 2H), 1.28 (s, 1H).

No.	NMR
389	1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 8.48 (s, 1H), 7.78 – 7.71 (m, 1H), 7.65 (d, J = 4.6 Hz, 1H), 7.64 – 7.58 (m, 1H), 7.55 – 7.46 (m, 2H), 4.79 (s, 4H), 4.55 (s, 3H), 4.41 (s, 4H), 4.16 (d, J = 1.9 Hz, 5H), 3.78 (d, J = 39.5 Hz, 4H), 2.83 (d, J = 40.2 Hz, 4H).
390	1H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 1H), 8.48 (s, 1H), 7.75 (dd, J = 7.7, 1.7 Hz, 1H), 7.65 (d, J = 4.7 Hz, 1H), 7.62 (td, J = 7.7, 2.2 Hz, 1H), 7.55 – 7.47 (m, 2H), 4.78 (s, 4H), 4.64 (s, 2H), 4.39 (s, 3H), 4.16 (d, J = 1.9 Hz, 5H), 2.61 (t, J = 7.8 Hz, 4H), 2.47 (t, J = 7.8 Hz, 4H).
391	1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 8.48 (s, 1H), 7.75 (dd, J = 7.7, 1.7 Hz, 1H), 7.65 (d, J = 4.7 Hz, 1H), 7.61 (td, J = 7.7, 2.3 Hz, 1H), 7.54 – 7.48 (m, 2H), 4.76 (s, 9H), 4.39 (d, J = 43.4 Hz, 2H), 4.15 (d, J = 1.9 Hz, 6H), 4.09 (s, 2H).
392	1H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.53 (s, 1H), 7.80 – 7.45 (m, 6H), 4.57 (d, J = 3.9 Hz, 3H), 4.17 (d, J = 1.9 Hz, 6H), 3.40 (t, J = 5.7 Hz, 3H), 2.61 – 2.36 (m, 5H), 2.02 (dt, J = 13.3, 4.9 Hz, 2H).
397	1H NMR (400 MHz, Methanol-d4) δ 8.62 (s, 1H), 7.62 (dd, J = 8.5, 3.1 Hz, 1H), 7.42 (dd, J = 8.1, 2.9 Hz, 1H), 4.58 (s, 2H), 4.18 (s, 3H), 2.46 (d, J = 7.0 Hz, 3H), 1.98 (s, 2H), 1.33 (s, 2H).
398	1H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 8.54 (s, 1H), 7.74 (dd, J = 7.6, 1.7 Hz, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.55 (dd, J = 8.6, 3.0 Hz, 1H), 7.50 (dd, J = 7.7, 1.7 Hz, 1H), 7.33 (dd, J = 8.1, 3.1 Hz, 1H), 4.53 (dd, J = 4.1, 1.5 Hz, 4H), 4.13 (s, 4H), 4.12 (s, 3H), 3.36 – 3.32 (m, 8H), 2.49 – 2.36 (m, 6H), 1.96 (dd, J = 17.9, 9.9 Hz, 2H).
399	1H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.53 (s, 1H), 7.77 (dd, J = 7.7, 1.6 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.58 (dd, J = 8.7, 3.1 Hz, 1H), 7.54 (dd, J = 7.6, 1.7 Hz, 1H), 7.37 (dd, J = 8.2, 3.1 Hz, 1H), 4.82 – 4.66 (m, 8H), 4.43 (s, 1H), 4.34 (s, 1H), 4.16 (s, 4H), 4.15 (s, 3H), 4.09 (s, 2H).
400	1H NMR (400 MHz, Methanol-d4) δ 8.52 (d, J = 3.6 Hz, 1H), 7.75 (dd, J = 7.7, 1.8 Hz, 1H), 7.62 (t, J = 7.7 Hz, 1H), 7.52 (dd, J = 7.6, 1.7 Hz, 1H), 4.77 (s, 3H), 4.43 (s, 3H), 4.16 (s, 3H), 3.42 (s, 4H).
401	1H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 7.77 (dd, J = 7.7, 1.7 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.53 (dd, J = 7.6, 1.7 Hz, 1H), 4.64 (s, 2H), 4.16 (s, 3H), 3.09 (s, 7H).
402	1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 7.71 (dd, J = 7.7, 1.5 Hz, 1H), 7.57 (t, J = 7.8 Hz, 1H), 7.48 (dd, J = 7.5, 1.9 Hz, 1H), 4.44 (s, 2H), 4.11 (s, 3H), 2.88 (s, 3H).
404	1H NMR (400 MHz, Methanol-d4) δ 8.70 – 8.59 (m, 2H), 8.57 – 8.47 (m, 3H), 7.72 (ddd, J = 7.7, 4.1, 1.7 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.52 (d, J = 3.8 Hz, 2H), 4.27 (d, J = 36.3 Hz, 2H), 4.12 (d, J = 5.3 Hz, 6H), 3.97 (d, J = 31.8 Hz, 2H), 3.84 – 3.45 (m, 5H), 3.35 (dd, J = 6.2, 5.2 Hz, 2H), 2.65 (s, 2H), 2.52 – 2.24 (m, 5H), 2.03 – 1.88 (m, 2H).

No.	NMR
405	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.79 (d, J = 2.1 Hz, 1H), 8.69 (dd, J = 5.4, 1.4 Hz, 1H), 8.53 (d, J = 7.3 Hz, 2H), 8.39 (dt, J = 8.1, 1.8 Hz, 1H), 7.86 (ddd, J = 8.1, 5.4, 0.8 Hz, 1H), 7.72 (ddd, J = 7.7, 2.8, 1.7 Hz, 2H), 7.63 – 7.54 (m, 2H), 7.48 (ddd, J = 7.6, 1.7, 0.9 Hz, 2H), 4.52 (d, J = 3.8 Hz, 2H), 4.12 (d, J = 4.0 Hz, 6H), 4.04 – 3.46 (m, 5H), 3.42 – 3.32 (m, 2H), 2.76 – 2.60 (m, 2H), 2.53 – 2.28 (m, 5H), 2.03 – 1.87 (m, 2H).
406	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.60 (ddd, J = 5.0, 1.8, 1.0 Hz, 1H), 8.54 (d, J = 7.0 Hz, 2H), 7.83 (td, J = 7.7, 1.8 Hz, 1H), 7.72 (ddd, J = 7.7, 4.8, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 7.43 (d, J = 7.8 Hz, 1H), 7.35 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H), 4.52 (d, J = 3.8 Hz, 2H), 4.12 (d, J = 6.2 Hz, 6H), 3.94 (s, 2H), 3.87 – 3.51 (m, 3H), 3.35 (dd, J = 6.2, 5.1 Hz, 2H), 2.65 (s, 2H), 2.51 – 2.36 (m, 3H), 2.34 (d, J = 10.0 Hz, 2H), 2.03 – 1.89 (m, 2H).
407	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (d, J = 3.7 Hz, 2H), 7.72 (ddd, J = 7.7, 2.5, 1.7 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.76 (s, 2H), 4.52 (d, J = 4.0 Hz, 2H), 4.16 – 4.08 (m, 7H), 3.34 (d, J = 4.5 Hz, 4H), 2.97 (s, 2H), 2.53 – 2.35 (m, 4H), 2.33 (d, J = 21.4 Hz, 2H), 2.04 – 1.89 (m, 2H).
408	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.80 (d, J = 4.9 Hz, 2H), 8.54 (d, J = 7.9 Hz, 2H), 7.72 (ddd, J = 7.6, 5.2, 1.7 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 7.41 (t, J = 5.0 Hz, 1H), 4.52 (d, J = 3.9 Hz, 2H), 4.37 (s, 1H), 4.33 – 4.20 (m, 1H), 4.12 (d, J = 4.4 Hz, 6H), 4.06 (d, J = 20.5 Hz, 2H), 3.84 (s, 1H), 3.55 (s, 1H), 3.39 – 3.32 (m, 2H), 2.75 (s, 1H), 2.64 (s, 1H), 2.54 – 2.31 (m, 4H), 2.05 – 1.89 (m, 2H).
409	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (d, J = 1.1 Hz, 2H), 7.72 (ddd, J = 7.7, 2.5, 1.7 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.68 (d, J = 9.0 Hz, 2H), 4.52 (d, J = 3.9 Hz, 2H), 4.12 (d, J = 2.9 Hz, 6H), 3.88 (dd, J = 22.3, 9.7 Hz, 4H), 3.76 (q, J = 7.5 Hz, 2H), 3.40 – 3.32 (m, 3H), 2.51 – 2.32 (m, 4H), 2.13 – 1.89 (m, 5H), 1.57 (s, 2H), 1.30 (t, J = 7.4 Hz, 1H).
410	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.77 – 8.71 (m, 2H), 8.54 (d, J = 7.4 Hz, 2H), 7.92 – 7.83 (m, 2H), 7.72 (ddd, J = 7.7, 2.8, 1.7 Hz, 2H), 7.58 (td, J = 7.6, 0.8 Hz, 2H), 7.48 (ddd, J = 7.6, 1.7, 1.0 Hz, 2H), 4.52 (d, J = 4.0 Hz, 2H), 4.12 (d, J = 3.7 Hz, 6H), 3.97 (d, J = 28.1 Hz, 2H), 3.88 (d, J = 39.6 Hz, 4H), 3.42 – 3.33 (m, 2H), 2.73 (dt, J = 11.9, 6.3 Hz, 2H), 2.50 – 2.30 (m, 4H), 2.06 – 1.87 (m, 2H).
411	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.57 – 8.49 (m, 2H), 7.72 (dt, J = 7.7, 1.9 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.70 (s, 2H), 4.52 (d, J = 3.9 Hz, 2H), 4.16 – 4.06 (m, 6H), 3.86 (ddd, J = 17.9, 8.2, 5.2 Hz, 3H), 3.75 (q, J = 7.9 Hz, 1H), 3.56 – 3.33 (m, 5H), 3.13 – 2.96 (m, 1H), 2.49 – 2.24 (m, 5H), 2.22 – 2.01 (m, 2H), 2.03 – 1.88 (m, 2H), 1.65 (ddd, J = 29.0, 12.6, 7.4 Hz, 2H).

No.	NMR
412	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.52 (d, J = 7.0 Hz, 2H), 8.27 (d, J = 1.6 Hz, 1H), 8.22 (d, J = 2.5 Hz, 1H), 7.83 – 7.79 (m, 1H), 7.71 (dt, J = 7.7, 1.6 Hz, 2H), 7.58 (td, J = 7.7, 0.8 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.52 (d, J = 3.3 Hz, 4H), 4.11 (d, J = 2.8 Hz, 6H), 3.56 (dd, J = 8.9, 6.8 Hz, 2H), 3.40 – 3.32 (m, 2H), 3.27 (t, J = 7.8 Hz, 2H), 2.50 – 2.30 (m, 4H), 2.04 – 1.88 (m, 2H).
413	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.52 (d, J = 6.9 Hz, 2H), 7.71 (dt, J = 7.8, 1.9 Hz, 2H), 7.58 (td, J = 7.6, 0.7 Hz, 2H), 7.48 (ddd, J = 7.6, 1.7, 0.7 Hz, 2H), 4.52 (d, J = 4.4 Hz, 4H), 4.49 – 4.37 (m, 1H), 4.17 – 4.06 (m, 7H), 3.43 – 3.31 (m, 6H), 3.24 (dd, J = 12.9, 9.2 Hz, 2H), 2.52 – 2.30 (m, 4H), 2.12 (s, 4H), 2.05 – 1.87 (m, 2H).
414	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.57 (s, 1H), 8.53 (s, 1H), 8.25 (d, J = 2.7 Hz, 1H), 7.73 (ddd, J = 7.6, 6.9, 1.7 Hz, 2H), 7.59 (td, J = 7.7, 2.2 Hz, 2H), 7.53 – 7.43 (m, 3H), 4.97 (d, J = 11.8 Hz, 6H), 4.53 (d, J = 3.9 Hz, 2H), 4.12 (d, J = 2.7 Hz, 7H), 3.90 (s, 3H), 3.41 – 3.32 (m, 2H), 2.51 – 2.33 (m, 3H), 2.06 – 1.89 (m, 1H).
415	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.52 (d, J = 1.7 Hz, 2H), 7.90 (dd, J = 1.6, 0.9 Hz, 1H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.65 – 7.54 (m, 3H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 6.64 (dd, J = 1.9, 0.9 Hz, 1H), 4.52 (d, J = 4.2 Hz, 4H), 4.12 (d, J = 2.1 Hz, 6H), 3.63 (tt, J = 11.7, 4.1 Hz, 1H), 3.42 – 3.32 (m, 2H), 3.12 (t, J = 1.7 Hz, 4H), 2.51 – 2.35 (m, 3H), 2.35 – 2.22 (m, 2H), 2.04 – 1.89 (m, 2H), 1.69 (qd, J = 12.4, 4.5 Hz, 2H).
416	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.52 (d, J = 1.2 Hz, 2H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.57 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.57 – 4.47 (m, 4H), 4.12 (d, J = 2.9 Hz, 6H), 3.89 – 3.76 (m, 1H), 3.53 – 3.41 (m, 2H), 3.41 – 3.32 (m, 2H), 3.04 – 2.89 (m, 4H), 2.58 (dd, J = 16.9, 10.6 Hz, 1H), 2.53 – 2.31 (m, 4H), 2.16 – 1.89 (m, 3H).
417	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.61 (ddd, J = 5.1, 1.8, 0.9 Hz, 1H), 8.52 (d, J = 6.6 Hz, 2H), 8.00 (td, J = 7.8, 1.8 Hz, 1H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.62 – 7.54 (m, 3H), 7.53 – 7.43 (m, 3H), 4.58 – 4.48 (m, 4H), 4.12 (s, 7H), 3.67 (t, J = 7.0 Hz, 2H), 3.44 – 3.32 (m, 4H), 2.51 – 2.33 (m, 3H), 2.03 – 1.89 (m, 1H).
418	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.66 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 8.53 (d, J = 0.9 Hz, 2H), 7.88 (td, J = 7.7, 1.8 Hz, 1H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.62 – 7.54 (m, 2H), 7.48 (dt, J = 7.6, 1.6 Hz, 3H), 7.43 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H), 4.57 (d, J = 3.7 Hz, 4H), 4.52 (d, J = 3.9 Hz, 2H), 4.11 (d, J = 5.4 Hz, 6H), 3.38 – 3.33 (m, 2H), 2.50 – 2.32 (m, 4H), 2.01 – 1.91 (m, 1H).
419	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.52 (s, 1H), 8.47 (s, 1H), 7.80 – 7.73 (m, 2H), 7.70 (td, J = 7.5, 1.7 Hz, 2H), 7.61 – 7.54 (m, 4H), 7.48 (dt, J = 7.5, 1.5 Hz, 2H), 4.59 – 4.46 (m, 4H), 4.11 (m, 7H), 3.47 – 3.33 (m, 6H), 2.52 – 2.34 (m, 5H), 2.03 – 1.90 (m, 1H).

No.	NMR
420	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.87 (d, J = 4.9 Hz, 2H), 8.54 (s, 2H), 7.72 (ddd, J = 7.6, 3.4, 1.7 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.53 – 7.46 (m, 3H), 4.70 (s, 2H), 4.65 (s, 2H), 4.52 (d, J = 3.9 Hz, 2H), 4.12 (d, J = 0.9 Hz, 6H), 3.38 – 3.33 (m, 2H), 2.51 – 2.35 (m, 4H), 1.98 – 1.92 (m, 1H).
421	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.56 (ddd, J = 5.0, 1.7, 0.9 Hz, 1H), 8.52 (d, J = 5.5 Hz, 2H), 7.87 (td, J = 7.9, 1.8 Hz, 1H), 7.71 (ddd, J = 7.7, 4.2, 1.7 Hz, 2H), 7.58 (td, J = 7.6, 0.7 Hz, 2H), 7.48 (dt, J = 7.6, 1.5 Hz, 2H), 7.36 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.21 (dt, J = 8.2, 1.0 Hz, 1H), 4.60 (s, 2H), 4.53 (d, J = 3.9 Hz, 2H), 4.19 – 4.08 (m, 4H), 4.06 (s, 3H), 3.41 – 3.33 (m, 2H), 2.53 – 2.31 (m, 4H), 2.03 – 1.90 (m, 1H), 1.84 – 1.74 (m, 2H), 1.64 – 1.53 (m, 2H).
422	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.80 – 8.72 (m, 2H), 8.53 (d, J = 1.4 Hz, 2H), 7.83 – 7.76 (m, 2H), 7.71 (ddd, J = 7.6, 1.7, 0.6 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.57 (d, J = 2.6 Hz, 4H), 4.52 (d, J = 3.9 Hz, 2H), 4.11 (d, J = 3.5 Hz, 6H), 3.42 – 3.32 (m, 2H), 2.55 – 2.32 (m, 4H), 2.03 – 1.89 (m, 1H).
423	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (d, J = 7.5 Hz, 2H), 7.72 (ddd, J = 7.7, 4.5, 1.7 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 5.03 (d, J = 15.5 Hz, 1H), 4.69 (d, J = 15.4 Hz, 1H), 4.57 (s, 1H), 4.52 (d, J = 3.9 Hz, 2H), 4.12 (s, 7H), 4.02 (dd, J = 12.3, 3.6 Hz, 1H), 3.84 (ddd, J = 26.3, 12.5, 5.0 Hz, 2H), 3.49 – 3.32 (m, 3H), 2.53 – 2.32 (m, 3H), 2.23 (dd, J = 13.7, 6.7 Hz, 1H), 2.18 – 2.04 (m, 1H), 2.06 – 1.88 (m, 2H).
424	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.93 (dd, J = 2.3, 0.8 Hz, 1H), 8.67 (dd, J = 5.2, 1.5 Hz, 1H), 8.52 (s, 1H), 8.42 (s, 1H), 8.33 (ddd, J = 8.0, 2.2, 1.5 Hz, 1H), 7.75 – 7.61 (m, 3H), 7.56 (td, J = 7.7, 4.8 Hz, 2H), 7.46 (dd, J = 7.6, 1.7 Hz, 2H), 4.52 (d, J = 3.9 Hz, 2H), 4.45 (s, 2H), 4.11 (s, 4H), 4.04 (s, 3H), 3.43 – 3.32 (m, 2H), 2.54 – 2.31 (m, 3H), 2.05 – 1.88 (m, 1H), 1.74 – 1.61 (m, 2H), 1.52 – 1.39 (m, 2H).
425	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.88 (d, J = 2.5 Hz, 1H), 8.77 (dd, J = 5.3, 1.5 Hz, 1H), 8.52 (s, 2H), 8.34 (dt, J = 8.0, 1.9 Hz, 1H), 7.79 (ddd, J = 8.0, 5.3, 0.8 Hz, 1H), 7.71 (dt, J = 7.7, 1.5 Hz, 2H), 7.57 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.57 (d, J = 4.7 Hz, 4H), 4.52 (d, J = 3.9 Hz, 2H), 4.11 (d, J = 2.9 Hz, 6H), 3.44 – 3.31 (m, 2H), 2.56 – 2.31 (m, 3H), 2.06 – 1.88 (m, 2H).
426	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.52 (d, J = 3.8 Hz, 2H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.58 (td, J = 7.6, 0.9 Hz, 2H), 7.48 (dt, J = 7.6, 1.6 Hz, 2H), 4.58 – 4.48 (m, 4H), 4.12 (d, J = 1.2 Hz, 6H), 3.41 – 3.31 (m, 5H), 2.51 – 2.32 (m, 3H), 2.03 – 1.88 (m, 1H), 0.96 – 0.88 (m, 2H), 0.83 – 0.70 (m, 2H).

No.	NMR
427	¹ H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 4.0 Hz, 2H), 7.72 (ddd, J = 7.7, 2.5, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.69 (s, 2H), 4.52 (d, J = 3.9 Hz, 2H), 4.22 (s, 1H), 4.11 (d, J = 3.0 Hz, 6H), 3.93 (d, J = 3.0 Hz, 2H), 3.36 (d, J = 8.6 Hz, 6H), 2.53 – 2.32 (m, 4H), 2.19 (d, J = 34.8 Hz, 2H), 2.07 – 1.84 (m, 2H).
428	¹ H NMR (400 MHz, Methanol-d4) δ 8.52 (d, J = 1.5 Hz, 2H), 7.71 (dt, J = 7.7, 1.7 Hz, 2H), 7.57 (t, J = 7.7 Hz, 2H), 7.48 (ddd, J = 7.6, 1.7, 0.8 Hz, 2H), 4.64 (s, 2H), 4.52 (d, J = 3.9 Hz, 2H), 4.12 (d, J = 2.5 Hz, 7H), 3.86 (s, 6H), 3.40 – 3.32 (m, 2H), 2.54 – 2.32 (m, 3H), 2.01 – 1.89 (m, 1H).
429	¹ H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 3.6 Hz, 2H), 7.71 (ddd, J = 7.7, 1.7, 1.1 Hz, 2H), 7.57 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.55 (s, 2H), 4.52 (d, J = 3.8 Hz, 2H), 4.18 – 4.06 (m, 7H), 3.43 (s, 2H), 3.40 – 3.32 (m, 2H), 2.52 – 2.31 (m, 3H), 2.04 – 1.91 (m, 1H), 1.57 – 1.48 (m, 2H), 1.39 – 1.29 (m, 2H).
430	¹ H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 4.2 Hz, 2H), 7.72 (ddd, J = 7.7, 2.6, 1.8 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.8 Hz, 2H), 4.69 (s, 2H), 4.52 (d, J = 3.9 Hz, 2H), 4.22 (s, 1H), 4.11 (d, J = 2.9 Hz, 6H), 4.05 – 3.83 (m, 2H), 3.36 (d, J = 8.4 Hz, 6H), 2.52 – 2.32 (m, 4H), 2.24 (s, 2H), 2.04 – 1.90 (m, 2H).
431	¹ H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 4.2 Hz, 2H), 7.72 (ddd, J = 7.7, 3.0, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.72 (d, J = 34.7 Hz, 2H), 4.61 (s, 1H), 4.52 (d, J = 3.9 Hz, 2H), 4.11 (d, J = 2.5 Hz, 6H), 4.08 – 3.75 (m, 3H), 3.54 (s, 1H), 3.37 (tt, J = 12.6, 7.7 Hz, 3H), 2.51 – 2.35 (m, 3H), 2.14 (d, J = 34.6 Hz, 2H), 2.02 – 1.91 (m, 1H).
432	¹ H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 2H), 9.25 (s, 2H), 9.15 (s, 2H), 8.60 (d, J = 5.8 Hz, 2H), 7.78 (d, J = 7.5 Hz, 2H), 7.68 - 7.65 (m, 2H), 7.59 (d, J = 7.6 Hz, 2H), 4.49 (s, 3H), 4.31 (d, J = 6.0 Hz, 2H), 4.05 (d, J = 3.8 Hz, 5H), 3.97 (s, 2H), 3.22 (s, 4H), 2.29 (s, 2H), 2.21 (q, J = 7.4, 6.5 Hz, 3H), 1.82 (d, J = 8.4 Hz, 2H).
433	¹ H NMR (400 MHz, DMSO-d6) δ 9.32 (s, 3H), 9.15 (s, 2H), 8.60 (d, J = 6.5 Hz, 2H), 7.78 (d, J = 7.8 Hz, 2H), 7.69 - 7.65 (m, 2H), 7.59 (d, J = 7.7 Hz, 2H), 5.77 (s, 5H), 5.28 - 5.21 (m, 1H), 4.48 (d, J = 13.6 Hz, 4H), 4.04 (t, J = 4.2 Hz, 7H), 4.00 - 3.90 (m, 4H), 2.26 - 2.14 (m, 3H), 1.82 (d, J = 8.8 Hz, 2H).
434	¹ H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 2H), 7.71 (dd, J = 7.7, 1.7 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.84 (s, 2H), 4.48 (s, 4H), 4.12 (s, 6H), 3.85 – 3.73 (m, 2H), 3.26 (dd, J = 10.2, 6.4 Hz, 2H), 2.44 – 2.26 (m, 6H), 2.11 – 1.92 (m, 4H), 1.90 – 1.73 (m, 2H)

No.	NMR
435	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.55 (s, 2H), 7.74 (dd, J = 7.7, 1.7 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.51 (dd, J = 7.6, 1.7 Hz, 2H), 4.60 – 4.46 (m, 4H), 4.14 (s, 7H), 3.67 (dd, J = 10.2, 8.0 Hz, 1H), 3.46 – 3.35 (m, 4H), 3.27 (dd, J = 10.2, 6.5 Hz, 1H), 3.10 – 2.95 (m, 1H), 2.70 – 2.56 (m, 1H), 2.56 – 2.40 (m, 3H), 2.32 (dd, J = 16.9, 7.6 Hz, 1H), 2.07 – 1.91 (m, 1H)
436	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.50 (s, 1H), 7.82 (d, J = 7.7 Hz, 1H), 7.73 – 7.60 (m, 2H), 7.60 – 7.49 (m, 2H), 7.47 (s, 1H), 7.41 (d, J = 5.9 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 4.34 (s, 2H), 4.16 (s, 2H), 4.11 (s, 3H), 4.08 (s, 3H).
437	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.48 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.69 (dd, J = 7.6, 1.7 Hz, 1H), 7.65 (dd, J = 7.7, 1.7 Hz, 1H), 7.61 – 7.48 (m, 2H), 7.46 (dd, J = 7.6, 1.7 Hz, 1H), 7.41 (dd, J = 7.6, 1.7 Hz, 1H), 7.36 (d, J = 7.5 Hz, 1H), 4.74 (s, 2H), 4.57 – 4.21 (m, 10H), 4.11 (s, 3H), 4.08 (s, 3H), 3.86 – 3.60 (m, 4H), 2.95 – 2.67 (m, 4H).
439	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (d, J = 1.8 Hz, 1H), 7.92 (s, 2H), 7.72 (dd, J = 12.1, 7.4 Hz, 3H), 7.64 – 7.38 (m, 7H), 4.77 (s, 1H), 4.53 (s, 1H), 4.15 (s, 3H), 4.13 (s, 5H).
440	¹ H NMR (400 MHz, DMSO-d ₆) δ 9.00 (d, J = 43.2 Hz, 2H), 8.15 (s, 2H), 7.84 (s, 4H), 7.74 - 7.64 (m, 2H), 7.56 (d, J = 31.3 Hz, 3H), 6.54 (s, 4H), 4.55 (s, 1H), 4.23 (s, 1H), 3.99 (s, 1H), 2.88 (dq, J = 11.1, 6.4 Hz, 3H), 2.17 (td, J = 12.3, 6.5 Hz, 6H), 1.87 - 1.67 (m, 3H).
629	¹ H NMR (400 MHz, Acetonitrile-d ₃) δ 8.43 (s, 2H), 7.71 (dd, J = 7.7, 1.8 Hz, 2H), 7.59 (t, J = 7.7 Hz, 2H), 7.50 (dd, J = 7.6, 1.7 Hz, 2H), 4.61 (m, 4H), 4.37 (m, 2H), 4.25 (m, 3H), 4.03 (s, 6H), 3.97 (m, 3H), 1.52 (s, 3H).
630	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.50 (s, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.70 (dd, J = 7.7, 1.7 Hz, 1H), 7.67 (dd, J = 7.7, 1.7 Hz, 1H), 7.55 (dt, J = 14.2, 7.7 Hz, 2H), 7.47 (dd, J = 7.6, 1.7 Hz, 1H), 7.43 (dd, J = 7.6, 1.7 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 4.35 (d, J = 2.7 Hz, 4H), 4.11 (d, J = 4.8 Hz, 6H), 4.09 – 4.02 (m, 1H), 3.26 (dd, J = 6.2, 4.2 Hz, 2H), 2.48 – 2.33 (m, 3H), 1.98 – 1.86 (m, 1H).
631	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.48 (s, 1H), 7.89 (dd, J = 7.6, 1.2 Hz, 1H), 7.74 – 7.61 (m, 2H), 7.59 – 7.48 (m, 2H), 7.48 – 7.38 (m, 2H), 7.35 (d, J = 7.5 Hz, 1H), 4.72 (d, J = 22.2 Hz, 2H), 4.51 – 4.24 (m, 4H), 4.09 (d, J = 5.0 Hz, 8H), 3.28 – 3.18 (m, 2H), 2.54 – 2.27 (m, 4H), 2.02 – 1.83 (m, 1H), 1.58 (s, 3H).
632	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.47 (s, 1H), 7.89 (dd, J = 7.6, 1.1 Hz, 1H), 7.74 – 7.61 (m, 2H), 7.60 – 7.48 (m, 2H), 7.46 (dd, J = 7.6, 1.7 Hz, 1H), 7.40 (ddd, J = 7.6, 3.1, 1.7 Hz, 1H), 7.35 (d, J = 7.5 Hz, 1H), 4.69 (s, 2H), 4.54 (d, J = 64.1 Hz, 5H), 4.34 (d, J = 2.5 Hz, 2H), 4.24 (d, J = 26.8 Hz, 2H), 4.09 (d, J = 4.0 Hz, 7H), 4.08 – 4.03 (m, 1H), 3.28 – 3.19 (m, 2H), 2.48 – 2.28 (m, 3H), 1.98 – 1.87 (m, 1H), 1.85 (s, 3H).

No.	NMR
633	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.48 (s, 1H), 7.89 (d, <i>J</i> = 7.6 Hz, 1H), 7.73 – 7.62 (m, 2H), 7.61 – 7.50 (m, 2H), 7.44 (ddd, <i>J</i> = 20.5, 7.6, 1.8 Hz, 2H), 7.36 (d, <i>J</i> = 7.5 Hz, 1H), 4.74 (s, 2H), 4.49 (s, 4H), 4.34 (d, <i>J</i> = 2.6 Hz, 2H), 4.10 (d, <i>J</i> = 4.6 Hz, 7H), 4.05 (q, <i>J</i> = 6.5 Hz, 1H), 3.72 (s, 1H), 3.29 – 3.16 (m, 2H), 2.80 (s, 2H), 2.50 – 2.29 (m, 3H), 2.01 – 1.84 (m, 1H).
634	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.56 (s, 2H), 7.75 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.60 (t, <i>J</i> = 7.6 Hz, 2H), 7.51 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 4.70 (s, 4H), 4.14 (s, 6H), 3.92 (t, <i>J</i> = 11.0 Hz, 4H), 3.73 – 3.53 (m, 8H), 3.45 (q, <i>J</i> = 9.9 Hz, 2H), 3.25 (d, <i>J</i> = 11.9 Hz, 2H), 2.28 – 2.14 (m, 2H), 2.08 (q, <i>J</i> = 13.2, 11.0 Hz, 2H).
635	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (s, 1H), 7.90 (d, <i>J</i> = 7.6 Hz, 1H), 7.73 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.68 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.59 (t, <i>J</i> = 7.9 Hz, 1H), 7.54 (d, <i>J</i> = 7.7 Hz, 1H), 7.49 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.44 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.39 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 4.61 (d, <i>J</i> = 9.5 Hz, 2H), 4.55 – 4.41 (m, 4H), 4.33 (dd, <i>J</i> = 10.7, 6.2 Hz, 1H), 4.18 (dt, <i>J</i> = 18.4, 9.3 Hz, 5H), 4.10 (d, <i>J</i> = 1.3 Hz, 3H), 2.94 (dp, <i>J</i> = 26.4, 8.7 Hz, 2H), 1.18 (d, <i>J</i> = 23.4 Hz, 13H), 0.94 – 0.79 (m, 4H).
636	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (s, 1H), 7.90 (d, <i>J</i> = 7.6 Hz, 1H), 7.73 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.68 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.59 (t, <i>J</i> = 7.7 Hz, 1H), 7.55 (t, <i>J</i> = 7.8 Hz, 1H), 7.50 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.45 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.40 (d, <i>J</i> = 7.5 Hz, 1H), 4.71 (s, 2H), 4.63 (s, 4H), 4.51 (dp, <i>J</i> = 6.3, 3.0 Hz, 3H), 4.41 (q, <i>J</i> = 12.2, 11.4 Hz, 6H), 4.11 (s, 3H), 2.56 (dt, <i>J</i> = 23.8, 7.6 Hz, 4H), 2.48 – 2.34 (m, 4H), 1.02 – 0.78 (m, 4H).
637	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.54 (s, 1H), 7.91 (d, <i>J</i> = 7.6 Hz, 1H), 7.73 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.68 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.64 – 7.56 (m, 1H), 7.54 (d, <i>J</i> = 7.6 Hz, 1H), 7.49 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.44 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.39 (d, <i>J</i> = 7.5 Hz, 1H), 4.70 (s, 2H), 4.64 – 4.44 (m, 4H), 4.35 (s, 6H), 4.11 (s, 3H), 3.72 (s, 3H), 2.77 (s, 3H), 0.96 – 0.74 (m, 2H).
638	¹ H NMR (400 MHz, Methanol- <i>d</i> ₄) δ 8.59 (s, 1H), 7.92 (d, <i>J</i> = 7.6 Hz, 1H), 7.74 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.69 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.60 (t, <i>J</i> = 7.7 Hz, 1H), 7.55 (t, <i>J</i> = 7.7 Hz, 1H), 7.50 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.45 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.39 (d, <i>J</i> = 7.5 Hz, 1H), 4.53 (dt, <i>J</i> = 6.1, 3.2 Hz, 1H), 4.48 (d, <i>J</i> = 4.1 Hz, 2H), 4.37 (d, <i>J</i> = 2.6 Hz, 2H), 4.12 (s, 5H), 3.47 – 3.35 (m, 2H), 3.29 – 3.17 (m, 2H), 2.54 – 2.25 (m, 6H), 1.96 (dddd, <i>J</i> = 18.9, 11.6, 6.1, 3.2 Hz, 2H), 0.94 – 0.77 (m, 5H).

No.	NMR
639	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.54 (s, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.73 (dd, J = 7.7, 1.7 Hz, 1H), 7.68 (dd, J = 7.7, 1.7 Hz, 1H), 7.57 (dt, J = 15.7, 7.6 Hz, 2H), 7.49 (dd, J = 7.6, 1.7 Hz, 1H), 7.45 (dd, J = 7.6, 1.7 Hz, 1H), 7.39 (d, J = 7.5 Hz, 1H), 4.39 (s, 2H), 4.34 (s, 2H), 4.14 (s, 3H), 4.12 (s, 3H), 3.93 (p, J = 7.8 Hz, 1H), 3.64 (dd, J = 10.2, 8.0 Hz, 1H), 3.31 – 3.26 (m, 1H), 3.21 (dd, J = 10.1, 6.6 Hz, 1H), 3.07 (q, J = 8.4 Hz, 1H), 3.02 – 2.91 (m, 1H), 2.75 – 2.63 (m, 2H), 2.58 (dd, J = 16.8, 8.8 Hz, 1H), 2.53 – 2.40 (m, 2H), 2.26 (dd, J = 16.8, 7.8 Hz, 1H).</p>
640	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.55 (s, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.73 (dd, J = 7.7, 1.7 Hz, 1H), 7.68 (dd, J = 7.7, 1.8 Hz, 1H), 7.57 (dt, J = 15.6, 7.7 Hz, 2H), 7.49 (dd, J = 7.6, 1.7 Hz, 1H), 7.44 (dd, J = 7.6, 1.7 Hz, 1H), 7.39 (d, J = 7.5 Hz, 1H), 4.49 (d, J = 5.8 Hz, 2H), 4.43 (td, J = 4.6, 2.2 Hz, 1H), 4.34 (s, 2H), 4.14 (s, 3H), 4.12 (s, 3H), 3.70 – 3.58 (m, 2H), 3.31 – 3.26 (m, 1H), 3.22 (dd, J = 10.2, 6.6 Hz, 1H), 2.97 (dt, J = 15.3, 7.8 Hz, 1H), 2.58 (dd, J = 16.9, 8.8 Hz, 1H), 2.34 – 2.23 (m, 1H), 2.18 (ddd, J = 12.4, 8.3, 3.9 Hz, 1H), 2.11 – 1.89 (m, 2H), 1.89 – 1.80 (m, 1H), 1.80 – 1.66 (m, 1H).</p>
641	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.84 (s, 1H), 7.97 - 7.78 (m, 2H), 7.78 - 7.52 (m, 4H), 7.52 - 7.34 (m, 2H), 4.61 - 4.32 (m, 6H), 4.29 (s, 3H), 4.18 (s, 4H), 4.12 (s, 3H), 2.64 - 2.32 (m, 4H).</p>
642	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.84 (s, 1H), 7.97 - 7.78 (m, 2H), 7.73 - 7.52 (m, 4H), 7.50 - 7.31 (m, 2H), 4.51 (d, J = 28.6 Hz, 2H), 4.32 - 4.02 (m, 14H), 1.56 (s, 3H).</p>
643	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.84 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.84 (dd, J = 7.7, 1.7 Hz, 1H), 7.74 - 7.50 (m, 4H), 7.46 (dd, J = 7.6, 1.7 Hz, 1H), 7.40 (d, J = 7.5 Hz, 1H), 4.60 (ddd, J = 11.3, 7.9, 6.2 Hz, 1H), 4.37 (d, J = 2.8 Hz, 2H), 4.34 - 4.21 (m, 3H), 4.18-4.03 (m, 4H), 3.75 (dd, J = 11.7, 8.0 Hz, 1H), 3.28 (dd, J = 6.2, 4.0 Hz, 2H), 2.51 - 2.30 (m, 3H), 2.01 - 1.83 (m, 1H), 1.52 (d, J = 6.4 Hz, 3H).</p>
644	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.84 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.84 (dd, J = 7.7, 1.8 Hz, 1H), 7.75 - 7.50 (m, 5H), 7.51 - 7.30 (m, 2H), 4.60 (ddd, J = 11.5, 7.9, 6.3 Hz, 1H), 4.37 (d, J = 2.8 Hz, 2H), 4.36 - 4.22 (m, 3H), 4.16-4.02 (m, 4H), 3.75 (dd, J = 11.7, 8.0 Hz, 1H), 3.28 (dd, J = 6.2, 4.0 Hz, 2H), 2.52 - 2.31 (m, 3H), 1.94 (ddt, J = 8.8, 5.4, 2.9 Hz, 1H), 1.52 (d, J = 6.3 Hz, 3H).</p>
645	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.84 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.84 (dd, J = 7.7, 1.8 Hz, 1H), 7.74 - 7.50 (m, 4H), 7.51 - 7.32 (m, 2H), 4.37 (d, J = 2.8 Hz, 2H), 4.29 (s, 3H), 4.21-3.99 (d, J = 19.3 Hz, 8H), 3.29 - 3.23 (m, 2H), 2.53 - 2.30 (m, 3H), 2.02 - 1.82 (m, 1H).</p>

No.	NMR
646	1H NMR (400 MHz, Methanol-d4) δ 8.84 (s, 1H), 8.57 (s, 1H), 7.85 (dd, J = 7.7, 1.7 Hz, 1H), 7.76 (dd, J = 7.7, 1.7 Hz, 1H), 7.74 - 7.45 (m, 4H), 4.57 (dd, J = 16.5, 4.2 Hz, 3H), 4.34 - 4.21 (m, 4H), 4.17-4.06 (m, 4H), 3.75 (dd, J = 11.7, 8.0 Hz, 1H), 3.37 (t, J = 5.6 Hz, 2H), 2.57 - 2.32 (m, 3H), 2.09 - 1.85 (m, 1H), 1.52 (d, J = 6.4 Hz, 3H).
647	1H NMR (400 MHz, Methanol-d4) δ 8.84 (s, 1H), 8.57 (s, 1H), 7.85 (dd, J = 7.7, 1.7 Hz, 1H), 7.76 (dd, J = 7.7, 1.8 Hz, 1H), 7.72 - 7.40 (m, 4H), 4.67 - 4.48 (m, 3H), 4.38 - 4.22 (m, 4H), 4.15 (s, 4H), 3.75 (dd, J = 11.7, 8.0 Hz, 1H), 3.37 (t, J = 5.7 Hz, 2H), 2.58 - 2.32 (m, 3H), 2.08 - 1.87 (m, 1H), 1.52 (d, J = 6.4 Hz, 3H).
648	1H NMR (400 MHz, Methanol-d4) δ 8.55 (d, J = 11.6 Hz, 2H), 7.74 (dt, J = 7.7, 2.0 Hz, 2H), 7.61 (td, J = 7.7, 1.3 Hz, 2H), 7.51 (dt, J = 7.6, 1.7 Hz, 2H), 4.62 - 4.33 (m, 4H), 4.20-4.07 (m, 7H), 3.93 - 3.73 (m, 1H), 3.69 - 3.51 (m, 2H), 3.37 (dd, J = 6.2, 5.1 Hz, 2H), 2.59 - 1.52 (m, 11H).
649	1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 8.24 - 8.13 (m, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.79 - 7.36 (m, 6H), 4.82 - 4.24 (m, 12H), 4.16 (d, J = 11.4 Hz, 6H), 2.69 - 2.29 (m, 8H).
650	1H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 8.21 - 8.09 (m, 1H), 7.72 (dd, J = 7.4, 2.1 Hz, 1H), 7.67 - 7.52 (m, 2H), 7.52 - 7.36 (m, 3H), 4.81 - 4.25 (m, 12H), 4.15 (d, J = 4.4 Hz, 6H), 2.69 - 2.35 (m, 11H).
651	1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 8.16 (td, J = 7.2, 3.1 Hz, 1H), 7.72 (dd, J = 7.4, 2.0 Hz, 1H), 7.66 - 7.51 (m, 2H), 7.51 - 7.36 (m, 3H), 4.80 - 4.07 (m, 18H), 3.87-3.64 (m, 4H), 2.82 (d, J = 34.6 Hz, 4H), 2.53 (s, 3H).
652	1H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 7.73 (dd, J = 7.7, 1.7 Hz, 1H), 7.65 (dd, J = 7.7, 1.7 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.49 (dd, J = 7.6, 1.8 Hz, 1H), 7.43 (dd, J = 7.6, 1.7 Hz, 1H), 7.25 (m, 1H), 4.60 - 4.50 (m, 2H), 4.42 (q, J = 6.7 Hz, 1H), 4.38 - 4.28 (m, 2H), 4.15 (s, 4H), 4.10 (d, J = 2.0 Hz, 3H), 3.42 - 3.35 (m, 2H), 3.28 (m, 3H), 2.81 - 2.66 (m, 2H), 2.52 (s, 3H), 2.50 - 2.38 (m, 3H), 2.27 - 2.19 (m, 4H), 2.04 - 1.94 (m, 1H).
653	1H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 7.73 (dd, J = 7.7, 1.7 Hz, 1H), 7.65 (dd, J = 7.7, 1.7 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.49 (dd, J = 7.6, 1.7 Hz, 1H), 7.43 (dd, J = 7.6, 1.7 Hz, 1H), 7.27 (s, 1H), 4.55 (t, J = 2.0 Hz, 4H), 4.43 (d, J = 24.3 Hz, 2H), 4.22 (s, 1H), 4.17 (s, 1H), 4.15 (m, 4H), 4.10 (s, 3H), 3.41 - 3.35 (m, 2H), 2.55 (s, 3H), 2.51 - 2.36 (m, 3H), 2.06 - 1.93 (m, 1H), 1.87 (s, 3H).

No.	NMR
654	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (s, 1H), 7.73 (dd, J = 7.7, 1.7 Hz, 1H), 7.67 (dd, J = 7.7, 1.7 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.54 (t, J = 7.7 Hz, 1H), 7.49 (dd, J = 7.6, 1.7 Hz, 1H), 7.44 (dd, J = 7.6, 1.8 Hz, 1H), 7.29 (s, 1H), 4.69 (s, 1H), 4.55 (d, J = 3.9 Hz, 2H), 4.15 (s, 3H), 4.12 (s, 3H), 4.09 (s, 1H), 4.02 – 3.83 (m, 1H), 3.76 (s, 7H), 3.62 – 3.50 (m, 1H), 3.43 – 3.35 (m, 3H), 2.57 (s, 3H), 2.53 (s, 1H), 2.52 – 2.36 (m, 3H), 2.21 (s, 1H), 2.10 – 1.91 (m, 1H).</p>
655	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.56 (s, 1H), 7.73 (dd, J = 7.7, 1.8 Hz, 1H), 7.67 (dd, J = 7.7, 1.8 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.54 (t, J = 7.7 Hz, 1H), 7.49 (dd, J = 7.6, 1.7 Hz, 1H), 7.44 (dd, J = 7.6, 1.7 Hz, 1H), 7.28 (s, 1H), 4.57 (d, J = 3.0 Hz, 2H), 4.55 (d, J = 4.0 Hz, 2H), 4.28 (d, J = 11.6 Hz, 1H), 4.15 (m, 4H), 4.11 (s, 3H), 3.88 (t, J = 9.7 Hz, 1H), 3.37 (m, 3H), 3.15 (p, J = 1.6 Hz, 1H), 3.08 (d, J = 11.7 Hz, 1H), 3.00 (t, J = 10.6 Hz, 1H), 2.54 (s, 3H), 2.52 – 2.32 (m, 3H), 2.08 (d, J = 9.9 Hz, 1H), 2.05 – 1.87 (m, 2H), 1.79 (s, 1H).</p>
656	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.54 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.73 (dd, J = 7.7, 1.7 Hz, 1H), 7.59 (t, J = 7.8 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.49 (dd, J = 7.6, 1.7 Hz, 1H), 7.44 (dd, J = 7.6, 1.7 Hz, 1H), 7.39 (d, J = 7.5 Hz, 1H), 4.47 (s, 2H), 4.43 – 4.32 (m, 3H), 4.14 (s, 3H), 4.12 (s, 3H), 4.11 – 4.05 (m, 1H), 3.31 – 3.23 (m, 2H), 2.72 (qp, J = 8.5, 4.5 Hz, 1H), 2.51 – 2.33 (m, 3H), 2.33 – 2.16 (m, 4H), 2.01 – 1.87 (m, 1H).</p>
657	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.51 (s, 2H), 7.73 (m, 2H), 7.59 (t, J = 7.6 Hz, 2H), 7.50 (dd, J = 7.6, 1.7 Hz, 2H), 4.78 (s, 6H), 4.69 – 4.19 (m, 6H), 4.13 (s, 6H), 4.08 (s, 4H).</p>
658	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (dd, J = 5.3, 0.7 Hz, 2H), 7.72 (ddt, J = 7.7, 1.7, 0.8 Hz, 2H), 7.58 (tt, J = 7.6, 0.7 Hz, 2H), 7.48 (dtd, J = 7.6, 1.8, 0.7 Hz, 2H), 4.60 – 4.45 (m, 4H), 4.12 (d, J = 0.7 Hz, 7H), 3.54 – 3.38 (m, 5H), 3.38 – 3.27 (m, 6H), 3.04 – 2.91 (m, 2H), 2.52 – 2.31 (m, 5H), 2.05 – 1.86 (m, 3H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.75.</p>
659	<p>¹H NMR (400 MHz, Methanol-d₄) δ 8.53 (t, J = 0.8 Hz, 2H), 7.72 (ddt, J = 7.6, 1.6, 0.8 Hz, 2H), 7.58 (td, J = 7.6, 0.7 Hz, 2H), 7.48 (dd, J = 7.7, 1.5 Hz, 2H), 4.60 – 4.46 (m, 4H), 4.12 (d, J = 0.7 Hz, 6H), 3.40 (ddd, J = 12.6, 5.7, 3.2 Hz, 1H), 3.39 – 3.28 (m, 3H), 3.33 – 3.20 (m, H), 3.19 (dd, J = 12.7, 6.9 Hz, 1H), 2.57 (ddd, J = 17.2, 5.3, 1.9 Hz, 1H), 2.52 – 2.33 (m, 4H), 2.17 (dd, J = 17.3, 10.8 Hz, 1H), 2.07 (d, J = 13.7 Hz, 1H), 2.03 – 1.90 (m, 1H), 1.59 (ddt, J = 17.0, 11.2, 5.6 Hz, 1H). ¹⁹F NMR (376 MHz, Methanol-d₄) δ -77.73 (d, J = 2.3 Hz).</p>

No.	NMR
660	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (d, J = 0.6 Hz, 2H), 7.72 (ddd, J = 7.6, 1.7, 0.6 Hz, 2H), 7.58 (td, J = 7.6, 0.6 Hz, 2H), 7.48 (ddd, J = 7.6, 1.7, 0.6 Hz, 2H), 4.51 (s, 4H), 4.12 (d, J = 0.7 Hz, 6H), 3.45 – 3.14 (m, 5H), 2.57 (ddd, J = 17.3, 5.2, 1.9 Hz, 2H), 2.40 (t, J = 11.3 Hz, 2H), 2.17 (dd, J = 17.2, 10.8 Hz, 2H), 2.12 – 2.02 (m, 2H), 1.59 (dtd, J = 13.2, 11.1, 5.6 Hz, 2H). ¹⁹ F NMR (376 MHz, Methanol-d ₄) δ -77.84.
661	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.52 (d, J = 0.7 Hz, 2H), 7.72 (ddd, J = 7.7, 1.7, 0.7 Hz, 2H), 7.58 (td, J = 7.7, 0.7 Hz, 2H), 7.48 (ddd, J = 7.6, 1.8, 0.7 Hz, 2H), 4.60 – 4.45 (m, 5H), 4.12 (d, J = 0.7 Hz, 6H), 3.52 – 3.36 (m, 9H), 3.30 (p, J = 1.7 Hz, 5H), 2.98 (dtd, J = 10.5, 8.8, 6.9 Hz, 3H), 2.49 – 2.35 (m, 3H), 2.05 – 1.86 (m, 3H). Multiplet Report ¹⁹ F NMR (376 MHz, Methanol-d ₄) δ -77.63 – -77.74 (m), -77.76, -77.77 – -77.95 (m).
662	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.48 (s, 1H), 8.33 (d, J = 1.9 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.56 (t, J = 7.7 Hz, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.42 (s, 1H), 7.30 (d, J = 7.4 Hz, 1H), 4.69 (s, 3H), 4.68 (s, 2H), 4.62 (s, 2H), 4.49 (s, 1H), 4.44 (s, 2H), 4.26 (s, 1H), 4.15 (s, 1H), 4.11 (d, J = 1.9 Hz, 4H), 4.08 (s, 3H), 2.16 (s, 4H), 2.03 (d, J = 1.9 Hz, 2H), 1.86 (s, 8H).
663	¹ H NMR (400 MHz, Methanol-d ₄) δ 8.53 (s, 2H), 7.72 (dd, J = 7.7, 1.7 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.6, 1.7 Hz, 2H), 4.69 (s, 4H), 4.11 (s, 6H), 3.90 (d, J = 15.1 Hz, 4H), 3.61 (s, 1H), 3.41 (d, J = 9.7 Hz, 4H), 3.00 (d, J = 10.1 Hz, 1H), 2.72 (d, J = 48.1 Hz, 3H), 2.27 (d, J = 35.2 Hz, 3H), 1.95 (s, 6H), 1.81 (d, J = 16.7 Hz, 2H).

Biological Example 1:

PD-1/PD-L1 & CTLA/CD80 Biochemical Protein-Protein Interaction Assay

Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1 or CTLA/CD80. Binding of the protein pairs is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Disruption of the protein-protein interaction with a test compound results in a decrease in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.3 nM (His tagged PD-L1), 2.5 nM (biotinylated Fc-PD-1), 1 nM (His tagged CTLA4) and 1 nM (biotinylated CD80). After an assay reaction time of 60 minutes at 25 °C, binding was measured with addition of 20 µg/mL ALPHA assay acceptor beads (anti-His coated) and 20 µg/mL ALPHA assay donor beads (streptavidin coated). IC₅₀ values were calculated from the fit of the dose-response curves to a four-parameter equation. Representative data are shown below in Table 3.

Table 3

No.	IC ₅₀ PD-L1-PD1 (nM)
1	0.080
2	0.135
3	0.318
4	0.086
5	0.213
6	0.099
7	0.430
8	0.590
9	0.490
10	0.270
11	0.172
12	1.492
13	0.482
14	0.224
15	7.508
16	0.173
17	0.163
18	0.266
19	0.199
20	0.546
21	0.525
22	0.506
23	0.221
24	0.179
25	0.080
26	0.060
27	0.090
28	0.436
29	1.091
30	0.475
31	0.334
32	0.187
33	0.138
34	0.231
35	0.191

No.	IC ₅₀ PD-L1-PD1 (nM)
36	1.290
37	1.697
38	0.660
39	0.390
40	0.238
41	0.083
42	3.419
43	0.083
44	0.113
45	0.064
46	0.081
47	0.160
48	0.822
49	0.356
50	0.259
51	0.301
52	0.170
53	0.100
54	0.180
55	0.260
56	0.090
57	8.780
58	6.760
59	0.100
60	0.140
61	0.070
62	0.160
63	2.990
65	0.165
66	0.610
67	0.292
68	0.403
69	2.622
70	0.784
71	0.081

No.	IC ₅₀ PD-L1-PD1 (nM)
72	0.198
73	0.370
74	1.340
75	0.877
76	0.090
77	0.192
78	0.064
79	0.292
80	0.360
81	4.176
82	0.335
83	0.560
84	0.189
85	0.976
86	3.050
87	5.883
88	0.217
89	0.286
90	0.156
91	0.978
92	1.026
93	0.566
94	0.862
95	0.233
96	1.495
97	0.701
98	0.647
99	0.407
100	0.146
101	0.130
102	0.223
103	0.071
104	0.077
105	0.302
106	0.360

No.	IC ₅₀ PD-L1-PD1 (nM)
107	1.540
108	0.474
109	0.586
110	0.327
111	0.297
112	0.076
113	0.211
114	0.064
115	0.115
116	0.064
117	0.281
118	0.715
119	0.115
120	0.320
121	0.064
122	1.692
123	0.112
124	0.190
125	0.225
126	0.272
127	0.064
128	0.557
129	0.064
130	0.185
131	0.309
132	0.753
133	0.064
134	0.064
135	0.733
136	0.147
137	0.168
138	0.161
139	0.213
140	0.260
141	0.064

No.	IC ₅₀ PD-L1-PD1 (nM)
142	0.200
143	0.410
144	0.240
145	0.100
146	0.130
147	0.060
148	0.060
149	0.270
150	0.200
151	0.684
152	0.073
153	0.396
154	0.126
155	1.647
156	0.084
157	0.064
158	0.162
159	0.150
160	0.128
161	0.167
162	0.116
163	0.177
164	0.122
165	0.187
166	0.233
167	0.262
168	0.196
169	0.344
170	0.227
171	0.208
172	0.222
173	0.209
174	0.219
175	0.110
176	0.111

No.	IC ₅₀ PD-L1-PD1 (nM)
177	0.330
178	0.553
179	0.211
180	1.032
181	1.510
182	0.547
183	0.888
184	0.763
185	0.480
186	0.100
187	0.280
188	0.120
189	0.094
190	0.200
191	0.143
192	0.156
193	0.133
194	0.149
195	0.064
196	0.170
197	0.230
198	0.121
199	0.126
200	0.132
201	0.280
202	0.144
203	0.129
204	0.110
205	0.079
206	0.113
207	0.104
208	0.223
209	0.175
210	0.30
211	0.095

No.	IC ₅₀ PD-L1-PD1 (nM)
212	0.48
213	0.840
214	0.260
215	0.110
216	0.210
217	0.140
218	0.140
219	0.190
220	0.360
221	0.227
222	0.291
223	0.584
224	0.393
225	0.288
226	0.474
227	0.136
228	0.168
229	0.229
230	0.331
231	0.064
232	0.312
233	0.451
234	0.088
235	0.106
236	0.064
237	0.064
238	0.297
239	0.300
240	0.090
241	0.270
242	0.140
243	0.110
244	0.080
245	0.150
246	0.210

No.	IC ₅₀ PD-L1-PD1 (nM)
247	0.130
248	0.180
249	2.670
250	0.120
251	0.070
252	0.060
253	0.090
254	0.110
255	0.080
256	0.160
257	0.426
258	0.673
259	0.273
260	0.295
261	0.128
262	0.465
263	0.379
264	0.407
265	0.225
266	0.243
267	0.606
268	0.352
269	0.230
270	0.378
271	1.704
272	2.426
273	0.265
274	0.117
275	0.064
276	0.270
277	0.652
278	0.538
279	0.343
280	0.180
281	1.194

No.	IC ₅₀ PD-L1-PD1 (nM)
282	1.573
283	0.711
284	0.816
285	0.358
286	0.060
287	0.340
288	0.260
289	0.060
290	0.259
291	0.216
292	0.229
293	0.516
294	0.298
295	0.414
296	0.222
297	0.254
298	0.181
299	0.260
300	0.299
301	0.250
302	0.089
303	0.256
304	0.290
305	0.244
306	0.245
307	0.167
308	0.337
309	0.178
310	0.216
311	0.240
312	0.295
313	0.327
314	0.142
315	0.18
316	0.17

No.	IC ₅₀ PD-L1-PD1 (nM)
317	0.220
318	0.150
319	3.870
320	3.720
321	0.460
322	0.230
323	0.120
324	0.358
325	1.860
326	0.180
327	0.238
328	4.042
329	0.955
330	5.676
331	0.669
332	0.743
333	0.171
334	0.246
335	0.172
336	0.137
337	1.102
338	0.565
339	0.192
340	0.118
341	0.094
342	0.107
343	0.126
344	0.114
345	0.313
346	0.323
347	0.245
348	0.138
349	0.389
350	0.737
351	0.283

No.	IC ₅₀ PD-L1-PD1 (nM)
352	4.633
353	0.064
354	0.133
355	0.129
356	0.102
357	0.096
358	0.141
359	0.132
360	0.401
361	0.130
362	0.074
363	0.424
364	0.244
365	0.070
366	0.115
367	0.064
368	0.064
369	0.078
370	0.064
371	0.213
372	0.104
373	0.130
374	0.183
375	0.459
376	0.208
377	0.098
378	0.396
379	0.155
380	0.203
381	0.085
382	0.289
383	0.887
384	0.154
385	0.292
386	0.879

No.	IC ₅₀ PD-L1-PD1 (nM)
387	0.625
388	1.223
389	0.211
390	0.146
391	0.232
392	0.246
393	2.229
394	1.782
395	9.235
396	2.015
397	0.561
398	0.195
399	0.324
400	0.173
401	0.295
402	0.175
403	0.070
404	0.070
405	0.160
406	0.280
407	0.186
408	0.139
409	0.124
410	0.316
411	0.321
412	0.187
413	0.162
414	0.559
415	0.195
416	0.140
417	0.196
418	0.219
419	0.542
420	0.449
421	0.603

No.	IC ₅₀ PD-L1-PD1 (nM)
422	0.554
423	0.237
424	0.617
425	0.414
426	0.273
427	0.136
428	0.272
429	0.349
430	0.071
431	0.124
432	0.084
433	0.259
434	0.064
435	0.064
436	5.463
437	0.086
438	1.34
439	0.646
440	1.873
441	0.064
442	0.146
443	0.246
444	0.074
445	0.069
446	0.138
447	0.064
448	0.064
449	0.285
450	0.064
451	0.101
452	0.086
453	0.139
454	0.064
455	0.145
456	0.186

No.	IC ₅₀ PD-L1-PD1 (nM)
457	0.172
458	0.087
459	0.344
460	0.157
461	0.159
462	0.346
463	0.076
464	0.11
465	0.158
466	0.073
467	0.146
468	0.123
469	0.26
470	0.094
471	0.119
472	0.066
473	0.093
474	0.219
475	0.162
476	0.622
477	0.246
478	0.064
479	0.239
480	0.064
481	0.227
482	0.108
483	0.341
484	0.122
485	0.229
486	0.29
487	0.123
488	0.064
489	0.332
490	0.565
491	0.064

No.	IC ₅₀ PD-L1-PD1 (nM)
492	0.092
493	0.109
494	0.139
495	0.247
496	0.386
497	0.276
498	0.169
499	0.203
500	0.232
501	0.087
502	0.064
508	0.084
509	0.106
510	0.192
511	0.197
512	0.101
513	0.064
514	0.09
515	0.342
516	0.064
517	0.106
518	0.144
519	0.277
520	0.072
521	0.071
522	0.064
523	0.181
524	0.115
525	0.105
526	0.168
527	0.089
528	0.064
529	0.091
530	0.212
531	0.225

No.	IC ₅₀ PD-L1-PD1 (nM)
532	0.273
533	0.096
534	0.299
535	0.095
536	0.276
537	0.064
538	0.199
539	0.171
540	0.072
541	0.094
542	0.392
543	0.2
544	0.238
545	0.214
546	0.089
547	0.064
548	0.665
549	0.194
550	0.593
551	0.464
552	0.144
553	0.118
554	0.099
555	0.345
556	0.176
557	0.09
558	0.064
559	0.12
560	0.144
561	0.164
562	0.151
563	0.431
564	0.2
565	0.43
566	0.13

No.	IC ₅₀ PD-L1-PD1 (nM)
567	0.064
568	0.293
569	0.59
570	0.414
571	0.064
572	0.064
573	0.089
574	0.133
575	0.064
576	0.641
577	0.064
578	0.182
579	0.782
580	0.359
581	0.201
582	0.19
583	0.064
584	0.118
585	0.442
586	0.29
587	0.515
588	0.17
589	0.291
590	0.131
591	0.138
592	0.151
593	0.346
594	0.12
595	0.064
596	0.181
597	0.129
598	0.178
599	0.174
600	0.064
601	0.196

No.	IC ₅₀ PD-L1-PD1 (nM)
602	0.145
603	0.073
604	0.064
605	0.113
606	0.077
607	0.064
608	0.064
609	0.079
610	0.313
611	0.21
612	0.064
613	0.182
614	0.079
615	0.291
616	0.069
617	0.064
618	0.064
619	0.178
620	0.101
621	1.054
622	0.26
623	0.064
624	0.152
625	0.074
626	0.064
627	0.081
628	0.064
629	0.083
630	0.437
631	0.064
632	0.172
633	0.064
634	0.064
635	0.098
636	0.12

No.	IC ₅₀ PD-L1-PD1 (nM)	No.	IC ₅₀ PD-L1-PD1 (nM)	No.	IC ₅₀ PD-L1-PD1 (nM)
637	0.134	646	0.064	655	0.064
638	0.079	647	0.064	656	0.167
639	0.066	648	0.08	657	0.064
640	0.167	649	0.128	658	0.196
641	0.064	650	0.064	659	0.121
642	0.064	651	0.064	660	0.135
643	0.064	652	0.12	661	0.064
644	0.093	653	0.064	662	0.082
645	0.064	654	0.071	663	0.281

The above data shows that compounds of the present disclosure are generally effective at blocking the PD-1/PD-L1 interaction.

PD-1/PD-L1 NFAT Reporter Assay:

Compounds were tested in a functional co-culture reporter assay in which TCR-mediated NFAT activity is inhibited by the engagement of PD-1 with PD-L1. Blocking the PD-1/PD-L1 interaction impairs PD-1 mediated blunting of TCR signaling and significantly increases NFAT-mediated transcription of luciferase. CHO cells expressing surface-bound anti-CD3 antibodies and PD-L1 (artificial antigen presenting cells, aAPC-PD-L1) were first seeded overnight. Jurkat cells overexpressing PD-1 and expressing a luciferase construct under NFAT control are diluted in RPMI assay medium (RPMI 1640 with 2%FBS), mixed with compounds, and immediately seeded on the monolayer of aAPC-PD-L1. The co-culture is then incubated for 6 hrs at 37 °C. Luciferase activity is assessed by adding the ONE-Glo reagent and measuring luminescence with a plate reader. EC₅₀ values are calculated from the fit of the dose-response curves to a four-parameter equation (Table 4).

PD-L1/PD-L1 Dimerization Biochemical Protein-Protein Interaction Assay:

Compounds were tested in biochemical protein-protein interaction assays to determine if they can specifically dimerize the extracellular domains of PD-L1. Dimerization of the proteins (His-tagged PD-L1 and FLAG-tagged PD-L1) is measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA) platform. Compound induced dimerization of PD-L1 results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Assays are performed in 25 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, and 0.01% BSA. Final protein concentration in the assays were 0.5 nM (His tagged PD-L1) and 0.5 nM (FLAG tagged PD-L1). After an assay reaction time of 2 hours at 25°C, 20 µg/mL (final assay concentration) ALPHA assay acceptor beads (anti-His coated) were added and incubated for 60 minutes at 25 °C. Binding was measured following a final 60 minute incubation with 40 µg/mL (final assay concentration) ALPHA assay donor beads (anti-FLAG coated). AC₅₀ values were calculated from the fit of the dose-response curves to a four-parameter equation (Table 4).

Table 4

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
1	240.33	66
2	202.6	90
3	392.74	218
4	335.51	59
5	393.97	274
6	305.57	126
7	583.46	3442
8	644.47	5852
9	607.65	375
10	403.62	142
11	462.83	163
12	757.1	299
13	347.99	403
14	353.78	87
15	10000	50000
16	282.19	49
17	408.39	99
18	426.95	391
19	611.82	50000
20	10000	1164
21	731.29	193
22	685.61	252
23	335.84	108
24	338.33	89
25	229.05	76
26	215.35	78
27	205.5	157
28	530.34	156
29	1357.1	50000
30	446.13	181
31	247.95	325
32	252.14	242
33	527.94	138
34	668.28	271

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
35	371.63	40
36	10000	1608
37	516.49	667
38	1702.4	1607
39	282.95	291
40	694.13	3977
41	840.99	1206
42	10000	3046
43	372.8	214
44	369.96	145
45	325.08	68
46	311.32	55
47	694.52	215
48	2569.1	332
49	402.54	123
50	578.04	77
51	653.49	3264
52	586.85	220
53	353.66	104
54	201.78	131
55	421.05	211
56	259.11	104
57	319.44	277
58	728.88	711
59	291.2	56
60	260.45	59
61	211.47	50
62	311.93	201
63	387.65	314
65	167.34	957
66	306.4	1717
67	509.76	1806
68	769.42	50000
69	1489.1	50000

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
70	356.8	1131
71	298.23	842
72	144.68	175
73	141.66	222
74	120.4	128
75	733.44	606
76	364.58	81
77	243.78	44
78	276.77	55
79	428.2	221
80	481.52	286
81	10000	50000
82	1287.4	193
83	2505.1	94
84	749.38	75
85	1984.9	1027
86	10000	50000
87	10000	314
88	443.98	209
89	984.05	145
90	459.79	90
91	1327.2	579
92	10000	906
93	3077.7	234
94	7667.6	844
95	935.74	1008
96	6153.3	10199
97	755	50000
98	4099.2	296
99	694.66	568
100	733.69	94
101	319.17	250
102	916.48	194
103	273.94	63
104	762.09	108

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
105	631.44	630
106	766.54	6565
107	10000	922
108	3331.7	105
109	9105.7	11321
110	3779.4	893
111	2805.9	1010
112	334.96	92
113	345.93	121
114	128.97	169
115	215.77	251
116	182.89	221
117	208.11	281
118	10000	75
119	199.58	684
120	445.1	54
121	49.136	118
122	273.52	178
123	162.4	66
124	141.41	189
125	75.808	96
126	149.37	89
127	147.82	573
128	850.98	597
129	138.43	412
130	362.76	90
131	380.73	51
132	1987.6	335
133	80.854	73
134	93.585	121
135	893.64	323
136	497.22	64
137	911.52	185
138	478.77	74
139	316.16	119

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
140	523.32	40
141	61.477	83
142	444.64	86
143	935.68	218
144	821.08	160
145	284.53	62
146	376.2	84
147	219.91	21
148	240.84	50
149	644.02	174
150	555.04	198
151	10000	3920
152	193.3	2405
153	10000	50000
154	10000	6236
155	354.32	461
156	198.61	57
157	199.71	35
158	195.23	103
159	242.49	86
160	257.43	98
161	447.76	217
162	220.19	60
163	178.77	92
164	169.19	52
165	363.23	116
166	396.99	137
167	416.64	188
168	328.93	91
169	614.81	144
170	289.16	114
171	332.93	88
172	352.96	107
173	344.94	87
174	418.66	75

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
175	301.88	89
176	255.56	71
177	458.57	126
178	342.2	181
179	243.89	133
180	7553.7	610
181	10000	50000
182	734.41	315
183	838.01	360
184	502.06	271
185	368.99	617
186	253.73	124
187	498.41	232
188	290.06	129
189	489.49	41
190	704.99	41
191	602.43	279
192	473.83	64
193	513.8	92
194	593.95	169
195	437.96	48
196	434.26	95
197	412.83	68
198	331.55	125
199	361.43	61
200	593.43	100
201	250.63	181
202	330.42	47
203	602.8	121
204	415.43	70
205	423.98	73
206	509	59
207	367.58	52
208	446.16	41
209	442.05	18

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
210	250.74	123
211	161.64	74
212	284.89	189
213	942.18	458
214	345.44	536
215	287.86	154
216	566.87	191
217	295.45	98
218	267.04	154
219	136.53	144
220	443.54	180
221	425.01	186
222	567.51	134
223	667.4	305
224	613.37	245
225	299.81	117
226	559.43	368
227	318.49	65
228	337.06	96
229	320.33	201
230	627.52	284
231	317.88	49
232	377.77	117
233	472.96	353
234	212.85	37
235	306.18	45
236	213.57	54
237	301.81	52
238	363.63	337
239	1266	250
240	301.58	121
241	912.47	274
242	424.01	81
243	396.89	83
244	255.87	130

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
245	309.98	202
246	724.79	2078
247	366.02	156
248	408.37	138
249	10000	50000
250	253.1	929
251	261.95	50000
252	357.76	82
253	255.07	78
254	202.9	633
255	138.35	172
256	613.08	263
257	528.03	268
258	10000	3534
259	372.54	1977
260	869.26	1872
261	494.43	117
262	1383.3	1409
263	796.17	1060
264	806.91	1136
265	579.77	238
266	606.61	640
267	416.46	484
268	405.02	275
269	455.1	347
270	490.29	208
271	10000	50000
272	2199.5	1519
273	299.55	261
274	374.67	94
275	177.21	27
276	558.56	278
277	2992.8	616
278	1886.1	923
279	996.73	423

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
280	577.23	1093
281	1110.6	256
282	10000	352
283	810.85	203
284	928.54	520
285	636.77	156
286	233.86	101
287	911.62	5209
288	221.54	132
289	253.52	61
290	757.43	234
291	431.8	10913
292	329.88	205
293	768.18	243
294	510.87	267
295	528.13	217
296	351.75	95
297	404.21	223
298	343.89	126
299	320.99	122
300	509.06	175
301	852.36	311
302	351.12	156
303	564.3	173
304	589.38	391
305	390.28	102
306	417.73	138
307	366.17	70
308	376.22	152
309	392.45	84
310	391.31	173
311	318.45	158
312	476.32	176
313	637.34	426
314	311.4	77

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
315	110.9	52
316	219.01	85
317	625.74	169
318	197.44	87
319	10000	50000
320	186.69	111
321	934.73	1025
322	596.63	276
323	187.05	87
324	443	195
325	1664.9	50000
326	235.57	135
327	1194.4	150
328	10000	50000
329	647.48	223
330	10000	286
331	332.12	236
332	1070.4	50000
333	355.27	100
334	484.05	120
335	397.45	146
336	328.96	200
337	419.55	238
338	393.49	344
339	392.15	204
340	542.53	91
341	669.95	83
342	459.66	54
343	519.17	92
344	403.75	57
345	423.04	80
346	452.36	95
347	567.07	84
348	407.79	64
349	268.4	151

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
350	5440.8	550
351	566.15	83
352	10000	2822
353	262.56	47
354	392.78	58
355	336.38	68
356	345.82	44
357	316.85	77
358	445.56	69
359	398.4	52
360	636.01	115
361	380.23	56
362	273.29	51
363	419.83	162
364	562.57	126
365	395.18	88
366	418.51	136
367	401.17	34
368	494.92	46
369	451.56	193
370	246.32	48
371	423.53	68
372	375.51	47
373	396.81	159
374	310.58	46
375	810.72	179
376	455.77	88
377	461.33	83
378	492.68	124
379	304.77	24
380	903.67	86
381	220.58	35
382	1018.8	173
383	438.4	321
384	1529.5	87

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
385	246.71	143
386	1139	1070
387	658.16	233
388	831.08	5277
389	711.54	98
390	537.01	110
391	412.01	64
392	418.26	116
393	10000	50000
394	10000	50000
395	10000	50000
396	10000	50000
397	3410.2	291
398	434.16	139
399	589.87	60
400	601.31	47
401	652.27	121
402	256.72	147
403	223.08	68
404	206.21	107
405	371.33	186
406	348.29	255
407	320.76	92
408	245.75	89
409	276.42	68
410	265.76	94
411	220.22	109
412	177.99	121
413	190.09	159
414	477.79	410
415	463.96	227
416	297.81	102
417	254.17	339
418	353.69	134
419	154.71	304

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
420	648.16	188
421	10000	50000
422	360.44	132
423	1137.7	216
424	5708.9	50000
425	689.58	230
426	465.34	98
427	567.52	107
428	533.99	178
429	539.48	133
430	426.93	76
431	301.45	56
432	221.18	249
433	411.65	95
434	138.15	31
435	119.7	27
436	252.11	114
437	248.47	41
438	1067.7	446
439	639.68	158
440	3589.1	1357
441	354.66	112
442	205.36	88
443	267.4	57
444	336.13	32
445	249.34	35
446	309.41	54
447	354.48	24
448	388.09	28
449	420.34	46
450	83.295	153
451	246.61	131
452	197.92	95
453	208.68	98
454	548.84	140

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
455	307.89	79
456	220.61	55
457	350.98	120
458	291.36	169
459	467.3	146
460	422.41	198
461	280.93	130
462	313.97	165
463	250.21	88
464	394.11	139
465	276.08	84
466	328.83	97
467	293.02	90
468	148.43	44
469	377.61	166
470	251.52	121
471	141.95	49
472	159.64	40
473	178.06	57
474	637.08	95
475	338.67	50
476	384.96	171
477	393.47	66
478	209.93	16
479	517.18	109
480	218.25	29
481	245.05	72
482	309.56	56
483	304.7	153
484	195.44	72
485	293.8	63
486	234.14	148
487	180.17	65
488	321.37	67
489	1160.7	43

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
490	1365.8	104
491	225.05	43
492	127.28	65
493	165.61	40
494	139.69	57
495	373.48	180
496	450.5	176
497	242.05	158
498	179.03	80
499	455.99	110
500	324.11	89
501	262.7	76
502	209.05	40
508	193.02	80
509	179.77	81
510	161	41
511	198.59	60
512	255.73	127
513	155.63	141
514	187.1	135
515	326.79	162
516	277.85	68
517	282.44	100
518	318.12	151
519	438.99	71
520	179.81	82
521	126.14	50
522	209.96	79
523	268.2	84
524	274.9	54
525	322.25	43
526	307.95	155
527	238.19	92
528	187.07	76
529	157.29	104

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
530	392.15	100
531	449.69	74
532	271.56	68
533	156.78	37
534	153.8	46
535	156.47	60
536	234.37	99
537	160.28	46
538	559.01	99
539	314.53	63
540	401.53	46
541	345.59	80
542	275.46	83
543	199.23	62
544	1741.3	111
545	493.12	124
546	373.32	125
547	248.97	73
548	353.21	142
549	393.57	96
550	1165.1	148
551	358.35	92
552	352.37	169
553	425.98	122
554	240.08	130
555	379.07	106
556	513.98	74
557	313.91	115
558	210.24	50
559	261.43	66
560	433.11	162
561	203.15	31
562	473.43	58
563	545.94	98
564	330.63	58

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
565	326.42	90
566	293.18	63
567	227.96	21
568	646.29	164
569	593.64	153
570	427.87	184
571	259.53	96
572	351.82	130
573	257.44	75
574	310.5	150
575	227.13	73
576	432.38	187
577	90.285	63
578	267.8	198
579	448.31	165
580	306.36	194
581	187.05	149
582	135.62	121
583	53.288	65
584	84.945	115
585	492.38	129
586	469.53	85
587	496.67	105
588	390.01	58
589	307.89	99
590	676.48	56
591	195.23	28
592	246.23	43
593	246.65	82
594	239.11	21
595	117.9	17
596	215.39	32
597	281.77	31
598	174.83	60
599	189.42	99

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
600	137.66	34
601	268.53	88
602	217.64	73
603	195.39	159
604	254.67	34
605	256.04	60
606	203.59	74
607	142.37	36
608	379.95	18
609	396.2	56
610	227.28	73
611	233.34	145
612	282.68	19
613	377.69	92
614	169.8	63
615	294.52	144
616	188.86	60
617	309.56	74
618	205.79	27
619	223.42	102
620	154.07	143
621	224.96	71
622	231.74	79
623	192.23	94
624	163.79	39
625	129.55	32
626	263.43	25
627	189.61	58
628	171.09	53
629	157.06	14
630	200.17	40
631	130.42	25
632	229.73	47
633	233.21	46
634	232.31	14

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
635	134.19	50
636	180.16	25
637	243.34	42
638	98.219	42
639	563.95	31
640	525.75	50
641	64.437	44
642	60.016	31
643	44.34	48
644	35.75	48
645	36.462	49
646	66.651	48
647	51.449	37
648	287.34	38
649	220.43	21

No.	AC ₅₀ PDL1 Dimer	EC ₅₀ NFAT Luciferase
650	76.27	35
651	68.737	26
652	104.79	46
653	64.175	15
654	142.04	39
655	154.84	50
656	199.94	43
657	274.75	21
658	253.78	49
659	306.76	39
660	663.58	39
661	356.06	30
662	688.81	36
663	618.38	49

Biological Example 2:

In Vitro Activity of Compound 139 on HBV-specific T Cells from CHB Patient PBMCs

This example shows the effect of compound 139 on HBV-specific T cell function in peripheral blood mononuclear cells obtained from chronic hepatitis B (CHB) patients. Inhibition of the interaction between programmed death 1 (PD-1) with its ligand (PD-L1) with specific monoclonal antibodies has been reported to enhance the antiviral function of HBV-specific T cells. This study evaluated the ability of a PD-L1 inhibitor described herein (i.e., compound 139), to enhance HBV-specific T cell functions in peripheral blood mononuclear cells (PBMC) isolated from chronic hepatitis B (CHB) patients. PBMCs from CHB patients were treated for 6 days with compound 139 or DMSO in the presence of HBV core peptides, followed by re-stimulation for 16 hours before analysis of CD8⁺ and CD4⁺ T cells by flow cytometry. Compared to DMSO-treated controls, treatment with compound 139 increased the percentage of interferon- γ (IFN- γ)⁺ CD8⁺ T cells by 2.5 fold ($p = 0.01$) and IFN- γ ⁺ CD4⁺ T cells by 2.5 fold ($p = 0.003$). Compound 139 also significantly increased the expression of granzyme B (GrB) in HBV-specific CD8⁺ T cells by 1.2 fold ($p = 0.015$) and in CD4⁺ T cells by 1.8 fold ($p = 0.045$). The increases in IFN- γ and GrB production in CD8⁺ T cells following treatment with compound 139 was comparable to those induced by durvalumab, a marketed anti-PD-L1 monoclonal antibody. These data demonstrate that compound 139 enhances the antiviral function of HBV-specific CD8⁺ and CD4⁺ T cells from CHB patients in vitro to a degree comparable to anti-PD-L1 monoclonal antibodies.

Materials and Methods

Compounds

Compound 139 was dissolved in 100% DMSO to prepare a 10 mM stock solution and stored at -20°C. The anti-PD-L1 Ab durvalumab was produced and purified at Gilead Sciences. In all assays, compound 139 was evaluated at the dose of 650 nM, which is 2x concentration above the EC₉₀ value as determined in a human blood polyclonal activation assay. Durvalumab (durva) was used at 10 µg/mL concentration as per previously reported studies (Boni et al. *J Virol*, 2007; 81(8); 4215-4225).

Whole Blood from CHB Donors

CHB donors were sourced by C&M LabPro, LLC (San Francisco, CA), MT Group, Inc. (Van Nuys, CA), and BioIVT (Westbury, NY). Whole blood from CHB donors was drawn into K2 EDTA Tubes (Becton Dickinson, Franklin Lakes, NJ) and shipped overnight to Gilead Sciences, Inc. PBMCs from the blood samples were isolated at Gilead Sciences using the protocol described below. Table 5 summarizes HBV s antigen (HBsAg) and HBV e antigen (HBeAg) reactivity as well as demographic data for the CHB patients in this study.

Table 5. CHB Patient Demographics.

Donor ID#	HBsAg	HBeAg	Age	Sex
1	+	+	74	M
2	+	-	59	M
3	+	n/a	36	F
4	+	-	65	M
5	+	+	63	F
6	+	n/a	67	F
7	+	-	53	F
8	+	+	59	M
9	+	-	44	F
10	+	-	69	M
11	+	-	48	M
12	+	-	55	M
13	+	+	49	F
14	+	n/a	48	M

n/a = not available

Assays

PBMC Isolation from Whole Blood

PBMCs were isolated from whole blood using a standard Ficoll[®] Paque gradient. Briefly, 25-30 mL of blood was gently overlaid on top of 15 mL Ficoll[®] Paque Plus solution (GE Healthcare, Chicago, IL) in a 50 mL Falcon tube, and centrifuged in an Allegra X-14R (Beckman Coulter, Indianapolis, IN) at

520g for 20 minutes at 25 °C. The mononuclear cell layer was washed twice with PBMC wash buffer (RPMI Medium 1640 – GlutaMAX-I (Life Technologies, Carlsbad, CA)) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS; Hyclone, Logan, UT). Next, the cells were centrifuged at 520g for 5 minutes and red blood cells (RBC) lysed for 5 minutes at room temperature using RBC Lysis Buffer (eBioscience, San Diego, CA). After a final wash with PBMC wash buffer, the cells were resuspended in cell culture medium consisting of RPMI 1640 culture medium supplemented with 25 mM HEPES (Life Technologies), 100 U/mL Penicillin/Streptomycin (Sigma Aldrich, St Louis, MO), 1x non-essential amino acids (Life Technologies, Carlsbad, CA), 10% FBS, and 20 U/mL interleukin-2 (IL-2) (Miltenyi Biotec, Sunnyvale, CA) before cell number and viability were determined using trypan blue (VWR, Radnor, PA) exclusion. PBMCs were either subsequently used for the T cell expansion assay, or were cryopreserved with 10% DMSO in FBS before further use.

CD8⁺ and CD4⁺ T Cell 7-day Expansion and Recall Response Assay

PBMCs were seeded at 2 - 4 x 10⁵ cells/well in 96-well round bottom plates (Corning, NY). A pool of 15-mer 11-amino acid (AA) overlapping peptides spanning the entire HBV core sequence was added at 100-300 ng/mL concentration in the presence of 650 nM compound 139, or 10 µg/mL durvalumab, or the equivalent volume of DMSO (Sigma Aldrich). PBMCs were incubated for 7 days at 37 °C with 5% CO₂ in a humidified incubator. Cell culture medium (as described above) was replenished with fresh medium containing IL-2 (without peptides, compound 139, or durvalumab) after 4 days. On Day 6, PBMCs were re-stimulated by the addition of 100 - 300 ng/mL HBV core peptides, or DMSO. Compound 139 or durvalumab was also added during the re-stimulation. To inhibit protein transport, 1 µg/mL brefeldin A solution (Sigma) was added to each well. After overnight incubation, cells were processed for immunostaining and flow cytometry as described herein.

Immunostaining and Flow Cytometry

After re-stimulation overnight with the peptide pool and compound 139 or durvalumab, PBMCs were pelleted by centrifugation on Day 7 and washed twice with PBS. Washed cells were resuspended in Live/Dead Aquamine Stain (Invitrogen) per manufacturer's instructions to determine the viability of the cells by flow cytometry. Live/Dead Aqua stained PBMCs were washed twice with FACS staining buffer (1 % FBS in PBS), and then incubated with 50 µL of Fc blocking reagent (BD Biosciences, Franklin Lakes, NJ) for 10 minutes at room temperature. A mixture of antibodies (50 µL/well) described in Table 6 were added to the blocking solution for surface staining, and PBMCs were incubated with the antibodies for 40 minutes at 4 °C. PBMCs were pelleted by centrifugation as described above and washed twice with FACS buffer, followed by fixation with 1x FoxP3 Fix/Perm buffer (eBioscience) for 1 hour. Cells were washed twice with the permeabilization reagent included in the FoxP3 staining kit and incubated with antibodies for intracellular staining of IFN-γ and GrB (Table 6) at 1.0 µg/mL. After 1 hour incubation at 4 °C, PBMCs were centrifuged and washed twice before being resuspended in FACS buffer. Stained PBMCs were analyzed by flow cytometry using a BD LSRFortessa X-20 Cell Analyzer (Becton Dickinson). BD Comp Beads (BD Biosciences) were used as compensation controls. CD8⁺ and

CD4⁺ T cells were identified by gating on the live Aquamine⁻CD3⁺CD8⁺ and Aquamine⁻CD3⁺CD4⁺ PBMC population respectively.

Table 6. Flow Cytometry Antibodies

Antibody	Fluorophore	Clone	Supplier
CD3	Percp-Cy5.5	UCHT1	BD Biosciences
CD4	BV650	SK3	BD Biosciences
CD8	BV605	SK1	BD Biosciences
Granzyme B	Alexa Fluor [®] 647	GB11	BD Biosciences
IFN- γ	APC-Cy7	B27	BioLegend [®]

Data Analysis

Flow cytometry data was analyzed using FlowJo Flow Cytometry Analysis Software v10 (TreeStar, Ashland, OR). Data was exported and statistical analysis was performed using GraphPad Prism v6 (GraphPad Software, La Jolla, CA). Statistical significance relative to the DMSO control was calculated by two-tailed, paired t-test.

Results

To evaluate the effects of compound 139 on the activation of HBV-specific T cells, PBMCs isolated from 14 CHB donors were stimulated with a pool of 15-mer peptides spanning the HBV core sequence. During peptide stimulation, PBMCs were treated with compound 139 (650 nM) or vehicle control (DMSO) for 6 days. After 6 days of peptide stimulation and treatment with compound 139, PBMCs were re-stimulated for 16 hours with fresh peptides and compound 139 or DMSO. As surrogates of effector function, intracellular levels of IFN- γ (antiviral cytokine) and GrB (a marker of cytotoxic function) were measured by flow cytometry in CD3⁺CD8⁺ and CD3⁺CD4⁺ T cell populations.

In HBV core peptide-stimulated PBMCs isolated from 14 CHB donors, compound 139 significantly increased the frequencies of both IFN- γ ⁺ (2.5-fold, $p = 0.01$) and GrB⁺ (1.2-fold, $p = 0.015$) CD8⁺ T cells, as compared with DMSO treated PBMCs (Figure 1A and Table 7). For control purposes, durvalumab, a marketed monoclonal α -PD-L1 antibody, was also tested in PBMCs isolated from 9 out of the 14 CHB donors. We found that both compound 139 and durvalumab induced a comparable increase of IFN- γ ⁺ CD8⁺ T cells (2.5-fold versus 2.7-fold, respectively, $p = 0.21$) and GrB⁺ CD8⁺ T cells (1.2-fold versus 1.1-fold, respectively, $p = 0.53$) (Figure 1B and Table 7). These data agree with a previous report where IFN- γ ⁺ cells in CD8⁺ T and CD4⁺ T cells were enhanced by 1.8- to 8.2-fold ($p = 0.028$) and 2.2- to 4.3-fold ($p = 0.01$) respectively in 8 responsive patients out of 24 total patients after in vitro treatment with an α -PD-L1 antibody (Fiscaro et al., *Gastroenterology*, 2010; 138(2): 682-693, 93 e1-4).

Table 7. Compound 139 Enhances IFN- γ and Granzyme B Production in CHB CD8⁺ T Cells.

Donor ID#	IFN- γ ⁺ CD8 ⁺ T cells					GrB ⁺ CD8 ⁺ T cells				
	% IFN- γ ⁺			Fold change over DMSO		% GrB ⁺			Fold change over DMSO	
	DMSO	Cmpd 139	Durva ¹	Cmpd 139	Durva	DMSO	Cmpd 139	Durva	Cmpd 139	Durva
1	0.94	1.53	n.d. ²	1.63	n.d.	33.40	32.30	n.d.	0.97	n.d.
2	1.85	2.63	n.d.	1.42	n.d.	47.30	47.80	n.d.	1.01	n.d.
3	0.26	0.94	n.d.	3.62	n.d.	5.27	8.78	n.d.	1.67	n.d.
4	0.04	0.41	0.36	11.08	9.73	38.80	50.30	47.20	1.30	1.22
5	0.20	0.61	n.d.	3.00	n.d.	14.31	30.67	n.d.	2.14	n.d.
6	1.45	3.06	3.99	2.12	2.76	24.80	28.15	17.70	1.14	0.71
7	0.94	0.90	1.20	0.95	1.27	23.93	24.10	22.93	1.01	0.96
8	0.79	3.28	0.85	4.13	1.07	38.02	45.05	47.23	1.18	1.24
9	3.90	4.69	n.d.	1.20	n.d.	19.30	20.20	n.d.	1.05	n.d.
10	0.20	0.30	0.73	1.46	3.61	30.07	33.50	31.77	1.11	1.06
11	6.69	7.74	8.18	1.16	1.22	50.83	52.67	56.20	1.04	1.11
12	1.56	1.86	2.98	1.19	1.91	18.70	18.93	27.25	1.01	1.46
13	5.60	4.69	7.58	0.84	1.35	22.17	23.23	28.40	1.05	1.28
14	8.42	11.17	14.16	1.33	1.68	35.83	55.80	35.80	1.56	1.00
Average \pm SD	2.35 \pm 2.71	3.13 \pm 3.12	4.45 \pm 4.67	2.51 \pm 2.67	2.73 \pm 2.75	28.77 \pm 12.78	33.68 \pm 14.46	34.94 \pm 12.78	1.23 \pm 0.34	1.11 \pm 0.22

1. Durva = Durvalumab

2. n.d. = not done

Additionally, treatment of CD4⁺ T cells with compound 139 significantly enhanced the frequency of HBV-specific IFN- γ ⁺ cells (2.5 fold, $p = 0.003$) and GrB⁺ cells (1.8 fold, $p = 0.045$) over DMSO-treated PBMCs (Figure 2A and Table 8). The frequencies of CD4⁺ IFN- γ ⁺ T cells between compound 139 and durvalumab treated PBMCs were not statistically significant (2.5% versus 3.1% respectively; $p = 0.2018$). Compound 139 and durvalumab also enhanced the frequency of GrB⁺ CD4⁺ T cells to similar levels (4.7% versus 4.3% respectively, $p=0.07$) (Figure 2B), as compared with DMSO treatment (3.5%) (Table 8).

Table 8. Compound 139 Enhances IFN- γ and Granzyme B Production in CHB CD4⁺ T Cells.

Donor ID#	IFN- γ ⁺ CD4 ⁺ T cells					GrB ⁺ CD4 ⁺ T cells				
	% IFN- γ ⁺			Fold change over DMSO		% GrB ⁺			Fold change over DMSO	
	DMSO	Cmpd 139	Durva ¹	Cmpd 139	Durva	DMSO	Cmpd 139	Durva	Cmpd 139	Durva
1	0.94	1.53	n.d. ²	1.63	n.d.	5.79	4.91	n.d.	0.85	n.d.
2	7.78	9.22	n.d.	1.19	n.d.	12.8	15.2	n.d.	1.19	n.d.
3	0.56	1.39	n.d.	2.48	n.d.	0.60	3.80	n.d.	6.33	n.d.
4	0.29	1.42	5.38	4.90	18.55	2.27	5.63	7.88	2.48	3.47
5	0.11	0.79	n.d.	7.48	n.d.	4.05	7.76	n.d.	1.92	n.d.
6	0.24	0.41	3.41	1.73	14.39	0.74	0.93	0.55	1.25	0.74
7	0.23	1.40	0.44	6.18	1.95	0.82	0.88	1.53	1.07	1.87
8	0.85	0.94	1.18	1.11	1.39	1.28	2.43	1.25	1.89	0.97
9	1.01	1.76	n.d.	1.74	n.d.	2.96	3.72	n.d.	1.26	n.d.
10	3.09	2.83	2.94	0.92	0.95	5.83	3.27	3.74	0.56	0.64
11	0.45	0.61	0.60	1.37	1.33	2.27	3.98	3.89	1.75	1.72
12	0.29	0.54	0.51	1.86	1.74	3.84	6.04	9.17	1.57	2.38
13	6.33	6.83	8.24	1.08	1.30	4.51	5.21	7.60	1.16	1.69
14	4.03	5.64	4.97	1.40	1.23	0.72	1.44	3.49	2.01	4.86
Average \pm SD	1.87 \pm 2.49	2.52 \pm 2.72	3.07 \pm 2.71	2.51 \pm 2.10	4.76 \pm 6.73	3.46 \pm 3.25	4.66 \pm 3.63	4.34 \pm 3.15	1.81 \pm 1.40	2.04 \pm 1.38

¹. Durva = durvalumab; ². n.d. = not done

Conclusion

Compound 139 significantly increased the frequencies of HBV-specific IFN- γ ⁺ cells in both CD4⁺ (2.5-fold, p=0.01) and CD8⁺ T cells (2.5-fold, p=0.003). Compound 139 also enhanced the frequency of GrB⁺ cells among HBV-specific CD8⁺ (1.2 fold, p=0.015) and CD4⁺ T cells (1.8 fold, p=0.045). Furthermore, the ability of compound 139 to enhance the antiviral functions of HBV-specific CD8⁺ and CD4⁺ T cells in vitro was comparable to those of durvalumab, a marketed α -PD-L1 antibody. Taken together, these data indicate that compound 139 enhances the antiviral/effector functions of HBV-specific CD8⁺ and CD4⁺ T cells from CHB patients in vitro.

Biological Example 3:

Pharmacologic Assessment in Mouse Tumor Model

The compounds described herein are small molecule PD-L1 inhibitors that block the PD-1/PD-L1 interaction through a mechanism of action that is distinct from the clinically approved monoclonal antibodies. The objective of this study was to assess the relationship of pharmacokinetics (PK), TO and

anti-tumor activity of compound 139 in a human PD-L1 expressing MC38 mouse colorectal tumor model.

Compound 139 does not bind murine PD-L1, precluding the use of traditional syngeneic murine tumor models to assess compound 139 activity in vivo. However, compound 139 blocks the interaction between mouse PD-1 and human PD-L1 as determined by a biochemical binding assay. Therefore, a human PD-L1-expressing MC38 mouse colorectal tumor model was utilized to evaluate the activity of compound 139 in vivo. An α -PD-L1 antibody that is unable to bind to murine PD-L1 was included as a positive control.

At 10, 25, and 50 mg/kg compound 139 or 10 mg/kg PD-L1 antibody, > 90% PD-L1 target occupancy (TO) on the tumor cells was observed for at least 24 hours. This result translated to similar tumor growth inhibition (TGI) of 32% to 38% for both compound 139 and PD-L1 antibody at indicated dose groups. In parallel, compound 139 plasma concentrations were determined at the same time points used to determine intratumoral TO. At 10 mg/kg, compound 139 plasma concentrations dropped below the whole blood EC₉₀ value for compound 139 but > 90% TO was retained, indicating that compound 139 TO on the tumor extended beyond plasma exposure. Moreover, there was no treatment-related effect on body weight, indicating compound 139 was well-tolerated at all doses for the entire study.

Materials and Methods

Test Articles

Compound 139 was synthesized at Gilead Sciences, Inc. (Foster City, CA). Durvalumab; α -PD-L1 antibody and Isotype control antibody (human IgG1, hIgG1) were produced and purified at Gilead Sciences.

In Vivo Formulation of Compound 139

The vehicle formulation for compound 139 was 10% ethanol, 40% PEG 300 and 50% DI water and was formulated in a single batch for the entire study. Compound 139 formulations were prepared weekly and stored under refrigerated conditions (4°C-8°C). Before dosing, the solution was warmed to room temperature while stirring. Solution was stirred constantly during the whole process of dosing. Compound 139 was formulated as a 2 mg/mL and 5 mg/mL solution in the vehicle. Compound 139 powder was brought to room temperature before use, weighed and added to a suitable container. Appropriate volume of ethanol was dispensed into the container. Next, an appropriate volume of PEG-300 was added to the container while stirring. Once the powder was fully dissolved, an appropriate volume of water was slowly added while stirring. The powder was allowed to fully dissolve in solution and the pH was adjusted to 3 using 1N NaOH. The solution was sterile filtered using a nylon syringe filter before administration.

In Vivo Formulation of durvalumab and isotype control antibody

The isotype control antibody (hIgG1) contains the same mutation in the Fc domain as durvalumab α -PD-L1 antibody. Isotype control antibody and durvalumab stock solutions (20 mM Histidine-HCl pH 5.8, 9% Sucrose and 0.05% Tween-80) were diluted in PBS to 2 mg/mL. The dosing volume was 5 mL/kg.

Animals

Female C57BL/6 mice were purchased from Shanghai Lingchang Bio-Technology. Animals were between 8 to 10 weeks when tumors were inoculated. Mice were acclimated for 1 week before tumor inoculation.

Human PD-L1-Expressing MC38 Colorectal Tumor Model

To create a human PD-L1-expressing MC38 tumor cell line (Crown Bioscience), murine PD-L1 knockout cells were generated by using the CRISPR-Cas9 system (Figure 3). Stable clones expressing human PD-L1 (driven by a cytomegalovirus promoter) were then generated from knockout cells by lipofectamine (Thermo Fisher Scientific) transfection.

Cell Culture

Human PD-L1-expressing MC38 tumor cells were cultured in DMEM medium (GE Healthcare) supplemented with 10% heat-inactivated fetal bovine serum (ExCell Biology) and 50 μ g/mL hygromycin B at 37°C in an atmosphere of 5% CO₂ in air.

Tumor Inoculation

Before inoculation, human PD-L1-expressing MC38 tumor cells were measured by trypan blue staining to assess viability. Cells with viability greater than 90% were used for inoculation. Each mouse was inoculated subcutaneously (SC) at the right hind flank with the tumor cells (1×10^6 cells suspended in 100 μ L PBS for each mouse). After inoculation, the remaining cells were measured by trypan blue staining again for viability to confirm viability did not drop below 90%.

Group Randomization

108 mice were enrolled in the study. All animals were randomly allocated to the study groups. Day 0 was defined as the time when mean tumor size at randomization was approximately 50 mm³ and mice weighted between 17 to 20 grams. Randomization was performed based on “Matched Distribution” randomization method using multi-task method (StudyDirector™ software, version 3.1.399.19).

Animal Observation and Tumor Measurement

After tumor cell inoculation, the animals were checked daily for morbidity and mortality. During routine monitoring, the animals were checked for any effects of tumor growth, changes with behavior such as mobility, food and water consumption, body weight gain/loss (body weights were measured

twice per week), and any gross abnormalities. Mortality and observed clinical signs were recorded for individual animals. Body weight was measured twice per week.

Tumor volumes were measured twice weekly in two dimensions using a caliper, and the volume was expressed in mm³ using the formula: $V = (L \times W \times W) / 2$, where V is tumor volume, L is tumor length (the longest tumor dimension) and W is tumor width (the longest tumor dimension perpendicular to L).

Termination

Any animal with tumor size exceeding 2500 mm³ (or group of mice with mean tumor size exceeding 2000 mm³) was euthanized.

In vivo TO on Human PD-L1-Expressing MC38 Tumor Cells

Tumor Dissociation

Tumors were collected from mice, washed in PBS with extra tissues removed (i.e. blood vessel, fat and fascia). In each well of a sterile 6-well plate (Corning), the tumor was placed in 3 mL of dissociation media (Murine Tumor Dissociation Kit, Miltenyi). Tumors were held in place with sterile tweezers and forceps and sliced with a scalpel until small tumor pieces of ~ 1 mm³ were obtained. Tumor pieces were then transferred to gentleMACS C tubes (Miltenyi) and placed on ice until digestion. Once all the tumors had been sliced, C tubes were transferred to gentleMACS Octo Dissociator with Heaters (Miltenyi). Dissociation program (37_c_m_TDK_1) was selected for tumor digestion. After completion of the program, C tubes were spun down at 300 x g. Samples were re-suspended and added to a cell strainer (Corning) placed above a 50 mL centrifuge tube (Corning). Cells were washed through the cell strainer with 10 mL of wash buffer (10% FBS, Gibco; 40 mM EDTA, Boston BioProducts; PBS without calcium and magnesium, GE Healthcare) to obtain single cell suspensions. The tubes were then centrifuged at 300g for 5 minutes. Supernatants were removed and cells were counted and adjusted to 1×10^6 per tube in Staining Buffer (BD Biosciences).

Assessment of TO on Tumor

1×10^6 cells from tumor were re-suspended in 15 mL centrifuge tubes (Corning) with 200 μ L of Staining Buffer (BD Biosciences) and 1 μ g/mL Mouse Fc Block (Purified rat α -mouse CD16/CD32, BD Biosciences). Tubes were incubated for 15 mins in the dark at 4°C. Antibody cocktail (Table 9) was added to each tube and further incubated for 30 mins in the dark at 4°C. 2 mL of ice cold PBS was added and tubes were centrifuged at 300 x g for 5 mins. The wash step was performed twice. After discarding the supernatants from the last wash, cell pellets were re-suspended in 200 μ L of Fixation/Permeabilization working solution (Thermo Fisher Scientific) for 10 minutes at room temperature in the dark. Tubes were centrifuged at 300 x g for 5 minutes and supernatants were removed. Cells were resuspended with 150 μ L of Staining Buffer and data was acquired on LSRFortessa X-20 (BD Biosciences).

Table 9. Flow Cytometry Reagents to Determine TO

Markers	Fluorochrome	Clone	Catalogue #	Isotype	Vender
Mouse BD Fc Block		2.4G2	553141	Rat IgG2b, κ	BD
CD45	BUV661	30-F11	565079	Rat IgG2b,κ	BD
CD3	BUV395	145-2C11	563565	Hamster IgG1, κ	BD
CD11b	BV605	M1/70	101257	Rat IgG2b,κ	Biologend
Human PD-L1	PE-Cyanine7	MIH1	25-5983-42	Mouse IgG1,κ	Thermo Fisher
Fixable Viability Dye	eFluor-506 (BV510)	NA	65-0866-14	NA	Thermo Fisher

Plasma Concentration Analysis of Compound 139

In parallel to the assessment of TO on tumor cells at the pre-determined time points, 100 μL of WB was collected into K₂EDTA lavender tubes (BD Biosciences), mixed by inverting and subjected to centrifugation. Plasma was transferred to labeled microcentrifuge tubes and stored at -80°C until analysis.

To a 10 μL aliquot of each plasma sample with exception of the matrix blanks, 60 μL of 100 ng/mL Carbutamide in acetonitrile (ACN) was added. The matrix blank samples received 60 μL of acetonitrile only. The precipitated proteins were removed by centrifugation and 50 μL of supernatant was transferred into a clean 96 deep-well plate (Thermo Fisher Scientific). A 50 μL aliquot of water was added to each sample. An aliquot of 5 μL was injected into a Sciex API-5500 LC/MS/MS system.

Data Analysis

Calculation of Compound 139 TO on Tumor

TO of compound 139 or durvalumab, α-PD-L1, antibody was calibrated using tumor-bearing mice treated with either vehicle or isotype control antibody using the following equation:

$$TO = \frac{(\text{Average Control Group MFI} - \text{Average Sample MFI}) * 100}{(\text{Average Control Group MFI})}$$

where:

TO is the Target occupancy (i.e., % PD-L1 occupied);

Average Sample MFI is the Mean fluorescence intensity averaged from tumors treated with either compound 139 or durvalumab, α-PD-L1 antibody (n= 3); and

Average Control Group MFI is the Mean fluorescence intensity averaged from tumors treated either with vehicle or isotype control antibody (n = 3).

Calculation of Compound 139 TGI in Human PD-L1-Expressing MC38 Tumor Model

TGI of compound 139 or durvalumab α -PD-L1 antibody groups was calibrated using tumor volumes obtained from either vehicle or isotype control antibody groups on day 15 post dosing using the following equation:

$$\text{TGI} = \frac{(\text{Average Control Group Tumor Volume} - \text{Average Sample Tumor Volume}) * 100}{(\text{Average Control Group Tumor Volume})}$$

where:

TGI is the % of tumor growth inhibition;

Average Control Group Tumor Volume is the Mean tumor volume averaged from vehicle or isotype control antibody treated groups (n = 12); and

Average Sample Tumor Volume is the Mean tumor volume averaged from compound 139 or durvalumab α -PD-L1 antibody treated groups (n = 12).

Results

This example demonstrated that compound 139 can block the interaction between mouse PD-1 and human PD-L1 in a functional biochemical binding assay with a potency of < 0.75 nM (Table 10). Therefore, a human PD-L1-expressing MC38 colorectal tumor model was utilized to demonstrate the activity of compound 139 in vivo.

Table 10. Activity of Compound 139 and durvalumab Against Mouse PD-1/Human PD-L1 Interaction

	Blockade of PD-1 and PD-L1 binding (IC ₅₀)		
	Human (nM)	Mouse (μ M)	Mouse PD-1/ Human PD-L1 (nM)
Compound 139	< 0.15 ^a	61	< 0.75 ^a
durvalumab α -PD-L1 antibody	< 0.15 ^a	> 1	< 0.75 ^a

^a Values have been rounded to the theoretical bottom of the assay.

Relationship between PK, target occupancy and anti-tumor activity

The objective of this study was to assess the relationship between PK and TO of compound 139, as well as changes in body weight and tumor volume. Human PD-L1 MC38 tumor cells were implanted sSC) into the right flank of female C57BL/6 mice. Once tumors reached a mean volume of about 50 mm³, mice were randomized and treatment administered as an IP injection.

Compound 139 plasma concentration was determined at 1, 6 and 24 hours post dosing on day 6 when tumors were ~250 mm³ in size (Table 12). In parallel, TO was measured at those same time points and evaluated by flow cytometry, measured as a reduction in PD-L1 MFI and normalized to either

vehicle or isotype control. At 10, 25, and 50 mg/kg, compound 139 or 10 mg/kg durvalumab, a α -PD-L1 antibody, greater than 90% TO was observed for the duration of 24 hours post dosing (Table 13). For the 10 mg/kg dose (Figure 4A), when compound 139 plasma concentration dropped below the whole blood EC₉₀ value, greater than 90% TO was retained (Figure 4B).

With greater than 90% TO observed, comparable TGI between 31.8 % and 37.9% was obtained at 10, 25, and 50 mg/kg compound 139 (Table 13 and 14), which was similar to the TGI of 37.3% achieved with the α -PD-L1 antibody dosed at 10 mg/kg twice weekly (Figure 5). Compound 139 was well tolerated at all doses for the entire study with no effect on body weights.

Table 11. PK and TO Experimental Groups with Compound 139

Test Articles	Schedule	Time Points After Last Dose on Day 6 (N ^d)		
		1 hr	6 hr	24 hr
Human IgG1 isotype	BIW ^a (days 1, 4, 6)	3	3	3
Vehicle	BID ^b * 6 (days 1 - 6)	3	3	3
50 mg/kg (compound 139)	QD ^c * 6 (days 1 - 6)	3	3	3
25 mg/kg (compound 139)	BID * 6 (days 1 - 6)	3	3	3
10 mg/kg (compound 139)	QD * 6 (days 1 - 6)	3	3	3
1 mg/kg (compound 139)	QD * 6 (days 1 - 6)	3	3	3
α -PD-L1 antibody (durvalumab)	BIW (days 1, 4, 6)	3	3	3

^a BIW, Twice a week.

^b BID, Twice a day.

^c QD, Once a day.

^d N, Number of animals.

Table 12. PK Parameters of Compound 139 on Day 6 (Mean \pm SD)^a

	1 mg/kg QD	10 mg/kg QD	25 mg/kg BID	50 mg/kg QD	α -PDL1
AUC _{0-24/0-12hr} (μ M \cdot h) ^b	4.9 \pm 1.3	18.6 \pm 2.7	47.1 \pm 9.0	152 \pm 51	ND ^c
C _{max} (μ M)	0.41 \pm 0.05	3.2 \pm 0.5	7.3 \pm 1.0	15.9 \pm 2.4	16.8 \pm 5.9
T _{max} (hour)	2.7 \pm 2.9	1.0 \pm 0.0	1.0 \pm 0.0	1.0 \pm 0.0	ND

^a n = 3 animals per time point.

^b AUC was estimated based on a sparse sampling method.

^c ND, not determined.

Table 13. TO of Compound 139 on Day 6 (Mean \pm SD)^a

Time (hours)	1 mg/kg QD	10 mg/kg QD	25 mg/kg BID	50 mg/kg QD	α -PDL1
1	67.8 \pm 2.9	94.7 \pm 1.6	98.4 \pm 0.4	98.8 \pm 0.2	99.6 \pm 0.5
6	43.2 \pm 4.6	89.6 \pm 0.9	96.6 \pm 0.3	98.1 \pm 0.3	99.9 \pm 0.1
24	70.4 \pm 3.2	93.9 \pm 2.1	99.3 \pm 0.0	99.4 \pm 0.2	99.9 \pm 0.3

^a n = 3 animals per time point.

Table 14. Tumor Volumes (TV) and Percentage of Tumor Growth Inhibition (TGI)

	Vehicle	50 mg/kg QD	25 mg/kg BID	10 mg/kg QD	1 mg/kg QD	10 mg/kg isotype control antibody (hIgG1) BIW * 3	10 mg/kg durvalumab (α -PD-L1 antibody) BIW * 3
TV (mm ³ \pm SEM ^b)	1842.2 \pm 167.1	1143.7 \pm 132.7	1169.2 \pm 109.6	1255.7 \pm 104.8	1546.3 \pm 137.0	1549.5 \pm 132.7	
% TGI (Mean \pm SEM)		37.9 \pm 5.4	36.5 \pm 5.9	31.8 \pm 5.2	16.1 \pm 6.3		37.3 \pm 7.9
P value ^c		0.001	0.001	0.003	0.128		0.004

^a % TGI of compound 139 (normalized to vehicle) and α -PD-L1 mAb (normalized to isotype) on day 15, the last day both controls groups (vehicle and isotype) were on study.

^b Standard error of the mean.


^c All data were analyzed with SPSS (Statistical Product and Service Solutions) version 18.0 (IBM, Armonk, NY, U.S.) and were two-sided. P < 0.05 was considered to be statistically significant. Compound 139 groups were compared to vehicle. Durvalumab group was compared to isotype.

Conclusion

The in vivo activity of compound 139 was assessed in a human PD-L1-expressing MC38 mouse colorectal tumor model. Intraperitoneal administration of 10 (QD), 25 (BID), and 50 mg/kg (QD) compound 139 showed greater than 90% TO on the tumors for the duration of at least 24 hours post dosing and resulted in anti-tumor activity comparable to the PD-L1 antibody.

CLAIMS:

1. A compound of Formula (I):



wherein:

each n is independently 0, 1, 2, 3 or 4;

each Z^1 is independently halo, $-OR^a$, $-NO_2$, $-CN$, $-NR^aR^b$, $-N_3$, $-S(O)_2R^a$, $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-O-C_{1-6}$ alkyl, $-O-C_{1-6}$ haloalkyl, $-C_{3-8}$ cycloalkyl or $-C_{1-6}$ alkyl C_{3-8} cycloalkyl;

wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, $-NO_2$, $-N_3$, $-OR^a$, halo, and cyano;

Q is aryl, heteroaryl or heterocyclyl, wherein the aryl, heteroaryl and heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of halo, oxo, $-OR^a$, $-SR^a$, N_3 , NO_2 , $-CN$, $-NR^1R^2$, $-S(O)_2R^a$, $-S(O)_2NR^aR^b$, $-NR^aS(O)_2R^a$, $-NR^aC(O)R^a$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-NR^aC(O)OR^a$, $-NR^aC(O)NR^1R^2$, $-O-C(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2NR^aR^b$, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-O-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, $-C_{1-6}$ alkyl C_{3-8} cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N ;

wherein the alkyl, alkenyl, alkynyl, C_{3-8} cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, $-NO_2$, N_3 , $-OR^a$, halo, cyano, $-NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-O-C_{1-6}$ alkylCN, $-C(O)NR^aR^b$, $NR^aC(O)R^a$, $-NR^aC(O)OR^a$, $-S(O)_2R^a$, $-NR^aS(O)_2R^b$, $-S(O)_2NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2NR^aR^b$ and $-C_{3-8}$ cycloalkyl; and wherein the heteroaryl or heterocyclyl group may be oxidized on a nitrogen atom to form an N-oxide or oxidized on a sulfur atom to form a sulfoxide or sulfone;


m is 0, 1 or 2;

each Z^3 is independently halo, oxo, $-OR^a$, SR^a , N_3 , NO_2 , $-CN$, $-NR^1R^2$, $-S(O)_2R^a$, $-S(O)_2NR^aR^b$, $-NR^aS(O)_2R^a$, $-NR^aC(O)R^a$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-NR^aC(O)OR^a$, $-NR^aC(O)NR^1R^2$, $-O-C(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2NR^aR^b$, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-O-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, $-C_{1-6}$ alkyl C_{3-8} cycloalkyl, aryl, heteroaryl, heterocyclyl and R^N ;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of

oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b and -C₃₋₈ cycloalkyl;

each R^N is independently -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆ alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)NR¹R², -O-C₁₋₆ alkylC(O)OR¹, -S-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOR^a, or



wherein

L¹ is independently a bond, O, NR^a, S, S(O), or S(O)₂;

V is independently selected from the group consisting of a bond, C₁₋₆alkyl, C₂₋₆alkenyl, and C₂₋₆alkynyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;


L² is independently a bond, O, NR^a, S, S(O), or S(O)₂;

ring A is independently cycloalkyl, aryl, heteroaryl or heterocyclyl;

wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -O-C₁₋₆ haloalkyl, NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, -NR^aC(O)R^a, -NR^aC(O)OR^a, -NR^aC(O)OR^a, -C(O)N(R^a)OR^b, -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, C₃₋₈cycloalkyl and C₁₋₆alkylC₃₋₈ cycloalkyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and -C₃₋₈ cycloalkyl;

R^E and R^W are each independently -NR¹R², -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylN⁺R¹R²R³, -S-C₁₋₆ alkylNR¹R², -C(O)NR¹R², -S(O)₂R^a, -(CH₂)_uS(O)₂NR¹R², -(CH₂)_uNR^aS(O)₂NR^aR^b, -S(O)₂NR^aC₁₋₆ alkylNR¹R², -NR^aS(O)₂C₁₋₆ alkylNR¹R², -(CH₂)_uC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_uN⁺R¹R²O⁻, -(CH₂)_uP⁺R^bR^cR^d, -(CH₂)_uP⁺R^cR^dO⁻, -(CH₂)_uP⁺O[NR^aR^b][NR^cR^d], -(CH₂)_uNR^cP(O)(OR^c)₂, -(CH₂)_uCH₂OP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)NR^aR^b(OR^a), or



wherein:

V² is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

L³ is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

ring B is cycloalkyl, aryl, heteroaryl or heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^e or (CH₂)_qC(O)R^e;

p is independently 0, 1, 2, 3, 4, or 5;

q is independently 0, 1, 2, 3, 4, or 5;

u is 0, 1, 2, 3 or 4;

z is 0, 1, 2 or 3; and

wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group of R^E and R^W is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b, halo, cyano, oxo, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, -C₃₋₈ cycloalkyl and -C₁₋₃ alkylC₃₋₈cycloalkyl;

provided that at least one of V², L³, ring B and T contains a nitrogen atom;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₁₋₆ alkylC(O)OR^a, -C₂₋₆ alkenylC(O)OR^a, -S(O)₂R^a, -S(O)₂OR^a, -S(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^a, and C₁₋₆ alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, -NO₂, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -OC(O)NR^aR^b, -NR^aC(O)OR^b, -NR^aC(O)R^b, -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -S(O)₂OR^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b, -NR^aC(O)NR^b, -C₁₋₆ alkylC(O)NR^aS(O)₂R^b, -NR^aC(O)R^b, and -C₁₋₆alkylNR^aC(O)R^b;

each R² is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkyl-OR^a, -C₁₋₆ alkylC(O)OR^a, and -C₂₋₆ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b,

$-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, C_{1-6} alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a,
 $-S(O)_2NR^aR^b$, $-C_{1-6}$ alkylS(O)₂NR^aR^b, $-C(O)NR^aS(O)_2R^b$ and $-NR^aC(O)R^b$;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, aryl, heteroaryl, heterocyclyl, $-OR^a$, $-CN$, halo, $-C(O)OR^a$, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ haloalkyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, C_{1-6} alkylC(O)R^a, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$, $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-NR^aS(O)_2R^b$, $-C_{1-6}$ alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, and C_{1-6} alkylS(O)₂NR^aR^b;

each R³ is independently H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, $-C_{1-6}$ alkylheterocyclyl, $-C_{2-6}$ alkyl-OR^a, $-C_{1-6}$ alkylC(O)OR^a, or $-C_{2-6}$ alkenylC(O)OR^a;

each R^a is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-C_{3-8}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, and $-C_{1-6}$ alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-C_{3-8}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, and $-C_{1-6}$ alkylheterocyclyl;

or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S; wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of $-OR^f$, $-CN$, halo, $-C_{1-6}$ alkylOR^f, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, $-C_{3-8}$ cycloalkyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^f$, $-C_{1-6}$ alkylC(O)R^f, $-C(O)OR^f$, $-C_{1-6}$ alkylC(O)OR^f, $-NR^fR^g$, $-C_{1-6}$ alkylNR^fR^g, $-C(O)NR^fR^g$, C_{1-6} alkylC(O)NR^fR^g, $-S(O)_2R^f$, $-C_{1-6}$ alkylS(O)₂R^f, $-S(O)_2NR^fR^g$, $-C_{1-6}$ alkylS(O)₂NR^fR^g, $-C(O)NR^fS(O)_2R^g$ and $-NR^fC(O)R^g$;

each R^c is independently selected from the group consisting of H, OH, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-3}$ alkylC₃₋₈ cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, and $-C_{1-6}$ alkylheterocyclyl;

each R^d is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, and $-C_{1-6}$ alkylheterocyclyl;


each R^e is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-O-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-O-C_{3-8}$ cycloalkyl, $-O$ -aryl, $-O$ -heteroaryl, $-O$ -heterocyclyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, $-NR^fR^g$, $-C_{1-6}$ alkylNR^fR^g, $-C(O)NR^fR^g$, $-C_{1-6}$ alkylC(O)NR^fR^g, $-NHS(O)_2R^f$, $-C_{1-6}$ alkylS(O)₂R^f, and $-C_{1-6}$ alkylS(O)₂NR^fR^g;

each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

2. A compound of Formula (I):



wherein:

each n is independently 0, 1, 2, 3 or 4;

each Z¹ is independently halo, -OR^a, -NO₂, -CN, -NR^aR^b, -N₃, -S(O)₂R^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, monocyclic -C₃₋₈ cycloalkyl or monocyclic -C₁₋₆ alkylC₃₋₈ cycloalkyl;

wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, -N₃, -OR^a, halo, and cyano;

Q is monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl group optionally substituted with 1 to 4 groups independently selected from the group consisting of halo, oxo, -OR^a, N₃, NO₂, -CN, -NR¹R², -S(O)₂R^a, -S(O)₂NR^aR^b, -NR^aS(O)₂R^a, -NR^aC(O)R^a, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, -NR^aC(O)OR^a, -NR^aC(O)NR¹R², -OC(O)NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -O-C₁₋₆ alkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic -C₁₋₆ alkylC₃₋₈ cycloalkyl, monocyclic aryl, and R^N;


wherein the alkyl, alkenyl, alkynyl, monocyclic C₃₋₈ cycloalkyl, or monocyclic aryl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, -NO₂, N₃, -OR^a, halo, cyano, -NR^aR^b, -C(O)R^a, -C(O)OR^a, -O-C₁₋₆ alkylCN, -C(O)NR^aR^b, NR^aC(O)R^a, -NR^aC(O)OR^a, -S(O)₂R^a, -NR^aS(O)₂R^b, -S(O)₂NR^aR^b, -NR^aS(O)₂NR^aR^b, -C(O)NR^aS(O)₂NR^aR^b and monocyclic -C₃₋₈ cycloalkyl; and wherein the monocyclic heteroaryl or monocyclic heterocyclyl group may be oxidized on a nitrogen atom to form an N-oxide or oxidized on a sulfur atom to form a sulfoxide or sulfone;

m is 0, 1 or 2;

each Z^3 is independently halo, oxo, $-OR^a$, N_3 , NO_2 , $-CN$, $-NR^1R^2$, $-S(O)_2R^a$, $-S(O)_2NR^aR^b$, $-NR^aS(O)_2R^a$, $-NR^aC(O)R^a$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-NR^aC(O)OR^a$, $-NR^aC(O)NR^1R^2$, $-OC(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2NR^aR^b$, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-O-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic $-C_{1-6}$ alkyl C_{3-8} cycloalkyl, monocyclic aryl, and R^N ;

wherein the alkyl, alkenyl, alkynyl, monocyclic C_{3-8} cycloalkyl, or monocyclic aryl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, $-NO_2$, N_3 , $-OR^a$, halo, cyano, $-NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-O-C_{1-6}$ alkylCN, $-C(O)NR^aR^b$, $NR^aC(O)R^a$, $-NR^aC(O)OR^a$, $-S(O)_2R^a$, $-NR^aS(O)_2R^b$, $-S(O)_2NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2NR^aR^b$ and monocyclic $-C_{3-8}$ cycloalkyl;

each R^N is independently $-C_{1-6}$ alkyl NR^1R^2 , $-O-C_{1-6}$ alkyl NR^1R^2 , $-C_{1-6}$ alkyl OC_{1-6} alkyl NR^1R^2 , $-NR^a-C_{1-6}$ alkyl NR^1R^2 , $-C_{1-6}$ alkyl $C(O)NR^1R^2$, $-O-C_{1-6}$ alkyl $C(O)NR^1R^2$, $-O-C_{1-6}$ alkyl $C(O)OR^1$, $-S-C_{1-6}$ alkyl NR^1R^2 , $-C_{1-6}$ alkyl OR^a , or



wherein

L^1 is independently a bond, O, NR^a , S, $S(O)$, or $S(O)_2$;

V is independently selected from the group consisting of a bond, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with $-OR^a$, halo, cyano, NR^aR^b and monocyclic $-C_{3-8}$ cycloalkyl;


L^2 is independently a bond, O, NR^a , S, $S(O)$, or $S(O)_2$;

ring A is independently monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl;

wherein the monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl, or monocyclic heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of oxo, $-NO_2$, N_3 , $-OR^a$, halo, cyano, $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-O-C_{1-6}$ haloalkyl, NR^aR^b , $-C(O)R^a$, $-C(O)OR^a$, $-O-C_{1-6}$ alkylCN, $-C(O)NR^aR^b$, $-NR^aC(O)R^a$, $-NR^aC(O)OR^a$, $-NR^aC(O)OR^a$, $-C(O)N(R^a)OR^b$, $-S(O)_2R^a$, $-S(O)_2NR^aR^b$, $-NR^aS(O)_2R^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2NR^aR^b$, monocyclic C_{3-8} cycloalkyl and monocyclic C_{1-6} alkyl C_{3-8} cycloalkyl;

wherein the alkyl, alkenyl or alkynyl group is optionally independently substituted with -OR^a, halo, cyano, NR^aR^b and monocyclic -C₃₋₈ cycloalkyl;

R^E and R^W are each independently -NR¹R², -C₁₋₆ alkylNR¹R², -O-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylOC₁₋₆alkylNR¹R², -NR^a-C₁₋₆ alkylNR¹R², -C₁₋₆ alkylN⁺R¹R²R³, -S-C₁₋₆ alkylNR¹R², -C(O)NR¹R², -S(O)₂R^a, -(CH₂)_uS(O)₂NR¹R², -(CH₂)_uNR^aS(O)₂NR^aR^b, -S(O)₂NR^aC₁₋₆ alkylNR¹R², -NR^aS(O)₂C₁₋₆ alkylNR¹R², -(CH₂)_uC(O)NR^aS(O)₂NR^aR^b, -(CH₂)_uN⁺R¹R²O⁻, -(CH₂)_uP⁺R^bR^cR^d, -(CH₂)_uP⁺R^cR^dO⁻, -(CH₂)_uP⁺O[NR^aR^b][NR^cR^d], -(CH₂)_uNR^cP(O)(OR^c)₂, -(CH₂)_uCH₂OP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)(OR^c)(OR^d), -(CH₂)_uOP(O)NR^aR^b(OR^a), or



wherein:

V² is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

L³ is independently a bond, O, NR^a, S, S(O), S(O)₂, C(O)NR^a, NR^aC(O), S(O)₂NR¹, or NR^aS(O)₂;

ring B is independently monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl or spirocyclic heterocyclyl;

T is independently H, -OR^a, (CH₂)_qNR¹R², (CH₂)_qNR^aC(O)R^e or (CH₂)_qC(O)R^e;

p is independently 0, 1, 2, 3, 4, or 5;

q is independently 0, 1, 2, 3, 4, or 5;

u is 0, 1, 2, 3 or 4;

z is 0, 1, 2 or 3; and

wherein the alkyl, monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl or spirocyclic heterocyclyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of NR^aR^b, halo, cyano, oxo, -OR^a, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylNR^aR^b, -C₁₋₆ alkylOH, monocyclic -C₃₋₈ cycloalkyl and monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl;

provided that at least one of V², L³, ring B and T contains a nitrogen atom;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, monocyclic -C₃₋₆ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆ alkylheteroaryl, monocyclic -C₁₋₆ alkylheterocyclyl,

$-C_{1-6}$ alkylC(O)OR^a, $-C_{2-6}$ alkenylC(O)OR^a, $-S(O)_2R^a$, $-S(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2R^a$, and monocyclic C_{1-6} alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of $-OR^a$, $-CN$, halo, C_{1-6} alkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, monocyclic C_{3-8} cycloalkyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, $-C_{1-6}$ alkylC(O)R^a, $-C(O)OR^a$, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$, $-OC(O)NR^aR^b$, $NR^aC(O)OR^b$, $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, $-C_{1-6}$ alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, $-C_{1-6}$ alkylS(O)₂NR^aR^b, $-C(O)NR^aS(O)_2R^b$, $-C_{1-6}$ alkylC(O)NR^aS(O)₂R^b, $-NR^aC(O)R^b$, and $-C_{1-6}$ alkylNR^aC(O)R^b;

each R² is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, monocyclic $-C_{3-6}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, monocyclic $-C_{1-6}$ alkylheterocyclyl, $-C_{2-6}$ alkyl-OR^a, $-C_{1-6}$ alkylC(O)OR^a, and $-C_{2-6}$ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, monocyclic cycloalkyl, monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of $-OR^a$, $-CN$, halo, C_{1-6} alkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, $-C_{1-6}$ alkylC(O)R^a, $-C(O)OR^a$, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$, $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, C_{1-6} alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, $-C_{1-6}$ alkylS(O)₂NR^aR^b, $-C(O)NR^aS(O)_2R^b$ and $-NR^aC(O)R^b$;

or R¹ and R², when bound to the same atom, may combine with the atom to which they are attached to form a monocyclic heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, $-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-OR^a$, $-C(O)OR^a$, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ haloalkyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, C_{1-6} alkylC(O)R^a, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$, $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, $-C_{1-6}$ alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, and C_{1-6} alkylS(O)₂NR^aR^b;

each R³ is independently H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, monocyclic $-C_{3-6}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, monocyclic $-C_{1-6}$ alkylheterocyclyl, $-C_{2-6}$ alkyl-OR^a, $-C_{1-6}$ alkylC(O)OR^a, or $-C_{2-6}$ alkenylC(O)OR^a;

each R^a is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, monocyclic $-C_{3-8}$ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic $-C_{1-3}$ alkylC₃₋₈cycloalkyl, monocyclic $-C_{1-6}$ alkylaryl, monocyclic $-C_{1-6}$ alkylheteroaryl, and monocyclic $-C_{1-6}$ alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, -C₁₋₆ alkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆ alkylheteroaryl, and monocyclic -C₁₋₆ alkylheterocyclyl;

or R^a and R^b, when bound to the same atom, may combine together to form a monocyclic ring consisting of 3-8 ring atoms that are C, N, O, or S; wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆ alkylOR^f, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆ alkylC(O)R^f, -C(O)OR^f, -C₁₋₆ alkylC(O)OR^f, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆ alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, -S(O)₂NR^fR^g, -C₁₋₆ alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

each R^c is independently selected from the group consisting of H, OH, -C₁₋₆ alkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -C₁₋₃ alkylC₃₋₈ cycloalkyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆ alkylheteroaryl, and monocyclic -C₁₋₆ alkylheterocyclyl; and

each R^d is independently selected from the group consisting of H, -C₁₋₆ alkyl, monocyclic -C₃₋₈cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆ alkylheteroaryl, and monocyclic -C₁₋₆ alkylheterocyclyl;


each R^e is independently selected from the group consisting of H, -C₁₋₆ alkyl, -O-C₁₋₆alkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -OC₃₋₈ cycloalkyl, monocyclic -O-aryl, monocyclic -O-heteroaryl, monocyclic -O-heterocyclyl, monocyclic -C₁₋₃ alkylC₃₋₈cycloalkyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆alkylheteroaryl, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, -C₁₋₆ alkylC(O)NR^fR^g, -NHS(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, and -C₁₋₆ alkylS(O)₂NR^fR^g;

each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -C₁₋₃ alkylC₃₋₈ cycloalkyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆ alkylheteroaryl, and monocyclic -C₁₋₆ alkylheterocyclyl;

each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, monocyclic -C₃₋₈ cycloalkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic heterocyclyl, monocyclic -C₁₋₃ alkylC₃₋₈ cycloalkyl, monocyclic -C₁₋₆ alkylaryl, monocyclic -C₁₋₆ alkylheteroaryl, and monocyclic -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

3. The compound of claim 1, wherein the compound is represented by Formula (Ia):




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

each X is independently CH, CZ³ or N;

each m is independently 0, 1 or 2; and

Z¹, Z³, R^E, R^W and n are as defined in claim 1.

4. The compound of claim 1, wherein the compound is represented by Formula (Ib):




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

each m is independently 0, 1 or 2; and

Z¹, Z³, R^E, R^W and n are as defined in claim 1.

5. The compound of claim 1, wherein the compound is represented by Formula (Ic):




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

each m is independently 0, 1 or 2; and

Z¹, Z³, R^E, R^W and n are as defined in claim 1.

6. The compound of claim 1, wherein the compound is represented by Formula (Id):




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

each m is independently 0, 1 or 2; and

Z^1 , Z^3 , R^E , R^W and n are as defined in claim 1.


7. The compound of claim 1, wherein the compound is represented by Formula (II):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

Z^1 , Z^3 , R^E and R^W are as defined in claim 1.

8. A compound of Formula (III):



wherein:

each X is independently CH , CZ^3 or N ;

each Z^1 is independently halo or $-C_{1-6}$ alkyl;

each n is independently 0, 1, 2, 3 or 4;

each Z^3 is independently halo or $-O-C_{1-6}$ alkyl;

each m is independently 0, 1 or 2;

each R^1 is independently selected from the group consisting of H , $-C_{1-8}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl,

$-C_{1-6}$ alkylheterocyclyl, $-C_{1-6}$ alkylC(O)OR^a, $-C_{2-6}$ alkenylC(O)OR^a, $-S(O)_2R^a$, $-S(O)_2NR^aR^b$, $-C(O)NR^aS(O)_2R^a$, and C_{1-6} alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of $-OR^a$, $-CN$, halo, C_{1-6} alkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, C_{3-8} cycloalkyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, $-C_{1-6}$ alkylC(O)R^a, $-C(O)OR^a$, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$, $-OC(O)NR^aR^b$, $NR^aC(O)OR^b$, $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, $-C_{1-6}$ alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, $-C_{1-6}$ alkylS(O)₂NR^aR^b, $-C(O)NR^aS(O)_2R^b$, $-C_{1-6}$ alkylC(O)NR^aS(O)₂R^b, $-NR^aC(O)R^b$, and $-C_{1-6}$ alkylNR^aC(O)R^b;

each R² is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, $-C_{1-6}$ alkylheterocyclyl, $-C_{2-6}$ alkylOR^a, $-C_{1-6}$ alkylC(O)OR^a, and $-C_{2-6}$ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of $-OR^a$, $-CN$, halo, C_{1-6} alkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ haloalkyl, $-C_{3-8}$ cycloalkyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, $-C_{1-6}$ alkylC(O)R^a, $-C(O)OR^a$, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$, $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, C_{1-6} alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, $-C_{1-6}$ alkylS(O)₂NR^aR^b, $-C(O)NR^aS(O)_2R^b$ and $-NR^aC(O)R^b$;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-OR^a$, $-C(O)OR^a$, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ alkylOR^a, $-C_{1-6}$ haloalkyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C(O)R^a$, C_{1-6} alkylC(O)R^a, $-C_{1-6}$ alkylC(O)OR^a, $-NR^aR^b$, $-C_{1-6}$ alkylNR^aR^b, $-C(O)NR^aR^b$, $-C_{1-6}$ alkylC(O)NR^aR^b, $-S(O)_2R^a$, $-C_{1-6}$ alkylS(O)₂R^a, $-S(O)_2NR^aR^b$, and C_{1-6} alkylS(O)₂NR^aR^b;

R⁵ is independently selected from the group consisting of NR^aR^b, halo, cyano, $-OR^a$, $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-C_{1-6}$ cyanoalkyl, $-C_{1-6}$ alkylNR^aR^b, $-C_{1-6}$ alkylOH, $-C_{3-8}$ cycloalkyl and $-C_{1-3}$ alkylC₃₋₈cycloalkyl;

each R^a is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, and $-C_{1-6}$ alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, aryl, heteroaryl, heterocyclyl, $-C_{1-3}$ alkylC₃₋₈cycloalkyl, $-C_{1-6}$ alkylaryl, $-C_{1-6}$ alkylheteroaryl, and $-C_{1-6}$ alkylheterocyclyl;


or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S; wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆ alkylOR^f, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆ alkylC(O)R^f, -C(O)OR^f, -C₁₋₆ alkylC(O)OR^f, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆ alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, -S(O)₂NR^fR^g, -C₁₋₆ alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

9. A compound of Formula (IIIa):



wherein:

each X is independently CH, CZ³ or N;

each Z¹ is independently halo or -C₁₋₆ alkyl;

each Z³ is independently halo or -O-C₁₋₆ alkyl;

each R¹ is independently selected from the group consisting of H, -C₁₋₈ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₁₋₆ alkylC(O)OR^a, -C₂₋₆ alkenylC(O)OR^a, -S(O)₂R^a, -S(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^a, and C₁₋₆ alkylC₃₋₈cycloalkyl;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆ alkylC(O)R^a, -C(O)OR^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -OC(O)NR^aR^b, NR^aC(O)OR^b, -C₁₋₆ alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆ alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b, -C₁₋₆ alkylC(O)NR^aS(O)₂R^b, -NR^aC(O)R^b, and -C₁₋₆alkylNR^aC(O)R^b;

each R² is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₃₋₆ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, -C₁₋₆ alkylheterocyclyl, -C₂₋₆ alkylOR^a, -C₁₋₆ alkylC(O)OR^a, and -C₂₋₆ alkenylC(O)OR^a;

wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl or heterocyclyl group is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^a, -CN, halo, C₁₋₆alkyl, -C₁₋₆alkylOR^a, -C₁₋₆cyanoalkyl, -C₁₋₆haloalkyl, -C₃₋₈cycloalkyl, -C₁₋₃alkylC₃₋₈cycloalkyl, -C(O)R^a, -C₁₋₆alkylC(O)R^a, -C(O)OR^a, -C₁₋₆alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, C₁₋₆alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆alkylS(O)₂R^a, -S(O)₂NR^aR^b, -C₁₋₆alkylS(O)₂NR^aR^b, -C(O)NR^aS(O)₂R^b and -NR^aC(O)R^b;

or R¹ and R² combine to form a heterocyclyl group optionally containing 1, 2, or 3 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 3 groups independently selected from the group consisting of oxo, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -OR^a, -C(O)OR^a, -C₁₋₆ cyanoalkyl, -C₁₋₆ alkylOR^a, -C₁₋₆ haloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^a, C₁₋₆ alkylC(O)R^a, -C₁₋₆ alkylC(O)OR^a, -NR^aR^b, -C₁₋₆alkylNR^aR^b, -C(O)NR^aR^b, -C₁₋₆ alkylC(O)NR^aR^b, -S(O)₂R^a, -C₁₋₆ alkylS(O)₂R^a, -S(O)₂NR^aR^b, and C₁₋₆ alkylS(O)₂NR^aR^b;

each R^a is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆alkylheterocyclyl;

each R^b is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;


or R^a and R^b may combine together to form a ring consisting of 3-8 ring atoms that are C, N, O, or S; wherein the ring is optionally substituted with 1 to 4 groups independently selected from the group consisting of -OR^f, -CN, halo, -C₁₋₆ alkylOR^f, -C₁₋₆ cyanoalkyl, -C₁₋₆ haloalkyl, -C₃₋₈ cycloalkyl, -C₁₋₃ alkylC₃₋₈cycloalkyl, -C(O)R^f, -C₁₋₆ alkylC(O)R^f, -C(O)OR^f, -C₁₋₆ alkylC(O)OR^f, -NR^fR^g, -C₁₋₆ alkylNR^fR^g, -C(O)NR^fR^g, C₁₋₆ alkylC(O)NR^fR^g, -S(O)₂R^f, -C₁₋₆ alkylS(O)₂R^f, -S(O)₂NR^fR^g, -C₁₋₆ alkylS(O)₂NR^fR^g, -C(O)NR^fS(O)₂R^g and -NR^fC(O)R^g;

each R^f is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

each R^g is independently selected from the group consisting of H, -C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, -C₁₋₃ alkylC₃₋₈ cycloalkyl, -C₁₋₆ alkylaryl, -C₁₋₆ alkylheteroaryl, and -C₁₋₆ alkylheterocyclyl;

or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.


10. The compound of claim 9, wherein the compound is represented by Formula (IIIb):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

Z^1 , Z^3 , R^1 and R^2 are as defined in claim 9.


11. The compound of claim 9, wherein the compound is represented by Formula (IIIc):



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

Z^1 , Z^3 , R^1 and R^2 are as defined in claim 9.

12. The compound of claim 9, wherein the compound is represented by Formula (IIIId):




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein:

Z^1 , Z^3 , R^1 and R^2 are as defined in claim 9.


13. A compound selected from Table 1, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

14. A compound which is:




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

15. A compound which is:




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

16. A compound which is:




or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

17. A compound which is:



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

18. A compound which is:



or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof.

19. A pharmaceutical composition comprising a compound according to any one of claims 1-18 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one pharmaceutically acceptable excipient.

20. The pharmaceutical composition according to claim 19, further comprising at least one additional anticancer agent or therapy selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, and ipilimumab, and at least one pharmaceutically acceptable excipient.
21. The pharmaceutical composition according to claim 19, wherein the additional anticancer agent is nivolumab, pembrolizumab, atezolizumab, or ipilimumab.
22. A method for inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction comprising administering a compound according to any one of claims 1-18 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof, to a patient in need thereof.
23. A method for treating cancer comprising administering a therapeutically effective amount of a compound according to any one of claims 1-18 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, to a patient in need thereof.
24. The method according to claim 23, wherein the cancer is pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer or colon cancer.
25. The method according to claim 23, wherein the cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldstrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma or diffuse large B-cell lymphoma (DLBCL).
26. The method according to claim 22 or 23, further comprising administering at least one additional anticancer agent or therapy selected from nivolumab, pembrolizumab, atezolizumab, ipilimumab, chemotherapy, radiation therapy, and resection therapy, to a patient in need thereof.
27. The method according to claim 22 or 23, wherein the additional anticancer agent or therapy is nivolumab, pembrolizumab, atezolizumab, and nivolumab, pembrolizumab, atezolizumab, or ipilimumab.
28. A method for improving T cell function in chronic hepatitis B (CHB) patients comprising administering thereto an effective amount of a compound according to any one of claims 1-18 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof.
29. A compound according to any one of claims 1-18 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof for use in therapy.

30. A compound according to any one of claims 1-18 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, for use in the manufacture of a medicament for treating cancer.
31. A compound according to any one of claims 1-18 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, and at least one additional anti-cancer agent selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, and ipilimumab for use in the manufacture of a medicament for treating cancer.
32. A compound according to any one of claims 1-18 or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, for use in the manufacture of a medicament for improving T cell function in chronic hepatitis B (CHB) patients.
33. A kit for treating or preventing cancer or a disease or condition that is amenable to treatment by inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction in a patient in need thereof, comprising:
- a) a compound according to any of claims 1-18, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof;
 - b) a monoclonal antibody checkpoint inhibitor or antigen binding fragment thereof; and optionally
 - c) a label or instructions for use.
34. A kit for treating or preventing cancer or a disease or condition that is amenable to treatment by inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction in a patient in need thereof, comprising:
- a) a compound according to any of claims 1-18, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof;
 - b) a monoclonal antibody checkpoint inhibitor or antigen binding fraction thereof; and optionally
 - c) an additional therapeutic agent; and optionally;
 - d) a label or instructions for use.
35. A kit for treating or preventing cancer or a disease or condition in a subject in need thereof, comprising:
- a) a compound according to any of claims 1-18, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof;
 - b) an anti-MMP9 antibody or antigen binding fragment thereof; and optionally
 - c) an additional therapeutic agent; and optionally;
 - d) a label or instructions for use.




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 3




FIG. 4A




FIG. 4B




FIG. 5

INTERNATIONAL SEARCH REPORT

International application No PCT/US2019/017721

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C07D405/14 A61K31/497 C07D403/14 C07D241/18 C07D241/20
 C07D487/08 C07D487/10 C07D491/107 C07D519/00 A61P35/00
ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 C07D A61K A61P
 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TRYFON ZARGANES-TZITZIKAS ET AL: "Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 26, no. 9, 19 September 2016 (2016-09-19), pages 973-977, XP055394015, ISSN: 1354-3776, DOI: 10.1080/13543776.2016.1206527 introduction; page 2973 page 974; figure 2; compounds 3, BMS-37, BMS-202, BMS-230, BMS-8, BMS-242 ----- -/--	1-35

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 29 March 2019	Date of mailing of the international search report 08/04/2019
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Bissmire, Stewart
--	---

INTERNATIONAL SEARCH REPORT

International application No PCT/US2019/017721

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2016/194307 A1 (CHUPAK LOUIS S [US] ET AL) 7 July 2016 (2016-07-07) abstract page 36 - page 81; examples 5-297 claim 1 -----	1-35
A	US 2015/352206 A1 (GAJEWSKI THOMAS F [US] ET AL) 10 December 2015 (2015-12-10) abstract page 21 - page 46; examples 1-24 claim 1 -----	1-35
A	WO 2011/082400 A2 (HARVARD COLLEGE [US]; SHARPE ARLENE H [US]; BUTTE MANISH J [US]; OYAMA) 7 July 2011 (2011-07-07) abstract claims 1, 75 -----	1-35

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2019/017721

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2016194307 A1	07-07-2016	AU 2014315457 A1	28-04-2016
		CA 2923184 A1	12-03-2015
		CL 2016000508 A1	04-11-2016
		CL 2018000150 A1	11-05-2018
		CN 105705489 A	22-06-2016
		EA 201690316 A1	29-07-2016
		EP 3041822 A1	13-07-2016
		ES 2642074 T3	15-11-2017
		HK 1223366 A1	28-07-2017
		JP 6417419 B2	07-11-2018
		JP 2016536333 A	24-11-2016
		KR 20160048946 A	04-05-2016
		PE 04322016 A1	11-05-2016
		SG 11201601225R A	30-03-2016
		US 2016194307 A1	07-07-2016
WO 2015034820 A1	12-03-2015		
US 2015352206 A1	10-12-2015	CA 2889182 A1	01-05-2014
		EP 2911669 A1	02-09-2015
		US 2015352206 A1	10-12-2015
		US 2018333492 A1	22-11-2018
		WO 2014066834 A1	01-05-2014
WO 2011082400 A2	07-07-2011	US 2013022629 A1	24-01-2013
		WO 2011082400 A2	07-07-2011